[
  {
    "id": "covid_fact-000001",
    "statement": "Measuring sars-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence discusses measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses, which is precisely what the claim states. The provided evidence also explains that they use HIV-1 and VSV surrogate viruses, specifically mentioning 'SARS-CoV-2 spike-pseudotyped' and 'replication-competent VSV/SARS-CoV-2 chimeric virus', confirming the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000002",
    "statement": "Measuring chs-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes the use of surrogate viruses such as SARS-CoV-2 spike-pseudotyped, single-cycle replication-defective HIV-1 and VSV, as well as a replication-competent VSV/SARS-CoV-2 chimeric virus for measuring the neutralizing antibody activity of convalescent plasma and human monoclonal antibodies. This aligns with the claim that methods using pseudotyped and chimeric viruses are used to measure neutralizing antibody activity related to SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000003",
    "statement": "Measuring aces-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about measuring the neutralizing activity of antibodies against SARS-CoV-2 using pseudotyped and chimeric viruses. The provided evidence shows that researchers have developed surrogate viruses, namely SARS-CoV-2 spike-pseudotyped HIV-1 and VSV, as well as a replication-competent VSV/SARS-CoV-2 chimeric virus to measure the neutralizing activity of convalescent plasma and human monoclonal antibodies. These viruses are used as substitutes for SARS-CoV-2 because they exhibit similar sensitivity in detecting neutralizing activity, which correlates with the results obtained using an authentic SARS-CoV-2 neutralization assay.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000004",
    "statement": "Measuring gps-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that methods for measuring the activity of GPS-COV-2 neutralizing antibodies using various surrogate viruses are supported by evidence presented in the text. The text describes the use of SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective HIV-1 and VSV, as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. Furthermore, it is shown that the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using these surrogate viruses correlates quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000005",
    "statement": "Long-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the IgG antibodies against SARS-CoV were detected in healthcare workers until 2015, which is 12 years after the initial infection. This suggests that the long-term persistence of these antibodies can indeed be up to 12 years.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000006",
    "statement": "short-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that IgG titers in SARS-CoV infected healthcare workers remained at a significantly high level until 2015. Furthermore, the conclusion states that IgG antibodies against SARS-CoV can persist for at least 12 years (12 years after 2015). Thus, it is supported that short-term persistence of IgG antibodies in SARS-CoV infected healthcare workers exists and can last for at least 12 years.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000007",
    "statement": "Low-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that IgG titers in SARS-CoV infected healthcare workers remained at a significantly high level until 2015, suggesting the presence of these antibodies for at least 12 years (as concluded in the study). This implies that low-term persistence of IgG antibodies in SARS-CoV infected individuals is supported.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000008",
    "statement": "Pre-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that IgG titers in SARS-CoV infected healthcare workers remained at a significantly high level until 2015, and the conclusion is that IgG antibodies against SARS-CoV can persist for at least 12 years. This suggests that pre-term persistence of igg antibodies in SARS-CoV infected healthcare workers is supported by the evidence.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000009",
    "statement": "Coronavirus dons a new crown",
    "label": "SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about the structure of the Coronavirus and its resemblance to a crown. The evidence presents two pieces of information that support this claim: first, it mentions a 'crown-like pore complex' on coronavirus RCs (Relevant Structure Components), which suggests a structural similarity to a crown. Second, it also describes a similar crown of viral proteins on nodavirus RCs for comparison (Structural Parallel with Nodaviruses). While the claim does not explicitly state that the virus dons a new crown, the evidence shows that the structure of the coronavirus includes a crown-like component, which aligns with the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000010",
    "statement": "Coronavirus dons a new question",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided explains properties of Coronavirus (CoV) such as its RNA synthesis and the structure of its proteins. However, it does not provide any information about a 'new question' that CoV dons. The claim appears to be making a figurative statement, but without additional context or evidence supporting this interpretation, it cannot be confirmed.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000011",
    "statement": "Coronavirus dons a new term",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not directly supported by the evidence provided. The evidence explains that coronaviruses have a protein called Crown-forming protein A, which plays a role in RNA synthesis and shares similarities with other viral proteins. Additionally, it describes a crown-like pore complex on coronaviruses' ribonucleocapsid (RC) and mentions that nodaviruses also have a similar structure. However, the claim is about coronaviruses 'donning a new term,' which doesn't seem to be addressed or inferred by the given evidence.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000012",
    "statement": "Immune memory in mild covid-19 patients and unexposed donors from india reveals persistent t cell responses after sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Moreover, we found detectable immune reactivity up to 5 months in mild COVID-19 recovered patients in the two major arms of protective adaptive immunity; CD4+ T cells and B cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that immune memory (specifically CD4+ T cells and B cells) in mild COVID-19 recovered patients from India was found to be persistent up to 5 months after SARS-CoV-2 infection. Since no information is provided about unexposed donors from India, the claim can only be supported for the former group.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000013",
    "statement": "Immune memory in mild covid-19 patients and unexposed donors from india reveals persistent t cell depletion after sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Moreover, we found detectable immune reactivity up to 5 months in mild COVID-19 recovered patients in the two major arms of protective adaptive immunity; CD4+ T cells and B cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that immune reactivity (CD4+ T cells) was detectable up to 5 months in mild COVID-19 recovered patients. This implies an ongoing immune response, which is a characteristic of memory immunity. The claim suggests persistent t cell depletion after SARS-CoV-2 infection in these patients. The evidence supports this claim as it shows that even after 5 months, the CD4+ T cells were still being activated, suggesting a potential depletion or exhaustion due to the ongoing response to the virus.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000014",
    "statement": "Simple probiotics might help inhibit covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Other research suggests that probiotic supplementation may promote antiviral activity in general to improve immune, pulmonary, and anti-inflammatory response that might help clear the SARS-CoV-2 infection (70, 71)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests a possible association between probiotics and antiviral activity, which might theoretically be beneficial against SARS-CoV-2 infection (Covid-19). However, the evidence does not specifically state or prove that 'simple probiotics' inhibit Covid-19 infection. More research is needed to support such a claim.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000015",
    "statement": "Simple probiotics might help cause covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Other research suggests that probiotic supplementation may promote antiviral activity in general to improve immune, pulmonary, and anti-inflammatory response that might help clear the SARS-CoV-2 infection (70, 71)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses how probiotics may improve immune response and potentially aid in the clearance of SARS-CoV-2 infection. However, it does not support the claim that probiotics might cause COVID-19 infection.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000016",
    "statement": "Uk bans parallel export and hoarding of lopinavir+ritonavir , chloroquine and hydroxychloroquine",
    "label": "SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear information that the export of AbbVie's Kaletra/Aluvia (lopinavir+ritonavir), chloroquine phosphate, and hydroxychloroquine is restricted in the UK. This restriction suggests a ban on parallel export and hoarding of these medications within the UK.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000017",
    "statement": "Uk bans parallel training and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the export of lopinavir+ritonavir, chloroquine phosphate and hydroxychloroquine is being restricted by the UK government. Therefore, it can be inferred that a ban on parallel training and hoarding of these drugs exists.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000018",
    "statement": "Ukakes parallel export and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions 'Ukakes parallel export and hoarding' but there is no clear evidence provided about hoarding in this context. The evidence focuses on the restriction of exporting certain medicines to meet the needs of UK patients, including lopinavir+ritonavir, chloroquine phosphate, and hydroxychloroquine. However, it does not provide any information about 'hoarding' by Ukakes.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000019",
    "statement": "Ukolls parallel export and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state that Ukolls (if it refers to a specific entity) is parallel exporting or hoarding the mentioned drugs (Lopinavir+Ritonavir, Chloroquine, and Hydroxychloroquine). Instead, it states that the export of these specific drugs is being restricted to meet the needs of UK patients. The claim requires additional evidence showing Ukolls' involvement in parallel export or hoarding.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000020",
    "statement": "Air quality influences the pandemic - communiqués de presse",
    "label": "SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a study that highlights the correlation between fine particle concentrations and the severity of influenza waves, suggesting air quality can influence the severity of similar viral infections like the coronavirus. The researchers also emphasize multiple factors influencing the pandemic, but they specifically mention particulate matter pollution as one of them.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000021",
    "statement": "Virus quality influences the pandemic - communiqués de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that air pollution can affect the severity of influenza waves and potentially coronaviruses by increasing the virulence of the virus and possible severe disease progression. Although it does not directly state 'Virus quality influences the pandemic,' it indirectly supports this claim by showing a correlation between air pollution (a quality factor) and pandemic severity.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000022",
    "statement": "Health quality influences the pandemic - communiqués de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that there is a correlation between air pollution and the severity of influenza waves, which are similar to coronaviruses in terms of their airborne transmission. Although the study does not explicitly state that health quality directly influences the pandemic, it suggests that poorer health quality due to air pollution can worsen the virulence of the virus and possible severe disease progression, thus indirectly supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000023",
    "statement": "Global quality influences the pandemic - communiqués de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the correlation between air pollution and the severity of influenza waves, but it does not directly support or refute the claim that global quality influences the pandemic in general. While air pollution can impact the virulence of a virus, it is only one factor among many that influence the course of a pandemic. The evidence does not provide sufficient context to make a definitive conclusion about the claim.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000024",
    "statement": "Single-cell omics reveals dyssynchrony of the innate and adaptive immune system in progressive covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we utilize multiomics single-cell analysis to probe dynamic immune responses in patients with stable or progressive manifestations of COVID-19, and assess the effects of tocilizumab, an anti-IL-6 receptor monoclonal antibody."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that single-cell omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. However, the evidence provided discusses the use of multiomics single-cell analysis to probe dynamic immune responses in patients with stable or progressive manifestations of COVID-19, but it does not explicitly state that this reveals dyssynchrony between the innate and adaptive immune system, nor is it clear if the study was specifically focused on progressive COVID-19. More specific evidence would be required to support this claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000025",
    "statement": "Single-brain omics reveals dyssynchrony of the innate and adaptive immune system in progressive covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we utilize multiomics single-cell analysis to probe dynamic immune responses in patients with stable or progressive manifestations of COVID-19, and assess the effects of tocilizumab, an anti-IL-6 receptor monoclonal antibody."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that a study is being conducted on the immune responses in patients with COVID-19, focusing on both the innate and adaptive immune system. The claim that there might be dyssynchrony between these two systems in progressive cases of COVID-19 is supported by this research since it aims to probe dynamic immune responses. Additionally, the study mentions an intervention using tocilizumab, an anti-IL-6 receptor monoclonal antibody, which is often used to modulate the immune response in severe or progressive cases of COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000026",
    "statement": "Fenofibrate increases the amount of sulfatide which seems beneficial against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that treatment with fenofibrate increases sulfatide levels, and there is also separate evidence showing that increased sulfatide levels could potentially have a beneficial effect against coronavirus infection. Therefore, the claim that fenofibrate increasing the amount of sulfatide seems beneficial against covid-19 can be supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000027",
    "statement": "Fenofibrate reduces the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that Fenofibrate reduces the amount of sulfatide which seems beneficial against covid-19. While the evidence mentions that treatment with agents like fenofibrate increases sulfatide levels, this does not imply a reduction in sulfatide will be beneficial against COVID-19. The mechanism by which these substances affect coronavirus infection is not clear.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000028",
    "statement": "Fenofibrate reduced the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that Fenofibrate is an agent that increases sulfatide levels and its potential beneficial effect against coronavirus infection should be investigated. This implies a possible reduction in the amount of sulfatide with Fenofibrate treatment could have a positive impact on COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000029",
    "statement": "Fenofibrate decreased the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that treating a population with fenofibrate increases sulfatide levels and should be investigated for a beneficial effect against coronavirus infection. Therefore, the claim that fenofibrate decreased the amount of sulfatide is incorrect but implies that reducing sulfatide levels may be beneficial against COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000030",
    "statement": "Gns561 exhibits potent in vitro antiviral activity against sars-cov-2 through autophagy inhibition",
    "label": "SUPPORTED",
    "evidences": [
      "Overall, our study highlights GNS561 as a powerful drug in SARS- CoV-2 infection and supports that the hypothesis that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.",
      "Our data indicated that GNS561 showed the highest antiviral effect for two SARS-CoV-2 strains compared to CQ and remdesivir.",
      "Finally, our study revealed that the combination of GNS561 and remdesivir was associated with a strong synergistic antiviral effect against SARS-CoV-2.",
      "Here, we investigated the antiviral activity and associated mechanism of GNS561, a small basic lipophilic molecule inhibitor of late-stage autophagy, against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the study conducted on GNS561 indicates potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition, as it shows the highest antiviral effect compared to other drugs (CQ and remdesivir) tested. Additionally, the study reveals that the combination of GNS561 and remdesivir has a strong synergistic antiviral effect against SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000031",
    "statement": "Gns561 exhibits no in vitro antiviral activity against sars-cov-2 through autophagy inhibition",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall, our study highlights GNS561 as a powerful drug in SARS- CoV-2 infection and supports that the hypothesis that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.",
      "Our data indicated that GNS561 showed the highest antiviral effect for two SARS-CoV-2 strains compared to CQ and remdesivir.",
      "Finally, our study revealed that the combination of GNS561 and remdesivir was associated with a strong synergistic antiviral effect against SARS-CoV-2.",
      "Here, we investigated the antiviral activity and associated mechanism of GNS561, a small basic lipophilic molecule inhibitor of late-stage autophagy, against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes the antiviral effects of GNS561 against SARS-CoV-2 and suggests that it has a stronger effect than chloroquine (CQ) and remdesivir. However, the evidence does not directly support or refute the claim that GNS561 exhibits no in vitro antiviral activity against sars-cov-2 through autophagy inhibition, as it only mentions an investigation of the mechanism of GNS561 without specifically stating whether it acts via autophagy inhibition.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000032",
    "statement": "Suspicions grow that nanoparticles in pfizer 's covid-19 vaccine trigger rare allergic reactions.",
    "label": "SUPPORTED",
    "evidences": [
      "Severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech over the past 2 weeks may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccines main ingredient, scientists say.",
      "Patients with severe allergies in the US are getting nervous about the possibility that they may not be able to get vaccinated, at least with those two vaccines, Togias wrote in an invitation to meeting participants.",
      "Some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.",
      "NIAID is also setting up a study in collaboration with FDA to analyze the response to the vaccine in people who have high levels of anti-PEG antibodies or have experienced severe allergic responses to drugs or vaccines before."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there are reports of allergy-like reactions in individuals who received the Pfizer-BioNTech COVID-19 vaccine and it mentions the potential culprit as a compound in the packaging of the vaccine's main ingredient, which is PEG. Additionally, experts are setting up a study to analyze the response to the vaccine in people with high levels of anti-PEG antibodies or those who have experienced severe allergic reactions before.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000033",
    "statement": "Suspicions grow that nanoparticles in pfizer's covid-19 vaccine trigger systemic allergic reactions.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech over the past 2 weeks may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccines main ingredient, scientists say.",
      "Patients with severe allergies in the US are getting nervous about the possibility that they may not be able to get vaccinated, at least with those two vaccines, Togias wrote in an invitation to meeting participants.",
      "Some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.",
      "NIAID is also setting up a study in collaboration with FDA to analyze the response to the vaccine in people who have high levels of anti-PEG antibodies or have experienced severe allergic responses to drugs or vaccines before."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there are reports of severe allergy-like reactions in individuals who received the Pfizer-BioNTech COVID-19 vaccine. These reactions may be due to a compound called PEG (polyethylene glycol) found in the packaging of the mRNA in the vaccines. Some allergists and immunologists believe that people previously exposed to PEG might have high levels of antibodies against it, potentially putting them at risk of an anaphylactic reaction to the vaccine.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000034",
    "statement": "Berberine and obatoclax inhibit sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides data demonstrating the effectiveness of berberine and obatoclax in inhibiting SARS-CoV-2 replication in primary human nasal epithelial cells. The study mentions that both compounds were effective against multiple isolates of SARS-CoV-2, and they directly show that both berberine and obatoclax inhibited SARS-CoV-2 replication in these primary target cells.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000035",
    "statement": "Berberine and obatoclax induce sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the study demonstrates berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells. This directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000036",
    "statement": "Berberine and obatoclax induced sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that Berberine and obatoclax induced SARS-CoV-2 replication in primary human nasal epithelial cells in vitro. The evidence provided presents a study demonstrating that both compounds are effective against multiple isolates of SARS-CoV-2 and inhibited its replication in these specific target cells.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000037",
    "statement": "Berberine and obatoclax are sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that Berberine and Obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells in vitro. The evidence provided from the study demonstrates that both compounds are effective against multiple isolates of SARS-CoV-2 and specifically mention that they inhibited SARS-CoV-2 replication in these primary target cells.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000038",
    "statement": "Taiwan completes synthesis of potential covid-19 drug",
    "label": "SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Taiwan has completed synthesis of a potential COVID-19 drug. While it is confirmed that the center mentioned (DCB) was able to synthesize the drug in four days and aims to transfer the process for mass production, there is no direct evidence provided in the statement to suggest that this drug is indeed a potential treatment or cure for COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000039",
    "statement": "Taiwan inhibits synthesis of potential covid-19 drug",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not show that Taiwan inhibits the synthesis of the potential Covid-19 drug. Instead, it indicates that a center in Taiwan is able to synthesize the drug for mass production. However, without additional context about what other parties might be involved or responsible for preventing the production or distribution of this drug, it cannot be definitively concluded that Taiwan is actively blocking its synthesis.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000040",
    "statement": "Taiwan requires synthesis of potential covid-19 drug",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Taiwan has synthesized a potential COVID-19 drug. While the evidence indicates that DCB President Herbert Wu claimed they could synthesize the drug in four days and aims to transfer the process to domestic companies for mass production, it does not necessarily mean that Taiwan has already synthesized the drug. The claim would be supported if the drug has been proven effective against COVID-19 and is being used to fight the epidemic in Taiwan.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000041",
    "statement": "25-hydroxyvitamin d concentrations are lower in patients with positive pcr for sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents a study that found significantly lower 25-hydroxyvitamin D levels in PCR-positive for SARS-CoV-2 patients compared with negative patients. This suggests that 25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000042",
    "statement": "25-hydroxyvitamin d concentrations are elevated in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented in the study 'Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort' indicates that there is a significant difference in 25-hydroxyvitamin D concentrations between patients with a positive PCR for SARS-CoV-2 (median value of 11.1 ng/mL) and those with a negative PCR (median value of 24.6 ng/mL). This suggests that elevated 25-hydroxyvitamin D concentrations are not common in patients with positive PCR for SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000043",
    "statement": "25-hydroxyvitamin d concentrations are increased in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented in the study shows that significantly lower 25(OH)D levels were found in PCR-positive for SARS-CoV-2 patients compared with negative patients (p = 0.004). This indicates an increase in 25-hydroxyvitamin D concentrations in patients with positive PCR for SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000044",
    "statement": "25-hydroxyvitamin d concentrations are higher in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the median value of 25-hydroxyvitamin D concentrations was significantly lower (11.1 ng/mL) in patients with a positive PCR for SARS-CoV-2 compared to negative patients (24.6 ng/mL). The study also controlled for age >70 years and found the same trend, indicating higher 25-hydroxyvitamin D concentrations in negative patients.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000045",
    "statement": "Us racial inequality may be as deadly as covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that racial inequality may be as deadly as Covid-19. It cites a study which indicates that to raise mortality rates comparable to those caused by racial inequality, Covid-19 would need to erase several decades of mortality progress for whites. This suggests that there is evidence supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000046",
    "statement": "Us racial inequality may be as useful as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not directly supported by the provided evidence. While the evidence suggests that racial inequality can have a significant impact on mortality rates (comparable to Covid-19), it does not establish that racial inequality itself may be as deadly as the virus. The comparison between the two is speculative and requires further context and supporting evidence.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000047",
    "statement": "Us racial inequality may be as effective as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim compares the impact of racial inequality on mortality to that of Covid-19. The evidence provided suggests that racial inequality has a significant effect on mortality rates, as it would need to erase decades of progress for Whites to match Covid-19's mortality rate. While this comparison is not directly stating that racial inequality causes death, it does imply that the negative effects of racial inequality are substantial and deadly in a similar way to the virus.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000048",
    "statement": "Us racial transmission may be as deadly as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that racial inequality may have a similar impact on mortality as COVID-19. Specifically, the evidence states that to cause the same level of mortality increase as racial inequality does, COVID-19 would need to erase decades of progress in White mortality rates. This implies that the claim is supported.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000049",
    "statement": "Immunity to covid-19 is probably higher than tests have shown",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided in the form of a research study that indicates higher levels of T-cell immunity to COVID-19 than antibody tests have suggested.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000050",
    "statement": "Immunity to covid-19 is probably less than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that 'immunity to covid-19 is probably less than tests have shown.' However, the provided evidence indicates just the opposite - that immunity might be significantly higher than antibody tests have suggested.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000051",
    "statement": "Immunity to covid-19 is probably lower than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that the number of people with T-cell immunity to COVID-19 may be higher than the number of antibody positives. However, it does not provide enough information to make a definitive claim that immunity is probably lower than tests have shown.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000052",
    "statement": "Immunity to covid-19 is probably smaller than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about the size of immunity to COVID-19 being smaller than tests have shown. However, the evidence provided indicates that public immunity to COVID-19 might be significantly higher than antibody tests have suggested due to T-cell immunity in individuals with no verified COVID-19 or asymptomatic family members.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000053",
    "statement": "A novel in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is fully supported by the provided evidence which describes a novel assay for quantifying SARS-CoV-2 that can be used to analyze neutralizing antibodies and antiviral compounds. The evidence states this assay (icELISA) allows rapid and automated quantification of virus infection in cell culture, specifically mentioning its ability to evaluate the efficacy of NAbs and antiviral drugs.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000054",
    "statement": "A standard in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided, which describes a novel assay (icELISA) for rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000055",
    "statement": "A conventional in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a conventional in-cell ELISA assay can be used to rapidly and automatically quantify SARS-CoV-2, specifically for analyzing neutralizing antibodies and antiviral compounds. The passages mention the establishment of such an assay (icELISA) and its ability to evaluate the efficacy of NAbs and antiviral drugs in most routine diagnostics departments.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000056",
    "statement": "A simple in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a novel assay called SARS-CoV-2 icELISA that allows rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds. This directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000057",
    "statement": "Stanford professor balaji s. srinivasan 's peer review of the santa clara seroprevalence study indicates that its high reported positive rate results may be explained by the false positive rate of the test and/or by sample recruitment issues .",
    "label": "SUPPORTED",
    "evidences": [
      "The use of such certificates may therefore increase the risks of continued transmission. One of the most well-known attempts to justify sending workers back to offices and factories based on a supposed antibody count comes from the controversial Santa Clara study, as it has come to be known.",
      "The Stanford researchers acknowledged as much in the study and used test performance weights to scale results, but Rutherford was skeptical of these weights, as well as the population weights the researchers used.",
      "In a peer review of the antibody study published to Medium, former Stanford lecturer Balaji Srinivasan, who specializes in statistics and computational biology, argued the selection methods could have overstated the prevalence of the disease in the county.",
      "Dr. Natalie E. Dean, a professor of biostatistics at the University of Florida, tweeted that she had concerns with the adjustments made for clustering (some participants brought children and other household members with them to the test) and test characteristics (researchers assume no false positives but some false negatives)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that Stanford professor Balaji Srinivasan, who specializes in statistics and computational biology, did peer review the Santa Clara seroprevalence study and expressed concerns about potential sample recruitment issues and false positive rates of the test. The claim is supported by this evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000058",
    "statement": "Stanford professor balaji s. srinivasan's peer review of the santa clara seroprevalence study indicates that its high reported positive rate results cannot be explained by the false positive rate of the test and/or by sample recruitment issues.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The use of such certificates may therefore increase the risks of continued transmission. One of the most well-known attempts to justify sending workers back to offices and factories based on a supposed antibody count comes from the controversial Santa Clara study, as it has come to be known.",
      "The Stanford researchers acknowledged as much in the study and used test performance weights to scale results, but Rutherford was skeptical of these weights, as well as the population weights the researchers used.",
      "In a peer review of the antibody study published to Medium, former Stanford lecturer Balaji Srinivasan, who specializes in statistics and computational biology, argued the selection methods could have overstated the prevalence of the disease in the county.",
      "Dr. Natalie E. Dean, a professor of biostatistics at the University of Florida, tweeted that she had concerns with the adjustments made for clustering (some participants brought children and other household members with them to the test) and test characteristics (researchers assume no false positives but some false negatives)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that Balaji Srinivasan's peer review of the Santa Clara seroprevalence study indicates that its high reported positive rate results cannot be explained by the false positive rate of the test and/or by sample recruitment issues. However, the evidence provided does not directly support this statement. Instead, it shows concerns about the adjustments made for clustering and test characteristics in the study, expressed by Dr. Natalie E. Dean, but does not indicate that these are the reasons why Srinivasan believes the high positive rate cannot be explained. Additionally, the evidence does not confirm Srinivasan's specific position on false positives or sample recruitment issues.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000059",
    "statement": "Fda takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly states that the FDA has issued an emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine. This action is a key step in the fight against COVID-19 and can be considered as the first COVID-19 vaccine being authorized.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000060",
    "statement": "Sars takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that Sars (implied to be the World Health Organization's Strategic Advisory Group of Experts on Immunization) takes key action in the fight against Covid-19 by issuing emergency use authorization for a Covid-19 vaccine. The evidence provided, though not directly mentioning Sars, indicates that the FDA (Food and Drug Administration), an organization under the U.S. government, has authorized the Pfizer-BioNTech COVID-19 Vaccine for emergency use in the U.S., which is a key action to combat Covid-19 pandemic. Since Sars and FDA are closely related in their mission, it can be reasonably assumed that Sars played a role similar to the FDA by authorizing the vaccine.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000061",
    "statement": "China takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence is about the emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine in the United States, but it does not mention or imply that China has taken key action in fight against covid-19 by issuing an emergency use authorization for a covid-19 vaccine.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000062",
    "statement": "Who takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the FDA (Food and Drug Administration) issued the emergency use authorization for the first COVID-19 vaccine, specifically the Pfizer-BioNTech COVID-19 Vaccine. Thus, we can conclude that Stephen M. Hahn, who is the FDA Commissioner at the time of the event, takes key action in the fight against covid-19 by issuing this emergency use authorization.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000063",
    "statement": "Sherlock biosciences receives fda emergency use authorization for crispr sars-cov-2 rapid diagnostic",
    "label": "SUPPORTED",
    "evidences": [
      "In addition to SHERLOCK, the company is also developing its INSPECTR platform to create an instrument-free, handheld test  similar to that of an at-home pregnancy test  that utilizes Sherlock Biosciences Synthetic Biology platform to provide rapid detection of a genetic match of the SARS-CoV-2 virus.",
      "Cambridge, Mass., May 7, 2020  Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19, providing results in approximately one hour."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Sherlock biosciences receives fda emergency use authorization for crispr sars-cov-2 rapid diagnostic' is fully supported by the provided evidence. The text states that Sherlock Biosciences has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit, which is a diagnostic test for COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000064",
    "statement": "Sherlock biosciences receives no emergency use authorization for crispr sars-cov-2 rapid diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition to SHERLOCK, the company is also developing its INSPECTR platform to create an instrument-free, handheld test  similar to that of an at-home pregnancy test  that utilizes Sherlock Biosciences Synthetic Biology platform to provide rapid detection of a genetic match of the SARS-CoV-2 virus.",
      "Cambridge, Mass., May 7, 2020  Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19, providing results in approximately one hour."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Sherlock Biosciences received Emergency Use Authorization (EUA) from the FDA for its Sherlock CRISPR SARS-CoV-2 kit. The claim suggests that they do not receive EUA, which contradicts the information provided.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000065",
    "statement": "Lipoic acid helps response in g6pd population",
    "label": "SUPPORTED",
    "evidences": [
      "Α-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that A-lipoic acid supplementation helps to up-regulate antioxidant capacity in adults with G6PD deficiency. As such, it supports the claim that Lipoic acid helps response in a G6PD population.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000066",
    "statement": "Lipoic acid helps degradation in g6pd population",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Α-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency. This suggests that A-lipoic acid may help in the degradation or management of conditions related to G6PD deficiency due to its antioxidant effects.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000067",
    "statement": "Lipoic acid stress response in g6pd population",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Α-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that A-lipoic acid supplementation enhances the antioxidant capacity in individuals with G6PD deficiency. Therefore, it can be inferred that this is a lipoic acid stress response in the G6PD population.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000068",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan",
    "label": "SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that iota-carrageenan has demonstrated IC50 values similar to SARS-CoV-2 in vitro and has clinical effectiveness against common cold caused by various respiratory viruses. The in vitro data for SARS-CoV-2 specifically suggests that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000069",
    "statement": "Sars-cov-2 in-vitro neutralization assay blocked inhibition of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that 'Sars-cov-2 in-vitro neutralization assay blocked inhibition of virus entry by iota-carrageenan'. The evidence supports this by showing that iota-carrageenan has demonstrated similar IC50 values and clinical effectiveness against various Rhino- and Coronaviruses, and the reduction in symptoms of common cold caused by these viruses. Additionally, the evidence suggests that iota-carrageenan may be effective and safe as prophylaxis or treatment for SARS-CoV-2 infections.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000070",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals induction of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the effectiveness of iota-carrageenan against various respiratory viruses (including Rhino- and Coronaviruses) in vitro, but it does not directly prove or disprove that Sars-cov-2 is induced by iota-carrageenan through virus entry. While the evidence suggests a reduction in severity and duration of symptoms caused by respiratory viruses following iota-carrageenan administration, more specific evidence is needed to make a definitive claim about SARS-CoV-2 and iota-carrageenan interaction.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000071",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals enhancement of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions that an 'in vitro neutralization assay' of Sars-cov-2 showed enhancement of virus entry by iota-carrageenan. However, the provided evidence does not directly address this specific aspect. Instead, it states that iota-carrageenan has shown effectiveness in reducing symptoms caused by various respiratory viruses in a clinical setting and suggests that it may be effective for SARS-CoV-2 infections based on 'in vitro data on SSPL'. While the evidence supports the potential efficacy of iota-carrageenan against SARS-CoV-2, it does not directly support the enhancement claim made in the original statement.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000072",
    "statement": "Two thirds of people contacted through tracing did not fully cooperate , pilot scheme finds",
    "label": "SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states 'Two thirds of people contacted through tracing did not fully cooperate, pilot scheme finds'. The evidence provides statistics from the Sheffield Community Contact Tracers team's report that 39 out of 60 contacts (two thirds) did not provide their names and details, which implies they did not fully cooperate.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000073",
    "statement": "Two thirds of people contacted through tracing did indeed fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states 'Two thirds of people contacted through tracing did not fully cooperate.' The evidence provides the number (39 out of 60) of contacts who were unable or unwilling to give their names and details, which implies they did not fully cooperate. Additionally, the report mentions that many of these uncooperative individuals worked in health and care settings.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000074",
    "statement": "Two thirds of people contacted through tracing did it fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that two thirds of the contacts traced in the pilot scheme did not fully cooperate.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000075",
    "statement": "Two thirds of people contacted through tracing did still fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that two-thirds of contacts were unable or unwilling to give their names and details, but it does not explicitly mention whether they 'fully cooperated' with the tracing scheme as described in the claim.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000076",
    "statement": "The inhaled corticosteroid ciclesonide blocks coronavirus rna replication by targeting viral nsp15",
    "label": "SUPPORTED",
    "evidences": [
      "Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus.",
      "After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics.",
      "These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence demonstrates that ciclesonide suppresses human coronavirus replication in cultured cells, and a resistant mutation was generated in NSP15 after the eleventh consecutive MERS-CoV passage in the presence of ciclesonide. However, the evidence does not directly show that ciclesonide blocks coronavirus RNA replication by targeting viral nsp15.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000077",
    "statement": "The inhaled corticosteroid ciclesonide support coronavirus rna replication by targeting viral nsp15",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus.",
      "After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics.",
      "These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that ciclesonide suppresses human coronavirus replication in cultured cells but does not affect the replication of other viruses like respiratory syncytial virus or influenza virus. Additionally, after the eleventh passage of MERS-CoV in the presence of ciclesonide, a resistant mutation was generated specifically in the nonstructural protein 15 (NSP15) of the coronavirus. This suggests that ciclesonide may target viral NSP15, which is specific to coronaviruses. Therefore, it can be inferred that ciclesonide supports coronavirus RNA replication by targeting viral nsp15.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000078",
    "statement": "The us doesnt have enough hospital beds for a bad coronavirus outbreak",
    "label": "SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that the US does not have enough hospital beds for a bad coronavirus outbreak. The evidence indicates that doctors warned earlier in the outbreak about possible supply shortages of crucial medical supplies and potential overwhelm of emergency rooms during a larger coronavirus outbreak. Additionally, New York Governor Cuomo warns that the US will not have enough hospital beds for the coronavirus pandemic. This suggests that the lack of hospital beds is a concern due to the possibility of a large-scale outbreak.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000079",
    "statement": "The usset have enough hospital beds for a bad coronavirus outbreak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests that there is a potential for hospital bed shortages during a larger outbreak of the coronavirus in the U.S., as warned by officials such as New York Governor Cuomo. However, it does not provide any concrete information about the number of hospital beds currently available or whether they would be sufficient to handle a bad coronavirus outbreak.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000080",
    "statement": "The usert have enough hospital beds for a bad coronavirus outbreak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about the specific user having enough hospital beds for a bad coronavirus outbreak, but the provided evidence only mentions that there might be a shortage of hospital beds across the U.S., not regarding a specific user.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000081",
    "statement": "Oncogen researchers propose personalized vaccinomics strategy for the novel china coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "The candidate peptides were designed by applying to viral antigens a technology used for personalized vaccination in cancer, based on long neoantigen peptides, currently in clinical trials for cancer therapy.",
      "Technical details of the approach used are detailed below: We identified multiepitope peptide vaccine candidates against nCov that can potentially trigger both CD4+ and CD8+ T cell immune response.",
      "The approach that we used for designing potential peptide vaccine candidates takes a more personalized strategy, referred to as vaccinomics , which enables the selection of target viral proteins with low mutation rates, and the design of peptides tuned to the immune characteristics of the target populations, variable based on geographic location and ethnicity.",
      "Based on the human MHC (human leukocyte antigen) allele variation, the peptide vaccines can be made more relevant to a community or individual.",
      "The selection of the peptides that could act as vaccines is determined by the binding of the processed viral peptide with the major histocompatibility complex (MHC) class I and II molecules, and the relevant HLA alleles."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a proposal for a personalized vaccinomics strategy using peptides designed against viral antigens of the novel coronavirus (nCoV). This strategy is based on long neoantigen peptides that are currently being used in cancer therapy and are in clinical trials. The approach also mentions selecting target proteins with low mutation rates and designing peptides tuned to the immune characteristics of the population, which suggests a more personalized strategy. The method of selection is based on the binding of the processed viral peptide with major histocompatibility complex (MHC) class I and II molecules, and relevant HLA alleles. All these elements indicate that the claim is supported.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000082",
    "statement": "Oncogen researchers propose personalized vaccinomics strategy for the traditional china coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The candidate peptides were designed by applying to viral antigens a technology used for personalized vaccination in cancer, based on long neoantigen peptides, currently in clinical trials for cancer therapy.",
      "Technical details of the approach used are detailed below: We identified multiepitope peptide vaccine candidates against nCov that can potentially trigger both CD4+ and CD8+ T cell immune response.",
      "The approach that we used for designing potential peptide vaccine candidates takes a more personalized strategy, referred to as vaccinomics , which enables the selection of target viral proteins with low mutation rates, and the design of peptides tuned to the immune characteristics of the target populations, variable based on geographic location and ethnicity.",
      "Based on the human MHC (human leukocyte antigen) allele variation, the peptide vaccines can be made more relevant to a community or individual.",
      "The selection of the peptides that could act as vaccines is determined by the binding of the processed viral peptide with the major histocompatibility complex (MHC) class I and II molecules, and the relevant HLA alleles."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear details of a research strategy to design personalized peptide vaccines against nCov using a technology similar to that used in cancer immunotherapy. The approach they mention is called 'vaccinomics' and it is designed based on the immune characteristics of the target population, which could be interpreted as 'traditional China coronavirus' given the context.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000083",
    "statement": "Mathematical analysis of córdoba calcifediol trial suggests strong role for vitamin d in reducing icu admissions of hospitalized covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).",
      "Finally, comparison with two additional randomized clinical trials of vitamin D supplementation for COVID-19 in India and Brazil indicates that early intervention and rapid absorption may be crucial for the observed benefits of vitamin D. We conclude that the Córdoba study provides sufficient evidence to warrant immediate, well-designed pivotal clinical trials of early calcifediol administration in a broader cohort of inpatients and outpatients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions a mathematical analysis of the Córdoba calcifediol trial suggesting a strong role for vitamin D in reducing ICU admissions of hospitalized COVID-19 patients. However, no specific data or results are presented from this analysis to support this claim directly. The evidence relies on indirect comparisons with two additional randomized clinical trials of vitamin D supplementation for COVID-19 in India and Brazil.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000084",
    "statement": "Mathematical analysis of córdoba calcifediol trial suggests strong role against vitamin d in reducing icu admissions of hospitalized covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).",
      "Finally, comparison with two additional randomized clinical trials of vitamin D supplementation for COVID-19 in India and Brazil indicates that early intervention and rapid absorption may be crucial for the observed benefits of vitamin D. We conclude that the Córdoba study provides sufficient evidence to warrant immediate, well-designed pivotal clinical trials of early calcifediol administration in a broader cohort of inpatients and outpatients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that mathematical analysis of the cordoba calcifediol trial suggests a strong role against vitamin D in reducing ICU admissions of hospitalized COVID-19 patients. The evidence refers to a study's registration, comparison with other trials, and conclusion that the study warrants further investigation. However, it does not contain any data analysis or specific results that show a relationship between calcifediol administration and reduced ICU admissions.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000085",
    "statement": "Artificial intelligence model detects asymptomatic covid-19 infections through cellphone-recorded coughs",
    "label": "SUPPORTED",
    "evidences": [
      "New AI model detects asymptomatic Covid-19 infections through device-recorded coughs Vocal sentiments Prior to the pandemics onset, research groups already had been training algorithms on cellphone recordings of coughs to accurately diagnose conditions such as pneumonia and asthma.",
      "The model identified 98.5 percent of coughs from people confirmed with Covid-19, and of those, it accurately detected all of the asymptomatic coughs.",
      "When they fed the model new cough recordings, it accurately identified 98.5 percent of coughs from people who were confirmed to have Covid-19, including 100 percent of coughs from asymptomatics  who reported they did not have symptoms but had tested positive for the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a new AI model has been trained to accurately diagnose Covid-19 infections through cellphone-recorded coughs. It's also mentioned that the model was able to identify 100% of asymptomatic cases. This suggests strong support for the claim.",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000086",
    "statement": "Artificial intelligence model cannots asymptomatic covid-19 infections through cellphone-recorded coughs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "New AI model detects asymptomatic Covid-19 infections through device-recorded coughs Vocal sentiments Prior to the pandemics onset, research groups already had been training algorithms on cellphone recordings of coughs to accurately diagnose conditions such as pneumonia and asthma.",
      "The model identified 98.5 percent of coughs from people confirmed with Covid-19, and of those, it accurately detected all of the asymptomatic coughs.",
      "When they fed the model new cough recordings, it accurately identified 98.5 percent of coughs from people who were confirmed to have Covid-19, including 100 percent of coughs from asymptomatics  who reported they did not have symptoms but had tested positive for the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a new AI model has been trained to accurately diagnose Covid-19 through device-recorded coughs. The model was able to identify 98.5% of coughs from people confirmed with Covid-19, and all of these identified cases included asymptomatic individuals. This supports the claim that the AI model can detect asymptomatic Covid-19 infections through cellphone-recorded coughs.",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000087",
    "statement": "Stanford researchers test 3,200 people for covid-19 antibodies",
    "label": "SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the use of antibody tests in a Stanford study and their requirement for a fingerstick of blood to test for IgM and IgG antibodies. However, it does not indicate that 3,200 people were actually tested by these researchers.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000088",
    "statement": "Stanford researchers test 3,6 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Stanford researchers tested 3,6 people for COVID-19 antibodies. However, the evidence provided only states that the tests used in a study at Stanford require blood from a fingerstick and test for IgM and IgG antibodies. The evidence does not indicate the number of individuals who were actually tested.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000089",
    "statement": "Stanford researchers test 3,5 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specify the number of people tested in the Stanford study. While the test method is mentioned, the number of participants is crucial to determine if the claim is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000090",
    "statement": "Stanford researchers test 3,3 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specify the number of people tested in the Stanford study. While it explains the type of tests used, it does not confirm or deny how many participants were involved.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000091",
    "statement": "State lab finds 90 positive covid-19 test results were false",
    "label": "SUPPORTED",
    "evidences": [
      "Of those, a total of 91 specimens from 90 people showed false positive results.",
      "The department said the state public health laboratory uncovered a flaw in one of the testing systems it uses to test for SARS-CoV-2, the virus that causes COVID-19, and 90 of 144 people tested between June 15 and July 17 received a false positive COVID test report.",
      "Accurate and timely testing for the novel coronavirus is one of the pillars supporting effective response to the COVID-19 pandemic. She said adjustments have already been made to ensure the accuracy of future test results from this platform. They said all positive results will be further analyzed by multiple laboratory scientists, and if indicated, retested using another method.",
      "The lab used another FDA-authorized test and found the false positives.",
      "Any nursing home resident who received a false positive COVID-19 test result will be retested as soon as possible, according to the Department of Health."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that out of the 144 tests conducted between June 15 and July 17, 90 tests returned false positive results for COVID-19. The lab then used another FDA-authorized test to confirm these results and found them to be false positives. This indicates that the state lab has identified an issue with one of their testing systems and is taking steps to rectify it.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000092",
    "statement": "State lab finds 90 positive covid-19 test results were+.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Of those, a total of 91 specimens from 90 people showed false positive results.",
      "The department said the state public health laboratory uncovered a flaw in one of the testing systems it uses to test for SARS-CoV-2, the virus that causes COVID-19, and 90 of 144 people tested between June 15 and July 17 received a false positive COVID test report.",
      "Accurate and timely testing for the novel coronavirus is one of the pillars supporting effective response to the COVID-19 pandemic. She said adjustments have already been made to ensure the accuracy of future test results from this platform. They said all positive results will be further analyzed by multiple laboratory scientists, and if indicated, retested using another method.",
      "The lab used another FDA-authorized test and found the false positives.",
      "Any nursing home resident who received a false positive COVID-19 test result will be retested as soon as possible, according to the Department of Health."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that 90 out of 144 test results were false positives for COVID-19 due to a flaw in the testing system used by the state public health laboratory. The lab has since corrected the issue and retested using another FDA-authorized test method.",
    "confidence": 0.98
  },
  {
    "id": "covid_fact-000093",
    "statement": "Different mutations in sars-cov-2 associate with severe and mild outcome",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly correlates specific mutations in the SARS-CoV-2 virus with different clinical outcomes (severe and mild), supporting the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000094",
    "statement": "Different mutations in sars-cov-2 associate against severe and mild outcome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides data correlating specific mutations in the SARS-CoV-2 virus with both mild and severe clinical outcomes. This indicates that different mutations in the virus indeed associate with varying severity of Covid-19 symptoms.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000095",
    "statement": "Both mutations in sars-cov-2 associate with severe and mild outcome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim that both mutations in sars-cov-2 associate with severe and mild outcomes. The paper identifies specific mutations associated with mild outcome (ORF8, NSP6, ORF3a, NSP4, and nucleocapsid phosphoprotein N) and severe outcome (surface glycoprotein, RNA dependent RNA polymerase, 3-to5 exonuclease, NSP2, NSP7, and in ORF3a and N again).",
    "confidence": 1
  },
  {
    "id": "covid_fact-000096",
    "statement": "Moderna advances late-stage development of its vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "11, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced progress on late-stage development of mRNA-1273, the Companys mRNA vaccine candidate against COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that Moderna is making progress on late-stage development of its mRNA-1273 vaccine candidate against COVID-19, indicating that it is indeed in the advanced stages of developing a vaccine for Covid-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000097",
    "statement": "Moderna advances late-stage delivery of its vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "11, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced progress on late-stage development of mRNA-1273, the Companys mRNA vaccine candidate against COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions that Moderna is making progress on late-stage development of its mRNA-1273 vaccine against COVID-19, which indicates the claim is supported.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000098",
    "statement": "Mathematical modeling explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that there is a mathematical model suggesting differential kinetics of SARS CoV-2 in lung and nasal passages when treated with remdesivir in rhesus macaques. However, the evidence does not present concrete proof of this claim as it lacks data or results from the mathematical modeling to support the observation that remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000099",
    "statement": "Phylogenetic modeling explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests a mathematical model was used to explain differences in SARS-CoV-2 kinetics in the lung and nasal passages of remdesivir-treated rhesus macaques. However, it does not explicitly state that phylogenetic modeling was employed. Phylogenetic modeling is a specific technique used to infer evolutionary relationships among multiple species based on their DNA or protein sequences. While the evidence indicates a mathematical model was developed, the claim requires additional evidence confirming the use of phylogenetic modeling.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000100",
    "statement": "Mathematical depletion explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that a mathematical model explains differential SARS-CoV-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques. The provided evidence states the observations of increased viral loads in the nasal passages five days after therapy, but it does not provide any information about a mathematical model being used to explain these differences or the underlying mechanisms.",
    "confidence": 0.45
  },
  {
    "id": "covid_fact-000101",
    "statement": "Singapore , taiwan and hong kong have brought outbreaks under control",
    "label": "SUPPORTED",
    "evidences": [
      "Singapore and Taiwan were both seen as examples of how to handle the coronavirus outbreak: stanching the growth of infections, while largely keeping their economies open.",
      "The city, like Singapore and Taiwan, has made headway in containing Covid-19.Credit...Hannah Mckay/Reuters HONG KONG  While the spread of Covid-19 is picking up speed in Europe and the United States, among other regions, the outbreaks in some countries in Asia seem to be under control."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence as it mentions that Singapore and Taiwan have brought their outbreaks under control. The passage also includes Hong Kong among countries in Asia where the outbreak seems to be under control.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000102",
    "statement": "Singapore, taiwan and hong kong have no outbreaks under control",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Singapore and Taiwan were both seen as examples of how to handle the coronavirus outbreak: stanching the growth of infections, while largely keeping their economies open.",
      "The city, like Singapore and Taiwan, has made headway in containing Covid-19.Credit...Hannah Mckay/Reuters HONG KONG  While the spread of Covid-19 is picking up speed in Europe and the United States, among other regions, the outbreaks in some countries in Asia seem to be under control."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that Singapore, Taiwan, and Hong Kong have no outbreaks under control. The evidence provided suggests that the spread of Covid-19 in these countries seems to be under control compared to Europe and the United States. However, it does not explicitly state that there are currently no outbreaks, only that the spread of the virus is controlled.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000103",
    "statement": "Fda gives eua to saliva-based test kit",
    "label": "SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly states that the FDA has issued an Emergency Use Authorization (EUA) to Rutgers Clinical Genomics Laboratory for a COVID-19 test that allows self-collection of saliva samples. Additionally, it is mentioned that Yale School of Public Health submitted data with their EUA request, and the FDA determined that the test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000104",
    "statement": "Pcr gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the FDA has issued an Emergency Use Authorization (EUA) for a saliva-based COVID-19 test developed by Yale School of Public Health and Rutgers Clinical Genomics Laboratory. The EUA specifically mentions the use of a self-collection kit, implying that PCR testing is being used to analyze saliva samples.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000105",
    "statement": "Data gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions the FDA issuing an Emergency Use Authorization (EUA) to Rutgers Clinical Genomics Laboratory for a COVID-19 test that can use saliva samples self-collected by patients at home using a designated device. The claim is that data gives EUA to a saliva-based test kit, and the evidence supports this as it directly states the FDA gave an EUA for a saliva-based test.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000106",
    "statement": "Table gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that an emergency use authorization (EUA) has been issued by the FDA for a saliva-based test kit developed by Rutgers Clinical Genomics Laboratory. The EUA specifically mentions the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device as being used for self-collection of samples at home. Additionally, it is stated that Yale School of Public Health submitted data to support the emergency authorization request and the FDA determined that the test meets criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus causing COVID-19 infection.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000107",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but not associated with protection",
    "label": "SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that while antibodies to seasonal human coronaviruses (hCoVs) are boosted upon SARS-CoV-2 infection, they are not associated with protection against SARS-CoV-2 infections or hospitalizations. This is supported by the statement that these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection but were not associated with protection.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000108",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but also associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that humans had been previously exposed to other common human coronaviruses (hCoVs) before the COVID-19 pandemic and these antibodies were boosted upon SARS-CoV-2 infection. However, the evidence does not explicitly state or provide sufficient proof that these seasonal hCoV antibodies are associated with protection against SARS-CoV-2 infections or hospitalizations.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000109",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but are associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infection does boost seasonal human coronavirus antibodies (hCoV), but it does not explicitly support the claim that these antibodies are associated with protection against SARS-CoV-2 infections or hospitalizations. Instead, the evidence suggests a paradoxical outcome where hCoV cross-reactive antibodies are boosted upon SARS-CoV-2 infection without providing protection.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000110",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but strongly associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection and strongly associated with protection. However, the evidence provided suggests that these antibodies were boosted but were not associated with protection against SARS-CoV-2 infections or hospitalizations.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000111",
    "statement": "Preliminary results of nationwide representative screening are out",
    "label": "SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that 'Preliminary results of nationwide representative screening are out'. However, the provided evidence only mentions that the first nationwide representative screening's final results will be released at the end of May. It does not specify if preliminary results have already been gathered or released.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000112",
    "statement": "Preliminary results of nationwide representative screening are!",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions that the preliminary results will be released at the end of May and gives a description of who these results include. However, it does not provide any data or specific findings from the screening itself to support or contradict the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000113",
    "statement": "Preliminary results of nationwide representative screening are?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that the final results of a nationwide representative screening will be released at the end of May, but it does not provide any preliminary results.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000114",
    "statement": "Preliminary results of nationwide representative screening are\".",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim 'Preliminary results of nationwide representative screening are' is not directly supported by the given evidence as it only states when the final results will be released, and does not mention any preliminary results.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000115",
    "statement": "New self-administered coronavirus test found effective",
    "label": "SUPPORTED",
    "evidences": [
      "Self-administered COVID-19 coronavirus can be just as effective as physician- administered tests, according to a new study by UnitedHealth Group.",
      "Researchers found that self-administered swab tests accurately detected the disease in more than 90 percent of positive patients, which is consistent with physician-administered tests.",
      "Among 500 OptumCare patients in Washington state, the self-administered swabs were able to accurately detect the coronavirus that causes COVID-19 in 90% of those who are positive, a rate that's consistent with physician-administered swabs, the insurance giant announced.",
      "A new study found that self-administered tests may be as effective as those conducted by healthcare workers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided from the study by UnitedHealth Group indicates that self-administered COVID-19 tests are found to be as effective as physician-administered tests, with a consistent accuracy rate of 90% among positive patients.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000116",
    "statement": "No self-administered coronavirus test found effective",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Self-administered COVID-19 coronavirus can be just as effective as physician- administered tests, according to a new study by UnitedHealth Group.",
      "Researchers found that self-administered swab tests accurately detected the disease in more than 90 percent of positive patients, which is consistent with physician-administered tests.",
      "Among 500 OptumCare patients in Washington state, the self-administered swabs were able to accurately detect the coronavirus that causes COVID-19 in 90% of those who are positive, a rate that's consistent with physician-administered swabs, the insurance giant announced.",
      "A new study found that self-administered tests may be as effective as those conducted by healthcare workers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the claim states that a study found self-administered COVID-19 tests to be just as effective (more than 90% accuracy) as physician-administered tests. This matches with the definition of 'effective' when referring to medical testing, which implies the ability to produce accurate results.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000117",
    "statement": "Electrostatic spraying will prevent the spread of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions that electrostatic spraying can improve coverage of disinfectant on surfaces and reduce wastage, but it does not explicitly state or imply that this method prevents the spread of COVID-19. While proper sanitation is essential for reducing the risk of spreading COVID-19, more research would be needed to confirm that electrostatic spraying specifically has a proven effect on preventing the virus's transmission.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000118",
    "statement": "Electrostatic spraying will facilitate the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses the benefits of electrostatic spraying for improving coverage and reducing wastage of disinfectants. However, it does not mention anything about facilitating the spread of COVID-19. To properly evaluate this claim, we would need evidence showing a direct link between the use of electrostatic spraying and an increased risk or transmission of SARS-CoV-2 (the virus responsible for COVID-19).",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000119",
    "statement": "Electrostatic spraying will enhance the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state or imply that electrostatic spraying enhances the spread of COVID-19. Instead, it suggests that this method may improve coverage and reduce wastage of disinfectant. However, without additional information on how electrostatic spraying affects the survival and transmission of SARS-CoV-2 (the virus causing COVID-19), we cannot definitively conclude anything about its impact on the spread of the disease.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000120",
    "statement": "Electrostatic spraying will promote the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions that electrostatic spraying can improve coverage of disinfectant on surfaces and reduce wastage. It does not mention anything about promoting the spread of COVID-19. To evaluate this claim properly, one would need information regarding any specific studies or experiments demonstrating a link between electrostatic spraying and increased transmission of SARS-CoV-2, the virus that causes COVID-19.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000121",
    "statement": "Scientists trace severe covid-19 to faulty genes and autoimmune condition",
    "label": "SUPPORTED",
    "evidences": [
      "These findings provide compelling evidence that the disruption of type I interferon is often the cause of life-threatening COVID-19, says Jean-Laurent Casanova, head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University and a Howard Hughes Medical Institute investigator.",
      "COVID-19 may now be the best understood acute infectious disease in terms of having a molecular and genetic explanation for nearly 15 percent of critical cases across diverse ancestries, Casanova says.",
      "Genetics of COVID-19 outliers The way SARS-CoV-2 affects people differently has been puzzling.",
      "Science Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Zhang Q. et al.",
      "Whether the proteins have been neutralized by so-called auto- antibodies, or were not produced in sufficient amounts in the first place due to a faulty gene, their missing-in-action appears to be a common theme among a subgroup of COVID-19 sufferers whose disease has thus far been a mystery."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that a subgroup of severe COVID-19 patients have genetic conditions or autoimmune issues that disrupt type I interferon, which is crucial for the body's response to viral infections like COVID-19. This correlation between genetics and severe COVID-19 outcomes is supported by the findings presented in the study 'Genetics of COVID-19 outliers.'",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000122",
    "statement": "Mice trace severe covid-19 to faulty genes and autoimmune condition",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These findings provide compelling evidence that the disruption of type I interferon is often the cause of life-threatening COVID-19, says Jean-Laurent Casanova, head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University and a Howard Hughes Medical Institute investigator.",
      "COVID-19 may now be the best understood acute infectious disease in terms of having a molecular and genetic explanation for nearly 15 percent of critical cases across diverse ancestries, Casanova says.",
      "Genetics of COVID-19 outliers The way SARS-CoV-2 affects people differently has been puzzling.",
      "Science Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Zhang Q. et al.",
      "Whether the proteins have been neutralized by so-called auto- antibodies, or were not produced in sufficient amounts in the first place due to a faulty gene, their missing-in-action appears to be a common theme among a subgroup of COVID-19 sufferers whose disease has thus far been a mystery."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides compelling evidence that genetic factors and autoimmune conditions play a significant role in severe COVID-19 cases for about 15% of patients across diverse ancestries, as stated by Jean-Laurent Casanova. The evidence also suggests that the disruption of type I interferon is often the cause of life-threatening COVID-19, which aligns with the claim that mice tracing severe COVID-19 to faulty genes and autoimmune conditions is supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000123",
    "statement": "Uv-emitting led lights found to kill coronavirus efficiently and cheaply.",
    "label": "SUPPORTED",
    "evidences": [
      "In a recent study, researchers found that UV light-emitting diodes (LEDs) can quickly and effectively kill the human coronavirus HCoV-OC43.",
      "A new study suggests the novel coronavirus can be killed cheaply and efficiently by ultraviolet light-emitting diodes (UV-LEDs).",
      "LED lights found to kill coronavirus efficiently, quickly, and cheaply ",
      "\"We discovered that it is quite simple to kill the coronavirus using LED bulbs that radiate ultraviolet light.",
      "In the study, the researchers found a range of wavelengths at which UV-LEDs effectively kill coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that a recent study has shown that UV-emitting LED lights can efficiently and quickly kill human coronaviruses, including the novel coronavirus. The claim is supported by the findings of this study.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000124",
    "statement": "Uv-emitting bat lights found to kill coronavirus efficiently and cheaply.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a recent study, researchers found that UV light-emitting diodes (LEDs) can quickly and effectively kill the human coronavirus HCoV-OC43.",
      "A new study suggests the novel coronavirus can be killed cheaply and efficiently by ultraviolet light-emitting diodes (UV-LEDs).",
      "LED lights found to kill coronavirus efficiently, quickly, and cheaply ",
      "\"We discovered that it is quite simple to kill the coronavirus using LED bulbs that radiate ultraviolet light.",
      "In the study, the researchers found a range of wavelengths at which UV-LEDs effectively kill coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it shows that a study found UV-emitting diodes (LEDs) can effectively kill coronaviruses. The study specifically mentions human coronavirus HCoV-OC43 and suggests the same method could be effective for other coronaviruses, including SARS-CoV-2 which is the novel coronavirus causing COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000125",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol for covid-19 outpatients in saudi arabia",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents a conclusion that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting within the recommended protocol and criteria is safe, highly tolerable, and has minimum side effects.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000126",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol of covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented in this study concludes that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting is safe, highly tolerable, and with minimum side effects. The conclusion aligns with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000127",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol included covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided concludes that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting is safe and highly tolerable with minimum side effects. This directly supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000128",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol is covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the conclusion of a study reports that hydroxychloroquine is safe, highly tolerable, and has minimum side effects when used for COVID-19 patients in mild to moderate cases in an outpatient setting. The study mentions that this result was achieved by adhering to the recommended protocol and inclusion/exclusion criteria.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000129",
    "statement": "Covid-19 coronavirus spike holds infectivity details",
    "label": "SUPPORTED",
    "evidences": [
      "As a whole, details contained in the results reported in this weeks paper may help to explain the efficiency of the new coronavirus in delivering its viral code into human cells, and its rapid transmission among people.",
      "This finding might help account for the efficient spread of the new coronavirus between people.",
      "The spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia are divulging how they attach, fuse and gain entry to cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the Covid-19 coronavirus spikes contain details about how they attach, fuse, and gain entry into human cells. This information could help explain the virus's efficiency in delivering its viral code into human cells and its rapid transmission among people.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000130",
    "statement": "Covid-19 coronavirus genomes holds infectivity details",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "As a whole, details contained in the results reported in this weeks paper may help to explain the efficiency of the new coronavirus in delivering its viral code into human cells, and its rapid transmission among people.",
      "This finding might help account for the efficient spread of the new coronavirus between people.",
      "The spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia are divulging how they attach, fuse and gain entry to cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides details about the coronavirus genome and how it interacts with human cells, which can be considered as infectivity details.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000131",
    "statement": "We had the covid-19 vaccine the whole time",
    "label": "SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence suggests that a similar technology platform is used for influenza vaccines and Covid-19 vaccines, it does not provide sufficient information to confirm or deny the claim that we 'had the covid-19 vaccine the whole time.' The statement implies prior development and storage of a specific vaccine for Covid-19 before it emerged, which is not supported by the evidence provided.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000132",
    "statement": "We had the covid-19 vaccine the next time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states 'We had the covid-19 vaccine the next time.' However, the evidence provided discusses the process of developing vaccines using a technology platform and having them ready before new viruses emerge, but it does not indicate that such a vaccine was already available for COVID-19 at the time. The safety of the Moderna vaccine is also mentioned, but this doesn't imply that it had been developed for COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000133",
    "statement": "We had the covid-19 vaccine the following time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the use of a similar technology platform to other influenza vaccines and states that the vaccine development process would ideally be completed before a new virus emerges. However, it does not explicitly state when the covid-19 vaccine was developed or made available.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000134",
    "statement": "We had the covid-19 vaccine the second time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence suggests a general understanding of how vaccine development and technology work, it does not directly support the claim that 'We had the covid-19 vaccine the second time'. The given text mentions the safety of the Moderna vaccine, but it does not indicate whether a specific covid-19 vaccine was already available before the current pandemic.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000135",
    "statement": "Quantitative assays reveal cell fusion at minimal levels of sars-cov-2 spike protein and fusion-from-without",
    "label": "SUPPORTED",
    "evidences": [
      "Cell-cell fusion, in contrast, was only moderately inhibited despite requiring much lower levels of S protein, which were below the detection limit of flow cytometry and Western blot."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions that cell-cell fusion was 'moderately inhibited' at levels of S protein 'below the detection limit', but it does not explicitly state or imply that there is cell fusion at minimal levels of sars-cov-2 spike protein and fusion-from-without.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000136",
    "statement": "Quantitative assays reveal no fusion at minimal levels of sars-cov-2 spike protein and fusion-from-without",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cell-cell fusion, in contrast, was only moderately inhibited despite requiring much lower levels of S protein, which were below the detection limit of flow cytometry and Western blot."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or refute the claim about no fusion at minimal levels of SARS-CoV-2 spike protein and fusion-from-without. Instead, it suggests that cell-cell fusion was only moderately inhibited at lower levels of S protein, which were below the detection limit of flow cytometry and Western blot. The claim requires experimental evidence showing no fusion occurring at the minimal level specified.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000137",
    "statement": "Weekly national flu and covid-19 surveillance reports published",
    "label": "SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that weekly national flu and COVID-19 surveillance reports are being published, as the data presented refers to hospital admission rates for COVID-19 in different NHS regions and mentions an increase in COVID-19 hospital and critical care admission rates.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000138",
    "statement": "Weekly national flu and covid-19 pandemic reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not indicate that there are weekly national flu and COVID-19 pandemic reports published. The evidence only discusses hospital admission rates for COVID-19 in NHS regions and increasing COVID-19 hospital and critical care admission rates.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000139",
    "statement": "Weekly national flu and covid-19 epidemic reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does mention COVID-19 hospital admission rates, but it does not directly support the claim about weekly national flu and covid-19 epidemic reports being published. The evidence focuses on regional trends for COVID-19 hospital admissions.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000140",
    "statement": "Weekly national flu and covid-19 infection reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that weekly national flu and Covid-19 infection reports are published. The statement only mentions hospital admission rates for COVID-19 in a specific region (North West) and an increase in Covid-19 admissions without any reference to a weekly publication of infection reports.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000141",
    "statement": "Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors",
    "label": "SUPPORTED",
    "evidences": [
      "Furthermore, the HCV replication complexes may hide the viral RNA from recognition by host sensors (43)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. The evidence provided mentions that HCV replication complexes hide the viral RNA from recognition by host sensors (43). This implies that the virus has a mechanism for avoiding detection, which could include targeting specific sequences on its RNA as mentioned in the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000142",
    "statement": "Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host defense",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Furthermore, the HCV replication complexes may hide the viral RNA from recognition by host sensors (43)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about the Coronavirus endoribonuclease and its action on viral polyuridine sequences to evade host defense. The evidence provided discusses how HCV replication complexes may hide the viral RNA from recognition by host sensors, but it does not directly support or refute the claim about coronavirus and polyuridine sequences.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000143",
    "statement": "The spike glycoprotein of the new coronavirus 2019-ncov contains a furin-like cleavage site absent in cov of the same clade .",
    "label": "SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B βCoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear information that the spike glycoprotein of the new coronavirus 2019-ncov contains a furin-like cleavage site, which is absent in other SARS-like CoVs such as SARS-CoV. This aligns with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000144",
    "statement": "The spike glycoprotein of the new coronavirus a-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B βCoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that a furin-like cleavage site (FCS) is present in the spike protein of the new coronavirus a-ncov, which is not found in other SARS-like CoVs of the same clade. This supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000145",
    "statement": "The spike glycoprotein of the new coronavirus s-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B βCoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that there is a furin-like cleavage site in the Spike protein of the new coronavirus (2019-nCoV), which is absent in other SARS-like CoVs. This suggests that the spike glycoprotein of the new coronavirus contains a unique furin-like cleavage site.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000146",
    "statement": "The spike glycoprotein of the new coronavirus e-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B βCoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that a furin-like cleavage site is present in the spike protein of the new coronavirus (2019-nCoV), but absent in other SARS-like CoVs such as SARS-CoV. This difference suggests that the new coronavirus might have a unique property contributing to its high infectivity and transmissibility.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000147",
    "statement": "Breakthrough covid-19 antibody test with nearly 100 % accuracy can help reopen economy",
    "label": "SUPPORTED",
    "evidences": [
      "Scientists said Friday they found the test can determine if someone had COVID-19 with nearly 100% accuracy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that scientists have claimed a new covid-19 antibody test can determine if someone had COVID-19 with nearly 100% accuracy. This directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000148",
    "statement": "Breakthrough covid-19 antibody test with nearly 100 % accuracy cannot help reopen economy",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Scientists said Friday they found the test can determine if someone had COVID-19 with nearly 100% accuracy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that a highly accurate covid-19 antibody test cannot help reopen the economy. However, the provided evidence only states that scientists have found a test with nearly 100% accuracy for detecting COVID-19, not its implications on helping reopen the economy.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000149",
    "statement": "Pyridoxal 5'-phosphate to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNFα, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that Pyridoxal 5'-phosphate (PLP) may help mitigate immune dysregulation and coagulopathy in COVID-19. The evidence provided mentions that pharmacological doses of PLP can alleviate the immune suppression underlying viral spread, decrease circulating TNFα, IL-6 (inflammatory cytokines), and D-dimer (a marker of coagulopathy), and shorten the duration and severity of viral pneumonia. Additionally, animal studies support this effect on viral pneumonia. This evidence supports the claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000150",
    "statement": "Pyridoxal 5'- inability to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNFα, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that Pyridoxal 5'- (Vitamin B6) may help mitigate immune dysregulation and coagulopathy in COVID-19 by alleviating inflammatory cytokines, improving endothelial integrity, and preventing hypercoagulability. The evidence mentions pharmacological doses of PLP decreasing circulating TNFα, IL-6, and D-dimer (markers for inflammation and coagulation) and shows that supplemental PLP can shorten the duration and severity of viral pneumonia in animal studies.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000151",
    "statement": "Pyridoxal 5'-phosphate to mitigate cardiac dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNFα, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that Pyridoxal 5'-phosphate (PLP) can mitigate cardiac dysregulation and coagulopathy in COVID-19. The evidence provided indicates that PLP supplementation may alleviate the immune suppression underlying viral spread, pathological hypersecretion of inflammatory cytokines, bolster endothelial integrity, and prevent hypercoagulability – all conditions related to cardiac dysregulation and coagulopathy in COVID-19. The evidence also mentions that animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia, which is a common complication in COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000152",
    "statement": "Pyridoxal 5'-c to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNFα, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that Pyridoxal 5'-c (PLP) may help mitigate symptoms of COVID-19 by alleviating immune dysregulation and coagulopathy. This is supported by the fact that in inflammatory disease, PLP decreases circulating TNFα, IL-6 and D-dimer levels, which are markers of inflammation and coagulopathy. Additionally, animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia. While this evidence does not directly prove a causal relationship between PLP supplementation and improved COVID-19 outcomes in humans, it provides a biological rationale for further investigation.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000153",
    "statement": "Antibodies in infants born to mothers with covid-19 pneumonia",
    "label": "SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a study titled 'Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic.' The presence of the term 'transplacental antibody transfer' suggests that antibodies can be transferred from the mother to the infant during pregnancy. Since COVID-19 is caused by SARS-CoV-2, and the evidence is about SARS-CoV-2 during pregnancy, it implies that these are antibodies for COVID-19 pneumonia in infants born to mothers with COVID-19 pneumonia.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000154",
    "statement": "Antibodies in women born to mothers with covid-19 pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is a study titled 'Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic.' While it discusses antibodies (transplacentally transferred), it does not directly confirm or deny that women born to mothers with COVID-19 pneumonia have these antibodies. Further research or data is required to definitively answer this claim.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000155",
    "statement": "Mortality in infants born to mothers with covid-19 pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence is a study title regarding SARS-CoV-2 viral load, transplacental antibody transfer, and placental pathology in pregnancies during the COVID-19 pandemic. While it suggests that mothers with COVID-19 pneumonia may give birth to infants, it does not provide enough information about the mortality rate of these infants to support or refute the claim.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000156",
    "statement": "Aggregated mobility data could help fight covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that aggregated mobility data can provide near real-time information about changes in human movement patterns, which could be useful for refining interventions aimed at controlling the spread of infectious diseases such as COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000157",
    "statement": "Aggregated mobility data could not fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that aggregated mobility data can help refine interventions during a crisis like COVID-19 by offering near real-time information about changes in human movement patterns. However, it does not explicitly state or imply that this data cannot fight the virus itself.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000158",
    "statement": "Aggregated mobility data could help generate covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that aggregated mobility data could help 'generate' Covid-19. However, the provided evidence does not support this claim as it only discusses how aggregated mobility data can refine interventions for containing the spread of Covid-19 by providing information about changes in human movement.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000159",
    "statement": "Aggregated mobility data could help study covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that aggregated mobility data could indeed help study COVID-19 by providing near real-time information about changes in patterns of human movement, which might assist in refining interventions related to the pandemic.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000160",
    "statement": "Preliminary evidence that higher temperatures are associated with lower incidence of covid-19 , for cases reported globally up to 29th february 2020",
    "label": "SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1°C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim asserts that preliminary evidence suggests higher temperatures are associated with lower incidence of Covid-19 based on data up to February 29th, 2020. The evidence provided shows an analysis using global line-list data on COVID-19 cases and gridded temperature data, which suggests this association exists for temperatures of 1°C and higher after adjusting for surveillance capacity and time since the first imported case. However, it's important to note that temperature only explained a modest portion of the variation in Covid-19 incidence.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000161",
    "statement": "Preliminary evidence that lower temperatures are associated with lower incidence of covid-19, for cases reported globally up to 29th february 2020",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1°C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows an association between lower temperatures and lower incidence of COVID-19 cases. This is based on the analysis of global data until February 29th, 2020, after adjusting for surveillance capacity and time since first imported case. However, it's important to note that the explained variation in COVID-19 incidence due to temperature was modest.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000162",
    "statement": "Preliminary evidence that low temperatures are associated with lower incidence of covid-19, for cases reported globally up to 29th february 2020",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1°C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a higher average temperature is associated with a lower incidence of COVID-19 for temperatures 1°C and higher. This finding is based on global line-list data on COVID-19 cases reported until 29th February 2020, after adjusting for surveillance capacity and time since first imported case. The claim that low temperatures are associated with lower incidence of COVID-19 is supported by this evidence.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000163",
    "statement": "The fda weighs its first coronavirus vaccine",
    "label": "SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided in the link suggests that Moderna's vaccine has a strong protective effect against COVID-19, but it does not provide clear information on whether or not the FDA has weighed (i.e., evaluated) this specific vaccine. The claim needs direct evidence to confirm or refute it.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-000164",
    "statement": "The fda weighs its new coronavirus vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not explicitly state or imply that the FDA weighs its new coronavirus vaccine. The article discusses the results of the Moderna COVID-19 vaccine trial and mentions that the FDA is expected to grant approval soon. However, it does not provide information about how the FDA evaluates vaccines.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000165",
    "statement": "The fda weighs its sars coronavirus vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the effectiveness of a vaccine against SARS-CoV-2 (Covid-19) developed by Moderna and not the process or methodology by which the FDA weighs vaccines.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000166",
    "statement": "High incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided consists of multiple studies that investigate the incidence of venous thromboembolic events (VTE) in hospitalized COVID-19 patients, both non-ICU and critically ill ICU patients. This suggests a higher risk of VTE in anticoagulated severe COVID-19 patients.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000167",
    "statement": "Low incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence refers to the incidence of venous thromboembolism (VTE) in hospitalized and critically ill COVID-19 patients. However, it does not provide information about the rate of VTE in anticoagulated severe COVID-19 patients, which is the claim being made.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000168",
    "statement": "Median incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not explicitly state the median incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. While the evidence discusses the incidence of venous thromboembolism in hospitalized COVID-19 patients and critically ill ICU patients with COVID-19, it does not specify whether these patients were anticoagulated or the severity of their condition.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000169",
    "statement": "Average incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about the average incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. The provided evidence does not directly provide this information, but instead refers to various studies on the rate and incidence of venous thromboembolism in hospitalized COVID-19 patients and critically ill ICU patients with COVID-19. To support the claim, it would be necessary to find evidence that provides specific data on the average incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000170",
    "statement": "Epa proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the EPA proposed broad science restrictions during the coronavirus pandemic. However, the provided evidence only mentions the EPA's Science Advisory Board's criticism of a potential policy change regarding the use of science in decision-making, but it does not explicitly connect this to the coronavirus pandemic. Furthermore, the evidence discusses the scope of the proposed changes to science usage, but it does not state that these restrictions were proposed during the pandemic.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000171",
    "statement": "Epa proposes broad science support in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not support the claim that EPA proposes broad science support in midst of coronavirus pandemic. Instead, it indicates that concerns have been raised about a proposed policy change by the EPA, which could potentially limit the types of scientific studies considered when making decisions about vehicle emissions, clean air standards, and clean water protections, among other things. However, there is no mention or suggestion that this proposed policy directly relates to the coronavirus pandemic.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000172",
    "statement": "Cdc proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence indicates that the EPA's Science Advisory Board expressed concerns about potential politicization of science and the impact on decision-making processes, and describes broad science restrictions that would affect various types of studies and assessments within the EPA. However, there is no clear indication in this evidence that these restrictions are specifically being proposed 'in midst of coronavirus pandemic'. Therefore, it cannot be conclusively determined if the claim is supported.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000173",
    "statement": "Who proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that anyone 'proposes broad science restrictions' during the coronavirus pandemic. The information in the evidence pertains to a proposal by the EPA regarding certain studies, but it does not specify who is proposing this or whether it relates to the coronavirus pandemic.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000174",
    "statement": "Moderna provides covid-19 vaccine supply update.",
    "label": "SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions a 'covid-19 vaccine supply update', but the provided evidence does not contain any specific information regarding vaccine supply or updates about it.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000175",
    "statement": "Cdca provides covid-19 vaccine supply update.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the development and manufacturing process of the Moderna COVID-19 vaccine but does not directly provide information about any updates related to the supply or distribution of the vaccine by Cdca (Centers for Disease Control and Prevention).",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000176",
    "statement": "Wa provides covid-19 vaccine supply update.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that 'Wa' provides a covid-19 vaccine supply update, but the provided evidence only discusses the development and characteristics of the Moderna COVID-19 Vaccine by Moderna and NIAID, without any mention or implication of 'Wa' being involved in this process.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000177",
    "statement": "Engineered ace2 receptor traps potently neutralize sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that engineered ace2 receptor traps have been shown to neutralize sars-cov-2 effectively, with results comparable to high-affinity antibodies isolated from convalescent patients. The structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor further supports this claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000178",
    "statement": "Engineered ace2 receptor cannot potently neutralize sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence demonstrates that engineered ace2 receptors can effectively neutralize SARS-CoV-2 infections. However, the claim states 'cannot potently neutralize', which contradicts the information presented. In order to verify this claim, it is necessary to find additional evidence that shows engineered ace2 receptors have limited ability or insufficient efficacy in neutralizing SARS-CoV-2.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000179",
    "statement": "Recombinant ace2 receptor traps potently neutralize sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that mutations in ACE2 receptor (a protein that SARS-CoV-2 binds to enter cells) can enhance the neutralization of SARS-CoV-2 by an engineered ACE2 receptor trap. This implies that the recombinant ace2 receptor traps do potently neutralize sars-cov-2. Additionally, the statement states that these engineered ACE2 receptor traps are as effective as high-affinity antibodies isolated from convalescent patients in neutralizing SARS-CoV-2, further supporting the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000180",
    "statement": "Professional and home-made face masks reduce exposure to respiratory infections among the general population",
    "label": "SUPPORTED",
    "evidences": [
      "Face- masks worn by the general population could be an accessible and affordable intervention, if effective when worn under routine circumstances.",
      "Conclusions/significance: Any type of general mask use is likely to decrease viral exposure and infection risk on a population level, in spite of imperfect fit and imperfect adherence, personal respirators providing most protection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that face masks, both professional and homemade, can reduce exposure to respiratory infections among the general population by decreasing viral exposure and infection risk on a population level, even with imperfect fit and adherence. This claim is supported by studies demonstrating the effectiveness of mask-wearing in reducing the transmission of infectious diseases.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000181",
    "statement": "Genomic epidemiology of a densely sampled covid19 outbreak in china",
    "label": "SUPPORTED",
    "evidences": [
      "With few exceptions, genomic epidemiological analysis has focused on geographically distributed data sets with few isolates in any given location.",
      "Here we report an analysis of 20 whole SARS-CoV 2 genomes from a single relatively small and geographically constrained outbreak in Weifang, People's Republic of China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that genomic epidemiology of a densely sampled COVID-19 outbreak in China was reported. The evidence provides 20 whole SARS-CoV-2 genomes from a single relatively small and geographically constrained outbreak in Weifang, People's Republic of China. This suggests that a genomic epidemiological analysis was conducted on this specific outbreak, which supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000182",
    "statement": "Genomic epidemiology of a randomly sampled covid19 outbreak in china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With few exceptions, genomic epidemiological analysis has focused on geographically distributed data sets with few isolates in any given location.",
      "Here we report an analysis of 20 whole SARS-CoV 2 genomes from a single relatively small and geographically constrained outbreak in Weifang, People's Republic of China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that a genomic epidemiology analysis has been conducted on a single, relatively small and geographically constrained COVID-19 outbreak in Weifang, China. Thus, the claim is supported by the evidence.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000183",
    "statement": "Large sars-cov-2 outbreak caused by asymptomatic traveler , china",
    "label": "SUPPORTED",
    "evidences": [
      "Timeline of exposure and connections between cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among persons in Heilongjiang Province, China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided outlines a timeline of SARS-CoV-2 cases in Heilongjiang Province, China. However, it does not explicitly state or imply that the outbreak was caused by an asymptomatic traveler.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000184",
    "statement": "One sars-cov-2 outbreak caused by asymptomatic traveler, china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Timeline of exposure and connections between cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among persons in Heilongjiang Province, China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is a timeline of cases of SARS-CoV-2 in Heilongjiang Province, China. It does not explicitly state that one outbreak was caused by an asymptomatic traveler. While it is possible for such an event to have occurred within the timeline, the claim requires additional supporting evidence linking a specific case or cases to travel and asymptomatic status.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000185",
    "statement": "More than 80 clinical trials launch to test coronavirus treatments",
    "label": "SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that there are 'dozens' of clinical trials listed in the Chinese Clinical Trial Registry, which implies a significant number greater than one trial. Given that dozens is typically interpreted as more than twenty but less than a hundred, it supports the claim that more than 80 clinical trials may have launched to test coronavirus treatments.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000186",
    "statement": "less than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that there are ongoing clinical trials for coronavirus treatments in China, but it does not specify the exact number of these trials, nor does it claim them to be less than 80. Therefore, it is not possible to confirm or deny the claim based on this evidence.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000187",
    "statement": "fewer than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only states that there are 'dozens' of clinical trials for coronavirus treatments on the Chinese Clinical Trial Registry. It does not specify the exact number of trials launched, which is necessary to evaluate the claim.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000188",
    "statement": "younger than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim asserts that there are clinical trials launched to test coronavirus treatments where the subjects are younger than 80. The evidence shows the Chinese Clinical Trial Registry lists dozens of controlled trials on existing therapies and experimental procedures for treating coronavirus, but it does not state the age range of subjects. However, since clinical trials often involve a broad range of participants, it is reasonable to infer that some of these trials may include individuals younger than 80.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000189",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in mice.",
    "label": "SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the Ferritin nanoparticle based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice. The evidence provided shows that an efficient antibody response was induced which lasted for at least 7 months post immunization and significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge, which supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000190",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in humans.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that the vaccine induces an efficient antibody response in mice for at least 7 months post-immunization and generates a significant number of memory B cells with a high recall response upon antigen challenge. However, this study was conducted on mice, not humans, so it does not directly prove the claim about the human response.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000191",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in rabbits.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the ferritin nanoparticle based SARS-CoV-2 RBD vaccine induces an antibody response in mice that lasts for at least 7 months post immunization and produces a significantly higher number of memory B cells. Additionally, it mentions a significant higher level of recall response upon antigen challenge. These findings suggest persistent antibody response and long-term memory, which align with the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000192",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine cans persistent antibody response and long-term memory in mice.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Ferritin nanoparticle based SARS-CoV-2 RBD vaccine can induce persistent antibody response and long-term memory in mice' is supported by the provided evidence. The study shows that the ferritin nanoparticle-based COVID-19 vaccine induced an efficient antibody response which lasted for at least 7 months post-immunization, significantly higher numbers of memory B cells were maintained, and a higher level of recall response was induced upon antigen challenge.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000193",
    "statement": "Hydroxychloroquine fails to prevent covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented shows a large randomized, controlled trial that found no benefit of hydroxychloroquine in preventing people developing COVID-19 with a 14-day treatment course. The results were presented at IDWeek 2020 and indicate that those who took hydroxychloroquine were just as likely to get COVID-19 as those who received a placebo.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000194",
    "statement": "Hydroxychloroquine remains to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that a study has shown hydroxychloroquine to be ineffective as a preventative measure for COVID-19 when used with a 14-day treatment course. This contradicts the claim that it remains effective for preventing COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000195",
    "statement": "Hydroxychloroquine appears to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that hydroxychloroquine offers no benefit in preventing COVID-19 with a 14-day treatment course and indicates this conclusion is based on a large randomized, controlled trial. Therefore, the claim 'Hydroxychloroquine appears to prevent covid-19' is not supported by the provided evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000196",
    "statement": "Hydroxychloroquine is to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that hydroxychloroquine does not offer a benefit in preventing COVID-19 with a 14-day treatment course. However, the claim does not specify whether it is for treating or preventing COVID-19.",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000197",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a narrow bottleneck.",
    "label": "SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the transmission of SARS-CoV-2 in domestic cats is characterized by a narrow bottleneck, with new infections arising from fewer than ten viruses. This suggests that there are limits to the spread of the virus within this species, which supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000198",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a global bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided focuses on the narrow bottleneck of SARS-CoV-2 transmission in cats, but it does not explicitly state or imply that this impacts global transmission. The claim needs more information to confirm or deny its validity, such as discussing the significance of the bottleneck in the context of overall global transmission dynamics.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000199",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a major bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the transmission of SARS-CoV-2 in domestic cats is through a narrow bottleneck, with fewer than ten viruses being involved. This supports the claim that the transmission of SARS-CoV-2 in domestic cats imposes a major bottleneck.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000200",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a common bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the transmission of SARS-CoV-2 in cats is founded by fewer than ten viruses and the bottleneck involved is narrow. This implies a common bottleneck in the transmission of SARS-CoV-2 in domestic cats.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000201",
    "statement": "California state epidemiologist statement recommending providers pause administration of single lot of moderna covid-19 vaccine.",
    "label": "SUPPORTED",
    "evidences": [
      "California state epidemiologist Dr. Erica Pan issued a statement Sunday recommending providers pause the administration of lot 041L20A of the Moderna COVID-19 vaccine due to possible allergic reactions that are being investigated.",
      "Updated: 10:06 PM PST Jan 18, 2021 KCRA Staff UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials sayORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions.",
      "SACRAMENTO, Calif. -- UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials say Advertisement ORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that California's top epidemiologist Dr. Erica Pan recommended providers to pause the administration of lot 041L20A of Moderna COVID-19 vaccine due to possible allergic reactions. The updated statement further confirms that the pause was lifted, but initially it was in place.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000202",
    "statement": "California state epidemiologist statement recommending providers include administration of single lot of moderna covid-19 vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "California state epidemiologist Dr. Erica Pan issued a statement Sunday recommending providers pause the administration of lot 041L20A of the Moderna COVID-19 vaccine due to possible allergic reactions that are being investigated.",
      "Updated: 10:06 PM PST Jan 18, 2021 KCRA Staff UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials sayORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions.",
      "SACRAMENTO, Calif. -- UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials say Advertisement ORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that California's top epidemiologist Dr. Erica Pan has recommended providers to pause the administration of a specific lot (041L20A) of Moderna COVID-19 vaccine due to possible allergic reactions. This suggests that she is recommending the inclusion of a single lot of Moderna vaccine, but not necessarily its administration.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000203",
    "statement": "Baricitinib restrains the immune dysregulation in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that baricitinib, a JAK1/JAK2 inhibitor, has been shown to correct immune abnormalities observed in patients hospitalized with COVID-19. This implies it may restrain the immune dysregulation associated with the disease.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000204",
    "statement": "Uncitinib restrains the immune dysregulation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting immune abnormalities observed in COVID-19 patients. However, it does not directly support the claim about Uncitinib having the same effect.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-000205",
    "statement": "Excitinib restrains the immune dysregulation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that Excitinib restrains the immune dysregulation in Covid-19 patients. However, the evidence provided only discusses the efficacy of baricitinib (a JAK1/JAK2 inhibitor) in addressing the immune abnormalities observed in Covid-19 patients. Without explicit references or studies demonstrating Excitinib has similar effects, it cannot be confirmed that Excitinib restrains the immune dysregulation in Covid-19 patients.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000206",
    "statement": "Us covid-19 deaths poorly predicted by ihme model",
    "label": "SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that actual death rates in 70% of US states were outside the 95 percent prediction interval for those states, suggesting that the IHME model may have underestimated the uncertainty associated with COVID-19 deaths. This casts doubt on the model's ability to accurately predict US COVID-19 deaths.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000207",
    "statement": "Us covid-19 deaths as predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests that some states' actual death rates were outside the predicted range by the IHME model. However, it does not directly prove or disprove if the US COVID-19 deaths as predicted by the IHME model are supported. More specific data and analysis on the model's predictions for COVID-19 deaths would be required to determine this.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000208",
    "statement": "Us covid-19 deaths previously predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the IHME model for COVID-19 deaths has had difficulty in accurately predicting the actual death rate in 70% of US states and underestimates uncertainty. However, this does not conclusively prove whether the model previously predicted COVID-19 deaths or not as the evidence does not directly address this claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000209",
    "statement": "Us covid-19 deaths were predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that 'US Covid-19 deaths were predicted by IHME model'. Instead, it raises concerns about the accuracy of the predictions made by the IHME model for COVID-19 death rates in the United States, as 70% of states had an actual death rate outside the 95 percent prediction interval. This implies that the model may have been less accurate than intended. However, the evidence does not prove that the model did not predict Covid-19 deaths.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000210",
    "statement": "China 's changing coronavirus case count is not unusual in an outbreak , health official says",
    "label": "SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that China's changing coronavirus case count is not unusual in an outbreak, as supported by the quote from Sylvie Briand, WHO director of the infectious hazards management department. However, this statement does not provide any specific evidence about the 'normality' or 'unusualness' of changing case counts during an outbreak beyond suggesting that different methods of counting can be employed as an epidemic evolves. To fully support or refute the claim, more detailed information on how other countries handle case counting in similar situations would be required.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000211",
    "statement": "China's changing coronavirus case count is not available in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that China's changing coronavirus case count is not available in an outbreak, as stated by a health official. However, the provided evidence only states that there is confusion over how China is counting cases of infections and that this is making it harder to know how coronavirus is spreading. The evidence does not indicate that the case count is not available at all.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000212",
    "statement": "China's changing coronavirus case count is very unusual in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that China's changing coronavirus case count is 'very unusual in an outbreak.' The evidence indicates that there is confusion over how China is counting cases of infections, making it harder to know how the coronavirus is spreading. This contradicts the assertion that the change in case count is not unusual, supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000213",
    "statement": "China's changing coronavirus case count is particularly unusual in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence mentions Sylvie Briand of WHO stating that it's not unusual to count things in different ways as an epidemic evolves, this does not directly support or refute the claim that China's changing coronavirus case count is particularly unusual. More context is needed to confirm if the change in counting methods specifically refers to the coronavirus outbreak in China and whether it is indeed unusual compared to other outbreaks.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000214",
    "statement": "Results released for antibody and covid-19 testing of boston residents",
    "label": "SUPPORTED",
    "evidences": [
      "Mayor Martin J. Walsh, together with Massachusetts General Hospital (MGH), and the Boston Public Health Commission (BPHC), today announced the study to evaluate community exposure to COVID-19 through a representative sampling of asymptomatic Boston residents resulted in 9.9% testing positive for antibodies and 2.6% of currently asymptomatic individuals testing positive for COVID-19.",
      "In conclusion, approximately 1 in 10 residents in this study have developed antibodies and approximately 1 in 40 currently asymptomatic individuals are positive for COVID-19 and potentially infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided by Mayor Martin J. Walsh indicates a study of Boston residents resulted in approximately 1 in 10 (9.9%) testing positive for antibodies and about 1 in 40 currently asymptomatic individuals (2.6%) testing positive for COVID-19. This implies that the claim is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000215",
    "statement": "Results released for antibody and covid-19 production of boston residents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mayor Martin J. Walsh, together with Massachusetts General Hospital (MGH), and the Boston Public Health Commission (BPHC), today announced the study to evaluate community exposure to COVID-19 through a representative sampling of asymptomatic Boston residents resulted in 9.9% testing positive for antibodies and 2.6% of currently asymptomatic individuals testing positive for COVID-19.",
      "In conclusion, approximately 1 in 10 residents in this study have developed antibodies and approximately 1 in 40 currently asymptomatic individuals are positive for COVID-19 and potentially infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that a study evaluating community exposure to COVID-19 through a representative sampling of asymptomatic Boston residents found that 9.9% tested positive for antibodies and 2.6% of currently asymptomatic individuals tested positive for COVID-19. This indicates that the results released are related to antibody and COVID-19 production among Boston residents.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000216",
    "statement": "Vulnerable populations , such as older adults and those with underlying medical conditions , should wear face masks if available .",
    "label": "SUPPORTED",
    "evidences": [
      "Wearing a face covering can help to reduce the chance that those who may not know they are sick will spread the infection to others.",
      "Perhaps it would also be rational to recommend that people in quarantine wear face masks if they need to leave home for any reason, to prevent potential asymptomatic or presymptomatic transmission."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that vulnerable populations such as older adults and those with underlying medical conditions should wear face masks if available. The evidence suggests that wearing a face covering can help to reduce the chance of spreading infection from people who may not know they are sick. This supports the idea that wearing masks can protect others, which aligns with the claim when considering vulnerable populations.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000217",
    "statement": "Vulnerable populations, such as older adults and those with underlying medical conditions, not wear face masks if available.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wearing a face covering can help to reduce the chance that those who may not know they are sick will spread the infection to others.",
      "Perhaps it would also be rational to recommend that people in quarantine wear face masks if they need to leave home for any reason, to prevent potential asymptomatic or presymptomatic transmission."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that vulnerable populations should not wear face masks if available. However, the provided evidence supports the opposite - wearing a face covering can help to reduce the chance that those who may not know they are sick will spread the infection to others.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000218",
    "statement": "The differing immune system responses of patients with covid-19 can help predict who will experience moderate and severe consequences of disease , according to a new study",
    "label": "SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided presents tables showing differences in immune parameters between mild and severe COVID-19 cases, indicating differing immune system responses. Additionally, the claim states that these differences can help predict moderate and severe consequences of the disease, which aligns with findings in the study. Lastly, the claim suggests identifying high-risk individuals early in their hospitalization and potential treatment opportunities based on these differences, which is also consistent with the study.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000219",
    "statement": "The differing immune system responses of patients with covid-19 cannot help predict who will experience moderate and severe consequences of disease, according to a new study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence presents a new study suggesting that the differing immune system responses of Covid-19 patients may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19. However, the claim states that these differences cannot help predict who will experience moderate and severe consequences of disease, which contradicts the new study's findings.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000220",
    "statement": "The differing immune system responses of patients with covid-19 can help predict who will experience moderate and severe consequences of disease, according to a previous study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided presents tables showing differences in immune parameters between mild and severe COVID-19 cases. This implies that the differing immune system responses of patients with Covid-19 can potentially help predict the severity of disease. However, it's important to note that while this study suggests a potential link, more research would be needed to confirm it and establish its usefulness in clinical practice.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000221",
    "statement": "Father with motor neurone disease dies from coronavirus in uk",
    "label": "SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not confirm the death of a father with motor neurone disease from COVID-19 in the UK. It only states that a person named Craig Ruston was battling motor neurone disease, but no information about his demise is given or connected to COVID-19.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000222",
    "statement": "Father with motor neurone disease originated from coronavirus in uk",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not support the claim that a father with motor neurone disease originated from coronavirus in the UK. The evidence only states that Craig Ruston was battling motor neurone disease but does not provide any information about his health condition or origin related to COVID-19.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000223",
    "statement": "Father with motor neurone disease differs from coronavirus in uk",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not compare or contrast the characteristics of a father with motor neurone disease and coronavirus in the UK. To determine if they differ, additional information is required to understand what specific aspects are being compared.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000224",
    "statement": "Yale 's rapid covid-19 saliva test receives fda emergency use authorization",
    "label": "SUPPORTED",
    "evidences": [
      "Stat: FDA Clears Saliva Test For Covid-19, Opening Door To Wider Testing The Food and Drug Administration on Saturday authorized emergency use of a new and inexpensive saliva test for Covid-19 that could greatly expand testing capacity.",
      "A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.",
      "NEW HAVEN, Conn. \\- A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that the Food and Drug Administration (FDA) has granted an emergency use authorization to a new saliva-based laboratory diagnostic test for COVID-19 developed by researchers at Yale University's School of Public Health.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000225",
    "statement": "Yale's rapid covid-19 saliva test without fda emergency use authorization",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Stat: FDA Clears Saliva Test For Covid-19, Opening Door To Wider Testing The Food and Drug Administration on Saturday authorized emergency use of a new and inexpensive saliva test for Covid-19 that could greatly expand testing capacity.",
      "A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.",
      "NEW HAVEN, Conn. \\- A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly states that the Food and Drug Administration has granted an emergency use authorization for a saliva-based COVID-19 test developed by Yale University's School of Public Health. The test is not authorized without the FDA's approval.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000226",
    "statement": "The antiviral compound remdesivir potently inhibits rna-dependent rna polymerase from middle east respiratory syndrome coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.",
      "Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East Respiratory Syndrome Coronavirus' is supported by the evidence provided. The evidence states that remdesivir is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including MERS-CoV.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000227",
    "statement": "The antiviral compound remdesivir potently binds rna-dependent rna polymerase from middle east respiratory syndrome coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.",
      "Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that remdesivir is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including Middle East Respiratory Syndrome (MERS-CoV). This suggests that it binds the RNA-dependent RNA polymerase from MERS-CoV. The claim is therefore supported by the evidence.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000228",
    "statement": "Trials of oxford coronavirus vaccine begin in kenya",
    "label": "SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Kenya is one of the locations where the Oxford coronavirus vaccine trial is taking place, and it provides quotes from a professor involved in the trial confirming this. Additionally, the number of countries participating in the trials (including Kenya) and the number of volunteers across those countries are mentioned.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000229",
    "statement": "Lack of oxford coronavirus vaccine begin in kenya",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim mentions a trial of the Oxford coronavirus vaccine taking place in Kenya. The evidence provided confirms that necessary approvals have been granted for this trial to proceed with volunteers receiving their vaccinations in Kilifi County, Kenya. The trial is part of a larger study involving multiple countries including the United Kingdom, South Africa, and Brazil.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000230",
    "statement": "Trials of oxford coronavirus vaccine begin in great",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the trials of the Oxford coronavirus vaccine have begun in Kenya, as confirmed by the statement from Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000231",
    "statement": "Pandemic infection rates are deterministic but can not be modeled",
    "label": "SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that models of pandemic infection rates have limitations and are not perfect predictors. However, this does not mean that the infection rates themselves cannot be modeled, only that current models may fall short in their accuracy or prediction abilities. To support a claim that pandemic infection rates are inherently non-deterministic and unmodelable, more specific evidence showing that deterministic modeling is impossible under any circumstances would be required.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000232",
    "statement": "Pandemic infection rates are deterministic but can then be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that while infection rates can be calculated deterministically on a daily basis, they cannot be accurately modeled and predicted from fixed initial conditions or memories of past rates due to their unpredictable and rapidly changing nature. This is especially true near the peak of an epidemic.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000233",
    "statement": "Pandemic infection rates are deterministic but can therefore be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that while pandemic infection rates can be calculated deterministically on a daily basis (as seen in the statement 'infection rates can be calculated daily from the infections'), they cannot be accurately modeled and predicted with fixed initial conditions due to their complexity and unpredictable nature. This is further supported by the statement that models fail to reproduce observed infection rates. Therefore, the claim that pandemic infection rates are deterministic but can't be modeled is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000234",
    "statement": "Pandemic infection rates are deterministic but can also be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that while pandemic infection rates can be calculated daily (deterministic), they are difficult to predict using fixed initial conditions or models based on past rates. This is due to the dynamic and unpredictable nature of pandemics, especially near their peaks when a large number of factors come into play.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000235",
    "statement": "New coronavirus variant is identified in uk.",
    "label": "SUPPORTED",
    "evidences": [
      "England's Chief Medical Officer Prof Chris Whitty said current coronavirus swab tests would detect the new variant that has been found predominantly in Kent and neighbouring areas in recent weeks.",
      "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.",
      "It is thought the variant either emerged in a patient in the UK or has been imported from a country with a lower ability to monitor coronavirus mutations.",
      "A number of variants have already been detected in the UK.",
      "Matt Hancock said the new variant of coronavirus \"may be associated\" with the faster spread in the south-east of England."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a new coronavirus variant has been identified predominantly in Kent and neighboring areas in the UK. This is supported by statements from England's Chief Medical Officer Prof Chris Whitty, as well as Matt Hancock, who both acknowledge its existence. The variant is associated with faster spread in the south-east of England.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000236",
    "statement": "No coronavirus variant is identified in uk.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "England's Chief Medical Officer Prof Chris Whitty said current coronavirus swab tests would detect the new variant that has been found predominantly in Kent and neighbouring areas in recent weeks.",
      "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.",
      "It is thought the variant either emerged in a patient in the UK or has been imported from a country with a lower ability to monitor coronavirus mutations.",
      "A number of variants have already been detected in the UK.",
      "Matt Hancock said the new variant of coronavirus \"may be associated\" with the faster spread in the south-east of England."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does mention the detection of variants within the UK, but it does not state that no new variant is currently identified in the country.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000237",
    "statement": "The coronavirus has mutated and appears to be more contagious now , new study finds",
    "label": "SUPPORTED",
    "evidences": [
      "The coronavirus has mutated and May52020 COVID19 KEY POINTS: The coronavirus that emerged in Wuhan, China, has mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study.",
      "If the coronavirus doesnt subside in the summer like the seasonal flu, it could mutate further and potentially limit the effectiveness of the coronavirus vaccines being developed by scientists around the world, the researchers warned.",
      "The coronavirus that emerged in Wuhan, China, over four months ago has since mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that the coronavirus has mutated and the new dominant strain spreading across the U.S. appears to be more contagious. The study also warns that if the virus doesn't subside in the summer like seasonal flu, it could further mutate and potentially limit the effectiveness of the vaccines being developed.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000238",
    "statement": "The coronavirus has mutated and appears to be more contagious before, new study finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The coronavirus has mutated and May52020 COVID19 KEY POINTS: The coronavirus that emerged in Wuhan, China, has mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study.",
      "If the coronavirus doesnt subside in the summer like the seasonal flu, it could mutate further and potentially limit the effectiveness of the coronavirus vaccines being developed by scientists around the world, the researchers warned.",
      "The coronavirus that emerged in Wuhan, China, over four months ago has since mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence which states that the coronavirus has mutated and the new dominant strain spreading in the US appears to be more contagious.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000239",
    "statement": "Two known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that two therapies are potentially beneficial in treating COVID-19 patients critically ill, but it does not provide any specific data or results from clinical trials to support this claim. While the therapies may be recommended due to their potential benefits, further clinical research is required to confirm their efficacy as adjuvant therapy for critical COVID-19 patients.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000240",
    "statement": "Many known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions that two specific therapies could be useful for COVID-19 patients and that clinical trials are necessary. It does not provide sufficient data to conclude that 'many known therapies' have been found to be useful as adjuvant therapy in critical patients infected by COVID-19.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000241",
    "statement": "Several known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that certain therapies are useful as adjuvant therapy for critical COVID-19 patients. However, the evidence provided only recommends adding these therapies to the therapeutic arsenal without providing any specific data or results from clinical trials that support their efficacy.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000242",
    "statement": "All known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that all known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19. However, the provided evidence only suggests two specific therapies and recommends them for consideration. It does not provide evidence or reasoning that these are the only treatments nor that they will work on all patients, thus it does not confirm the claim.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-000243",
    "statement": "Protein structure and sequence reanalysis of 2019-ncov genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and hiv-1",
    "label": "SUPPORTED",
    "evidences": [
      "In this Communication, we first analyzed two recent studies that concluded that snakes are the intermediate hosts of 2019-nCoV and that the 2019-nCoV spike protein insertions share a unique similarity to HIV-1."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence mentions two studies that have concluded snakes as an intermediate host of 2019-nCoV and a similarity between its spike protein insertions and HIV-1, but it does not present any new data or analysis to refute these conclusions. To determine the validity of this claim, one would need access to the reanalysis of the protein structure and sequence of the 2019-nCoV genome as well as an explanation of how such reanalysis contradicts the findings from the original studies.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000244",
    "statement": "Protein structure and sequence reanalysis of 2019-ncov genome refutes bats as its intermediate host and the unique similarity between its spike protein insertions and hiv-1",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this Communication, we first analyzed two recent studies that concluded that snakes are the intermediate hosts of 2019-nCoV and that the 2019-nCoV spike protein insertions share a unique similarity to HIV-1."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence mentions two studies that concluded snakes as intermediate hosts and the unique similarity between 2019-nCoV spike protein insertions and HIV-1, but it does not contain any direct analysis or reanalysis of the genome sequence of 2019-nCoV to refute bats as an intermediate host or support the claim about a unique similarity with HIV-1.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000245",
    "statement": "Mhra suspends recruitment to covid-19 hydroxychloroquine trials",
    "label": "SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that MHRA suspended recruitment to COVID-19 hydroxychloroquine trials based on the results of two different trials, including the UK's RECOVERY trial and a study published in the New England Journal of Medicine. The evidence provided shows that these studies concluded that hydroxychloroquine did not have a beneficial effect in hospitalized patients with COVID-19 or as postexposure prophylaxis. Given that the MHRA is a regulatory body responsible for ensuring the safety and efficacy of medicines, it is reasonable to infer that they would act upon such findings by suspending recruitment to trials involving hydroxychloroquine for COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000246",
    "statement": "Mhra acts recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the MHRA (Medicines and Healthcare products Regulatory Agency) considering the results of hydroxychloroquine trials, including the RECOVERY trial, and concluding that it does not provide a meaningful mortality benefit or prevent illness compatible with COVID-19. However, the claim specifically states 'MHRA acts recruitment to covid-19 hydroxychloroquine trials', which is not directly supported by the evidence.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000247",
    "statement": "Mhra 1990s recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about recruitment of individuals in the MHRA (Medicines and Healthcare products Regulatory Agency) to hydroxychloroquine trials during the 1990s. The provided evidence discusses the results from trials conducted specifically on hospitalized patients with COVID-19, focusing mainly on the RECOVERY trial and a publication from the New England Journal of Medicine in relation to postexposure prophylaxis of COVID-19. No information was found about any recruitment for hydroxychloroquine trials by MHRA during the 1990s.",
    "confidence": 0.65
  },
  {
    "id": "covid_fact-000248",
    "statement": "Mhra 1980s recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the MHRA (Medicines and Healthcare products Regulatory Agency) recruited for hydroxychloroquine trials in the 1980s related to COVID-19. However, there is no mention of any such trials conducted by MHRA during the 1980s in relation to COVID-19 or its predecessors. The evidence provided concerns two different trials (RECOVERY trial and a NEJM publication) regarding hydroxychloroquine use for COVID-19 patients, but there is no information on any historical trials.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000249",
    "statement": "Transcriptional profiling reveals trpm5-expressing cells involved in viral infection in the olfactory epithelium",
    "label": "SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about the involvement of trpm5-expressing cells in viral infection in the olfactory epithelium. The provided evidence discusses specialized chemosensory epithelial cells expressing TRPM5 and their role in responses to viral infection, including the finding of profuse expression of transcripts involved in inflammation, immunity, and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons. Thus, the evidence supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000250",
    "statement": "Transcriptional profiling reveals trpm5-deficient cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence. The evidence mentions that TRPM5-expressing cells are involved in responses to viral infection and shows profuse expression of transcripts related to inflammation, immunity, and viral infection in these cells within the olfactory epithelium.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000251",
    "statement": "Transcriptional profiling reveals trpm5-depleted cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that 'Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.' Additionally, it mentions that 'We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons' specifically in the olfactory epithelium. This implies that trpm5-depleted cells are involved in viral infection in the olfactory epithelium.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000252",
    "statement": "Immunal profiling reveals trpm5-expressing cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear support for the claim that trpm5-expressing cells are involved in viral infection in the olfactory epithelium. The evidence directly states this involvement and also supports it with findings of expression of transcripts related to inflammation, immunity, and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000253",
    "statement": "Aprotinin inhibits sars-cov-2 replication",
    "label": "SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that aprotinin inhibits SARS-CoV-2 replication in therapeutically achievable concentrations. The evidence shows this effect against multiple cell types and virus isolates.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000254",
    "statement": "Aprotinin 1980s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that aprotinin inhibits SARS-CoV-2 replication in therapeutically achievable concentrations. The experiment was conducted on different cell types and against multiple virus isolates.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000255",
    "statement": "Aprotinin (s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that aprotinin inhibits SARS-CoV-2 replication in therapeutically achievable concentrations. This supports the claim that aprotinin has anti-SARS-CoV-2 activity.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000256",
    "statement": "Aprotinin 1970s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that aprotinin inhibits SARS-CoV-2 replication in therapeutically achievable concentrations, as demonstrated across multiple cell types and virus isolates. Therefore, the claim that aprotinin has anti-SARS-CoV-2 activity is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000257",
    "statement": "Homozygous l-sign plays a protective role in sars coronavirus infection",
    "label": "SUPPORTED",
    "evidences": [
      "Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection.",
      "Thus, homozygosity for L-SIGN plays a protective role during SARS infection.",
      "Homozygous L-SIGN ( CLEC4M ) plays a protective role in SARS coronavirus infection.",
      "This observation confirms that homozygous L-SIGN does have a protective role in SARS-CoV infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that 'Homozygous l-sign plays a protective role in sars coronavirus infection'. The evidence directly supports this claim by stating that 'homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection', implying that the presence of two copies of the l-sign gene (homozygosity) protects against SARS-CoV infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000258",
    "statement": "Homozygous l-atpase plays a protective role in sars coronavirus infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection.",
      "Thus, homozygosity for L-SIGN plays a protective role during SARS infection.",
      "Homozygous L-SIGN ( CLEC4M ) plays a protective role in SARS coronavirus infection.",
      "This observation confirms that homozygous L-SIGN does have a protective role in SARS-CoV infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about homozygous l-ATPase, but the evidence provided only mentions homozygous L-SIGN (CLEC4M). While L-SIGN plays a protective role in SARS coronavirus infection, it does not prove that l-ATPase does. To support this claim, we would need additional evidence showing that homozygosity for l-ATPase also plays a protective role during SARS infection.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000259",
    "statement": "The us doesnt have enough hospital beds for a bad coronavirus outbreak.",
    "label": "SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that the US does not have enough hospital beds for a bad coronavirus outbreak. The evidence is an article where New York Gov. Dillinger warns about this exact issue during the coronavirus pandemic.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000260",
    "statement": "The usset have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that New York Governor Cuomo has warned that America does not have enough hospital beds to fight the coronavirus pandemic. However, this does not necessarily mean that The usset (presumably a misspelling of 'Houston', as it's the only city in the US starting with 'Usset') specifically has enough hospital beds for a bad outbreak of the virus.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000261",
    "statement": "The uswt have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that there are concerns about the availability of hospital beds during a coronavirus pandemic in the US, as stated by New York Governor Cuomo. However, this does not directly imply that the uswt (United States Women's National Team, which is not related to healthcare infrastructure) have enough hospital beds for a bad coronavirus outbreak.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000262",
    "statement": "The usert have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not indicate that a specific user has enough hospital beds for a bad coronavirus outbreak. Instead, it mentions New York Governor Andrew Cuomo warning that America (as a whole) might not have enough hospital beds to fight the coronavirus pandemic.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000263",
    "statement": "La doctor seeing 100 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that a 'LA doctor' is seeing 100% success with hydroxychloroquine and zinc to treat COVID-19. While the evidence suggests that Dr. Anthony Cardillo has seen 'very promising results' when prescribing hydroxychloroquine in combination with zinc for severely ill COVID-19 patients, it does not provide a definitive statement about 100% success or generalizability of these findings to all patients.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000264",
    "statement": "La doctor seeing 80 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from the provided source indicates that Dr. Anthony Cardillo has seen success when prescribing hydroxychloroquine in combination with zinc for severely-ill COVID-19 patients. The claim suggests a drug cocktail involving hydroxychloroquine and zinc, which is supported by the evidence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000265",
    "statement": "La doctor seeing 60 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Dr. Anthony Cardillo claims to have seen success in treating COVID-19 patients with hydroxychloroquine and zinc, but the specific combination with azithromycin mentioned in the claim is not explicitly stated in the provided evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000266",
    "statement": "La doctor seeing 70 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that a doctor named Dr. Anthony Cardillo is seeing success with hydroxychloroquine in combination with zinc for severely-ill COVID-19 patients. However, the claim suggests a specific success rate of 70% with this treatment, and there's no concrete evidence presented to support such a percentage. Additionally, the claim mentions a drug cocktail that includes azithromycin, but the evidence only discusses hydroxychloroquine and zinc.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000267",
    "statement": "Repurposing existing drugs for covid-19 a more rapid alternative to a vaccine , say researchers",
    "label": "SUPPORTED",
    "evidences": [
      "Although clinical trials found it to be insufficiently effective at treating Ebola, clinical trials in the USA have suggested the drug may be beneficial for treating patients hospitalised with COVID-19, and the FDA has now approved it for emergency use.",
      "> \"[Repurposed drugs] will have already been shown to be safe and so, if they > can now be shown to be effective in COVID-19, they could be brought to > clinical use relatively quickly\" > > Anthony Davenport Since the emergence of the SARS-CoV-2 virus in late 2019, more than 3.5 million people are known to have been infected, leading to over 240,000 deaths worldwide from COVID-19, the disease caused by the novel coronavirus.",
      "While we're waiting for a vaccine, drugs currently being used to treat other illnesses can be investigated as treatments for COVID-19  in other words repurposed, said Dr Steve Alexander from the University of Nottingham.",
      "These treatments will have already been shown to be safe and so, if they can now be shown to be effective in COVID-19, they could be brought to clinical use relatively quickly. One promising candidate is remdesivir, a drug originally developed for Ebola."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that researchers are investigating repurposing existing drugs as treatments for COVID-19 due to their known safety and the potential to bring them to clinical use relatively quickly if they prove effective against COVID-19. The drug remdesivir is presented as an example of such a repurposed drug, having been previously developed for Ebola treatment.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000268",
    "statement": "Repurposing existing drugs for covid-19 a less rapid alternative to a vaccine, say researchers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although clinical trials found it to be insufficiently effective at treating Ebola, clinical trials in the USA have suggested the drug may be beneficial for treating patients hospitalised with COVID-19, and the FDA has now approved it for emergency use.",
      "> \"[Repurposed drugs] will have already been shown to be safe and so, if they > can now be shown to be effective in COVID-19, they could be brought to > clinical use relatively quickly\" > > Anthony Davenport Since the emergence of the SARS-CoV-2 virus in late 2019, more than 3.5 million people are known to have been infected, leading to over 240,000 deaths worldwide from COVID-19, the disease caused by the novel coronavirus.",
      "While we're waiting for a vaccine, drugs currently being used to treat other illnesses can be investigated as treatments for COVID-19  in other words repurposed, said Dr Steve Alexander from the University of Nottingham.",
      "These treatments will have already been shown to be safe and so, if they can now be shown to be effective in COVID-19, they could be brought to clinical use relatively quickly. One promising candidate is remdesivir, a drug originally developed for Ebola."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that researchers are indeed investigating the repurposing of existing drugs as an alternative to a vaccine for COVID-19 treatment. The claim is supported by statements such as 'these treatments will have already been shown to be safe and so, if they can now be shown to be effective in COVID-19, they could be brought to clinical use relatively quickly'.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000269",
    "statement": "68 per cent of patients hospitalized for severe covid-19 , who were treated with compassionate-use remdesivir , showed clinical improvement",
    "label": "SUPPORTED",
    "evidences": [
      "Although data from several ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for Covid-19, the outcomes observed in this compassionate-use program are the best currently available data."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that '68 per cent of patients hospitalized for severe covid-19 , who were treated with compassionate-use remdesivir , showed clinical improvement'. The evidence provided describes ongoing randomized controlled trials as the source for more informative data about safety and efficacy of remdesivir for Covid-19, but it does not provide any specific numbers or percentages of patients showing clinical improvement in a compassionate-use program.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000270",
    "statement": "68 per cent of patients hospitalized for severe covid-19, who were treated with compassionate-use remdesivir, without clinical improvement",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although data from several ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for Covid-19, the outcomes observed in this compassionate-use program are the best currently available data."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not give a clear percentage of patients who were hospitalized for severe COVID-19 and treated with compassionate-use remdesivir without clinical improvement. The statement alludes to the best currently available data from a compassionate-use program, but no specific numerical data is presented in this context.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000271",
    "statement": "Years of life lost due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in this case clearly supports the claim that there are years of life lost (YLL) due to the psychosocial consequences of COVID-19 mitigation strategies based on Swiss data. The study uses YLL as a main outcome measure for Switzerland and projects an average loss of 0.205 YLL per person.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000272",
    "statement": "Years of life increases due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the loss of years of life (YLL) due to psychosocial consequences of COVID-19 mitigation measures in Switzerland, but it does not support or refute a claim that life expectancy increases as a result of these strategies.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000273",
    "statement": "Years of life remains due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is based on the results provided in the evidence that states an average person would suffer 0.205 years of life lost (YLL) due to psychosocial consequences of COVID-19 mitigation measures.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000274",
    "statement": "Years of life occurred due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a calculation of Years of Life Lost (YLL) due to the psychosocial consequences of COVID-19 mitigation strategies using Switzerland as an example. The results indicate that the average person would suffer 0.205 YLL.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000275",
    "statement": "Astrazeneca covid-19 vaccine study is put on hold",
    "label": "SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that a study for AstraZeneca's COVID-19 vaccine has been put on hold. The evidence provided shows that an AstraZeneca spokesperson confirmed the pause of vaccination due to a review of safety data, and AstraZeneca themselves also stated they initiated the study hold. This directly supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000276",
    "statement": "Astrazeneca covid-19 vaccine study is put on!",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that AstraZeneca has paused their standard review process for safety data regarding the Covid-19 vaccine study. However, it does not confirm if the study itself was put on hold or what the current status of the study is.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000277",
    "statement": "Astrazeneca covid-19 vaccine study is put on.\"",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that 'AstraZeneca covid-19 vaccine study is put on hold'. The evidence provided by the statement from AstraZeneca's spokesperson clearly indicates that they initiated a study hold for their Phase 3 Covid-19 vaccine trial. This suggests that the vaccine study was indeed put on hold, as stated in the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000278",
    "statement": "Astrazeneca covid-19 vaccine study is put on.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'AstraZeneca Covid-19 vaccine study is put on hold' is supported by the evidence provided. A spokesperson for AstraZeneca confirmed that they paused vaccination to review safety data, and it was their first Phase 3 Covid-19 vaccine trial known to have been halted.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000279",
    "statement": "Giuliani-promoted covid-19 therapy from celularity nabs fda speedy trial start",
    "label": "SUPPORTED",
    "evidences": [
      "Trials need to be EXPEDITED. It seems he got his wish: Today, New Jersey-based Celularity said it has been given the all-clear from the FDA to start its clinical trial of CYNK-001, its allogeneic, off-the-shelf, cryopreserved natural killer cell therapy to be used in a phase 1/2 study in up to 86 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Celularity has received FDA approval for a clinical trial of CYNK-001 therapy to be used in COVID-19 patients. The claim suggests Giuliani played a role in expediting this trial, but the text does not provide information on his involvement; however, the fact that the trial was given the go-ahead indicates it has been expedited.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000280",
    "statement": "Giuliani-free covid-19 therapy from celularity nabs fda speedy trial start",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Trials need to be EXPEDITED. It seems he got his wish: Today, New Jersey-based Celularity said it has been given the all-clear from the FDA to start its clinical trial of CYNK-001, its allogeneic, off-the-shelf, cryopreserved natural killer cell therapy to be used in a phase 1/2 study in up to 86 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence since the FDA has given approval for Celularity's clinical trial of CYNK-001 to start. The therapy in question is a 'Giuliani-free covid-19 therapy', which aligns with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000281",
    "statement": "Mucus production stimulated by ifn-ahr signaling triggers hypoxia of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented suggests a link between IFN-ARH signaling and mucus production in the lungs of COVID-19 patients, which could potentially contribute to hypoxia (lack of oxygen) in these patients. The schematic and the results from BAL (Bronchoalveolar Lavage) fluid analysis support this hypothesis.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000282",
    "statement": "Mucus production stimulated by ifn-ahr signaling prevents hypoxia of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that there is an upregulation of AhR (Aryl Hydrocarbon Receptor) signaling in COVID-19 patients, which leads to increased mucus production in lung epithelial cells. This could help prevent hypoxia as the mucus might serve as a protective barrier against harmful agents and facilitate gas exchange.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000283",
    "statement": "Mucus damage stimulated by ifn-ahr signaling triggers hypoxia of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients and suggests that mucus-like substance might be present in the BAL (Bronchoalveolar lavage) of COVID-19 patients. While it does not explicitly state that ifn-ahr signaling triggers hypoxia, the connection can be reasonably inferred given the context of the schematic and the known role of AhR (Aryl hydrocarbon receptor) in mucin production. Therefore, it supports the claim that mucus damage stimulated by ifn-ahr signaling may contribute to hypoxia in COVID-19 patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000284",
    "statement": "Gilead has suspended access to remdesivir",
    "label": "SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that while Gilead was previously accepting compassionate-use requests for remdesivir, they are now planning to provide treatment only through expanded access programs. This implies a suspension of the previous method (individual patient requests) of providing remdesivir.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000285",
    "statement": "Gilead has allowed access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that before a suspension, Gilead was providing access to remdesivir through compassionate-use requests and individual patients for emergency use. The statement about them pivoting to only providing treatment through expanded access programs implies they will continue to provide access to remdesivir, just not in the same manner as before.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000286",
    "statement": "Gilead has received access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Gilead was providing remdesivir through 'compassionate-use requests' before a suspension. Now, they are only providing treatment through expanded access programs, which implies they still have access to remdesivir.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000287",
    "statement": "Gilead has provided access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Gilead had been providing access to remdesivir through compassionate-use requests before a suspension and is now pivoting to expanded access programs. This change of approach implies that they still provide access but through different channels.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000288",
    "statement": "Immune cell activation in severe covid-19 resembles lupus .",
    "label": "SUPPORTED",
    "evidences": [
      "The scientists found that patients with severe COVID-19 displayed many of these hallmarks of extrafollicular B cell responses associated with lupus.",
      "The critically-ill COVID-19 patients who survived and recovered from the infection also showed lingering symptoms similar to those experienced by lupus patients during acute flare-ups."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that COVID-19 patients with severe cases display extrafollicular B cell responses and lingering symptoms similar to lupus patients during acute flare-ups. This suggests a resemblance between the immune cell activation in severe COVID-19 and lupus.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000289",
    "statement": "Immune cell death in severe covid-19 resembles lupus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The scientists found that patients with severe COVID-19 displayed many of these hallmarks of extrafollicular B cell responses associated with lupus.",
      "The critically-ill COVID-19 patients who survived and recovered from the infection also showed lingering symptoms similar to those experienced by lupus patients during acute flare-ups."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that patients with severe COVID-19 display some similarities to extrafollicular B cell responses associated with lupus and also experience lingering symptoms similar to those experienced by lupus patients during acute flare-ups. However, this does not necessarily mean the immune cell death in severe covid-19 resembles lupus directly. Further evidence is required to establish a clear connection between COVID-19 and lupus.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000290",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few weeks.",
    "label": "SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly supported by the provided evidence which states that the new CDC director predicts up to 100,000 more COVID-19 deaths in the next few weeks.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000291",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few decades.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly supported by the provided evidence. The CDC director states that up to 100,000 more COVID-19 deaths in less than a month are possible.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000292",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few years.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly supported by the provided evidence. The statement that 'New CDC director Dr. Rochelle Walensky says the United States could face as many as 100,000 more COVID-19 deaths in less than a month' supports the claim that the CDC forecasts up to 100,000 more covid-19 deaths in the next few years.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000293",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few century.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly stated by Dr. Rochelle Walensky, the new director of the CDC, in a CNN report dated January 21st, 2021. Thus, the claim is supported.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000294",
    "statement": "Gaps in early surveillance of coronavirus led to record-breaking us trajectory",
    "label": "SUPPORTED",
    "evidences": [
      "As illustrated in the COVID-19 study, while public health officials must work quickly to understand how a new virus functions, without appropriate testing or coordinated response strategies the risk grows for infections to go unreported.",
      "The study provides insight into how limited testing and gaps in surveillance during the initial phase of the epidemic resulted in so many cases going undetected.",
      "The potential for misdiagnosis and the limitations of surveillance are huge issues across infectious diseases, especially emerging infectious diseases, he added."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the study discusses how gaps in early surveillance of the coronavirus led to many cases going undetected. This could have contributed significantly to the rise of COVID-19 infections, potentially leading to a record-breaking trajectory in the U.S.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000295",
    "statement": "Efforts in early surveillance of coronavirus led to record-breaking us trajectory",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "As illustrated in the COVID-19 study, while public health officials must work quickly to understand how a new virus functions, without appropriate testing or coordinated response strategies the risk grows for infections to go unreported.",
      "The study provides insight into how limited testing and gaps in surveillance during the initial phase of the epidemic resulted in so many cases going undetected.",
      "The potential for misdiagnosis and the limitations of surveillance are huge issues across infectious diseases, especially emerging infectious diseases, he added."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided claim is that 'Efforts in early surveillance of coronavirus led to record-breaking US trajectory'. However, the evidence given only discusses the challenges in understanding and detecting new viruses, as well as potential issues with misdiagnosis and gaps in surveillance. It does not provide any information about how these efforts specifically affected the 'record-breaking' US trajectory of coronavirus cases.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000296",
    "statement": "Immunosuppression is associated with a lower risk of moderate to severe acute respiratory distress syndrome in covid-19 .",
    "label": "SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that 'immunosuppression was associated with a lower risk of moderate-severe ARDS in COVID-19 patients.' This claim is supported by the evidence presented.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000297",
    "statement": "Immunosuppression is associated with a increased risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided in the conclusion suggests that immunosuppression is associated with a lower risk of moderate to severe acute respiratory distress syndrome (ARDS) in COVID-19 patients, which contradicts the claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000298",
    "statement": "Immunosuppression is associated with a higher risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence presented states that immunosuppression is associated with a lower risk of moderate-severe ARDS in COVID-19 patients, which contradicts the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000299",
    "statement": "Immunosuppression is associated with a high risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence contradicts the claim by stating that immunosuppression is associated with a lower risk of moderate-severe ARDS in COVID-19 patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000300",
    "statement": "Human soluble ace2 improves the effect of remdesivir in sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 µg/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only mentions that human soluble ACE2 inhibits SARS-CoV2 infections in Vero E6 cells and the treatment of remdesivir on these infected cells. It does not contain information on whether combining human soluble ACE2 with remdesivir improves the effect of remdesivir in SARS-CoV2 infection.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000301",
    "statement": "Human soluble ace2 inhibits the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 µg/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only demonstrates the inhibition of SARS-CoV2 infections by hrsACE2 and remdesivir separately on Vero E6 cells. It does not provide direct or indirect information about whether human soluble ace2 inhibits the effect of remdesivir in sars-cov-2 infection.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000302",
    "statement": "Human soluble ace2 blocked the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 µg/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that the interaction of hrsACE2 (human soluble ACE2) and remdesivir affected SARSCoV2 infections in Vero E6 cells. However, the claim specifically states that hrsACE2 'blocked' the effect of remdesivir. The evidence does not directly support this specific statement, as it does not show a clear case of blocking but rather an interaction.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000303",
    "statement": "Human soluble ace2 reduces the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 µg/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions the inhibition of SARS-CoV2 infections by hrsACE2 and remdesivir in Vero E6 cells, without explicitly stating or implying a reduction in the effect of remdesivir due to human soluble ace2.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000304",
    "statement": "A five day course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that a 5-day course of ivermectin has been found to be effective and safe in treating adult patients with mild COVID-19, and it resulted in an earlier clearance of the virus compared to placebo (p = 0.005). This suggests that early intervention with ivermectin may reduce the duration of illness.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000305",
    "statement": "A five years course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0
  },
  {
    "id": "covid_fact-000306",
    "statement": "A five year course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a five-day course of Ivermectin is effective in treating adult patients with mild COVID-19 and may reduce the duration of illness. The study found that ivermectin led to an earlier clearance of the virus compared to placebo.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000307",
    "statement": "A fivemonth course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests a five-month course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. This is because one of the pieces of evidence states that a 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo, which implies that ivermectin could limit viral replication within the host and potentially shorten the duration of the illness.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000308",
    "statement": "Brd4-bound enhancers drive cell intrinsic sex differences in glioblastoma",
    "label": "SUPPORTED",
    "evidences": [
      "These observations led us to hypothesize that Brd4-bound enhancers might underlie sex differences in stem cell function and tumorigenicity in GBM.",
      "We report that sex-biased Brd4 activity drive sex differences in GBM and render male and female tumor cells differentially sensitive to BET inhibitors.",
      "These sex- biased gene expression patterns were also evident in human glioblastoma stem cells (GSCs).",
      "In an established isogenic murine model of glioblastoma, we discovered correlated transcriptome-wide sex differences in gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites.",
      "Thus, for the first time, Brd4 activity is revealed to drive a sex differences in stem cell and tumorigenic phenotype, resulting in diametrically opposite responses to BET inhibition in male and female GBM cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a hypothesis that Brd4-bound enhancers drive sex differences in glioblastoma (GBM) and supports this claim by reporting sex-biased activity of Brd4 affecting GBM cells differently in male and female tumors. The evidence also shows that these differences are observed in human GSCs, an isogenic murine model of glioblastoma, and in transcriptome-wide gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites. This suggests a direct link between Brd4 activity and sex differences in stem cell function and tumorigenicity in GBM.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000309",
    "statement": "Brd4-bound enhancers drive cell surface sex differences in glioblastoma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations led us to hypothesize that Brd4-bound enhancers might underlie sex differences in stem cell function and tumorigenicity in GBM.",
      "We report that sex-biased Brd4 activity drive sex differences in GBM and render male and female tumor cells differentially sensitive to BET inhibitors.",
      "These sex- biased gene expression patterns were also evident in human glioblastoma stem cells (GSCs).",
      "In an established isogenic murine model of glioblastoma, we discovered correlated transcriptome-wide sex differences in gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites.",
      "Thus, for the first time, Brd4 activity is revealed to drive a sex differences in stem cell and tumorigenic phenotype, resulting in diametrically opposite responses to BET inhibition in male and female GBM cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides multiple lines of supporting arguments for the claim that Brd4-bound enhancers drive cell surface sex differences in glioblastoma. The text mentions that Brd4 activity drives sex differences in GBM and that these differences are correlated with transcriptome-wide sex differences, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites. Additionally, the text mentions that the sex-biased gene expression patterns were also evident in human glioblastoma stem cells (GSCs) and an established isogenic murine model of glioblastoma.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000310",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome",
    "label": "SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents in vitro data showing that IL-6 trans-signaling promotes PAI-1 production from vascular endothelial cells and also indicates a reduction in endothelial cell activation with an IL-6 signaling blockade by tocilizumab. This supports the claim that IL-6 trans-signaling induces PAI-1 from vascular endothelial cells in cytokine release syndrome.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000311",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine development syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly indicates that endothelial IL-6 trans-signaling promotes PAI-1 production in vitro and a blockade of IL-6 signaling by tocilizumab blunts endothelial cell activation.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000312",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine production syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly supports the claim that Il-6 trans-signaling induces plasminogen activator inhibitor-1 (PAI-1) from vascular endothelial cells in cytokine production syndrome. The evidence indicates an increase in IL-6, IL-8, and MCP-1 production as well as PAI-1 production through Il-6 trans-signaling, and further suggests that this process can be blocked by the human monoclonal antibody tocilizumab.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000313",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine differentiation syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that IL-6 trans-signaling promotes PAI-1 production from vascular endothelial cells and also mentions a blockade of IL-6 signaling by tocilizumab reducing endothelial cell activation. Therefore, the claim that Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine differentiation syndrome is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000314",
    "statement": "Fauci says he wears a mask to be a symbol of what 'you should be doing '",
    "label": "SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly supported by the provided evidence. Anthony Fauci, the nation's top infectious disease expert, stated that he wears a mask not just to protect himself but also 'to make it be a symbol for people to see that that's the kind of thing you should be doing.' This statement implies that wearing a mask is symbolic of following proper safety protocols during the pandemic.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000315",
    "statement": "Fauci says he wears a point to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Fauci stated that he wears a mask to protect himself and others, as well as to serve as a symbol for people to see that they should be doing the same. This directly supports the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000316",
    "statement": "Fauci says he wears a license to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that Dr. Fauci wears a mask to protect himself and others as well as to serve as a symbol of what 'you should be doing' in terms of public health measures during the COVID-19 pandemic.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000317",
    "statement": "Fauci says he wears a question to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by direct quote from Fauci where he explicitly states that wearing a mask is a symbol of what 'you should be doing'. The quote also explains his personal reason for wearing a mask, which includes protecting himself and others as well as serving as a symbol.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000318",
    "statement": "Iga dominates the early neutralizing antibody response to sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the provided evidence showing that human IgA antibodies are often detected before the appearance of SARS-CoV-2-specific IgG and that the early response to SARS-CoV-2 infection is dominated by IgA-secreting cells.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000319",
    "statement": "Iga dominates the full neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the subject's IgA response to SARS-CoV-2 appears earlier than their IgG response and dominates the early humoral response. The results also show an expansion of plasmablast cells producing IgA antibodies, implying a significant role in virus neutralization.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000320",
    "statement": "Iga dominates the enhanced neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that IgA antibodies are present before the appearance of SARS-CoV-2-specific IgG and that these early responses are dominated by IgA antibodies. This suggests that Iga plays a significant role in the enhanced neutralizing antibody response to SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000321",
    "statement": "Iga dominates the effective neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that human IgA antibodies are often detected before the appearance of SARS-CoV-2-specific IgG and suggests a role for IgA antibodies in early virus neutralization. Additionally, it is mentioned that early SARS-CoV-2-specific humoral responses were dominated by IgA antibodies.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000322",
    "statement": "Fda authorizes first diagnostic test for screening of people without known or suspected covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Last month, the FDA posted updated templates with recommendations for test developers to demonstrate validation for a test to be authorized for screening of asymptomatic people, as well as for sample pooling.",
      "The FDA reissued the LabCorp COVID-19 RT-PCR Test EUA to expand use of the test to anyone, after the company provided scientific data showing the tests ability to detect SARS-CoV-2 in a general, asymptomatic population.",
      "Additionally, the data reviewed by the FDA demonstrated that the test is as accurate in the broader asymptomatic population as it is among people suspected to have COVID-19.",
      "Until now, molecular diagnostic tests have generally been authorized for people suspected of having COVID-19 by their health care provider, which has allowed asymptomatic people to be tested, when warranted, at the discretion of the health care provider."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the FDA has indeed authorized a diagnostic test for screening of people without known or suspected COVID-19 infection. The FDA posted updated templates to demonstrate validation for tests used in asymptomatic population and reissued a test (LabCorp COVID-19 RT-PCR Test) to expand its use for anyone, which was based on data showing the test's ability to detect SARS-CoV-2 in a general, asymptomatic population. The data also showed that the test is as accurate in the broader asymptomatic population as it is among people suspected to have COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000323",
    "statement": "Fda authorizes another diagnostic test for screening of people without known or suspected covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Last month, the FDA posted updated templates with recommendations for test developers to demonstrate validation for a test to be authorized for screening of asymptomatic people, as well as for sample pooling.",
      "The FDA reissued the LabCorp COVID-19 RT-PCR Test EUA to expand use of the test to anyone, after the company provided scientific data showing the tests ability to detect SARS-CoV-2 in a general, asymptomatic population.",
      "Additionally, the data reviewed by the FDA demonstrated that the test is as accurate in the broader asymptomatic population as it is among people suspected to have COVID-19.",
      "Until now, molecular diagnostic tests have generally been authorized for people suspected of having COVID-19 by their health care provider, which has allowed asymptomatic people to be tested, when warranted, at the discretion of the health care provider."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the FDA has reissued the LabCorp COVID-19 RT-PCR Test EUA to expand its use for anyone, not just people suspected of having COVID-19. The FDA also posted updated templates with recommendations for test developers to demonstrate validation for a test to be authorized for screening of asymptomatic people. Thus, the claim is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000324",
    "statement": "Johnson & johnson pauses covid-19 vaccine trials due to sick subject",
    "label": "SUPPORTED",
    "evidences": [
      "This is the second time trials for a Covid-19 vaccine trial have been paused over a safety concern."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only indicates that a COVID-19 vaccine trial has been paused before due to safety concerns, but it does not specify which company's trial this refers to or whether the current claim about Johnson & Johnson is correct.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000325",
    "statement": "Johnson & johnson developed covid-19 vaccine trials due to sick subject",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This is the second time trials for a Covid-19 vaccine trial have been paused over a safety concern."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only mentions that a Covid-19 vaccine trial by Johnson & Johnson was paused twice due to safety concerns. It does not provide any information about the reason for these pauses or whether they were related to a 'sick subject.' To fully evaluate the claim, we would need more specific details about the nature of each pause and its relationship to sick participants.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000326",
    "statement": "Asymptomatic cases may not be infectious , wuhan study indicates.",
    "label": "SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that in a study conducted in Wuhan post-lockdown, the detection rate of asymptomatic positive cases was very low (0.303/10,000), and there was no evidence to suggest that these identified asymptomatic positive cases were infectious.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000327",
    "statement": "Asymptomatic cases may also be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates a low detection rate of asymptomatic positive cases in post-lockdown Wuhan and no evidence that these identified cases were infectious. However, the claim states that 'Asymptomatic cases may also be infectious,' which contradicts the information in the evidence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000328",
    "statement": "Asymptomatic cases may only be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that in a Wuhan study, there was no 'evidence that the identified asymptomatic positive cases were infectious.' However, it does not indicate that only asymptomatic cases may be infectious.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-000329",
    "statement": "Asymptomatic cases may still be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that there is no evidence of asymptomatic cases being infectious in the post-lockdown Wuhan, which contradicts the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000330",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ace inhibitors or angiotensin receptor blockers",
    "label": "SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that there is no increase of ACE2 protein expression in the cilia of upper respiratory cells due to the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs). Additionally, there is potential for a decrease of ACE2 protein expression in ACEI patients.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000331",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is significantly increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is significantly increased by ace inhibitors or angiotensin receptor blockers. However, the evidence provided indicates a potential decrease in ACE2 protein expression in ACEI patients and no increase in patients taking either medication.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000332",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is greatly increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is greatly increased by ace inhibitors or angiotensin receptor blockers. The evidence shows that ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients. This contradicts the claim, as it suggests a decrease, rather than an increase, in ACE2 expression.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000333",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is further increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is further increased by ace inhibitors or angiotensin receptor blockers. However, the provided evidence suggests the opposite: ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000334",
    "statement": "A consensus covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that a consensus COVID-19 immune signature combines immuno-protection associated with virus infection or vaccination (adaptive B cell responses) with discrete traits linked to sepsis, such as monocyte and dendritic cell dampening, T cell subset hyperactivation, and depletion. These findings seem consistent with the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000335",
    "statement": "A novel covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence describes a novel COVID-19 immune signature that combines adaptive B cell responses typical of virus infection or vaccination with traits previously associated with sepsis such as monocyte and dendritic cell dampening, T cell subset hyperactivation, and depletion. The evidence does not explicitly say the signature is associated with good prognosis but it does associate these discrete sepsis-like traits with poor prognosis, which supports the claim indirectly.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000336",
    "statement": "A unique covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a unique covid-19 immune signature that combines immuno-protection (adaptive B cell responses typical of virus infection or vaccination) with discrete traits associated with sepsis (monocyte and dendritic cell dampening, T cell hyperactivation, and depletion). This supports the claim that such a signature exists.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000337",
    "statement": "The institute for disease modeling puts the cfr at 0.94 %",
    "label": "SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent. This value can be interpreted as the Case Fatality Ratio (CFR) when accounting for infections.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000338",
    "statement": "The institute for disease transmission puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent. This number can be interpreted as the cfr for the given institute.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000339",
    "statement": "The institute for disease surveillance puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent. This value represents the percentage of people who die from the disease after being infected.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000340",
    "statement": "The institute for disease detection puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that the institute for disease detection puts the cfr at 0.94 % (confirmation rate of infection to fatality), and the evidence presents a corrected estimate of the infection-fatality-ratio (IFR) as 0.94 %. Since IFR is essentially another way of expressing the same concept (the probability of dying from an infection given that you have been infected), this evidence supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000341",
    "statement": "Evolutionary arms race between virus and host drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that an evolutionary arms race between virus (bat SARS-related coronavirus) and host (bats) drives genetic diversity in the spike genes of the virus. The evidence indicates a coevolution between the SARSr-CoV spike protein and bat ACE2, suggesting selection pressure and potential genetic changes on both sides, which aligns with the concept of an evolutionary arms race.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000342",
    "statement": "Evolutionary arms race between virus and coronavirus drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is based on speculation and a single study indicating potential coevolution between bat ACE2 and SARSr-CoV spike proteins, which might imply an evolutionary arms race. However, the study does not directly support the claim that this interaction drives genetic diversity in bat SARS related coronavirus spike genes.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000343",
    "statement": "Evolutionary arms race between virus and viruses drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests an evolutionary arms race between viruses (specifically bat SARS-related coronaviruses) and a specific host (bats), driven by genetic diversity in the spike genes of the virus. The evidence provided supports the idea that the interaction between bat ACE2 and the SARSr-CoV spike proteins may lead to coevolution over time, but it does not directly support the claim of an evolutionary arms race driving genetic diversity in the virus's spike genes. Further research would be needed to establish a stronger connection.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000344",
    "statement": "Evolutionary arms race between virus and virus drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests an interaction between bat ACE2 and SARSr-CoV spike proteins, implying that these viruses coevolve and experience selection pressure from each other, which is consistent with the concept of an evolutionary arms race driving genetic diversity.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000345",
    "statement": "Active monitoring of persons exposed to patients with confirmed covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19 ( 2 ).",
      "The duration of time in the same airspace after the patient with confirmed COVID-19 was applied differently by health jurisdictions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that there is active monitoring for close contacts of patients with confirmed COVID-19 in the United States. The evidence provided mentions collaboration between state and local health departments and CDC to identify these contacts. This confirms the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000346",
    "statement": "Active monitoring of persons exposed to patients without confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19 ( 2 ).",
      "The duration of time in the same airspace after the patient with confirmed COVID-19 was applied differently by health jurisdictions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim refers to the active monitoring of persons exposed to patients with confirmed COVID-19. The evidence indicates that on January 20, health departments in the US began identifying and monitoring such individuals. Therefore, the claim is supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000347",
    "statement": "Convalescent plasma to treat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim about the use of convalescent plasma for treating COVID-19 is supported by several sources discussing its investigation as a treatment option for hospitalized patients with the disease and providing results from various clinical trials.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000348",
    "statement": "Unvalescent plasma to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence discusses the use and effectiveness of convalescent plasma in treating hospitalized patients with COVID-19, as well as clinical trials and expanded access to this treatment. This strongly suggests that unvalescent plasma (convalescent plasma) is being used to treat COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000349",
    "statement": "Convalescent antibiotics to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the use and effectiveness of convalescent plasma therapy for treating hospitalized patients with COVID-19 in several studies. This suggests that convalescent antibodies can potentially be used to treat COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000350",
    "statement": "Subvalescent plasma to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that subvalescent plasma is used to treat Covid-19 and the provided evidence includes studies about the effectiveness of convalescent plasma (which can include subvalescent plasma) in treating severe Covid-19 patients as well as information about its use for expanded access in treating Covid-19. This supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000351",
    "statement": "Man , 25 , catches coronavirus twice in first such us case",
    "label": "SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by direct evidence, as the study published in the Lancet Infectious Diseases journal confirms that a 25-year-old man was infected with COVID-19 on two separate occasions. The photograph does not provide conclusive evidence but seems to be related to the case. Furthermore, there is no information contradicting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000352",
    "statement": "13, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a 25-year-old man in the US was infected with Covid-19 on two separate occasions and required hospitalization and oxygen support during the second infection. Genetic sequencing of the virus showed that he was infected by different strains of SARS-CoV-2 each time, which supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000353",
    "statement": "2, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that a 25-year-old man in the US was infected with Covid-19 on two separate occasions and genetic sequencing of the virus confirmed that he was infected by different strains of Sars-CoV-2. Therefore, it can be concluded that the claim is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000354",
    "statement": "19, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that a 25-year-old man in the US was infected with Covid-19 on two separate occasions, and genetic sequencing of the virus confirmed that different strains of Sars-CoV-2 were involved each time. This indicates that he 'caught coronavirus twice', as claimed.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000355",
    "statement": "Black , hispanic communities struggle in covid-19 vaccine rollout across the u.s .",
    "label": "SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that Black and Hispanic communities have higher levels of vaccine hesitancy and distrust compared to white Americans due to a history of medical experimentation and unequal access to care. However, it does not provide specific or quantifiable data showing that these communities struggle more than others in the COVID-19 vaccine rollout across the U.S.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000356",
    "statement": "2, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses vaccine hesitancy and historical medical issues in Black and Latino communities, but it does not directly demonstrate that these communities are struggling more than others in the COVID-19 vaccine rollout across the U.S. To support this claim, data or examples of specific challenges faced by Hispanic communities during the vaccine rollout would be necessary.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000357",
    "statement": "6, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses higher vaccine hesitancy and distrust among Black and Latino communities compared to white Americans. However, it does not directly support the claim that Hispanic communities are struggling in the COVID-19 vaccine rollout across the U.S. The claim requires specific evidence about the distribution and accessibility of vaccines within Hispanic communities.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000358",
    "statement": "3, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses vaccine hesitancy and distrust among Black and Latino communities due to historical factors like the Tuskegee Study and ongoing healthcare disparities. However, it does not directly demonstrate or quantify that Hispanic communities struggle more than other groups in COVID-19 vaccine rollout across the U.S. The claim seems plausible based on the evidence provided, but additional data would be required to support it conclusively.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000359",
    "statement": "Past covid-19 infection provides some immunity but people may still carry and transmit virus.",
    "label": "SUPPORTED",
    "evidences": [
      "The PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "Published 14 January 2021 From: Public Health England People infected with COVID-19 in the past are likely to be protected against reinfection for several months, a Public Health England (PHE) study has found, although experts cautioned those with immunity may still be able carry the virus in their nose and throat and therefore have a risk of transmitting to others.",
      "PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "But a small number of people with antibodies may still be able to carry and transmit COVID-19 according to the study.",
      "iStock London, January 14 An official UK study released on Thursday concludes that a past COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a past COVID-19 infection provides some immunity to the disease, although people with antibodies may still carry and transmit the virus to others.",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000360",
    "statement": "Past covid-19 infection provides some immunity but people cannot still carry and transmit virus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "Published 14 January 2021 From: Public Health England People infected with COVID-19 in the past are likely to be protected against reinfection for several months, a Public Health England (PHE) study has found, although experts cautioned those with immunity may still be able carry the virus in their nose and throat and therefore have a risk of transmitting to others.",
      "PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "But a small number of people with antibodies may still be able to carry and transmit COVID-19 according to the study.",
      "iStock London, January 14 An official UK study released on Thursday concludes that a past COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that people with past COVID-19 infection have some protection from reinfection for several months, but it also warns that a small number of these individuals may still carry and transmit the virus to others.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000361",
    "statement": "Systematic analysis of innate immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-γ and IFN-λ1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows an analysis of innate immune antagonism against SARS-CoV-2 that reveals IFN-γ and IFN-λ1 signaling are least antagonized, suggesting vulnerabilities of SARS-CoV-2 to these two cytokines. The claim is directly supported by the provided evidence.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000362",
    "statement": "Systematic analysis of cellular immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-γ and IFN-λ1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a systematic analysis of cellular immune antagonism towards SARS-CoV-2 and suggests that IFN-γ and IFN-λ1 signalling are less antagonized compared to other cytokines. This makes the virus highly susceptible to these two cytokines, supporting the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000363",
    "statement": "Systematic analysis of adaptive immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-γ and IFN-λ1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents a systematic analysis of adaptive immune antagonism for SARS-CoV-2. It suggests that IFN-γ and IFN-λ1 signaling are the least antagonized, leaving SARS-CoV-2 highly susceptible to these two cytokines. Therefore, the claim that systematic analysis of adaptive immune antagonism reveals vulnerabilities of sars-cov-2 is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000364",
    "statement": "Systematic analysis of antiviral immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-γ and IFN-λ1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the antiviral immune response to SARS-CoV-2 is particularly weak when it comes to IFN-γ and IFN-λ1 signaling. This implies that SARS-CoV-2 may be more vulnerable to these two cytokines, supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000365",
    "statement": "Trial to promote recovery from covid-19 with ivermectin or endocrine therapy",
    "label": "SUPPORTED",
    "evidences": [
      "This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19.",
      "This will be a randomized, open-label study to determine if bicalutamide or ivermectin improves the time to clinical improvement in patients with COVID-19 over historical controls."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim about a trial to promote recovery from COVID-19 with ivermectin or endocrine therapy. The trials mentioned in the evidence are specifically for bicalutamide and do not include ivermectin or any form of endocrine therapy.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000366",
    "statement": "Trial to no recovery from covid-19 with ivermectin or endocrine therapy",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19.",
      "This will be a randomized, open-label study to determine if bicalutamide or ivermectin improves the time to clinical improvement in patients with COVID-19 over historical controls."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes a study on the effects of bicalutamide and ivermectin in improving the time to clinical improvement for patients with COVID-19 compared to historical controls. However, the claim is about recovery from COVID-19, not just clinical improvement, and it does not directly address the use of endocrine therapy.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-000367",
    "statement": "Coronavirus vaccines leap through safety trials",
    "label": "SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the Coronavirus vaccines have already 'leaped through safety trials' based on the evidence provided, which shows that scientists have released data from their first human trials and suggest that the candidate vaccines are broadly safe. However, to definitively state that the vaccines have 'leaped through safety trials', it would be necessary to have results from efficacy trials (which prove the vaccine is effective against the virus), and not just safety trials. Therefore, the claim is not yet supported by the evidence provided.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000368",
    "statement": "Coronavirus vaccines remain through safety trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that vaccines are being tested in human trials for safety and immune response, but it does not provide any information about whether they have remained through these trials or not.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000369",
    "statement": "Coronavirus vaccines work through safety trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that coronavirus vaccines work through safety trials. The evidence provided shows that the first human trials of the vaccines are focusing on their safety, as well as inducing immune responses similar to those of people who have been infected with the virus. This implies that if a vaccine proves safe in the initial trials, it would then move to efficacy trials to determine its effectiveness in protecting against COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000370",
    "statement": "Couple diagnosed with coronavirus flew on delta , hawaiian airlines flights , carriers confirm",
    "label": "SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that a couple diagnosed with coronavirus traveled on Delta and Hawaiian Airlines flights, and the evidence shows that both airlines have confirmed this fact.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000371",
    "statement": "Mice diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that mice were diagnosed with coronavirus and flew on Delta and Hawaiian Airlines flights. The evidence provided only confirms that a couple was diagnosed with the virus and traveled on these flights, not that mice were involved.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000372",
    "statement": "Dogs diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that dogs diagnosed with coronavirus flew on Delta and Hawaiian Airlines flights. However, the evidence only confirms that a couple who were diagnosed with the coronavirus traveled on these flights, not their pets or dogs.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000373",
    "statement": "Cats diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided confirms that a couple diagnosed with coronavirus traveled on Delta and Hawaiian Airlines flights. However, it does not mention cats were involved in these flights. To evaluate the claim fully, information about the travel of cats would be necessary.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000374",
    "statement": "Latest data show above 80 % efficacy for favipiravir in covid-19 , say rdif and chemrar",
    "label": "SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that favipiravir has an efficacy above 80%, which is the criterion for a drug with high antiviral activity. This implies that the latest data shows above 80% efficacy for favipiravir in COVID-19, as stated in the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000375",
    "statement": "Latest data show only 80 % efficacy for favipiravir in covid-19, say rdif and chemrar",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the latest data shows only 80% efficacy for favipiravir in COVID-19, as reported by RDIF and ChemRAR. The evidence provided indicates that the drug's efficacy is above a threshold of 80%, which is the criterion for a drug with high antiviral activity. This supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000376",
    "statement": "Latest data show nearly 80 % efficacy for favipiravir in covid-19, say rdif and chemrar",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the Dhaka Trial shows clear-cut evidence of favipiravir's effectiveness against COVID-19 with an efficacy above 80%. This is consistent with the criterion for a drug with high antiviral activity (>80%).",
    "confidence": 1
  },
  {
    "id": "covid_fact-000377",
    "statement": "Antibody test for covid-19 could help to control virus spread , says singapore medtech firm",
    "label": "SUPPORTED",
    "evidences": [
      "Yee estimates commissioning roughly two million COVID-19 test kits in the next two months from Nanjing-based Vazyme Biotech, a Chinese producer of enzymes and antibodies.",
      "The medtech company, which specializes in cancer treatment equipment and applications, has created a test kit that detects antibodies directed against the coronavirus thats sweeping the world.",
      "Meanwhile, Singapores Ministry of Health issued a document released to all registered medical practitioners on April 3 stating, There is currently no role for COVID-19 serology rapid test kits in the diagnosis of COVID-19 infections. The Biolidics test checks the blood for antibodies and can identify who was previously infected and may have already developed immunity to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that an antibody test for COVID-19 could help control the virus spread, but the evidence provided does not explicitly support this statement. The information mentions the creation of a test kit and its ability to detect antibodies in those who may have been previously infected, but it does not suggest any direct impact on controlling the virus spread.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000378",
    "statement": "Antibody test for covid-19 cannot help to control virus spread, says singapore medtech firm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Yee estimates commissioning roughly two million COVID-19 test kits in the next two months from Nanjing-based Vazyme Biotech, a Chinese producer of enzymes and antibodies.",
      "The medtech company, which specializes in cancer treatment equipment and applications, has created a test kit that detects antibodies directed against the coronavirus thats sweeping the world.",
      "Meanwhile, Singapores Ministry of Health issued a document released to all registered medical practitioners on April 3 stating, There is currently no role for COVID-19 serology rapid test kits in the diagnosis of COVID-19 infections. The Biolidics test checks the blood for antibodies and can identify who was previously infected and may have already developed immunity to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly state that an antibody test for COVID-19 cannot help control the virus spread. Instead, it describes the acquisition of test kits by a medtech company and the Ministry of Health's statement about the diagnostic role of these tests. While the test can identify who may have already been infected and developed immunity, this does not necessarily mean that it cannot help in controlling virus spread.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000379",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of two different serological tests.",
    "label": "SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows the results of two different serological tests for Covid-19 among healthcare workers in a large COVID hospital in Rome, Fondazione Policlinico Universitario A. Gemelli (FPG). The test positivity and negativity rates given indicate that the tests were performed on this group. Therefore, it is supported that the claim reveals strengths and limits of these two different serological tests.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000380",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of three different serological tests.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides data comparing the predictive values of three different serological tests among healthcare workers at a COVID hospital in Rome. This supports the claim that Covid-19 seroprevalence among these healthcare workers is used to evaluate the strengths and limits of the three tests.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000381",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of all different serological tests.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it discusses Covid-19 seroprevalence among healthcare workers of a large COVID hospital in Rome (Fondazione Policlinico Universitario A. Gemelli), and the provided data contrasts point-of-care tests versus venous blood tests for this specific population, thereby demonstrating the strengths and limits of different serological tests.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000382",
    "statement": "A neutralizing human antibody binds to the n-terminal domain of the spike protein of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.",
      "( B ) The correlations between the authentic SARS-CoV-2 neutralizing antibody (NAb) titers and the pseudotyped SARS-CoV-2 NAb titers in plasma."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence consists of studies that show the presence and correlation of human neutralizing antibodies elicited by SARS-CoV-2 infection. This indicates the existence of a human antibody binding to the spike protein of SARS-CoV-2, which is precisely what the claim asserts.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000383",
    "statement": "A neutralizing mouse antibody binds to the n-terminal domain of the spike protein of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.",
      "( B ) The correlations between the authentic SARS-CoV-2 neutralizing antibody (NAb) titers and the pseudotyped SARS-CoV-2 NAb titers in plasma."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that human neutralizing antibodies elicited by SARS-CoV-2 infection are correlated with the pseudotyped SARS-CoV-2 neutralizing antibody titers in plasma. This suggests that these antibodies are binding to some part of the virus, specifically the spike protein since it is what is being tested. Moreover, the n-terminal domain is mentioned as a possible target for such antibodies in other sources.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000384",
    "statement": "A novel point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents several points suggesting that a point mutation in the n gene of SARS-CoV-2 could affect the detection of the virus by RT-qPCR. It explains that the primers used in RT-qPCR are designed to amplify specific regions of the SARS-CoV-2 genome, and mutations or recombinations can make it difficult to effectively diagnose viral infection with existing primers. The evidence also suggests the possibility of selective mutations in SARS-CoV-2, highlighting the need to avoid certain regions when designing primers and probes. Lastly, an example is given where a mutation in a reverse primer affected the sensitivity of an RT-qPCR assay early in the pandemic, implying that further mutations could lead to false negative results.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000385",
    "statement": "A third point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides multiple references to the challenges that SARS-CoV-2 mutations pose for the sensitivity and specificity of RT-qPCR assays used in detecting the virus. While the claim focuses on a third point mutation in the n gene specifically, the general concern about the impact of mutations on RT-qPCR detection is supported by the evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000386",
    "statement": "A major point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that mutations in SARS-CoV-2 can potentially affect the detection of the virus by RT-qPCR due to changes in the target regions being amplified by the primers and probes. The examples provided show instances where a specific mutation in the reverse primer has already been shown to impact the sensitivity of an RT-qPCR assay.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000387",
    "statement": "99.9 % of sars-cov-2 gets destroyed after gargling betadine , claims study",
    "label": "SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided, which indicates that a 99.9% reduction of SARS-CoV-2 was observed within 15 seconds when using Betadine Gargle in the study.",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000388",
    "statement": "99.9 % of sars-cov-2 gets stable after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions that Betadine can destroy 99.9% of the virus within specific timeframes (15 to 30 seconds, 60 seconds, and 5 minutes). However, it does not claim or prove that gargling Betadine will result in a 99.9% reduction of SARS-CoV-2 in individuals who use it. Further evidence is needed to establish the claim about the effect of gargling Betadine on the virus in the body.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000389",
    "statement": "99.9 % of sars-cov-2 gets effective after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that gargling with Betadine effectively kills 99.9% of SARS-CoV-2 virus within a short period (15 to 30 seconds). The evidence provided indicates that Betadine products can destroy 99.9% of the coronavirus, but it does not explicitly confirm that this occurs after gargling for such a short duration or that the effect is effective on live virus in vivo.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000390",
    "statement": "99.9 % of sars-cov-2 gets active after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that Betadine can destroy 99.9% of Coronavirus within certain time periods, but it does not specifically mention or imply that 99.9% of SARS-CoV-2 (the specific strain causing COVID-19) gets active after gargling betadine.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000391",
    "statement": "Identification of sars-cov-2 vaccine epitopes predicted to induce long-term population-scale immunity",
    "label": "SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim discusses the identification of epitopes in the SARS-CoV-2 vaccine predicted to induce long-term population-scale immunity. The provided evidence presents a figure showing proposed vaccine epitopes and the crystal structure of the spike protein. However, this data does not directly confirm or disprove the claim as it lacks empirical evidence demonstrating that these specific epitopes indeed induce long-term immunity in populations when used as a vaccine.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000392",
    "statement": "Identification of sars-cov-2 vaccine epitopes fails to induce long-term population-scale immunity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes the proposed vaccine epitopes in SARS-CoV-2 Spike protein, which is a crucial step for vaccines development. However, it does not provide any direct data or results to support or refute the claim that identification of these epitopes fails to induce long-term population-scale immunity.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000393",
    "statement": "Identification of sars-cov-2 vaccine epitopes failed to induce long-term population-scale immunity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests proposed vaccine epitopes in SARS-CoV-2 and a spike protein structure (PDB: 6VYB). However, it does not provide information about the efficacy of these vaccines or their ability to induce long-term population-scale immunity. Long-term population-scale immunity requires data from real-world usage over time and comparison with placebo groups or unvaccinated populations. As such, the claim cannot be conclusively evaluated based on this evidence.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000394",
    "statement": "Serial interval of sars-cov-2 was shortened over time by nonpharmaceutical interventions",
    "label": "SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that empirical serial interval distributions show a shortening of the serial intervals for SARS-CoV-2 over time and that this change correlates with the introduction of nonpharmaceutical interventions. Furthermore, it is stated that the serial intervals substantially shortened in mainland China.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000395",
    "statement": "Serial interval of sars-cov-2 was increased over time by nonpharmaceutical interventions",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does indicate that the average serial interval of SARS-CoV-2 substantially shortened over time in mainland China. However, this observation does not necessarily imply that the serial interval was increased over time by nonpharmaceutical interventions. The causality is not explicitly stated or proven.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000396",
    "statement": "Serial interval of sars-cov-2 was obtained over time by nonpharmaceutical interventions",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the serial intervals for transmission of SARS-CoV-2 changed over time, and this change is linked to nonpharmaceutical interventions. The evidence also indicates that these changes were observed in mainland China.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000397",
    "statement": "Sars-cov-2 is not detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that Sars-cov-2 is not detectable in the vaginal fluid of women with severe Covid-19 infection. The evidence provided consists of 10 patients tested negative for SARS-CoV-2 in their vaginal fluid samples. Given that no positive results were found and a sufficient number of patients (10) were tested, it is reasonable to conclude, based on this evidence, that the virus does not exist in the vaginal fluids of these severe Covid-19 patients.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000398",
    "statement": "Sars-cov-2 is also detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that 10 women with severe COVID-19 were tested for SARS-CoV-2 in vaginal fluid and all samples came back negative. However, this is a small sample size and does not conclusively prove that the virus is not detectable in the vaginal fluid of severe COVID-19 patients. Further research with a larger sample size would be needed to support such a claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000399",
    "statement": "Sars-cov-2 is only detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only shows that SARS-CoV-2 was not detected in the vaginal fluid of ten severe COVID-19 patients. It does not imply that the virus is never detectable in the vaginal fluid of women with any form of COVID-19 infection.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000400",
    "statement": "Sars-cov-2 is still detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence presented shows that all 10 patients tested negative for SARS-CoV-2 in vaginal fluid, suggesting that the virus may not be present in this location for those specific patients. However, it does not definitively prove that the virus is never detectable in the vaginal fluid of women with severe COVID-19 infection because the sample size is too small to make such a generalization.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000401",
    "statement": "Sars-cov-2 infects monocytes and macrophages , without cytopathic effect",
    "label": "SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that SARS-CoV-2 can infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000402",
    "statement": "Sars-cov-2 infects monocytes and macrophages, cause cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence clearly states that SARS-CoV-2 infects monocytes and macrophages but does not cause a cytopathic effect. This means the virus replicates within these cells without killing them, which aligns with the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000403",
    "statement": "Sars-cov-2 infects monocytes and macrophages, an cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the claim directly states that SARS-CoV-2 infects monocytes and macrophages without causing a cytopathic effect. This aligns with the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000404",
    "statement": "Sars-cov-2 infects monocytes and macrophages, a cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that SARS-CoV-2 can infect monocytes and macrophages, but it does not induce a cytopathic effect. Thus, the claim is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000405",
    "statement": "Rapid clinical deterioration of severe covid-19 may be associated with stroke",
    "label": "SUPPORTED",
    "evidences": [
      "\"For those with severe COVID-19, rapid clinical deterioration or worsening could be associated with a neurologic event such as stroke, which would contribute to its high mortality rate,\" the team wrote in JAMA Neurology."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that rapid clinical deterioration or worsening of severe COVID-19 could be associated with a neurologic event such as stroke. This supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000406",
    "statement": "Rapid clinical deterioration of severe covid-19 may be associated with pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"For those with severe COVID-19, rapid clinical deterioration or worsening could be associated with a neurologic event such as stroke, which would contribute to its high mortality rate,\" the team wrote in JAMA Neurology."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that 'rapid clinical deterioration or worsening' in severe COVID-19 cases might be associated with neurologic events such as stroke. Pneumonia is a common complication of COVID-19 and can lead to rapid clinical deterioration, making it a plausible condition associated with the deterioration mentioned in the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000407",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for replication in primary human respiratory cells",
    "label": "SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides viral sequencing data and kinetic virus replication data from both non-human Vero cells and primary human bronchial epithelial cells (BEpCs). This comparison indicates that distinct phenotypes of SARS-CoV-2 isolates may reveal traits critical for replication in primary human respiratory cells.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000408",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for pathogenicity in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows an association of viral sequencing data from patient material, viral stocks, and passaging experiments with distinct phenotypes in both non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs). This suggests that these sequence features may be critical for the pathogenicity of SARS-CoV-2 isolates within primary human respiratory cells.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000409",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for infection in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes the analysis of viral sequencing data from different sources (patient material, viral stocks, and passaging experiments) in both non-human Vero-CCL81 cells and primary human bronchial epithelial cells (BEpCs). This process indicates a comparison between distinct phenotypes of SARS-CoV-2 isolates, suggesting that certain sequence features are associated with these phenotypes. As the evidence discusses critical traits for infection in primary human respiratory cells, it supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000410",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for mortality in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that there are distinct phenotypes of SARS-CoV-2 isolates associated with specific sequence features. However, it does not directly support the claim that these viral traits are critical for mortality in primary human respiratory cells. The association between these sequence features and mortality in human respiratory cells would require further experimental evidence.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000411",
    "statement": "Esc council on hypertension says ace-i and arbs do not increase covid-19 mortality",
    "label": "SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that 'the Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.' This suggests the claim 'Esc council on hypertension says ace-i and arbs do not increase covid-19 mortality' is supported by the given evidence.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000412",
    "statement": "Esc council on hypertension says ace-i and arbs do and increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that 'Esc council on hypertension says ace-i and arbs do and increase COVID-19 mortality'. The given evidence instead states that there is no clinical or scientific evidence to suggest that ACE-I or ARB treatment causes harm in COVID-19 infections.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000413",
    "statement": "Esc council on hypertension says ace-i and arbs do also increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided claim states that 'Esc council on hypertension says ace-i and arbs do also increase covid-19 mortality.' However, the evidence provided explicitly states that there is no clinical or scientific evidence to support the idea that ACE-I and ARB treatment causes harm in COVID-19 infections. The evidence suggests the opposite, implying that they should be continued.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000414",
    "statement": "Esc council on hypertension says ace-i and arbs do significantly increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the Esc council on hypertension states that ACE-i and ARBs significantly increase Covid-19 mortality, but the evidence provided says exactly the opposite: that there is no clinical or scientific evidence to suggest they cause harm in COVID-19 infections. Thus, the claim is contradicted by the information given.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000415",
    "statement": "Coronavirus threatens small businesses",
    "label": "SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Coronavirus threatens small businesses' is supported by the evidence provided. The text explicitly states that the crisis could be catastrophic for small businesses and mentions specific ways the economy is affecting them negatively (stock market declines, supply chain backups, company cancellations of business travel and meetings). It also points out that public alarm is impacting small businesses even in areas with no widespread outbreak or official guidance to stay inside. The quote from Amanda Ballantyne further emphasizes the threat to small businesses.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000416",
    "statement": "Coronavirus threatens worldwide businesses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about the impact of Coronavirus on worldwide businesses, with a focus on small businesses. The evidence provided demonstrates that the outbreak indeed affects the economy in various ways such as stock market declines, supply chain disruptions, and company travel cancellations. It also indicates that these effects are particularly significant for small businesses, which are on the 'front line' of this crisis. Therefore, the claim is supported by the evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000417",
    "statement": "Coronavirus threatens globally businesses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the coronavirus outbreak is having a significant impact on businesses globally, particularly small ones. The article mentions various ways the economy has been affected by the outbreak, such as stock market declines, supply chain disruptions, and cancellations of business travel and meetings. Additionally, the statement 'small businesses are on the front line of this crisis' indicates they are being directly impacted. Although the claim does not explicitly state that it threatens businesses globally, the evidence implies this by demonstrating the widespread negative effects on businesses due to the coronavirus outbreak.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000418",
    "statement": "Deaths in new york city are more than double the usual total",
    "label": "SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that over the 31 days ending April 4, the number of deaths in New York City was about 5,000 more than usual. This implies that the current number of deaths is more than double the typical number.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000419",
    "statement": "Deaths in new york city are more than below the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that over a 31-day period ending April 4th, the death toll in New York City was approximately 5,000 more than the typical number. This suggests that deaths in New York City are indeed more than usual.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000420",
    "statement": "Children in new york city are more than double the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that 'Children in new york city are more than double the usual total.' However, the provided evidence only discusses deaths of all causes for New Yorkers over a month period, not specifically focusing on children or comparing current numbers to a typical baseline.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000421",
    "statement": "Patients in new york city are more than double the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that approximately 5,000 more people died over the past month in New York City compared to usual. However, it does not directly compare this number to the total population of New York City patients, making it unclear whether the claim that patients are more than double the usual total is supported.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000422",
    "statement": "Covid-19 racial disparities could be worsened by location of test sites",
    "label": "SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that Covid-19 racial disparities could be worsened by location of test sites. The provided evidence suggests a case where the availability of tests in a specific area (Northern Dallas) is higher compared to another area (Southern Dallas), which may lead to disparities in access to testing based on location, potentially exacerbating racial disparities.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000423",
    "statement": "Covid-19 racial disparities cannot be worsened by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence points to a disparity in testing availability between the northern and southern parts of Dallas, which could potentially worsen racial disparities if access to testing is disproportionately lower in areas with higher minority populations. However, the evidence does not explicitly state or provide data on the racial makeup of these areas, nor does it rule out other factors that might contribute to racial disparities in Covid-19 cases and outcomes.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000424",
    "statement": "Covid-19 racial disparities could be assessed by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that location of test sites could contribute to racial disparities in access to Covid-19 testing, as indicated by the quote 'A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.' While it's important to note that other factors may also affect access to testing, location seems to be an important starting point.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000425",
    "statement": "Covid-19 racial disparities could be defined by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that a factor contributing to racial disparities in Covid-19 testing could be the location of test sites, as there might be differences in accessibility and availability of tests between northern and southern Dallas, potentially impacting racially diverse communities differently.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000426",
    "statement": "Overweight and obesity are risks factors of severe illness in patients with covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Having obesity may triple the risk of hospitalization due to a COVID-19 infection.",
      "Conclusions: Overweight and obesity were independent risk factors of severe illness in COVID-19 patients.",
      "Overweight, Obesity and Severe Obesity Having obesity, defined as a body mass index (BMI) between 30 kg/m2 and <40 kg/m2 or severe obesity (BMI of 40 kg/m2 or above), increases your risk of severe illness from COVID-19.",
      "Having obesity puts people at risk for many other serious chronic diseases and increases the risk of severe illness from COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that having obesity may triple the risk of hospitalization due to a COVID-19 infection. The conclusions also state that overweight and obesity are independent risk factors of severe illness in COVID-19 patients. Furthermore, the text explains that obesity increases the risk of severe illness from COVID-19. All these statements support the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000427",
    "statement": "Overweight and obesity are risks factors of severe illness in patients without covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Having obesity may triple the risk of hospitalization due to a COVID-19 infection.",
      "Conclusions: Overweight and obesity were independent risk factors of severe illness in COVID-19 patients.",
      "Overweight, Obesity and Severe Obesity Having obesity, defined as a body mass index (BMI) between 30 kg/m2 and <40 kg/m2 or severe obesity (BMI of 40 kg/m2 or above), increases your risk of severe illness from COVID-19.",
      "Having obesity puts people at risk for many other serious chronic diseases and increases the risk of severe illness from COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that having obesity or severe obesity (BMI over 30 kg/m2) increases the risk of hospitalization and severe illness from COVID-19. Overweight is not directly mentioned in this context but is often associated with increased BMI, so it can be inferred indirectly.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000428",
    "statement": "Intestinal inflammation modulates the expression of ace2 and tmprss2 and potentially overlaps with the pathogenesis of sars-cov-2 related disease",
    "label": "SUPPORTED",
    "evidences": [
      "These considerations led us to systematically examine the intersections between COVID-19 and the GI tract during health and intestinal inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it discusses the examination of the intersections between COVID-19 and the GI tract during intestinal inflammation. The article mentions the modulation of ACE2 (angiotensin-converting enzyme 2) and TMPRSS2 (transmembrane protease, serine 2), which are critical for SARS-CoV-2 entry into cells. Therefore, it suggests a potential overlap between intestinal inflammation and the pathogenesis of SARS-CoV-2 related disease.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000429",
    "statement": "Intestinal inflammation modulates the production of ace2 and tmprss2 and potentially overlaps with the pathogenesis of sars-cov-2 related disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These considerations led us to systematically examine the intersections between COVID-19 and the GI tract during health and intestinal inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that intestinal inflammation modulates the production of ACE2 and TMPRSS2, which potentially overlaps with the pathogenesis of SARS-CoV-2 related disease. The evidence provided mentions a systematic examination of the intersections between COVID-19 and the GI tract during health and intestinal inflammation, implying that changes in ACE2 and TMPRSS2 could be part of this examination. Thus, the claim is supported as it aligns with the line of investigation suggested by the evidence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000430",
    "statement": "Sars-cov-2 simulations go exascale to capture spike opening and reveal cryptic pockets across the proteome",
    "label": "SUPPORTED",
    "evidences": [
      "We also observe dramatic conformational changes across the proteome, which reveal over 50 cryptic pockets that expand targeting options for the design of antivirals.",
      "To address this challenge, over a million citizen scientists banded together through the Folding@home distributed computing project to create the first exascale computer and simulate an unprecedented 0.1 seconds of the viral proteome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that dramatic conformational changes across the proteome reveal over 50 cryptic pockets that expand targeting options for the design of antivirals. Additionally, it mentions that over a million citizen scientists came together to create the first exascale computer and simulate an unprecedented 0.1 seconds of the viral proteome. Therefore, the claim that Sars-Cov-2 simulations go exascale to capture spike opening and reveal cryptic pockets across the proteome is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000431",
    "statement": "Sars-cov-2 simulations go exascale to avoid spike opening and reveal cryptic pockets across the proteome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We also observe dramatic conformational changes across the proteome, which reveal over 50 cryptic pockets that expand targeting options for the design of antivirals.",
      "To address this challenge, over a million citizen scientists banded together through the Folding@home distributed computing project to create the first exascale computer and simulate an unprecedented 0.1 seconds of the viral proteome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that simulations of Sars-cov-2 go exascale to avoid spike opening and reveal cryptic pockets across the proteome. The evidence provided mentions over a million citizen scientists working together through the Folding@home project to create an exascale computer and simulate 0.1 seconds of the viral proteome, but it does not explicitly state that these simulations were specifically intended to avoid spike opening or reveal cryptic pockets across the proteome.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000432",
    "statement": "Experts divide into two camps of actionshielding versus blanket policies",
    "label": "SUPPORTED",
    "evidences": [
      "One group of doctors and academics is calling for segmentation and shielding of the most vulnerable groups of people rather than local or national lockdown measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a group of experts is advocating for segmentation and shielding of vulnerable groups instead of local or national lockdown measures. This can be interpreted as a division between 'actionshielding' (segmentation and shielding) and 'blanket policies' (local or national lockdowns).",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000433",
    "statement": "Poolkeh finds the optimal pooling strategy for a population-wide covid-19 testing",
    "label": "SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes a framework for maximizing COVID-19 testing throughput by finding optimal pooling strategies according to the current SIR-D status of a nation. However, it does not specify that Poolkeh is the tool or method used to find this optimal pooling strategy. Therefore, the claim that Poolkeh finds the optimal pooling strategy for population-wide COVID-19 testing is not supported by the given evidence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000434",
    "statement": "Poolkeh finds the initial pooling strategy for a population-wide covid-19 testing",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes a method for maximizing COVID-19 testing throughput by optimizing test pooling strategies according to the current SIR-D status of a nation. However, it does not mention or provide any information about 'Poolkeh' finding this initial strategy.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000435",
    "statement": "Poolkeh finds the first pooling strategy for a population-wide covid-19 testing",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses a framework that allows health agencies to optimize COVID-19 test throughput by selecting the best test pooling for a given SIR-D status, but it does not provide information about whether Poolkeh finds the first population-wide testing strategy.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000436",
    "statement": "Global coronavirus death toll could be 60 % higher than reported",
    "label": "SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the figure of excess deaths is 58% higher than the total number of reported Covid-deaths for the same period. This implies that the global coronavirus death toll could indeed be 60% higher than reported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000437",
    "statement": "Global coronavirus death toll could be 60 % less than reported",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the number of excess deaths is significantly higher than the official coronavirus fatalities, and this discrepancy is most pronounced in urban areas with the worst virus outbreaks. The figure for excess deaths is 76% higher than the average for the same week in the past five years, and the number of excess deaths is 58% higher than the total number of reported Covid-deaths for the same period. Therefore, it can be inferred that the global coronavirus death toll could be up to 60% less than reported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000438",
    "statement": "Global coronavirus death toll could be 60 % lower than reported",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the global coronavirus death toll could be 60% lower than reported. The evidence provides numbers suggesting an excess mortality of 58%, which is close to 60%. This difference may not only be due to underreporting of COVID-19 deaths, but also other factors such as deaths related to healthcare system overload and delays in reporting non-COVID deaths during the pandemic. However, the evidence suggests that the global coronavirus death toll could indeed be significantly lower than officially reported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000439",
    "statement": "In a phylogenetic network analysis of 160 complete human severe acute respiratory syndrome coronavirus 2 genomes , we find three central variants distinguished by amino acid changes , which we have named a , b , and c ...",
    "label": "SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support the claim that three central variants were identified in a phylogenetic network analysis of 160 complete SARS-CoV-2 genomes, as it only mentions the presentation of a phylogenetic network but does not specify or describe the discovery of these variants.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000440",
    "statement": "In a phylogenetic network analysis of five complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions a specific phylogenetic network analysis of five complete human SARS-CoV-2 genomes, but the evidence only provides a phylogenetic network of 160 largely complete SARS-CoV-2 genomes. It does not provide sufficient detail about the analysis mentioned in the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000441",
    "statement": "In a phylogenetic network analysis of four complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim does not provide enough information to determine if it is supported or not. The evidence only states that a phylogenetic network analysis was performed on 160 SARS-Cov-2 genomes, but it doesn't specify which four genomes the claim refers to, nor does it show any results of the analysis supporting the existence of variants 'a', 'b', and 'c'. To evaluate this claim, we would need details about the methodology used for the analysis, the specific genomes analyzed, and the findings regarding these three variants.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000442",
    "statement": "In a phylogenetic network analysis of six complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions a specific analysis of six human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes. However, the provided evidence only shows that a phylogenetic network of 160 largely complete SARS-CoV-2 genomes was presented. It does not specify if or which of these 160 genomes are part of the analysis mentioned in the claim.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000443",
    "statement": "The cellular immune response to covid-19 deciphered by single cell multi-omics across three uk centres.",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these data detail the cellular processes present in peripheral blood during an acute immune response to COVID-19, and serve as a template for multi-omic single cell data integration across multiple centers to rapidly build powerful resources to help combat diseases such as COVID-19.",
      "Full single cell transcriptomes coupled with quantification of 188 cell surface proteins, and T and B lymphocyte antigen receptor repertoires have provided several insights into COVID-19: 1. a new non-classical monocyte state that sequesters platelets and replenishes the alveolar macrophage pool; 2. platelet activation accompanied by early priming towards megakaryopoiesis in immature haematopoietic stem/progenitor cells and expansion of megakaryocyte-primed progenitors; 3. increased clonally expanded CD8+ effector:effector memory T cells, and proliferating CD4+ and CD8+ T cells in patients with more severe disease; and 4. relative increase of IgA plasmablasts in asymptomatic stages that switches to expansion of IgG plasmablasts and plasma cells, accompanied with higher incidence of BCR sharing, as disease severity increases.",
      "To characterise the systemic host immune response to SARS-CoV-2, we performed single-cell RNA- sequencing coupled with analysis of cell surface proteins, providing molecular profiling of over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided. The evidence describes a study that characterizes the cellular immune response to COVID-19 using single cell multi-omics across three UK centers. It details various insights into the immune response to COVID-19 such as non-classical monocyte states, platelet activation, T and B lymphocyte responses, etc. The evidence also mentions that this study used single-cell RNA sequencing coupled with analysis of cell surface proteins to profile over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000444",
    "statement": "The cellular immune response to covid-19 deciphered by single cell multi-omics across two uk centres.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these data detail the cellular processes present in peripheral blood during an acute immune response to COVID-19, and serve as a template for multi-omic single cell data integration across multiple centers to rapidly build powerful resources to help combat diseases such as COVID-19.",
      "Full single cell transcriptomes coupled with quantification of 188 cell surface proteins, and T and B lymphocyte antigen receptor repertoires have provided several insights into COVID-19: 1. a new non-classical monocyte state that sequesters platelets and replenishes the alveolar macrophage pool; 2. platelet activation accompanied by early priming towards megakaryopoiesis in immature haematopoietic stem/progenitor cells and expansion of megakaryocyte-primed progenitors; 3. increased clonally expanded CD8+ effector:effector memory T cells, and proliferating CD4+ and CD8+ T cells in patients with more severe disease; and 4. relative increase of IgA plasmablasts in asymptomatic stages that switches to expansion of IgG plasmablasts and plasma cells, accompanied with higher incidence of BCR sharing, as disease severity increases.",
      "To characterise the systemic host immune response to SARS-CoV-2, we performed single-cell RNA- sequencing coupled with analysis of cell surface proteins, providing molecular profiling of over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides detailed insights into the cellular immune response to COVID-19 through single cell multi-omics across two UK centres. The findings include characterization of various cell types and their behavior during an acute immune response to COVID-19. Additionally, the evidence includes specific analysis methods like single-cell RNA sequencing and analysis of cell surface proteins, which are commonly used for understanding the immune system's response to pathogens.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000445",
    "statement": "University of oxford resumes vaccine trial",
    "label": "SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'University of Oxford resumes vaccine trial' is based on the statement that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) recommended the trials to resume after a pause. Furthermore, it is supported by a tweet from someone stating 'Good news for everyone, the Oxford vaccine trials are back up and running.'",
    "confidence": 1
  },
  {
    "id": "covid_fact-000446",
    "statement": "Lack of oxford resumes vaccine trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that 'Lack of oxford resumes vaccine trial', which contradicts the provided evidence showing that the Oxford vaccine trial has resumed. The tweet only confirms that the trials are up and running but does not provide any information about a lack of something.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000447",
    "statement": "Development of oxford resumes vaccine trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that the development of the Oxford COVID-19 vaccine trial has resumed is supported by the evidence provided. The statement mentions that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) recommended the resumption of trials after a pause, which indicates that the trials had been halted previously and are now restarting.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000448",
    "statement": "Slight reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in this claim suggests that masking leads to a significant reduction in exposure to SARS-CoV-2 viral load, which in turn reduces transmission risk. The evidence supports this with the prediction of up to a 10-fold reduction in exposure viral load for those who get infected despite wearing masks, and the demonstration that even a 50% reduction in viral load substantially reduces the probability of successful transmission. Furthermore, it is noted that increasing mask adherence or efficacy would reduce the effective reproductive number (Re) below 1, which indicates a decrease in the spread of the virus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000449",
    "statement": "High reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that a high reduction in SARS-CoV-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation. The evidence provided supports this claim by predicting a 10-fold decrease in exposure viral load among people who get infected despite masking, which would limit infection severity. Additionally, it indicates that slight increases in mask adherence and/or efficacy could lower the effective reproductive number (Re) substantially below 1, thereby reducing transmission risk. The results also reinforce that the use of masks by both a potential transmitter and exposed person significantly reduces the probability of successful transmission.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000450",
    "statement": "Significant reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that masking leads to a significant reduction in SARS-CoV-2 exposure viral load, which in turn reduces the probability of transmission. The evidence includes statements about the effectiveness of masks in lowering exposure viral load and reducing the effective reproductive number (R0) below 1. Additionally, the results are quantitatively linked to mask efficacy and reductions in viral load.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000451",
    "statement": "National smoking rates correlate inversely with covid-19 mortality",
    "label": "SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a statistically significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate. This suggests that lower smoking rates may be associated with higher COVID-19 mortality.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000452",
    "statement": "National smoking rates correlate closely with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate in both 'hot' and 'cold' countries, as well as when considering all countries together. This suggests that lower smoking rates may correspond to higher COVID-19 mortality, aligning with the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000453",
    "statement": "National smoking rates correlate closerly with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate for both hot countries and cold countries, as well as the combined group. This supports the claim that national smoking rates correlate more closely with COVID-19 mortality.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000454",
    "statement": "National smoking rates correlate greaterly with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate in both hot and cold countries, as well as when considering all countries together. This suggests that higher smoking rates may be associated with lower COVID-19 mortality rates, which aligns with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000455",
    "statement": "Cryptic transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that cryptic transmission of SARS-CoV-2 can be revealed by genomic epidemiology. The evidence provides a paper about cryptic transmission of novel coronavirus being revealed by genomic epidemiology, which directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000456",
    "statement": "Viral transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes how genome sequencing of SARS-CoV-2 strains is used to reconstruct transmission history, which supports the claim that viral transmission of novel coronavirus SARS-CoV-2 can be revealed by genomic epidemiology.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000457",
    "statement": "Phylogenetic transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that genome sequencing of SARS-CoV-2 strains is used for the reconstruction of transmission history, which implies studying the phylogenetic transmission of the novel coronavirus. This is supported by the fact that genomic epidemiology focuses on understanding patterns of pathogen transmission and spread.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000458",
    "statement": "Initial transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history, which is consistent with the claim that initial transmission of novel coronavirus SARS-CoV-2 was revealed by genomic epidemiology.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000459",
    "statement": "Nurses and other union workers authorize oct. 7 strike against east bay hospitals",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that employees in the Alameda Health System, which serves minority communities, plan to start a five-day strike on Oct. 7 according to the California Nurses Association. This suggests that nurses and other union workers are authorizing this strike against east bay hospitals.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000460",
    "statement": "Nurses and other union workers authorize dr. 7 strike against east bay hospitals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the form of a photo caption indicates that employees in the Alameda Health System (which includes nurses and other union workers) have announced plans to begin a five-day strike on October 7. The California Nurses Association is mentioned as the announcer, further supporting the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000461",
    "statement": "Nurses and other union workers authorize s. 7 strike against east bay hospitals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that employees in the Alameda Health System, which largely serves minority communities, plan to begin a five-day strike on Oct. 7. This is according to the California Nurses Association as indicated by the photo caption. The mention of nurses and other union workers implies they are among the striking employees.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000462",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly vanishing in severe cases",
    "label": "SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides serological testing results on IgG and IgM responses to SARS-CoV-2 in hospitalized patients over a 2-month period. The text indicates a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients, suggesting that long-lived immunoglobulin g antibodies specific against SARS-CoV-2 virus are rapidly vanishing in severe cases.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000463",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly circulating in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that serological surveys were performed on hospitalized COVID-19 patients in Reunion Island to assess IgG and IgM responses against SARS-CoV-2. The evidence also indicates a significant decrease of IgG levels in severe (ICU) hospitalized patients, which implies the presence of long-lived immunoglobulin g antibodies specific against SARS-CoV-2 virus in these cases.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000464",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly produced in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that serological testing was performed on hospitalized patients with COVID-19 in Reunion Island to identify IgG and IgM responses against the SARS-CoV-2 virus. The results demonstrated a significant decrease in IgG levels in severe cases (ICU) by Western Blot and ELISA. However, the evidence does not directly indicate that long-lived immunoglobulin G antibodies specific against the SARS-CoV-2 virus are rapidly produced in severe cases, as stated in the claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000465",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly transmitted in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that serological surveys were conducted on hospitalized patients in Reunion Island to assess IgG and IgM responses to SARS-CoV-2. The results demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients, suggesting that long-lived immunoglobulin G antibodies specific against the SARS-CoV-2 virus are present and may be rapidly transmitted in severe cases.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000466",
    "statement": "Moderna announces first participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it states that Moderna is conducting a Phase 2/3 study of its COVID-19 vaccine candidate in adolescents, which aligns with the statement in the evidence.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000467",
    "statement": "Moderna announces all participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests Moderna is conducting a Phase 2/3 study on the COVID-19 vaccine candidate in adolescents to evaluate safety, reactogenicity, and immunogenicity. However, it does not explicitly state that all participants have been dosed.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000468",
    "statement": "Moderna announces from participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information about a Phase 2/3 study of Moderna's COVID-19 vaccine candidate in adolescents, but it does not state that the company has announced results from participants dosed in this study.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000469",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues",
    "label": "SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that ACE2, the receptor for SARS-CoV-2, is co-expressed with TMPRSS2 in specific cell subsets across tissues including lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells. The SARS-CoV-2 spike protein binds ACE2 and exploits interferon-driven upregulation of ACE2 to enhance infection. This evidence supports the claim that ACE2 is an interferon-stimulated gene in human airway epithelial cells.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000470",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in canine airway epithelial cells and is detected in specific cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that ACE2 and TMPRSS2 are co-expressed in specific cell subsets across tissues, including lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells. Additionally, the SARS-CoV-2 spike protein binds to ACE2, and this interaction is facilitated by TMPRSS2. Furthermore, the evidence suggests that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2 to enhance infection. Therefore, it can be inferred that ACE2 is an interferon-stimulated gene in canine airway epithelial cells and is detected in specific cell subsets across tissues.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000471",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in many cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), which is an interferon-stimulated gene in human airway epithelial cells and is detected in many cell subsets across tissues. The evidence also suggests that ACE2 could be upregulated by species-specific interferon during lung injury, enhancing SARS-CoV-2 infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000472",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in multiple cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that ACE2, the receptor for SARS-CoV-2, is expressed in multiple cell subsets across tissues such as lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells. The fact that these cells also express TMPRSS2, a host protease necessary for cellular entry of SARS-CoV-2, further supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000473",
    "statement": "Structure of sars-cov-2 orf8 , a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that SARS-CoV-2 ORF8 forms large scale assemblies not possible for SARS-CoV and potentially mediates unique immune suppression and evasion activities. The evidence presented supports this claim by discussing the interfaces present in SARS-CoV-2 ORF8 that allow it to form these unique structures, which could enable immune evasion.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000474",
    "statement": "Loss of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the ORF8 protein of SARS-CoV-2 (the virus causing COVID-19) can form unique large-scale assemblies and potentially mediate immune suppression and evasion activities, which is different from SARS-CoV. This implies a possible loss or evolution of this protein compared to its counterpart in SARS-CoV.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000475",
    "statement": "Mutation of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the ORF8 protein in SARS-CoV-2 is a rapidly evolving coronavirus protein implicated in immune evasion, as it forms unique large-scale assemblies not possible for SARS-CoV and potentially mediates unique immune suppression and evasion activities.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000476",
    "statement": "Activation of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the SARS-CoV-2 ORF8 protein, which is implicated in immune evasion, can form unique large-scale assemblies not possible for SARS-CoV. This implies a potential for unique immune suppression and evasion activities, which aligns with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000477",
    "statement": "Israel is arresting palestine 's doctors fighting covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not explicitly mention or imply that Israel is arresting Palestinian doctors fighting COVID-19.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000478",
    "statement": "China is arresting palestine's doctors fighting covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not mention any arrests of Palestinian doctors in China, only mentions Israel's actions to support the United Nations response and medical trainings for Palestinian health workers.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000479",
    "statement": "Israel is called palestine's doctors fighting covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that Israel is called 'Palestine's doctors fighting COVID-19.' While it shows Israel providing resources and medical training to Palestinian health workers during the pandemic, there is no mention of them being referred to as Israel's 'doctors' or Palestine's 'doctors.'",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000480",
    "statement": "Identification of an existing japanese pancreatitis drug , nafamostat , which is expected to prevent the transmission of new coronavirus infection",
    "label": "SUPPORTED",
    "evidences": [
      "The University of Tokyo plans to launch clinical trials in April 2020 in order to evaluate the effectiveness of these two drugs for treating COVID-19.",
      "Both Nafamostat and Camostat were developed in Japan as treatments for pancreatitis and some other diseases.",
      "According to the new research, Nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus SARS-CoV-2.",
      "Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Nafamostat is a Japanese drug developed for treating pancreatitis, and new research suggests it can prevent the fusion of the SARS-CoV-2 virus with host cell surface membranes, which is necessary for infection. The University of Tokyo plans to evaluate its effectiveness in treating COVID-19 through clinical trials.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000481",
    "statement": "Loss of an existing japanese pancreatitis drug, nafamostat, which is expected to prevent the transmission of new coronavirus infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Tokyo plans to launch clinical trials in April 2020 in order to evaluate the effectiveness of these two drugs for treating COVID-19.",
      "Both Nafamostat and Camostat were developed in Japan as treatments for pancreatitis and some other diseases.",
      "According to the new research, Nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus SARS-CoV-2.",
      "Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions a planned clinical trial for evaluating the effectiveness of Nafamostat in treating COVID-19. However, this does not directly prove or disprove that it can prevent the transmission of new coronavirus infection. Additional research and evidence would be needed to support such a claim.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000482",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice causes severe lung inflammation and impaired function",
    "label": "SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Sars-cov-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function' is supported by the evidence provided, which describes that SARS-CoV-2 infection leads to severe immune cell infiltration, inflammation, pulmonary disease, injury, inflammation, and subsequent respiratory distress in these mice.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000483",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice prevented severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that Sars-cov-2 infection of human ace2-transgenic mice prevented severe lung inflammation and impaired function. The evidence states that SARS-CoV-2 infection in these mice leads to severe immune cell infiltration, inflammation, and pulmonary disease. This contradicts the claim, so it is not supported.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000484",
    "statement": "Sars-cov-2 infection of human ace2-transgenic patients causes severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that SARS-CoV-2 infection of K18-hACE2-transgenic mice causes robust viral replication in the lung, leading to severe immune cell infiltration, inflammation, and pulmonary disease. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice suggests that it primarily targets type II pneumocytes within the lung, resulting in injury, inflammation, and subsequent respiratory distress.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000485",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice inhibited severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes the effect of SARS-CoV-2 infection on ACE2-transgenic mice (mice that have human ACE2), which leads to severe immune cell infiltration, inflammation, and pulmonary disease. However, it does not directly state whether or not the infection inhibits severe lung inflammation and impaired function as claimed.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000486",
    "statement": "Thrombotic microvascular injury is not mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that Thrombotic microvascular injury is not mediated by thrombotic microangiopathy despite systemic complement activation in COVID-19 patients. The evidence presented shows that the patients did not have signs of mechanical hemolytic anemia, schistocyte or thrombocytopenia, which are typically associated with Thrombotic microangiopathy. However, the absence of these symptoms does not necessarily mean that there is no association between thrombotic microvascular injury and Thrombotic microangiopathy in COVID-19 patients. More evidence is needed to confirm or refute this claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000487",
    "statement": "Thrombotic microvascular injury is mainly mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided focuses on laboratory results (hemoglobin, haptoglobuline, platelet count) in COVID-19 patients and the absence of signs related to thrombotic microangiopathy (mechanical hemolytic anemia, schistocyte, thrombocytopenia). However, it does not directly address the main claim that thrombotic microvascular injury is mainly mediated by thrombotic microangiopathy in COVID-19 patients. To confirm or refute this claim, additional evidence is needed showing a correlation between thrombotic microvascular injury and thrombotic microangiopathy in the context of COVID-19.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000488",
    "statement": "Thrombotic microvascular injury is primarily mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented in the study does not show signs of mechanical hemolytic anemia or schistocytes (common indicators of thrombotic microangiopathy), and there is no significant thrombocytopenia observed among COVID-19 patients. Instead, the study indicates moderate activation of complement and coagulation systems with presence of thrombotic microvascular injury in these patients. This suggests that thrombotic microvascular injury may be primarily mediated by thrombotic microangiopathy despite systemic complement activation.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000489",
    "statement": "Thrombotic microvascular injury is also mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The study indicates moderate activation of complement and coagulation in COVID-19 patients, with the presence of thrombotic microvascular injury. However, it does not show evidence of systemic thrombotic microangiopathy. This suggests that thrombotic microvascular injury can occur independently of thrombotic microangiopathy despite systemic complement activation in COVID-19 patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000490",
    "statement": "Serum amyloid p inhibits single stranded rna-induced lung inflammation , lung damage , and cytokine storm in mice",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these results suggest that aspiration of ORN06 is a simple model for both COVID-19 as well as cytokine storm in general, and that SAP is a potential therapeutic for diseases with COVID-19-like symptoms as well as diseases that generate a cytokine storm.",
      "A serum protein called serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials. Additionally, it indicates that SAP may be effective in preventing lung inflammation, damage, and cytokine storms, which are symptoms often associated with COVID-19. However, the evidence does not explicitly state that SAP has been proven to prevent these symptoms specifically in mice with COVID-19, but it implies this possibility due to its suggested effectiveness for diseases with similar symptoms.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000491",
    "statement": "Serum amyloid p inhibits single stranded rna-induced lung inflammation, lung damage, and cytokine storm in patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that aspiration of ORN06 is a simple model for both COVID-19 as well as cytokine storm in general, and that SAP is a potential therapeutic for diseases with COVID-19-like symptoms as well as diseases that generate a cytokine storm.",
      "A serum protein called serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that Serum amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in patients. The provided evidence supports this statement by suggesting that a protein called serum amyloid P (SAP) has a calming effect on the innate immune system and is effective as a therapeutic for diseases with COVID-19-like symptoms and diseases that generate a cytokine storm. The given evidence also suggests that aspiration of ORN06, a model for both COVID-19 and cytokine storm, can be influenced by SAP.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000492",
    "statement": "Fda approves the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the FDA issued an Emergency Use Authorization (EUA) for hydroxychloroquine sulfate and Resochin (chloroquine phosphate) to treat hospitalized teen and adult patients with COVID-19. This indicates that the drugs are approved by the FDA for emergency use in this context.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000493",
    "statement": "Fdaines the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that FDA has authorized the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of COVID-19 based on evidence provided. The evidence states that the FDA issued an EUA to allow these drugs to be distributed and prescribed in certain situations when a clinical trial is not available or feasible, implying they can be used as treatments for hospitalized teen and adult patients with COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000494",
    "statement": "Fdaards the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the FDA issued an Emergency Use Authorization (EUA) for chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19. The evidence provided shows that the FDA indeed issued such an authorization for these drugs in response to the pandemic, allowing them to be distributed and prescribed by doctors when a clinical trial is not available or feasible.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000495",
    "statement": "Fdaasts the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the FDA issued an Emergency Use Authorization (EUA) for hydroxychloroquine sulfate to be prescribed for hospitalized teen and adult patients with COVID-19 when a clinical trial is not available or feasible. This supports the claim that the FDA has authorized the emergency use of hydroxychloroquine sulfate for treatment of COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000496",
    "statement": "Genomic epidemiology reveals transmission patterns and dynamics of sars-cov-2 in aotearoa new zealand",
    "label": "SUPPORTED",
    "evidences": [
      "d The sampling location and proportion of SARS-CoV-2 genomes sampled from each viral genomic lineage is shown on the map of New Zealand.",
      "Notably, the genomic diversity of SARS-CoV-2 sequences sampled in New Zealand represented nearly all of the genomic diversity present in the global viral population, with nine second-level A and B lineages from a proposed global SARS-CoV-2 genomic nomenclature17 identified.",
      "3: Genomic transmission lineages of SARS-CoV-2 in New Zealand.",
      "2: Genomic diversity of SARS-CoV-2 in New Zealand."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence demonstrates that genomic epidemiology was used to study the transmission patterns and dynamics of SARS-CoV-2 in New Zealand by sampling its genomic diversity and identifying various lineages. The provided information shows a map illustrating the sampling location of these sequences, as well as their proportions for each viral genomic lineage. Furthermore, it highlights that nearly all global genomic diversity was represented among the sampled SARS-CoV-2 sequences in New Zealand.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000497",
    "statement": "Genomic epidemiology reveals evolutionary patterns and dynamics of sars-cov-2 in aotearoa new zealand",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "d The sampling location and proportion of SARS-CoV-2 genomes sampled from each viral genomic lineage is shown on the map of New Zealand.",
      "Notably, the genomic diversity of SARS-CoV-2 sequences sampled in New Zealand represented nearly all of the genomic diversity present in the global viral population, with nine second-level A and B lineages from a proposed global SARS-CoV-2 genomic nomenclature17 identified.",
      "3: Genomic transmission lineages of SARS-CoV-2 in New Zealand.",
      "2: Genomic diversity of SARS-CoV-2 in New Zealand."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that genomic sampling of SARS-CoV-2 in New Zealand revealed a high degree of diversity, representing nearly all global lineages, indicating the study of genomic epidemiology to reveal evolutionary patterns and dynamics in New Zealand is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000498",
    "statement": "Cross-species transmission of the newly identified coronavirus 2019-ncov",
    "label": "SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the 2019-nCoV is a recombinant virus between bat coronaviruses and an unknown origin coronavirus, implying potential cross-species transmission.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000499",
    "statement": "Cross-species transmission of the newly identified coronavirus e-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim discusses cross-species transmission of the newly identified coronavirus e-ncov. However, the evidence provided suggests only that the virus may be a recombinant between a bat coronavirus and an origin-unknown coronavirus. It does not directly provide information about whether this specific virus has been transmitted across species.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000500",
    "statement": "Cross-species transmission of the previously identified coronavirus 2019-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the coronavirus 2019-nCoV may be a recombinant virus between bat and an unknown coronavirus. Although it does not directly prove cross-species transmission, the implication is that such a recombination event could potentially occur through interspecies contact.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000501",
    "statement": "Cross-species transmission of the newly identified coronavirus b-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that the 2019-nCoV is a recombinant virus between the bat coronavirus and an origin-unknown coronavirus. This implies potential cross-species transmission.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000502",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody escape.",
    "label": "SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a preprint article titled 'Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape'. The article discusses natural deletions in the SARS-CoV-2 spike glycoprotein and their impact on antibody escape. Therefore, it supports the claim that recurrent deletions in the sars-cov-2 spike glycoprotein can drive antibody escape.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000503",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein prevent antibody escape.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. However, this claim does not necessarily mean that these deletions prevent antibody escape. Antibody escape can occur through various mechanisms, and the presence of deletions is just one of them. More evidence would be needed to confirm whether these deletions specifically prevent antibody escape.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000504",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody reactivity.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence is a preprint manuscript titled 'Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape'. The title and abstract of the study suggest that it investigates how deletions in the SARS-CoV-2 spike glycoprotein may impact antibody reactivity. Therefore, it supports the claim that recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody reactivity.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000505",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody production.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a preprint of a study titled 'Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape'. The study discusses how certain deletions (natural variations) in the SARS-CoV-2 spike protein can lead to antibody escape, implying that these deletions impact the body's production of antibodies. Therefore, the claim is supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000506",
    "statement": "Sars-coronavirus-1 open reading frame-8b triggers intracellular stress pathways and activates nlrp3 inflammasomes",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we identify several mechanisms by which a SARS-CoV open reading frame (ORF) activates intracellular stress pathways and targets the innate immune response."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided as it discusses a mechanism by which SARS-CoV ORF activates intracellular stress pathways and targets the innate immune response, specifically by activating NLRP3 inflammasomes.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000507",
    "statement": "Sars-coronavirus-1 open reading frame-8b inhibits intracellular stress pathways and activates nlrp3 inflammasomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we identify several mechanisms by which a SARS-CoV open reading frame (ORF) activates intracellular stress pathways and targets the innate immune response."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that SARS-CoV open reading frame (ORF) activates intracellular stress pathways and targets the innate immune response. This implies that ORF8b of Sars-coronavirus-1, being part of SARS-CoV, would have a similar effect. Furthermore, it's suggested that this activation leads to the inhibition of stress pathways and the activation of nlrp3 inflammasomes.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000508",
    "statement": "A chest-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a flowchart combining CO-RADS and lab-corona-score can result in rapid and accurate diagnosis of COVID-19 at Emergency Departments (ED). The sensitivity and specificity of this flowchart are given as 97% and 96%, respectively. This suggests the flowchart is effective in diagnosing COVID-19 cases. Furthermore, it's mentioned that the flowchart can be used in hospitals that use chest-CT for COVID-19 suspected patients at the ED.",
    "confidence": 0.98
  },
  {
    "id": "covid_fact-000509",
    "statement": "A non-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided claim is supported by evidence that shows a flowchart was developed and tested based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), with the stated sensitivity and specificity for COVID-19 diagnosis at Emergency Departments. The evidence also suggests that this method can be applied in hospitals using chest-CT scans.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000510",
    "statement": "A meta-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a flowchart based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score) for the rapid diagnosis of COVID-19 at emergency departments. It is also stated that this flowchart was developed using data from Slingeland Hospital, and it has high sensitivity and specificity. The evidence suggests that this flowchart can be used in hospitals that use chest-CT for COVID-19 suspected patients.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000511",
    "statement": "A pre-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence describes a pre-ct and clinical chemistry based flowchart developed for rapid covid-19 triage at emergency departments, specifically utilizing both radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score). The accuracy of this approach is supported by the sensitivity (97%) and specificity (96%) reported from data at Slingeland Hospital.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000512",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E. This directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000513",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected after the 2020 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2, which suggests that there is no cross-neutralization by intravenous immunoglobulins produced from plasma collected after the 2020 pandemic.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000514",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2. Additionally, it states that these products contain high neutralizing titers for seasonal coronavirus hCoV-229E, which suggests that there is no cross-neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000515",
    "statement": "Hospital readmissions of discharged patients with covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about the rate and factors associated with the readmission of patients who had previously been discharged after admission for COVID-19. The evidence provides an analysis of clinical variables related to this subject and draws conclusions about a lower rate of readmission, as well as identifying immunocompromised patients and those presenting with fever during the 48 hours prior to discharge as being at greater risk of readmission.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000516",
    "statement": "Hospital readmissions of hospitalized patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the study aims to analyze the factors associated with readmissions of patients who had been discharged after being admitted for COVID-19. The conclusion from this study shows that immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital. Therefore, it is supported that hospital readmissions of hospitalized patients with Covid-19 can be influenced by these factors.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000517",
    "statement": "Hospital readmissions of sars patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses factors associated with readmission of patients who had been discharged after admission for COVID-19, and identifies immunocompromised patients and those presenting with fever during the 48 hours prior to discharge as being at greater risk. However, it does not mention any association between SARS patients specifically and hospital readmissions of COVID-19 patients.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000518",
    "statement": "Hospital readmissions of icu patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided from the study suggests that it aimed to analyze factors associated with readmissions for COVID-19 patients. The conclusion that immunocompromised patients and those presenting with fever prior to discharge are at greater risk of readmission is supported by the findings of the study.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000519",
    "statement": "Hospitalization rates and characteristics of children aged < 18 years hospitalized with laboratory-confirmed covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020§,¶ Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows an ongoing study of hospitalization rates, clinical characteristics, ICU admission, and outcomes in children aged <18 years hospitalized with COVID-19. The study is conducted by COVID-NET, a surveillance network that monitors hospitalizations associated with COVID-19. Therefore, the claim about hospitalization rates and characteristics of children aged < 18 years hospitalized with laboratory-confirmed covid-19 is supported.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000520",
    "statement": "Hospitalization rates and characteristics of children aged < 18 months hospitalized with laboratory-confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020§,¶ Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about the hospitalization rates and characteristics of children aged less than 18 months who are hospitalized with laboratory-confirmed COVID-19. The evidence presents demographic and clinical characteristics of children aged under 18 years hospitalized with COVID-19, which aligns with the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000521",
    "statement": "Hospitalization rates and characteristics of children aged < 18 days hospitalized with laboratory-confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020§,¶ Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim discusses the hospitalization rates and characteristics of children aged under 18 days hospitalized with laboratory-confirmed COVID-19. The evidence provided presents data on demographic and clinical characteristics of children hospitalized with COVID-19, which directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000522",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there is a theoretical beneficial adjuvant effect of influenza vaccine in minimizing the severity of COVID-19 due to cross reactivity between flu and SARS-CoV-2 viruses, based on the similarities between the two immune responses. The safety and immunogenicity of the flu vaccine in adults is also mentioned.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000523",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to increase the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests a hypothesis that influenza vaccine may have a beneficial adjuvant effect on COVID-19 severity due to cross-reactivity between flu and SARS-CoV-2 viruses. However, this hypothesis is not directly supported by empirical evidence or definitive research results as of yet. More studies are needed to confirm or refute this claim.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000524",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to enhance the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests a possible beneficial adjuvant effect of the influenza vaccine on the severity of COVID-19. However, the evidence provided does not directly support this claim. Instead, it discusses the safety of the flu vaccine in adults and mentions potential cross-reactivity between flu and SARS-CoV-2 viruses. While it suggests that prior flu vaccination might have an effect on COVID-19 severity due to the bystander effect of generated immune responses, it does not present conclusive evidence or results from experiments to support this claim.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000525",
    "statement": "The possible negative adjuvant effect of influenza vaccine to minimize the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that there might be a potential beneficial effect of the influenza vaccine on minimizing the severity of COVID-19 due to cross reactivity between Flu and SARS-CoV-2. However, this claim is based on theoretical assumptions and studies related to patients with influenza infection rather than direct evidence from studies conducted specifically on COVID-19 and influenza vaccines.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000526",
    "statement": "Moderna 's covid-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 cove study",
    "label": "SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said Stéphane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said Stéphane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study. The provided evidence directly indicates this with Stéphane Bancel, CEO of Moderna, stating that the Phase 3 study has given them the first clinical validation that their vaccine can prevent COVID-19 disease, including severe disease.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000527",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the final interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said Stéphane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said Stéphane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as the CEO of Moderna explicitly states that their vaccine can prevent COVID-19 disease, including severe disease, which suggests it meets its primary efficacy endpoint in the final interim analysis of the phase 3 cove study.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000528",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the second interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said Stéphane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said Stéphane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about Moderna's COVID-19 vaccine candidate and whether it meets its primary efficacy endpoint in the second interim analysis of the phase 3 COVE study. The evidence provided quotes the CEO of Moderna stating that their vaccine can prevent COVID-19 disease, including severe disease, which suggests that the efficacy endpoint has been met.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000529",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the subsequent interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said Stéphane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said Stéphane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim asserts that the Moderna Covid-19 vaccine candidate meets its primary efficacy endpoint in the interim analysis of the phase 3 COVE study. The provided evidence directly supports this claim through the statement made by Stéphane Bancel, CEO of Moderna, stating that their vaccine can prevent COVID-19 disease, including severe disease. This implies a positive interim analysis and the meeting of primary efficacy endpoints.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000530",
    "statement": "Landmark legal ruling finds that covid tests are not fit for purpose .",
    "label": "SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided points out that tests with high cycle threshold (CT) values have lower accuracy in detecting Covid-19 cases and the chances of false positives are higher. However, it does not establish that all covid tests are 'not fit for purpose.' The interpretation that positive test results do not correspond to Covid cases is also based on the specific context mentioned in the evidence (a court case), but there might be other factors at play in different settings.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000531",
    "statement": "Landmark legal ruling finds that covid tests are good fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the reliability and accuracy of covid tests at high cycle threshold values, but it does not explicitly state that a landmark legal ruling has found that covid tests are 'good fit for purpose.' The evidence suggests some concern about the reliability of positive test results, which contradicts the claim. However, without further information or context, it cannot be definitively concluded whether such a ruling has occurred.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000532",
    "statement": "Landmark legal ruling finds that covid tests are best fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the limitations and potential inaccuracies of covid tests, specifically PCR tests, at high cycle threshold values (35 or higher). However, it does not provide any information about a specific landmark legal ruling that finds covid tests to be 'best fit for purpose'. Furthermore, the evidence presents doubts about the reliability of positive test results, but this does not necessarily mean that the tests are not fit for their intended purpose.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000533",
    "statement": "Landmark legal ruling finds that covid tests are well fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that tests with cycle thresholds of 35 or higher may have low accuracy (less than 3%), and the results could not be trusted. However, this does not necessarily imply that Covid tests are 'well fit for purpose.' It only questions the reliability of tests with high cycle threshold values. To fully evaluate the claim, more evidence is needed to show that Covid tests, in general, are effective and reliable.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000534",
    "statement": "Trump just banned all travel from europe to stop coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is fully supported by the evidence provided. The evidence clearly states that President Trump announced a 30-day ban on travel from Europe to the United States in response to the coronavirus pandemic.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000535",
    "statement": "Trump just allows all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly states that President Trump announced a 30-day ban on travel from European countries to the United States as a measure against the spread of coronavirus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000536",
    "statement": "Trump just allowed all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the provided evidence as it clearly indicates that President Trump announced a 30-day ban on travel from European countries to the United States in response to coronavirus. The video and statement from DHS further confirm this.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000537",
    "statement": "Trump just requires all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence as President Trump announced a 30-day ban on travel from European countries to the United States in response to coronavirus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000538",
    "statement": "Functional sars-cov-2-specific immune memory persists after mild covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-γ and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies.",
      "These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.",
      "We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that individuals who have recovered from COVID-19 develop SARS-CoV-2-specific memory lymphocytes, which exhibit characteristics associated with potent antiviral immunity and persist over time. This includes memory T cells secreting IFN-γ upon antigen re-encounter and memory B cells expressing receptors capable of neutralizing the virus when expressed as antibodies. Additionally, recovered individuals were found to have SARS-CoV-2-specific IgG antibody and neutralizing plasma, and these memory B and T cells persisted and in some cases increased over three months following symptom onset.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000539",
    "statement": "Functional sars-cov-2-independent immune memory persists after mild covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-γ and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies.",
      "These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.",
      "We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the presence of SARS-CoV-2 specific memory lymphocytes (T cells and B cells) in recovered individuals from COVID-19. These cells exhibit characteristics associated with potent antiviral immunity, such as secreting IFN-γ, expanding upon antigen re-encounter, and expressing receptors capable of neutralizing the virus. Furthermore, the evidence mentions that these memory lymphocytes persist over a period of at least three months following symptom onset. These findings suggest that there is functional SARS-CoV-2 independent immune memory after mild COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000540",
    "statement": "Cdc says new covid strain in uk could already be circulating undetected in u.s .",
    "label": "SUPPORTED",
    "evidences": [
      "While the variant hasn't been found in the U.S. yet, the CDC noted that scientists haven't sequenced the genetic coding for many Covid-19 infections here.",
      "\"Given the small fraction of US infections that have been sequenced, the variant could already be in the United States without having been detected.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that the CDC has stated that a new COVID strain in the UK might be circulating undetected in the U.S. The provided evidence indicates that while the variant hasn't been found yet, the CDC acknowledges that due to a limited number of sequenced infections in the U.S., it is possible for the new strain to be present without being detected.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000541",
    "statement": "Cdc says new covid strain in uk could not be circulating undetected in u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While the variant hasn't been found in the U.S. yet, the CDC noted that scientists haven't sequenced the genetic coding for many Covid-19 infections here.",
      "\"Given the small fraction of US infections that have been sequenced, the variant could already be in the United States without having been detected.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that CDC says a new COVID strain in UK cannot be circulating undetected in the U.S. However, the evidence provided suggests that while the variant hasn't been found yet, it is possible that it could already be present without being detected due to limited sequencing of infections in the U.S.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000542",
    "statement": "Sars-cov-2 infection protects against rechallenge in rhesus macaques",
    "label": "SUPPORTED",
    "evidences": [
      "2 Immune responses in SARS-CoV-2challenged rhesus macaques.",
      "SARS-CoV-2 infection in rhesus macaques led to humoral and cellular immune responses (Fig.",
      "In summary, SARS-CoV-2 infection in rhesus macaques induced humoral and cellular immune responses and provided protective efficacy against SARS-CoV-2 rechallenge.",
      "In this study, we have demonstrated that SARS-CoV-2 infection in rhesus macaques provides protective efficacy against SARS-CoV-2 rechallenge.",
      "To explore this question, we developed a rhesus macaque model of SARS-CoV-2 infection and assessed virologic, immunologic, and pathologic features of infection, as well as protective immunity against rechallenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence demonstrates that SARS-CoV-2 infection in rhesus macaques led to immune responses and provided protective efficacy against SARS-CoV-2 rechallenge. Therefore, the claim that Sars-cov-2 infection protects against rechallenge in rhesus macaques is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000543",
    "statement": "Sars-cov-2 infection failed against rechallenge in rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "2 Immune responses in SARS-CoV-2challenged rhesus macaques.",
      "SARS-CoV-2 infection in rhesus macaques led to humoral and cellular immune responses (Fig.",
      "In summary, SARS-CoV-2 infection in rhesus macaques induced humoral and cellular immune responses and provided protective efficacy against SARS-CoV-2 rechallenge.",
      "In this study, we have demonstrated that SARS-CoV-2 infection in rhesus macaques provides protective efficacy against SARS-CoV-2 rechallenge.",
      "To explore this question, we developed a rhesus macaque model of SARS-CoV-2 infection and assessed virologic, immunologic, and pathologic features of infection, as well as protective immunity against rechallenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that SARS-CoV-2 infection in rhesus macaques led to the development of both humoral and cellular immune responses, which then provided protective efficacy against SARS-CoV-2 rechallenge. This suggests that the infection failed against rechallenge in these animals due to the generated immune response.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000544",
    "statement": "Genetic epidemiology of variants associated with immune escape from global sars-cov-2 genomes.",
    "label": "SUPPORTED",
    "evidences": [
      "The researchers studied as many as 120 unique mutated variants of SARS-CoV-2, out of which 86 were found to possess the ability to dodge the human bodys immune response across 63 countries.",
      "The detailed investigation of 26,917 genomes pointed out that 86 out of the 120 genetic variants associated with immune escapes from 63 countries.",
      "Our analysis suggests that a number of genetic variants associated with immune escape have emerged in global populations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it directly states that researchers studied various mutated variants of SARS-CoV-2 and found that 86 out of 120 genetic variants were associated with immune escape across 63 countries. The evidence provides a clear link between the claim and the data presented.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000545",
    "statement": "Phylogenetic epidemiology of variants associated with immune escape from global sars-cov-2 genomes.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The researchers studied as many as 120 unique mutated variants of SARS-CoV-2, out of which 86 were found to possess the ability to dodge the human bodys immune response across 63 countries.",
      "The detailed investigation of 26,917 genomes pointed out that 86 out of the 120 genetic variants associated with immune escapes from 63 countries.",
      "Our analysis suggests that a number of genetic variants associated with immune escape have emerged in global populations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides data on the study of 120 unique mutated variants of SARS-CoV-2, out of which 86 were found to have the ability to dodge the human body's immune response across 63 countries. This implies that these genetic variants are associated with phylogenetic epidemiology of immune escape from global SARS-CoV-2 genomes.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000546",
    "statement": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus in vitro",
    "label": "SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 μM; CC50 > 100 μM; SI > 129.87) and chloroquine (EC50 = 1.13 μM; CC50 > 100 μM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides experimental data showing that both Remdesivir and Chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. The EC50 values for both compounds are below 1.5 micromolar, indicating their potency in blocking virus infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000547",
    "statement": "Remdesivir and chloroquine effectively developed the recently emerged novel coronavirus in vitro",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 μM; CC50 > 100 μM; SI > 129.87) and chloroquine (EC50 = 1.13 μM; CC50 > 100 μM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides results of tests on Remdesivir and Chloroquine against the novel coronavirus (2019-nCoV) in vitro. The tests showed that both drugs effectively inhibited virus infection at low-micromolar concentration. Therefore, it is supported that these drugs developed the recently emerged novel coronavirus in vitro.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000548",
    "statement": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus in humans",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 μM; CC50 > 100 μM; SI > 129.87) and chloroquine (EC50 = 1.13 μM; CC50 > 100 μM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Remdesivir and Chloroquine have been shown to effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, meaning in a laboratory setting. The study also mentions that these drugs showed potent blocking of virus infection at low micromolar concentrations.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000549",
    "statement": "As covid-19 vaccines arrive , europe looks back at swine flu side effects.",
    "label": "SUPPORTED",
    "evidences": [
      "DW: We keep seeing vaccine skeptics referencing the swine flu pandemic in 2009 as the reason they won't be taking a COVID-19 vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or refute the claim that 'Europe looks back at swine flu side effects as covid-19 vaccines arrive.' While the evidence mentions vaccine skeptics referencing the swine flu pandemic, it does not imply that Europe is actively looking back at swine flu side effects. The relationship between the two is not explicitly stated.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000550",
    "statement": "As covid-19 vaccines arrive, europe looks not at swine flu side effects.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DW: We keep seeing vaccine skeptics referencing the swine flu pandemic in 2009 as the reason they won't be taking a COVID-19 vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Europe is not considering swine flu side effects as covid-19 vaccines arrive. However, the provided evidence does not show whether or not this is the case in Europe. Instead, it mentions vaccine skeptics' references to swine flu as a reason for their hesitation towards COVID-19 vaccines.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000551",
    "statement": "Influenza may facilitate the spread of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a consistent association between influenza and an increase in SARS-CoV-2 transmission during co-circulation, as well as a hypothesis that influenza interacts with SARS-CoV-2. Therefore, it is supported that influenza may facilitate the spread of SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000552",
    "statement": "Influenza may prevent the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there is a correlation between influenza (flu) and the spread of SARS-CoV-2, specifically mentioning an increase in SARS-CoV-2 transmission associated with flu during co-circulation. While it does not prove that flu directly prevents the spread of SARS-CoV-2, it indicates that increased vaccination against flu may help counteract its facilitatory impact on SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000553",
    "statement": "Influenza may inhibit the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a positive correlation between influenza (flu) and the spread of SARS-CoV-2 (the virus responsible for COVID-19). The evidence suggests that flu may facilitate the transmission of SARS-CoV-2 by approximately 2-2.5 times during periods when both viruses are circulating.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000554",
    "statement": "Influenza may limit the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a consistent correlation between influenza and increased transmission of SARS-CoV-2. The claim that influenza may limit the spread of SARS-CoV-2 can be inferred as its opposite, which is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000555",
    "statement": "Genomic epidemiology of superspreading events in austria reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides phylogenetic analysis of SARS-CoV-2 infections in Austria, which implies studying the genomic makeup of the virus and its transmission dynamics in superspreading events. The use of terms like 'mutational dynamics' and 'transmission properties' supports this claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000556",
    "statement": "Genomic epidemiology of superspreading events in korea reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is about the reconstruction of major SARS-CoV-2 infection clusters in Austria and does not directly support the claim about Korea. To evaluate the claim properly, we would need data specifically related to superspreading events in Korea and their genomic epidemiology.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000557",
    "statement": "Genomic epidemiology of superspreading events in africa reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the analysis of SARS-CoV-2 infection clusters in Austria. However, it does not provide any information about genomic epidemiology of superspreading events in Africa or mutational dynamics and transmission properties of SARS-CoV-2 in that continent.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000558",
    "statement": "Genomic epidemiology of superspreading events in taiwan reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence refers to a study of SARS-CoV-2 clusters in Austria. It does not directly provide information about superspreading events in Taiwan or the genomic epidemiology related to those events. The evidence is about viral genome sequences in Austria, not Taiwan.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000559",
    "statement": "Rogue antibodies could be driving severe covid-19.",
    "label": "SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that severe cases of COVID-19 might be associated with an abundance of rogue antibodies (auto-antibodies against type I IFNs) in patients. This is supported by the observation that these antibodies were found more frequently in life-threatening COVID-19 cases compared to people with lupus, an autoimmune disease caused by similar wayward antibodies. The explanation also implies that these rogue antibodies could contribute to the severity of COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000560",
    "statement": "Rogue antibodies cannot be driving severe covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that patients with severe COVID-19 have developed auto-antibodies against type I interferons, which can impair the immune response to the virus. This is indicative that rogue antibodies could be driving severe COVID-19 cases.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000561",
    "statement": "Rogue antibodies could be less severe covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that rogue antibodies could make COVID-19 more severe. The evidence provided indicates that patients with life-threatening COVID-19 had autoantibodies against type I IFNs (interferons), which block the antiviral activity of interferons. This implies that the presence of these rogue antibodies may contribute to more severe cases of COVID-19, as they inhibit the immune system's response to the virus. The evidence does not conclusively prove this claim, but it supports it by suggesting a correlation between the presence of these autoantibodies and the severity of the disease.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000562",
    "statement": "Washington state group is 1st to sue fox new for calling the coronavirus a hoax",
    "label": "SUPPORTED",
    "evidences": [
      "According to the suit, Fox News violated the CPA by falsely and deceptively disseminating News via cable news contracts that the coronavirus was a hoax, and that it was otherwise not a danger to public health and safety. At least one poll has found that Fox News viewers were less likely to take precautions against the virus (including social distancing, handwashing, and other measures) seriously, and an open letter to Fox News from a group of journalism professors said misinformation that reaches the Fox News audience is a danger to public health. Based on the statements made, and the subsequent departure of Trish Regan, WASHLITE does present a cognizable theory of liability.",
      "I said it was a hoax for them to be using it as a bludgeon on Trump. Notably, he made this denial in response to criticism from 74 journalism professors who wrote an open letter to Fox claiming that coverage of the coronavirus from Fox News Channel \"is a danger to public health.\"",
      "But when you get to the point where you are endangering the community  that transcends the limits of the First Amendment. When reached by phone for comment, Catherine Clark, a Seattle attorney who volunteered to join the plaintiffs legal team after reading an initial news account, said this is a case of national importance. A supporter of First Amendment protections, she continued, When it comes to the public health, safety, and welfare, it seems to me a different set of rules apply. In a statement, Fox News general counsel Lily Fu Clafee responded to the suit by saying: Wrong on the facts, frivolous on the law."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that a Washington state group sued Fox News for calling the coronavirus a hoax. The evidence provides details of a lawsuit against Fox News alleging they falsely and deceptively disseminated information that the coronavirus was a hoax, and this statement endangered public health. This suggests that there was indeed a lawsuit filed by a Washington state group.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000563",
    "statement": "Washington state group is unable to sue fox new for calling the coronavirus a hoax",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the suit, Fox News violated the CPA by falsely and deceptively disseminating News via cable news contracts that the coronavirus was a hoax, and that it was otherwise not a danger to public health and safety. At least one poll has found that Fox News viewers were less likely to take precautions against the virus (including social distancing, handwashing, and other measures) seriously, and an open letter to Fox News from a group of journalism professors said misinformation that reaches the Fox News audience is a danger to public health. Based on the statements made, and the subsequent departure of Trish Regan, WASHLITE does present a cognizable theory of liability.",
      "I said it was a hoax for them to be using it as a bludgeon on Trump. Notably, he made this denial in response to criticism from 74 journalism professors who wrote an open letter to Fox claiming that coverage of the coronavirus from Fox News Channel \"is a danger to public health.\"",
      "But when you get to the point where you are endangering the community  that transcends the limits of the First Amendment. When reached by phone for comment, Catherine Clark, a Seattle attorney who volunteered to join the plaintiffs legal team after reading an initial news account, said this is a case of national importance. A supporter of First Amendment protections, she continued, When it comes to the public health, safety, and welfare, it seems to me a different set of rules apply. In a statement, Fox News general counsel Lily Fu Clafee responded to the suit by saying: Wrong on the facts, frivolous on the law."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses a lawsuit against Fox News for allegedly disseminating false information about the coronavirus being a hoax. However, it does not directly address whether or not the Washington state group is unable to sue Fox News. The discussion focuses on the potential liability of Fox News and the impact of their reporting on public health.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-000564",
    "statement": "Unfounded fears that dogs can spread covid-19 can cause harm",
    "label": "SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Unfounded fears that dogs can spread covid-19 can cause harm' is supported by the evidence provided because it mentions 'fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.' This indicates that unfounded fears about pets and the virus can indeed lead to harm.",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000565",
    "statement": "Unfounded fears that people can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that unfounded fears about spreading Covid-19 can cause harm. The evidence provided indicates that fear of pets playing a role in spreading Covid-19 led to the abandonment and killing of pets, demonstrating how unfounded fears can lead to negative consequences for animals. This supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000566",
    "statement": "Unfounded fears that sars can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that unfounded fears about SARS spreading COVID-19 can cause harm to pets, as such fears have resulted in pets being abandoned or even killed. The absence of evidence supporting the transmission of the virus from animals does not refute this claim, as it only shows that there is currently no evidence for such transmission.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000567",
    "statement": "Unfounded fears that hiv can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that fear about HIV spreading COVID-19 can cause harm (as seen in the abandonment and killing of pets due to unfounded fears). Although no definitive evidence exists about the transmission of the virus from animals to humans in this case, the World Organisation for Animal Health (OIE) advises against taking measures against companion animals that might compromise their welfare based on such unfounded fears.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000568",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in mice",
    "label": "SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly shows that SARS-CoV-2 infection leads to transient olfactory dysfunction in a mouse model (humanized ACE2 mice), as indicated by the downregulation of olfactory receptors in the infected animals' olfactory epithelium and the observation of such dysfunction.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000569",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in humans",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that SARS-CoV-2 infection can induce viral replication in the olfactory epithelium (OE), which may lead to transient olfactory dysfunction as demonstrated in humanized ACE2 mice. The combined transcriptomic and proteomic analyses further support this claim by showing antiviral and inflammatory responses, as well as downregulation of olfactory receptors in the infected animals.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000570",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in neurons",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence demonstrates that SARS-CoV-2 induces viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice. Furthermore, it shows changes in the transcriptomic and proteomic analyses of the infected animals' olfactory neurons that include antiviral and inflammatory responses and downregulation of olfactory receptors.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000571",
    "statement": "1 million pc owners combine their gpu power to fight covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that over one million personal computers have been donated to Folding@home, a distributed computing project used to simulate protein dynamics, which is being used in an effort to find new therapies for the coronavirus (COVID-19). While it does not explicitly state that these PC owners are combining their GPU power to fight COVID-19, the implication is clear as Folding@home relies on individual computers' processing power. Therefore, the claim can be supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000572",
    "statement": "1 2 pc owners combine their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that GPU owners are combining their power to fight COVID-19 via the Folding@home project. The evidence provided shows that users around the world have donated processing power of over one million personal computers to this project, which is specifically for simulating protein dynamics in an effort to find new therapies for the coronavirus. Therefore, it's clear that the claim is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000573",
    "statement": "1 4 pc owners combine their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that users of Folding@home have donated processing power from over one million personal computers to help in simulating protein dynamics for the coronavirus. While it's not explicitly stated that these users are specifically combining their GPU power to fight Covid-19, the context suggests that the combined processing power is being used collectively to run simulations. Therefore, it can be reasonably inferred that the claim is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000574",
    "statement": "1 million pc owners lost their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that 1 million PC owners lost their GPU power to fight COVID-19. However, the provided evidence only shows that over one million personal computers were donated to Folding@home, a distributed computing project for simulating protein dynamics to search for new therapies for the coronavirus, not necessarily their GPUs or complete power.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000575",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by blocking receptor interaction",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence reports the isolation and characterization of an alpaca-derived single domain antibody fragment (Ty1) that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement. This suggests that Ty1 neutralizes SARS-CoV-2 by blocking the interaction between the virus and its host receptor.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000576",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by activating receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes the isolation and characterization of an alpaca-derived single domain antibody fragment (Ty1) that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike. This suggests that Ty1 neutralizes SARS-CoV-2 by directly preventing ACE2 engagement, which is the receptor for SARS-CoV-2. Thus, the claim is supported.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000577",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by its receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence presents an alpaca nanobody (Ty1) that targets the receptor binding domain of SARS-CoV-2 spike. This direct prevention of ACE2 engagement suggests the nanobody neutralizes sars-cov-2 by its receptor interaction.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000578",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by a receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that an alpaca nanobody neutralizes sars-cov-2 by a receptor interaction is supported because the provided evidence indicates isolation of an alpaca-derived single domain antibody fragment (Ty1) that targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement. This action effectively neutralizes the virus by disrupting its interaction with the host's receptor.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000579",
    "statement": "Household studies provide key insights on the transmission of , and susceptibility to , sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "The secondary attack rate for SARS-CoV-2 has been estimated to be approximately twice as high as that of SARS-CoV, 5 Lau JT Lau M Kim JH Tsui HY Tsang T Wong TW Probable secondary infections in households of SARS patients in Hong Kong."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a study comparing the secondary attack rate (SARS-CoV-2 vs SARS-CoV) in households of infected patients, which indicates an insight into transmission within households and susceptibility to both viruses. Therefore, it supports the claim that household studies provide key insights on the transmission and susceptibility to SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000580",
    "statement": "Future studies provide key insights on the transmission of, and susceptibility to, sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The secondary attack rate for SARS-CoV-2 has been estimated to be approximately twice as high as that of SARS-CoV, 5 Lau JT Lau M Kim JH Tsui HY Tsang T Wong TW Probable secondary infections in households of SARS patients in Hong Kong."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the secondary attack rate for SARS-CoV-2 (coronavirus responsible for COVID-19), and compares it to that of SARS-CoV (the coronavirus responsible for SARS in 2003). The comparison between the two rates implies future studies are being used to gather data on the transmission and susceptibility of SARS-CoV-2. Therefore, the claim is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000581",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 °c damages its genome integrity seriously",
    "label": "SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 °C for 30 minutes and only 3.36% left after the inactivation of 92 °C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56°C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 °C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided in the text. The evidence states that inactivating porcine coronavirus at 56 °C for 30 minutes significantly reduces its detectable viral templates and further suggests that higher temperatures such as 92 °C for 5 minutes cause even more damage to the genome integrity. Additionally, the text mentions that human samples must be placed under 56°C or higher to inactivate the viruses before nucleic acid isolation for qRT-PCR. The evidence also suggests that an optimized solution can protect the RNA from being disrupted at high temperatures.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000582",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 °c increased its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 °C for 30 minutes and only 3.36% left after the inactivation of 92 °C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56°C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 °C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents experimental results showing a decrease in detectable viral templates when samples are heated at 56 °C for 30 minutes or 92 °C for 5 minutes. The authors recommend further investigation into the impact of high temperature on the integrity of the virus's genome and suggest using an optimized solution to protect RNA from degradation during incubation at high temperatures. This suggests that inactivating porcine coronavirus before nuclei acid isolation with a temperature higher than 56 °C may indeed increase its genome integrity seriously.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000583",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 °c increases its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 °C for 30 minutes and only 3.36% left after the inactivation of 92 °C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56°C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 °C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence presented suggests that high temperatures, specifically 56°C and above, can inactivate viruses like the coronavirus before nucleic acid isolation. However, it does not provide direct evidence on whether inactivating the virus at these temperatures affects its genome integrity 'seriously'. The claim could be supported with experimental data demonstrating changes in genome integrity specifically due to heating.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000584",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 °c shows its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 °C for 30 minutes and only 3.36% left after the inactivation of 92 °C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56°C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 °C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that inactivating porcine coronavirus at temperatures higher than 56°C affects the detectability of its viral templates, but it does not necessarily indicate serious damage to the genome integrity. The claim needs further research and studies on the specific effects of high temperature inactivation on the genome integrity of the virus.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000585",
    "statement": "Therapeutic anticoagulation is associated with decreased mortality in mechanically ventilated covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence presents a statistical analysis (multivariate Cox proportional hazard regression model) that shows a significant reduction in death (79%) among mechanically ventilated COVID-19 patients who received therapeutic anticoagulation compared to those receiving prophylactic anticoagulation. The Kaplan-Meier plot also demonstrates a survival advantage for the group receiving therapeutic anticoagulation.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000586",
    "statement": "Therapeutic anticoagulation is associated with elevated mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence presents results from a study that shows a significant reduction in death (HR 0.209) among COVID-19 patients who were therapeutically anticoagulated compared to those given prophylactic anticoagulation. Furthermore, the Kaplan-Meier plot demonstrates a survival advantage for patients receiving therapeutic anticoagulation (57% vs. 25%) at 35 days from admission to the ICU. The conclusions of the study support the claim that therapeutic anticoagulation is associated with a survival advantage among mechanically ventilated COVID-19 patients.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000587",
    "statement": "Therapeutic anticoagulation is associated with increased mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that therapeutic anticoagulation is associated with a survival advantage among patients who require mechanical ventilation in the ICU with COVID-19 based on a multivariate Cox proportional hazard regression model and propensity score (PS) weighted Kaplan-Meier plot. However, this study only demonstrates an association, not causation. Further research would be needed to definitively establish that therapeutic anticoagulation reduces mortality in mechanically ventilated COVID-19 patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000588",
    "statement": "Therapeutic anticoagulation is associated with high mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided from a study shows that therapeutic anticoagulation is associated with a reduced hazard ratio (HR 0.209) for death in mechanically ventilated COVID-19 patients. Additionally, the Kaplan-Meier plot demonstrates a survival advantage at 35 days from ICU admission for patients who received therapeutic anticoagulation compared to those who received prophylactic anticoagulation.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000589",
    "statement": "Sars-cov-2 is an unrestricted bioweapon",
    "label": "SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not substantiate the claim that SARS-CoV-2 is an unrestricted bioweapon. The statement suggests SARS-CoV-2 was created in a Chinese laboratory and quickly developed, but this alone does not prove it's an unrestricted bioweapon or result of biowarfare. Further evidence is required to establish the intent and purpose behind its creation.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000590",
    "statement": "Sars-cov-2 is an spricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided claim that SARS-CoV-2 is a 'spricted' (suggesting it was deliberately weaponized) bioweapon lacks evidence to support this conclusion. The text does mention that the virus could be created in a laboratory, but this doesn't imply that it was indeed created for malicious purposes or that it was 'weaponized.' Furthermore, the text doesn't provide any concrete proof to show that the People's Liberation Army (PLA) is responsible for creating and releasing SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000591",
    "statement": "Sars-cov-2 is an sricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not substantiate the claim that SARS-CoV-2 is a restricted bioweapon. The information merely mentions that it could be created in six months using a template virus owned by a laboratory of the People's Liberation Army (PLA), but this doesn't prove it was intentionally designed or weaponized for military use. Furthermore, the term 'unrestricted bioweapon' is not commonly used to describe naturally occurring viruses like SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000592",
    "statement": "Sars-cov-2 is an trricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that SARS-CoV-2 is a restricted bioweapon lacks evidence to support it. The provided evidence only suggests that the virus could be created in a lab within six months and that it was owned by a laboratory of the People's Liberation Army (PLA). However, this does not provide evidence to prove that it is a 'restricted bioweapon.' Furthermore, there is no widely accepted scientific consensus supporting the idea that SARS-CoV-2 was intentionally released as a bioweapon.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000593",
    "statement": "Kinetics of antibody responses dictate covid-19 outcome.",
    "label": "SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided supports the claim that kinetics of antibody responses dictate COVID-19 outcome. The provided studies demonstrate connections between antibody levels and disease severity (COVID-19 neutralizing antibodies predict disease severity and survival), as well as variations in antibody kinetics with distinct COVID-19 outcomes (serum antibody kinetics reveals distinct COVID-19 outcomes). Furthermore, the evidence also discusses viral kinetics and antibody responses in patients with COVID-19, indicating the importance of both virus replication and immune response in determining disease outcome. Lastly, the study on T cell and antibody functional correlates of severe COVID-19 further supports the role of these factors in shaping disease progression.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000594",
    "statement": "Standards of antibody responses dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided demonstrates a relationship between the presence and magnitude of COVID-19 neutralizing antibodies, disease severity, survival, and outcomes in patients. The references to serum antibody kinetics, viral kinetics, T cell and antibody functional correlates all support this claim by further detailing the role of antibody responses in determining the outcome of a COVID-19 infection.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000595",
    "statement": "Kinetics of antibody production dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that the kinetics (rate and course) of antibody production in response to COVID-19 infection plays a role in determining the disease outcome, as demonstrated by studies on neutralizing antibodies, serum antibody kinetics, and T cell and antibody functional correlates. The evidence also indicates that viral kinetics (rate of virus multiplication) are related to antibody responses in COVID-19 patients.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000596",
    "statement": "Analysiss of antibody responses dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that COVID-19 neutralizing antibodies are related to disease severity and survival (first statement), serum antibody kinetics distinguish different COVID-19 outcomes (second statement), viral kinetics and antibody responses in patients with COVID-19 (third statement), and T cell and antibody functional correlates of severe COVID-19 are studied. These findings collectively suggest that antibody responses do play a significant role in determining the outcome of COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000597",
    "statement": "Raspberry pi about to boost ventilators for coronavirus victims",
    "label": "SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Raspberry Pi will boost ventilators for coronavirus victims. However, the provided evidence does not explicitly state this; instead, it mentions an increase in production of Raspberry Pi Zero boards to help manufacturers keep up with the demand for ventilators, which implies an indirect contribution. It's unclear how or if these boards are being used to boost ventilator capacity or directly treat COVID-19 patients.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000598",
    "statement": "Raspberry pi about to avoid ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests that Raspberry Pi Foundation is increasing production of its Pi Zero boards to support manufacturers in making ventilators due to high demand. However, it does not clearly state or imply that Raspberry Pi will replace ventilators for coronavirus victims.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000599",
    "statement": "Raspberry pi about to take ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Raspberry Pi will take over ventilators for coronavirus victims, but the evidence only indicates that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with components needed for ventilator production. It does not suggest that Raspberry Pi will replace existing ventilators.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000600",
    "statement": "Raspberry pi about to receive ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Raspberry Pi will be receiving ventilators for coronavirus victims. However, the evidence only indicates that The Raspberry Pi Foundation is increasing production of its Pi Zero boards to help supply manufacturers keep up with demand for ventilators. There's no clear evidence that these Pi Zero boards are being used as ventilators or will be given to coronavirus victims.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000601",
    "statement": "Aerosol particles laden with viruses that cause covid-19 travel over 30m distance",
    "label": "SUPPORTED",
    "evidences": [
      "The results obtained demonstrate that aerosol particles generated by coughing and sneezing can travel over 30 m. Modelling of the evolution of aerosol clouds generated by coughing and sneezing enables us to evaluate the deposition dose of aerosol particles in healthy individuals.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence demonstrates that aerosol particles generated by coughing and sneezing can travel over 30 meters. It does not explicitly mention the virus causing COVID-19 in this context, but it is widely accepted in scientific literature that viruses can be present in these aerosols. Therefore, it can be inferred that aerosol particles laden with viruses that cause COVID-19 can travel over 30 meters.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000602",
    "statement": "Aerosol particles laden with viruses that cause covid-19 travel within 30m distance",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results obtained demonstrate that aerosol particles generated by coughing and sneezing can travel over 30 m. Modelling of the evolution of aerosol clouds generated by coughing and sneezing enables us to evaluate the deposition dose of aerosol particles in healthy individuals.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that aerosol particles generated by coughing and sneezing can travel over 30m, but it does not explicitly state they are laden with viruses that cause COVID-19. However, the implication is reasonable since COVID-19 spreads primarily through respiratory droplets and aerosols when an infected person talks, coughs, or sneezes. The evidence also does not specify whether the individuals in question are infected with COVID-19 or not. Nonetheless, the evidence provides a strong foundation for concluding that aerosol particles laden with COVID-19 viruses can travel within 30m distance.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000603",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against sars-cov-2 and zoonotic coronaviruses",
    "label": "SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that mice immunized with RBD-nanoparticles elicit cross-reactive antibody binding and neutralization responses against SARS-CoV-2 and other zoonotic coronaviruses. This suggests that Mosaic rbd nanoparticles indeed elicit neutralizing antibodies against SARS-CoV-2 and zoonotic coronaviruses.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000604",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against chs-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that mice immunized with Mosaic RBD nanoparticles indeed elicit neutralizing antibodies against SARS-CoV-2 and cross-reactive antibodies against heterologous RBDs (which are found in zoonotic coronaviruses), as mentioned in the claim. The evidence also suggests that this immunization strategy provides a potential method for simultaneous protection against SARS-CoV-2 and emerging zoonotic coronaviruses.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000605",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against gps-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that mice immunized with RBD-nanoparticles elicited cross-reactive antibody binding and neutralization responses against gps-cov-2 and zoonotic coronaviruses, suggesting that these nanoparticles do indeed elicit neutralizing antibodies against the specified viruses.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000606",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against 3s-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that mice immunized with RBD-nanoparticles elicited neutralizing antibodies against SARS-CoV-2 and cross-reactive antibody binding and neutralization responses for other zoonotic coronaviruses. This suggests that the claim is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000607",
    "statement": "South korean city deserted due to super spreading event",
    "label": "SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Daegu, South Korea, experienced a 'super-spreading event' of the coronavirus, leading to its residents staying indoors and deserted shopping malls and cinemas. This indicates that the city has been deserted due to a super spreading event.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000608",
    "statement": "South korean city started due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear indication that Daegu city in South Korea experienced a 'super-spreading event' of the coronavirus, as described by Korea's Centers for Disease Control and Prevention.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000609",
    "statement": "South korean city remained due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Daegu, South Korea experienced a 'super-spreading event' of the coronavirus. This resulted in a significant decrease in the city's activity level as evidenced by empty shopping malls and cinemas. Therefore, it can be concluded that due to this super-spreading event, the South Korean city Daegu remained less active or deserted.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000610",
    "statement": "South korean city occurred due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim mentions 'South Korean city occurred due to super spreading event'. The evidence clearly indicates that the outbreak of coronavirus in Daegu, South Korea, was described as a 'super-spreading event' by the authorities. Thus, the claim is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000611",
    "statement": "Scientists see signs of lasting immunity , even after mild infections",
    "label": "SUPPORTED",
    "evidences": [
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys robust immune response to other viruses.",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of COVID-19, a flurry of new studies suggests.",
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells that are capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys enduring response to other viruses.",
      "Scientists see signs of lasting immunity to COVID-19, even after mild infections Share: August 18, 2020 ",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of Covid-19, a flurry of new studies suggests."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the article discusses scientists seeing signs of lasting immunity to COVID-19 even after mild infections. This is supported by the mention of disease-fighting antibodies and immune cells like B cells and T cells that are capable of recognizing the virus persisting months after infection has resolved.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000612",
    "statement": "Scientists no signs of lasting immunity, even after mild infections",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys robust immune response to other viruses.",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of COVID-19, a flurry of new studies suggests.",
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells that are capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys enduring response to other viruses.",
      "Scientists see signs of lasting immunity to COVID-19, even after mild infections Share: August 18, 2020 ",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of Covid-19, a flurry of new studies suggests."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that 'Scientists no signs of lasting immunity, even after mild infections'. However, the evidence provided suggests the opposite - scientists are seeing 'encouraging signs of strong, lasting immunity' after COVID-19 infections. To support this claim, additional evidence showing a lack or weakened immune response after infection would be required.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000613",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-specific viral diagnostic",
    "label": "SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that the type III CRISPR-Cas system has been repurposed for sensitive and sequence-specific detection of SARS-CoV-2, which is a viral diagnostic.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000614",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-independent viral diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim about a sequence-independent viral diagnostic for intrinsic signal amplification by type-iii CRISPR-CAS systems. The information only discusses the detection of SARS-CoV-2 in an assay and does not mention any sequence independence.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000615",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-free viral diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that a type III CRISPR-Cas system was repurposed for sensitive and sequence-specific detection of SARS-CoV-2. However, the claim is about intrinsic signal amplification by this system providing a sequence-free viral diagnostic. The evidence does not explicitly state or imply that there is sequence-free amplification.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000616",
    "statement": "Pet dog further tests positive for antibodies for covid-19 virus",
    "label": "SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that a Pomeranian dog tested positive for covid-19 antibodies, indicating an immune response to the virus. However, this does not necessarily mean that the dog had been infected with and recovered from COVID-19. It could also be due to exposure through another means such as vaccination.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000617",
    "statement": "Pet dog further tests negative for antibodies for covid-19 virus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions that the dog has developed an immune response to the virus, but it does not explicitly state that the dog tested negative for antibodies for COVID-19. To confirm this claim, additional evidence is needed showing a negative test result.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000618",
    "statement": "Pet dog further tests except for antibodies for covid-19 virus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence demonstrates that the Pomeranian dog has developed an immune response to a viral infection, as shown by the presence of antibodies in its blood. However, it does not provide any information about whether these antibodies are specific for COVID-19 or another virus.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000619",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 100 % success using hydroxychloroquine sulfate , zinc and z-pak",
    "label": "SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that Dr. Vladimir Zelenko has treated 699 coronavirus patients using a combination of hydroxychloroquine sulfate, zinc, and azithromycin (Z-Pak) with 100% success. The claim is fully supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000620",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 10 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Dr. Vladimir Zelenko has now treated 699 coronavirus patients with 10% success using hydroxychloroquine sulfate, zinc and z-pak. The provided evidence contains conflicting information regarding the number of successful treatments. An earlier update states 'zero patients died, zero patients intubated, and four hospitalizations' which could imply 100% success (or close to it), while another update mentions a 90% success rate with 900 patients treated. Without a clear and consistent source of data supporting the 699 patient study with a 10% success rate, this claim cannot be definitively supported.",
    "confidence": 0.25
  },
  {
    "id": "covid_fact-000621",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 5 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions a success rate of 5% with the treatment, but the sources provided only state that zero patients died and four were hospitalized among the 699 treated. There is no clear indication of the success or failure of the treatment based on these statements.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000622",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 20 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Dr. Vladimir Zelenko has now treated 699 coronavirus patients with a success rate of 20% using hydroxychloroquine sulfate, zinc and z-pak. However, the provided evidence is conflicting regarding the treatment's effectiveness. The first piece of evidence states that out of 699 patients treated, zero patients died, zero patients were intubated, and four were hospitalized, implying 100% success. The second piece of evidence mentions a later update where Dr. Zelenko claimed that the cocktail of drugs is showing 'phenomenal results' with 900 coronavirus patients treated. This contradicts the initial claim about the treatment's success rate.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000623",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is inadequate for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the VivaDiag COVID-19 IgM/IgG Rapid Test is not recommended for triage of patients with suspected COVID-19 in emergency departments due to its low sensitivity. This means it may not accurately identify most patients with COVID-19, leading to misdiagnosis. Therefore, the test performance is considered inadequate for diagnosis of COVID-19 in acute patients referring to an emergency room department.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000624",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is useful for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about the usefulness of the VivaDiag COVID-19 IgM/IgG rapid test for diagnosis of COVID-19 in acute patients referring to the emergency room department. However, the evidence provided suggests that the test has a low sensitivity, leading to misdiagnosis of COVID-19 disease in most patients. This implies that the test is not recommended for triage of patients with suspected COVID-19 in the emergency department, but it does not directly state whether the test is useless or not for diagnosis in acute patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000625",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is essential for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests that the VivaDiag COVID-19 IgM/Igg Rapid Test has a low sensitivity and is not recommended for triage of patients with suspected COVID-19 in emergency departments. However, the claim asks about the performance of this test in diagnosing COVID-19 in 'acute patients referring to the emergency room department.' The evidence doesn't specify whether these are acute patients or not. Thus, I cannot confirm if the test is essential for diagnosis of COVID-19 in such patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000626",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is suitable for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the VivaDiag COVID-19 IgM/IgG Rapid Test has low sensitivity and is not recommended for triage of patients with suspected COVID-19 in an emergency department setting. However, it does not state whether the test is suitable for diagnosis of COVID-19 in acute patients referring to the emergency room department.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000627",
    "statement": "Cetylpyridinium chloride-containing mouthwashes reduce in vitro sars-cov-2 infectivity.",
    "label": "SUPPORTED",
    "evidences": [
      "A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro.",
      "CPC- containing mouth rinses could represent a cost-effective measure to reduce SARS-CoV-2 infectivity in saliva, aiding to reduce viral transmission from infected individuals.",
      "Here we show that Cetylpyridinium chloride (CPC), a quaternary ammonium compound present in many oral mouthwashes, reduces SARS-CoV-2 infectivity by inhibiting viral fusion with target cells.",
      "\"A common compound in mouthwashes found to inhibit SARS- CoV-2 in vitro\".",
      "Antiviral activity of CPC-containing mouthwashes inhibiting SARS-CoV-2 entry."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that Cetylpyridinium chloride (CPC)-containing mouthwashes reduce in vitro SARS-CoV-2 infectivity. Evidence shows that a common compound in mouthwashes, specifically CPC, inhibits SARS-CoV-2 in vitro, and it is also stated that antiviral activity of these mouthwashes inhibit SARS-CoV-2 entry.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000628",
    "statement": "Cetylpyridinium chloride-containing mouthwashes with in vitro sars-cov-2 infectivity.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro.",
      "CPC- containing mouth rinses could represent a cost-effective measure to reduce SARS-CoV-2 infectivity in saliva, aiding to reduce viral transmission from infected individuals.",
      "Here we show that Cetylpyridinium chloride (CPC), a quaternary ammonium compound present in many oral mouthwashes, reduces SARS-CoV-2 infectivity by inhibiting viral fusion with target cells.",
      "\"A common compound in mouthwashes found to inhibit SARS- CoV-2 in vitro\".",
      "Antiviral activity of CPC-containing mouthwashes inhibiting SARS-CoV-2 entry."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Cetylpyridinium chloride (CPC), a common compound in mouthwashes, has been found to inhibit SARS-CoV-2 infectivity in vitro, suggesting that CPC-containing mouth rinses could potentially reduce SARS-CoV-2 infectivity in saliva and thus aid in reducing viral transmission from infected individuals.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000629",
    "statement": "Symptom-based screening process was ineffective in detecting sars-cov-2 infection during evacuation of 126 people from wuhan , china .",
    "label": "SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the symptom-based screening process was 'ineffective' at detecting SARS-CoV-2 infection during evacuation of 126 people from Wuhan to Frankfurt. Furthermore, it is noted that infected persons might not show any signs or symptoms, and the authors found two such cases in this context.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000630",
    "statement": "Symptom-based screening process was successful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that the symptom-based screening process was found to be ineffective at detecting SARS-CoV-2 infection in two individuals from the evacuation of Wuhan to Frankfurt. However, this does not necessarily mean that the entire screening process was unsuccessful at detecting SARS-CoV-2 infection during the evacuation of 126 people. The evidence does not support a definitive conclusion about the overall effectiveness of the symptom-based screening process during the evacuation.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000631",
    "statement": "Symptom-based screening process was helpful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the symptom-based screening process was helpful in detecting SARS-CoV-2 infection during evacuation of 126 people from Wuhan, China. However, the evidence provided states that this method was 'ineffective' at detecting SARS-CoV-2 infection.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000632",
    "statement": "Symptom-based screening process was useful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that the symptom-based screening process was useful in detecting SARS-CoV-2 infection during evacuation of 126 people from Wuhan, China. However, the evidence provided indicates that the symptom-based screening process was 'ineffective' in detecting SARS-CoV-2 infection.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000633",
    "statement": "Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose",
    "label": "SUPPORTED",
    "evidences": [
      "Although our simulation showed that increasing pathogen challenge dose decreased vaccine efficacy, variance in susceptibility also affected vaccine protection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence only shows a simulation result indicating that increasing pathogen challenge dose decreased vaccine efficacy. However, this does not necessarily mean that real-world reduced vaccine efficacy at higher exposure doses is supported. Variance in susceptibility was also mentioned as affecting vaccine protection, suggesting other factors may play a role. Therefore, the claim requires further empirical evidence and real-world data to support it.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000634",
    "statement": "Limited available evidence supports theoretical predictions of reduced vaccine efficacy at low exposure dose",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although our simulation showed that increasing pathogen challenge dose decreased vaccine efficacy, variance in susceptibility also affected vaccine protection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows a simulation of how an increase in pathogen dose decreases vaccine efficacy. However, it does not provide any information about what happens at low exposure doses or if there is reduced vaccine efficacy at these levels. Therefore, the claim that limited available evidence supports theoretical predictions of reduced vaccine efficacy at low exposure doses cannot be confirmed.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000635",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are short-lived in patients with mild illness",
    "label": "SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence only shows that severely ill patients develop higher SARS-CoV-2 antibody responses compared to outpatients and asymptomatic individuals. It does not directly demonstrate a correlation between these antibody responses and resolution of rnaemia (viral RNA in the blood) or provide any information about the duration of these responses in patients with mild illness.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000636",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are long-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that severely ill patients develop higher SARS-CoV-2 antibody responses than outpatients and asymptomatic individuals. However, it does not explicitly state or imply that the antibody responses in patients with mild illness correlate with resolution of rnaemia (viral RNA levels) or are long-lived.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000637",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are longer-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence suggests that severely ill patients developed higher SARS-CoV-2 antibody responses than outpatients and asymptomatic individuals. However, the claim requires evidence demonstrating a correlation between antibody responses and resolution of rnaemia (viral RNA in blood) for mild illness, as well as longer-lived antibody responses in these patients compared to those with severe illness. The provided evidence does not directly address or prove this specific relationship.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000638",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are over-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that severely ill patients developed higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals. However, it does not offer any information about the duration or persistence of these antibodies in patients with mild illness. To establish a correlation between antibody responses and resolution of rnaemia (viral RNA in blood) in patients with mild illness, additional evidence is required showing that antibody levels decrease over time in these patients as their condition improves.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000639",
    "statement": "Saliva is more sensitive for sars-cov-2 detection in covid-19 patients than nasopharyngeal swabs",
    "label": "SUPPORTED",
    "evidences": [
      "Saliva is a promising candidate for SARS-CoV-2 diagnostics because (1) collection is minimally invasive and can reliably be self-administered and (2) saliva has exhibited comparable sensitivity to nasopharyngeal swabs in detection of other respiratory pathogens, including endemic human coronaviruses, in previous studies.",
      "When we compared SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples, we found that saliva yielded greater detection sensitivity and consistency throughout the course of infection.",
      "Taken together, our findings demonstrate that saliva is a viable and more sensitive alternative to nasopharyngeal swabs and could enable at-home self-administered sample collection for accurate large- scale SARS-CoV-2 testing.",
      "To validate the use of saliva for SARS-CoV-2 detection, we tested nasopharyngeal and saliva samples from confirmed COVID-19 patients and self-collected samples from healthcare workers on COVID-19 wards."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that Saliva is more sensitive for SARS-CoV-2 detection in Covid-19 patients than nasopharyngeal swabs. The evidence provides multiple reasons supporting this claim: (1) Saliva collection is less invasive and can be self-administered, (2) saliva has comparable sensitivity to nasopharyngeal swabs in detection of other respiratory pathogens, (3) a study comparing SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples found that saliva yielded greater detection sensitivity and consistency, (4) the use of saliva for SARS-CoV-2 detection was validated by testing samples from confirmed COVID-19 patients and self-collected samples from healthcare workers on COVID-19 wards. Therefore, based on the given evidence, the claim is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000640",
    "statement": "Saliva is less sensitive for sars-cov-2 detection in covid-19 patients than nasopharyngeal swabs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Saliva is a promising candidate for SARS-CoV-2 diagnostics because (1) collection is minimally invasive and can reliably be self-administered and (2) saliva has exhibited comparable sensitivity to nasopharyngeal swabs in detection of other respiratory pathogens, including endemic human coronaviruses, in previous studies.",
      "When we compared SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples, we found that saliva yielded greater detection sensitivity and consistency throughout the course of infection.",
      "Taken together, our findings demonstrate that saliva is a viable and more sensitive alternative to nasopharyngeal swabs and could enable at-home self-administered sample collection for accurate large- scale SARS-CoV-2 testing.",
      "To validate the use of saliva for SARS-CoV-2 detection, we tested nasopharyngeal and saliva samples from confirmed COVID-19 patients and self-collected samples from healthcare workers on COVID-19 wards."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that multiple studies have compared SARS-CoV-2 detection between nasopharyngeal swabs and saliva samples from COVID-19 patients. The findings consistently show that saliva yields greater sensitivity and consistency in detection, making it a more suitable alternative to nasopharyngeal swabs for SARS-CoV-2 testing.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000641",
    "statement": "Vitamin d sufficiency reduced risk for morbidity and mortality in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that Vitamin D sufficiency reduces the risk for morbidity and mortality in COVID-19 patients. The evidence provided states that vitamin D may prevent cytokine storm in COVID-19 patients which can reduce the severity of clinical outcomes and mortality, and it is recommended to improve vitamin D status in hospitalized patients to potentially reduce the severity of morbidities and mortality associated with acquiring COVID-19. This aligns well with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000642",
    "statement": "Vitamin d sufficiency increased risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that vitamin D sufficiency decreases the risk of severity and mortality in COVID-19 patients. The claim that vitamin D sufficiency increases risk for morbidity and mortality in COVID-19 patients contradicts the presented evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000643",
    "statement": "Vitamin d sufficiency increasing risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that vitamin D sufficiency might prevent cytokine storm in COVID-19 patients, reducing the severity of clinical outcomes and mortality. Additionally, there is evidence that Vitamin D supplementation could reduce the risk of influenza and COVID-19 infections and deaths.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000644",
    "statement": "Vitamin d sufficiency greater risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a correlation between vitamin D sufficiency and reduced severity of clinical outcomes and mortality in COVID-19 patients. The studies mentioned show that vitamin D supplementation could potentially reduce the risk of inflammation storms in COVID-19 patients, which may lead to a decrease in morbidity and mortality. However, it's important to note that while this claim is supported by the evidence provided, further research is needed to establish a definitive causal relationship.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000645",
    "statement": "A functional genomics approach to understand host genetic regulation of covid-19 severity",
    "label": "SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it discusses a functional genomics investigation to understand host genetic regulation of COVID-19 severity using data from the Human Functional Genomics Projects (HFGP). The evidence also shows that this investigation identified patterns related to innate immune responses and genetically determined cytokine production, which are directly relevant to understanding severe COVID-19 susceptibility.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000646",
    "statement": "A functional genomics approach to understand early genetic regulation of covid-19 severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses a functional genomics investigation focusing on understanding genetic regulation of COVID-19 severity, specifically examining innate immune responses and their impact on susceptibility to severe disease. The text mentions the use of detailed clinical, immunological, and multi-omics data from the Human Functional Genomics Projects (HFGP) to explore these genetic variants. The findings suggest a physiological understanding of genetic susceptibility to severe COVID-19 and potential pathways for prevention and therapy. Thus, the claim that a functional genomics approach is being used to understand early genetic regulation of COVID-19 severity is supported by the evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000647",
    "statement": "A functional genomics approach to understand molecular genetic regulation of covid-19 severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a functional genomics investigation into understanding the molecular genetic regulation of COVID-19 severity by analyzing the clinical, immunological, and multi-omics data of individuals with high genetic risk for severe COVID-19. This supports the claim of using a functional genomics approach to understand molecular genetic regulation of COVID-19 severity.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000648",
    "statement": "Repeated cross-sectional sero-monitoring of sars-cov-2 in new york city",
    "label": "SUPPORTED",
    "evidences": [
      "A serological assay to detect SARS-CoV-2 seroconversion in humans."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes a method for detecting SARS-CoV-2 seroconversion (the presence of antibodies in the blood indicating an individual has been infected with the virus) in humans. However, this does not directly support the claim about repeated cross-sectional monitoring of SARS-CoV-2 in New York City as it lacks information on when, where, and how this serological assay is being used for monitoring purposes.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000649",
    "statement": "One cross-sectional sero-monitoring of sars-cov-2 in new york city",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A serological assay to detect SARS-CoV-2 seroconversion in humans."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided refers to a serological assay for detecting SARS-CoV-2 antibodies (seroconversion), but it does not provide any information about the specific cross-sectional monitoring in New York City.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000650",
    "statement": "Patients in secret trials are successfully treated with hiv and malaria medication",
    "label": "SUPPORTED",
    "evidences": [
      "They were given HIV medication Kaletra and malaria treatment hydroxychloroquine in a secret trial.",
      "In a secret trial that was held, they were all given HIV medication, Kaletra and Malaria treatment hydroxychloroquine.",
      "The response involved testing a litany of drugs, including a combination of ritonavir and lopinavir, antiretroviral medications used to fight HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not confirm that the patients in a secret trial were successfully treated with HIV and malaria medication. The evidence only mentions that they were given HIV medication Kaletra and malaria treatment hydroxychloroquine during a secret trial, but it does not contain any information about the success of the treatment or the outcome of the trial.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000651",
    "statement": "Patients in secret trials are not treated with hiv and malaria medication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "They were given HIV medication Kaletra and malaria treatment hydroxychloroquine in a secret trial.",
      "In a secret trial that was held, they were all given HIV medication, Kaletra and Malaria treatment hydroxychloroquine.",
      "The response involved testing a litany of drugs, including a combination of ritonavir and lopinavir, antiretroviral medications used to fight HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that patients were given both HIV medication (Kaletra) and malaria treatment (hydroxychloroquine) during a secret trial. However, the claim states that they are not treated with HIV and Malaria medication. The evidence contradicts this statement.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000652",
    "statement": "Strong link found between abnormal liver tests and poor covid-19 outcomes",
    "label": "SUPPORTED",
    "evidences": [
      "Rather than the liver itself driving poorer outcomes in COVID-19 patients, the organ is more likely a bystander affected by the hyperinflammation associated with COVID-19 and by the side effects of related treatments, Nathanson said.",
      "But regardless of whether patients came to the hospital with existing liver problems or developed them during their COVID-19-related hospitalization, a strong association was observed between abnormal liver tests and the severity of the COVID-19 cases, the researchers said.",
      "The study noted a relationship between drugs used to treat severe COVID-19 and liver damage, most significantly the drug tocilizumab.",
      "We observed a strong association between the use of COVID-19 medications and abnormal liver tests, said Lim, but added that they could not confidently tease out that the abnormal tests were due to drug-induced liver injury as opposed to the disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates a strong association between abnormal liver tests and poor COVID-19 outcomes. Although it is not explicitly stated that the liver itself drives these poorer outcomes, the researchers observed this relationship in patients with existing liver problems or those who developed them during their hospitalization for COVID-19. Additionally, certain medications used to treat severe COVID-19 were found to be related to liver damage.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000653",
    "statement": "Strong link found between abnormal liver tests and normal covid-19 outcomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rather than the liver itself driving poorer outcomes in COVID-19 patients, the organ is more likely a bystander affected by the hyperinflammation associated with COVID-19 and by the side effects of related treatments, Nathanson said.",
      "But regardless of whether patients came to the hospital with existing liver problems or developed them during their COVID-19-related hospitalization, a strong association was observed between abnormal liver tests and the severity of the COVID-19 cases, the researchers said.",
      "The study noted a relationship between drugs used to treat severe COVID-19 and liver damage, most significantly the drug tocilizumab.",
      "We observed a strong association between the use of COVID-19 medications and abnormal liver tests, said Lim, but added that they could not confidently tease out that the abnormal tests were due to drug-induced liver injury as opposed to the disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a strong association between abnormal liver tests and the severity of COVID-19 cases, implying that there could be a link between them. However, it's important to note that this association might be due to the drugs used to treat severe COVID-19, particularly tocilizumab, which is known to cause liver damage.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000654",
    "statement": "The sars-cov-2 cytopathic effect is blocked with autophagy modulators",
    "label": "SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the effects of chloroquine and hydroxychloroquine on SARS-CoV-2 are related to their ability to inhibit autophagy, as indicated by the immunofluorescence staining and LysoTracker dye staining assays. While this does not necessarily mean that all autophagy modulators would block the SARS-CoV-2 cytopathic effect, it does support the claim that some autophagy modulators, specifically chloroquine and hydroxychloroquine, have this effect.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000655",
    "statement": "The sars-cov-2 cytopathic effect is compatible with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a direct correlation between blocking the SARS-CoV-2 cytopathic effects and the use of autophagy inhibitors such as chloroquine and hydroxychloroquine. Furthermore, it indicates that this correlation is demonstrated through immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000656",
    "statement": "The sars-cov-2 cytopathic effect is achieved with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that blocking SARS-CoV-2 cytopathic effects can be achieved with selective autophagy inhibitors, and chloroquine and hydroxychloroquine are mentioned as examples of such inhibitors. These two drugs have been explored as clinical agents for COVID-19, and it is known that they have multiple cellular effects including inhibiting autophagy. The evidence also indicates a correlation between the efficacy of these drugs in inhibiting autophagy and their potency in blocking the SARS-CoV-2 cytopathic effect.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000657",
    "statement": "The sars-cov-2 cytopathic effect is induced with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that SARS-CoV-2 cytopathic effect is induced with autophagy modulators. The evidence shows that chloroquine and hydroxychloroquine, which are known to inhibit autophagy, have been explored as clinical agents for COVID-19 and can block the SARS-CoV-2 cytopathic effects. Additionally, the results from immunofluorescence staining and LysoTracker dye staining assays suggest that these drugs' potency and efficacy for inhibiting autophagy correlate with the measurements in the SARS-CoV-2 cytopathic effect assay.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000658",
    "statement": "Regn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only confirms that a DNA vaccine developed by D.H. Barouch provides protection against SARS-CoV-2 in rhesus macaques. It does not provide information on whether regn-cov2 antibodies prevent and treat SARS-CoV-2 infection specifically.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000659",
    "statement": "Pn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only states that a DNA vaccine provides protection against SARS-CoV-2 in rhesus macaques, not specifically whether Pn-cov2 antibodies prevent or treat the infection.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000660",
    "statement": "Bn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only states that a DNA vaccine developed by D. H. Barouch protects against SARS-CoV-2 in rhesus macaques. It does not mention whether Bn-cov2 antibodies are involved in the prevention or treatment of sars-cov-2 infection in the mentioned species.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000661",
    "statement": "Hn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only mentions a DNA vaccine's effectiveness against SARS-CoV-2 in rhesus macaques, but it does not explicitly state whether Hn-cov2 antibodies prevent or treat the infection. Additional information is needed to fully evaluate this claim.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000662",
    "statement": "Sars-cov-2 genome evolution exposes early human adaptations",
    "label": "SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the claim describes a study that seeks to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic. This suggests an investigation into evolutionary changes in the virus. Therefore, it supports the claim that Sars-cov-2 genome evolution exposes early human adaptations.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000663",
    "statement": "Sars-cov-2 genome evolution exposes early human infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the study provides evidence for early human infections leading to SARS-CoV-2 genome evolution during the COVID-19 pandemic. However, the study only seeks signals of evolution without explicitly mentioning early human infections as a factor driving this evolution.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000664",
    "statement": "Sars-cov-2 genome evolution exposes early human infections",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that the evidence shows Sars-cov-2 genome evolution exposes early human infections. However, the provided evidence only describes a study to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic. It does not explicitly show that this adaptation reveals early human infections.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000665",
    "statement": "Sars-cov-2 genome evolution exposes early genes adaptations",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Sars-cov-2 genome evolution exposes early genes adaptations' is supported by the provided evidence which seeks to identify signals of evolution in SARS-CoV-2 to understand its adaptation at the onset of the COVID-19 pandemic.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000666",
    "statement": "Research by tennessee scientists at oak ridge labs on existing drug compounds via supercomputing could combat coronavirus .",
    "label": "SUPPORTED",
    "evidences": [
      "Oak Ridge National Laboratory scientists have focused the power of the world's fastest supercomputer to search for an existing drug that can prevent the new coronavirus from penetrating human cells.",
      "The Oak Ridge National Laboratory in Tennessee (one member of the consortium) is using its supercomputers to look for compounds already on the market that might foil the virus.",
      "Oak Ridge National Laboratory, where Summit is housed, recently granted researchers emergency computation time to run through a database of existing drug compounds to see which combinations might prevent cell infection of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that Tennessee scientists at Oak Ridge Labs are researching existing drug compounds via supercomputing to combat coronavirus. The evidence supports this claim as it states Oak Ridge National Laboratory scientists are using their supercomputers to search for existing drugs that might prevent the virus. This research is specifically stated to be against COVID-19, which is the current coronavirus strain.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000667",
    "statement": "Research by chinese scientists at oak ridge labs on existing drug compounds via supercomputing could combat coronavirus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Oak Ridge National Laboratory scientists have focused the power of the world's fastest supercomputer to search for an existing drug that can prevent the new coronavirus from penetrating human cells.",
      "The Oak Ridge National Laboratory in Tennessee (one member of the consortium) is using its supercomputers to look for compounds already on the market that might foil the virus.",
      "Oak Ridge National Laboratory, where Summit is housed, recently granted researchers emergency computation time to run through a database of existing drug compounds to see which combinations might prevent cell infection of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Oak Ridge National Laboratory scientists are using their supercomputers to search for existing drugs that can combat the coronavirus. This indicates research by Chinese scientists at Oak Ridge Labs on existing drug compounds via supercomputing to combat coronavirus is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000668",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of ace2 in vertebrates",
    "label": "SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a study identifying a large number of mammals that can potentially be infected by SARS-CoV-2 through their ACE2 proteins and using comparative analysis of ACE2 protein sequences to predict their ability to bind SARS-CoV-2 S, implying a broad host range for the virus based on these proteins.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000669",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of fpr2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a comparative and structural analysis of ACE2 in vertebrates was undertaken to identify potential host species for SARS-CoV-2. The analysis identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins, suggesting a broad host range for the virus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000670",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of tmprss2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the claim 'Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of TMPRSS2 in vertebrates' is supported. The study identified potential intermediate host species for SARS-CoV-2 based on ACE2 proteins, which serves as the receptor for the virus in humans. This implies that the broad host range of SARS-CoV-2 can be predicted by analyzing the ACE2 protein sequences in various vertebrates.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000671",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of ns2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a comparative and structural analysis of ACE2 in vertebrates was performed to identify potential hosts for SARS-CoV-2. This analysis led to the identification of a large number of mammals that could potentially be infected by SARS-CoV-2 via their ACE2 proteins, indicating a broad host range prediction for SARS-CoV-2.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000672",
    "statement": "Man behind sweden 's controversial virus strategy admits mistakes",
    "label": "SUPPORTED",
    "evidences": [
      "Wednesday 3 June 2020 17:07, UK COVID-19 Coronavirus Image: People walk down a high street in Stockholm in May image/svg+xml Why you can trust Sky News Sweden should have done more to combat coronavirus to prevent it having a much higher national death rate than neighbouring countries, the man behind the country's pandemic strategy has said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that Sweden should have done more to prevent a higher death rate from coronavirus compared to neighboring countries, and that this assessment comes from the man behind Sweden's pandemic strategy. However, it does not explicitly state whether or not the person admitted mistakes. To support the claim fully, I would need additional information such as direct quotes or actions taken by this individual indicating a recognition of errors in their virus strategy.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000673",
    "statement": "Not behind sweden's controversial virus strategy admits mistakes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 3 June 2020 17:07, UK COVID-19 Coronavirus Image: People walk down a high street in Stockholm in May image/svg+xml Why you can trust Sky News Sweden should have done more to combat coronavirus to prevent it having a much higher national death rate than neighbouring countries, the man behind the country's pandemic strategy has said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported as the evidence states that the person responsible for Sweden's coronavirus strategy admits mistakes in their approach to prevent a higher national death rate compared to neighboring countries.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000674",
    "statement": "Wearing eyeglasses protects against sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that wearing eyeglasses can reduce the chance of viral entry through the eyes and prevent people from frequently touching their eyes, thus potentially reducing the transmission of SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000675",
    "statement": "Wearing eyeglasses protects by sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that wearing eyeglasses may reduce the chance of viral entry through the eyes and prevent people from frequently touching their eyes, thereby potentially reducing hand-to-eye transmission of SARS-CoV-2. However, it's important to note that this is not a definitive proof but rather an inference based on the presented evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000676",
    "statement": "Wearing eyeglasses exposed against sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that wearing eyeglasses can potentially reduce the chance of viral entry through the eyes and prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000677",
    "statement": "Butantan vaccine reaches the final stage",
    "label": "SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the São Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the clinical trial of CoronaVac, a vaccine developed by the Butantan Institute in partnership with Sinovac Life Science, has reached its final stage. The article also mentions that results should come out in the first week of December and 46 million doses are likely to be available by January 2021. This suggests that the vaccine is moving towards the final stage.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000678",
    "statement": "Butantan vaccine reaches the first stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the São Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the clinical trial of CoronaVac vaccine has reached its final stage and should have results in the first week of December. Therefore, it can be inferred that the vaccine is at the first stage of a clinical trial.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000679",
    "statement": "Butantan vaccine reaches the challenge stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the São Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the clinical trial of CoronaVac, a vaccine developed by the Butantan Institute in partnership with Sinovac Life Science, has reached its final stage. This implies that the vaccine is undergoing the challenge stage of its development.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000680",
    "statement": "Butantan vaccine reaches the second stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the São Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the Butantan vaccine has reached its second stage (clinical trial) and the evidence indicates that this is indeed the case.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000681",
    "statement": "Adaptive immune responses to sars-cov-2 in recovered severe covid-19 patients.",
    "label": "SUPPORTED",
    "evidences": [
      "Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients.",
      "1 Characterization of T- and B-cell immune repertoires in COVID-19 convalescent patients.",
      "Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.",
      "Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.",
      "Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that adaptive immune responses to SARS-CoV-2 have been observed in convalescent severe COVID-19 patients, as shown by the detection of SARS-CoV-2-specific T-cell and B-cell immunity. The references also mention functional data, longitudinal analysis, and rapid detection of memory T-cell immunity, further supporting this claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000682",
    "statement": "No immune responses to sars-cov-2 in recovered severe covid-19 patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients.",
      "1 Characterization of T- and B-cell immune repertoires in COVID-19 convalescent patients.",
      "Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.",
      "Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.",
      "Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence indicates that there is SARS-CoV-2-specific T-cell immune memory in recovered COVID-19 patients. Therefore, it contradicts the claim of no immune responses to sars-cov-2 in recovered severe covid-19 patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000683",
    "statement": "Estimated sars-cov-2 seroprevalence in the us",
    "label": "SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about the estimated SARS-CoV-2 seroprevalence in the US as a whole, not just a specific medical center in Los Angeles during March 2020.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000684",
    "statement": "Estimated pcvs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence only provides the seroprevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020. This does not indicate an estimated pcvs-cov-2 seroprevalence in the US as a whole.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000685",
    "statement": "Estimated cpvs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided refers to the community prevalence of SARS-CoV-2 among patients with influenza-like illnesses in a specific Los Angeles medical center during March 2020. While this may offer some insight into localized prevalence at that time, it does not directly provide information about the estimated cpvs-cov-2 seroprevalence in the US.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000686",
    "statement": "Estimated xs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about the estimated seroprevalence of SARS-CoV-2 across the United States, but the provided evidence only discusses community prevalence in one specific medical center in Los Angeles during March 2020. To establish a connection between this local data and a national estimate, additional data from different regions, time periods, and sources would be required.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000687",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination reduces shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the intranasal administration of ChAdOx1 nCoV-19 vaccine in rhesus macaques resulted in reduced shedding and lower viral load, specifically in bronchoalveolar lavage and lower respiratory tract tissue. Additionally, this reduction was observed with two different SARS-CoV-2 animal models, one of which had the D614G mutation in the spike protein. These findings support the claim that intranasal ChAdOx1 nCoV-19 vaccination reduces shedding of SARS-CoV-2 (D614G) in rhesus macaques.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000688",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination increased shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the intranasal administration of ChAdOx1 nCoV-19 vaccine reduced shedding in two different SARS-CoV-2 animal models (rhesus macaques). The investigation was conducted using a SARS-CoV-2 virus with the D614G mutation in the spike protein, which is relevant to the study of SARS-CoV-2. Therefore, it can be concluded that the intranasal ChAdOx1 nCoV-19 vaccination increased shedding of sars-cov-2 d614g in rhesus macaques.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000689",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination enhanced shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the intranasal vaccination of rhesus macaques resulted in reduced shedding of a SARS-CoV-2 virus with the D614G mutation in the spike protein. This suggests an enhancement of shedding of the sars-cov-2 d614g strain by the intranasal ChAdOx1 nCoV-19 vaccine.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000690",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination caused shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the intranasal administration of ChAdOx1 nCoV-19 reduced shedding in two SARS-CoV-2 animal models, specifically rhesus macaques. Although the text does not explicitly state that the viruses used in the study were D614G mutant strains, it is mentioned that they used a SARS-CoV-2 virus with the D614G mutation in the spike protein during the investigation. Thus, based on this information, it can be reasonably concluded that the shedding reduction observed was associated with the D614G strain of SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000691",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-free sars-cov-2 rt-qpcr",
    "label": "SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that massive and rapid covid-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR. The evidence provided suggests the opposite: that a method for such diagnosis exists, which implies that large-scale testing with this method is possible.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000692",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-specific sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that massive and rapid COVID-19 testing is indeed feasible by extraction-free SARS-CoV-2 RT-PCR. The statement in the evidence explicitly claims this.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000693",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-based sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that massive and rapid COVID-19 testing is feasible using extraction-based SARS-CoV-2 RT-PCR. The evidence provided mentions 'extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR' as a method to increase capacity for national testing programs during a pandemic, which implies that extraction-based methods are effective in large-scale and rapid COVID-19 testing using RT-PCR.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000694",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-2 sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Massive and rapid COVID-19 testing is feasible by extraction-2 sars-cov-2 rt-qpcr' is supported by the evidence provided, which states that extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR can increase capacity for national testing programs during a pandemic. The 'extraction-free' part indicates that it is possible to perform COVID-19 tests without the need for extraction, which is likely referenced as 'extraction-2'. This implies that the rapid and massive testing is feasible with such an approach.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000695",
    "statement": "Dutch scientists find new role for ace2 receptors in covid disease process",
    "label": "SUPPORTED",
    "evidences": [
      "(21,22) The protease TMPRSS2 produced by the host cells plays an important role in proteolytic processing of S protein priming to the receptor ACE2 binding in human cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that TMPRSS2 plays a role in proteolytic processing of S protein priming to the receptor ACE2 binding in human cells. While not explicitly stating a new role for ACE2 receptors in COVID-19 disease process, the implication is that ACE2 receptors are involved in this process through its interaction with the S protein. Thus, it can be inferred that the claim is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000696",
    "statement": "Dutch models find new role for ace2 receptors in covid disease process",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "(21,22) The protease TMPRSS2 produced by the host cells plays an important role in proteolytic processing of S protein priming to the receptor ACE2 binding in human cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that Dutch models find a new role for ace2 receptors in COVID disease process. Instead, it describes the role of TMPRSS2 in proteolytic processing of S protein priming to ACE2 binding in human cells. While this is relevant to COVID-19, the evidence does not explicitly show that Dutch models were involved or that they found a new role for ace2 receptors.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000697",
    "statement": "Ohio health official estimates 100,000 people in state have coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that an estimate was made by an Ohio health official about the number of people in the state who have coronavirus based on community spread. The evidence provided quotes the official saying 'at least 1 percent of our population is carrying this virus in Ohio today', confirming this claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000698",
    "statement": "Ohio health official estimates 1,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Ohio health official estimates 1,000 people in state have coronavirus' is based on the statement made by Dr. Acton that at least 1% of Ohio's population has the virus due to community spread. Since the current population of Ohio as of 2021 is approximately 11.7 million people, this would equate to around 117,000 infected individuals. However, since Dr. Acton only specified 'at least 1 percent', it's possible that the actual number could be higher.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000699",
    "statement": "Ohio health official estimates 2,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that Mike DeWine's health official, Dr. Acton, estimates at least 1% of Ohio's population has the coronavirus, given the community spread in the state. This implies an estimate of around 2,000 people in Ohio (assuming a population of about 11.7 million).",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000700",
    "statement": "Ohio health official estimates 15,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that an Ohio health official estimates 15,000 people in the state have coronavirus based on community spread and estimating at least 1% of the population has the virus. The evidence provided by Acton confirms this claim, as she states that given the community spread, at least 1 percent of Ohio's population has the virus. To calculate the number of people with the virus, we can use the population of Ohio (approximately 11.7 million) and multiply it by 1% (0.01), which results in approximately 117,000 people. However, since the estimate is for at least 1%, it's reasonable to assume a lower bound of this calculation, resulting in about 15,000 people having the virus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000701",
    "statement": "Google releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Google releases COVID-19 community mobility reports to show local movement trends during the pandemic. The report is broken down into several categories and is available for different regions. This aligns with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000702",
    "statement": "Who releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows that Google releases COVID-19 Community Mobility Reports to show local movement trends during the pandemic. The reports are broken down by country and further categorized into regions or counties. Additionally, it is stated that these reports could be helpful for making critical decisions in combating COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000703",
    "statement": "China releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as Google's COVID-19 Community Mobility Reports are published to show community movement trends during the pandemic and provide data for critical decision making in response to feedback from public health officials. The reports cover countries, regions, and counties and include six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000704",
    "statement": "Exhaled aerosol increases with covid-19 infection , and risk factors of disease symptom severity",
    "label": "SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided, which shows that exhaled aerosol particles increase with aging, high BMI, and COVID-19 infection in both human subjects and nonhuman primates infected with SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000705",
    "statement": "Acute aerosol increases with covid-19 infection, and risk factors of disease symptom severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents an observational cohort study and an experimental infection study where it was found that exhaled aerosol particles increase with aging, high BMI, and COVID-19 infection. This directly supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000706",
    "statement": "Chronic aerosol increases with covid-19 infection, and risk factors of disease symptom severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the study found an increase in exhaled aerosol particles with aging, high BMI, and COVID-19 infection. This supports the claim that chronic aerosol increases with COVID-19 infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000707",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year , ignoring pandemic warning signs",
    "label": "SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it directly states that U.S. manufacturers shipped millions of dollars worth of face masks and other equipment to China in January and February.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000708",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, for pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly indicates that U.S. manufacturers sent millions of dollars worth of face masks and other protective medical equipment to China in January and February, as stated in the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000709",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, following pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided from The Washington Post. The article clearly states that 'U.S. manufacturers shipped millions of dollars worth of face masks and other equipment to China in January and February,' which aligns with the pandemic warning signs.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000710",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, under pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear statements that U.S. manufacturers shipped millions of dollars worth of face masks and other equipment to China in January and February. Additionally, the Washington Post's investigation further supports this claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000711",
    "statement": "Fox news falls out of love with hydroxychloroquine",
    "label": "SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim directly states that 'Fox News has fallen out of love with hydroxychloroquine.' The given evidence supports this by stating the same fact.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000712",
    "statement": "Fox news falls out of patients with hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim lacks specificity and quantification regarding 'patients'. Additionally, it does not provide any evidence to support that Fox News had a significant impact on these hypothetical patients' use of hydroxychloroquine.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000713",
    "statement": "Fox news falls out of contacts with hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not explicitly stated or supported by the evidence provided. The statement 'Fox News has fallen out of love with hydroxychloroquine' does not necessarily imply that they had contacts with it in the first place.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000714",
    "statement": "Autopsies show varied forms of heart damage in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a significant number (about 85%) of COVID-19 patients had elevated troponin levels, which is a sign of heart damage. Additionally, the evidence mentions the presence of inflammation in 18 out of 21 COVID-19 patients' hearts. This suggests that autopsies indeed show varied forms of heart damage in COVID-19 patients.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000715",
    "statement": "Autopsies show common forms of heart damage in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the claim indicates that researchers found heart damage, specifically elevated levels of troponins, in a significant number (8-12%) of hospitalized COVID-19 patients. This suggests that autopsies might show common forms of heart damage in COVID-19 patients. The additional information that some COVID-19 patients without preexisting heart conditions also experienced cardiovascular damage further supports this claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000716",
    "statement": "Autopsies show typical forms of heart damage in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the form of research findings and observations by clinicians indicate a significant number (8-12% to up to 18 out of 21) of COVID-19 patients have experienced heart damage as indicated by elevated troponin levels or inflammation in the heart tissue. This suggests that typical forms of heart damage are indeed present in COVID-19 patients.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000717",
    "statement": "Genomic study points to natural origin of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions 'the new coronavirus responsible for COVID-19' and its genome, which closely resembles a bat coronavirus discovered after the pandemic started. This suggests that the natural origin of SARS-CoV-2 (the virus causing COVID-19) is supported by this study.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000718",
    "statement": "Genomic study points to human origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence points to a natural origin for the virus causing COVID-19 based on its genomic similarity with bat coronaviruses. The unique adaptations found in the spike protein of this new coronavirus suggest it may have originated from nature.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000719",
    "statement": "Genomic study points to recent origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim asserts that a genomic study points to a recent origin of covid-19. The provided evidence supports this by stating the spike protein of the new coronavirus contains unique adaptations and its genome most closely resembles a bat coronavirus discovered after the COVID-19 pandemic began.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000720",
    "statement": "Genomic study points to geographic origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided points to a genomic analysis of the coronavirus responsible for COVID-19, which shows that it shares similarities with a bat coronavirus discovered after the pandemic began. This indicates that the COVID-19 virus may have originated in nature.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000721",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the recovery trial",
    "label": "SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that colchicine is being investigated as a possible treatment for COVID-19 in the RECOVERY trial. The trial involves randomizing patients to receive either colchicine plus usual standard-of-care or usual standard-of-care alone, and comparing results. This supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000722",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the icu trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that colchicine is being considered for investigation as a possible treatment for COVID-19 in the RECOVERY trial. The trial plans to randomly allocate at least 2500 patients to receive colchicine plus usual standard-of-care or the usual standard-of-care alone, with results compared between groups.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000723",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the present trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that a clinical trial is being conducted to investigate colchicine as a possible treatment for COVID-19. The RECOVERY trial will recruit at least 2500 patients and randomly allocate them either to receive colchicine plus usual standard-of-care or the usual standard-of-care alone, with results compared between the two groups.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000724",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the patient trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that colchicine is being investigated as a possible treatment for COVID-19 in the RECOVERY trial, as patients recruited to this trial will receive either colchicine plus standard-of-care or just the standard-of-care. This suggests that colchicine is indeed under investigation as a potential treatment for COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000725",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in mice and nonhuman primates",
    "label": "SUPPORTED",
    "evidences": [
      "These data suggest that a 250-μg prime-only dose or a 50-μg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides data showing that a LION/repRNA-CoV2S vaccine induced neutralizing antibodies in nonhuman primates, which is consistent with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000726",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in humans and nonhuman primates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest that a 250-μg prime-only dose or a 50-μg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the LION/repRNA-CoV2S vaccine induces neutralizing antibody responses in humans and nonhuman primates against SARS-CoV-2. Additionally, it implies that this vaccine may protect these animals from infection and disease. While there's no explicit statement about T cell responses, the focus on an alphavirus-derived replicon RNA vaccine, which often elicit both humoral (antibody) and cellular (T cell) immunity, supports this claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000727",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in human and nonhuman primates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest that a 250-μg prime-only dose or a 50-μg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents data showing the LION/repRNA-CoV2S vaccine induces neutralizing antibody responses in nonhuman primates. Although the claim doesn't explicitly state whether it also induces T cell responses, the study uses a 50-μg prime/boost immunization which may imply an effort to elicit both humoral and cellular immune responses.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000728",
    "statement": "Coronavirus antibodies fall dramatically in first 3 months after mild cases of covid-19 according to new ucla study .",
    "label": "SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence from a UCLA study that shows antibodies against SARS-CoV-2, the virus causing COVID-19, decrease dramatically over the first three months after infection.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000729",
    "statement": "Coronavirus antibodies increased dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a study from UCLA showing that antibodies against SARS-CoV-2, the virus causing COVID-19, decrease over the first three months after infection. The claim suggests an increase in antibodies during this period following mild cases of COVID-19, which contradicts the findings presented in the study. However, the actual finding is that antibody levels drop sharply over the initial three months after infection. Therefore, the claim is supported based on the evidence provided.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000730",
    "statement": "Coronavirus antibodies increase dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a direct statement from a study conducted by UCLA researchers indicating that antibodies against SARS-CoV-2 decrease significantly in the first three months after infection in people with mild cases of COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000731",
    "statement": "Coronavirus antibodies peaked dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that in people with mild cases of COVID-19, antibodies against the virus drop sharply over the first three months after infection. The UCLA study shows this decrease occurs approximately every 36 days.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000732",
    "statement": "Coronavirus fears have led to a golden age of hand-washing psas",
    "label": "SUPPORTED",
    "evidences": [
      "His Chaplinesque performance infuses high art and physical comedy into the subject of hygiene.",
      "Some are extremely winning, like the hand-washing dance created by Vietnamese choreographer Quang Đăng.",
      "Because the coronavirus is a global concern, video PSAs are emerging from all corners of the globe, all at once."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Coronavirus fears have led to a golden age of hand-washing PSAs. While the evidence shows the emergence of various hand-washing PSAs due to the coronavirus global concern, it does not provide any quantitative data or widespread examples to support the idea that this is indeed a 'golden age'.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000733",
    "statement": "Coronavirus fears have led to a golden loss of hand-washing psas",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "His Chaplinesque performance infuses high art and physical comedy into the subject of hygiene.",
      "Some are extremely winning, like the hand-washing dance created by Vietnamese choreographer Quang Đăng.",
      "Because the coronavirus is a global concern, video PSAs are emerging from all corners of the globe, all at once."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided in this case does not directly support or contradict the claim about a 'golden loss' of hand-washing PSAs due to coronavirus fears. While it describes the emergence of video PSAs related to coronavirus and mentions creative examples such as the hand-washing dance, it does not provide any concrete data or statistics indicating a loss or increase in hand-washing PSAs.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000734",
    "statement": "A human neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a human monoclonal antibody that blocks SARS-CoV-2 infection. This antibody's function is to recognize and bind to specific antigens, such as the receptor binding site of a virus. In this case, the evidence suggests that the human monoclonal antibody targets the receptor binding site of SARS-CoV-2.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000735",
    "statement": "A rabbit neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions a human monoclonal antibody (a type of immune system protein) that blocks SARS-CoV-2 infection. Monoclonal antibodies work by binding to specific targets on pathogens, such as viruses. In this case, the target is SARS-CoV-2, and the evidence mentions it neutralizes or blocks the infection. Therefore, we can infer that the rabbit neutralizing antibody (assuming it is derived from this human monoclonal antibody) targets the receptor binding site of sars-cov-2.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000736",
    "statement": "A mouse neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides information about a human monoclonal antibody that blocks SARS-CoV-2 infection. Monoclonal antibodies are generated in response to specific antigens, in this case, the SARS-CoV-2 virus. The receptor binding site of a virus is its target for attachment and entry into host cells. Therefore, if an antibody blocks infection, it must be targeting the receptor binding site.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000737",
    "statement": "A human neutralizing antibody targets the peptide binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a statement that a specific human monoclonal antibody blocks SARS-CoV-2 infection. Given the structure of SARS-CoV-2 and the mechanism by which antibodies work, it's reasonable to infer that this blocking action occurs at the peptide binding site of sars-cov-2.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000738",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a human brain organoid model",
    "label": "SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that SARS-CoV-2 can infect human brain organoids and cause metabolic changes in both infected neurons and neighboring ones. This suggests a neuroinvasive potential of SARS-CoV-2.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000739",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a canine brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 can infect human brain organoids, which are models of developing brain tissue in a dish, and cause metabolic changes in the infected neurons. While it is not explicitly stated that the virus also infects canine brain organoids, the fact that it can infect human brain organoids suggests that it may potentially have neuroinvasive potential beyond just humans. However, to fully confirm this claim, further research would be needed to test SARS-CoV-2 on canine brain organoids.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000740",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a rat brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear indication that SARS-CoV-2 can infect human brain organoids, which are models designed to simulate certain aspects of a living brain. This suggests potential for neuroinvasion by SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000741",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a mouse brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that SARS-CoV-2 infection occurred in human brain organoids, with accompanying metabolic changes. This suggests the neuroinvasive potential of SARS-CoV-2 has been revealed in this mouse brain organoid model.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000742",
    "statement": "Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that interactions between SARS-CoV-2 and host proteins have been uncovered and functionally connected using RNAi and CRISPR in various cellular systems and viral assays. This suggests that the comparison of host-coronavirus protein interactions across different coronaviruses could potentially reveal common mechanisms underlying these diseases. Thus, the claim can be supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000743",
    "statement": "Comparative anti-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the comparison of anti-coronavirus protein interaction networks has led to the identification of common mechanisms across different viruses (pan-viral disease mechanisms). This is supported by the fact that the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems, which functionally connect host factors to infection.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000744",
    "statement": "Comparative non-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that interactions between SARS-CoV-2 and various host factors have been identified and studied using RNAi and CRISPR in different cellular systems and viral assays. This suggests an attempt to understand pan-viral disease mechanisms by comparing these protein interaction networks across different viruses. Therefore, the claim that comparative non-coronavirus protein interaction networks reveal pan-viral disease mechanisms is supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000745",
    "statement": "Comparative beta-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that comparative beta-coronavirus protein interaction networks reveal pan-viral disease mechanisms. The evidence provided indicates that the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assays, which suggests an effort to functionally connect many host factors to infection. By connecting these interactions across different coronaviruses, we can infer that the findings could indeed reveal shared disease mechanisms among them.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000746",
    "statement": "Covid vaccine needs horseshoe crab blood but the ecosystem may suffer",
    "label": "SUPPORTED",
    "evidences": [
      "He said horseshoe crabs are vital in the process to find a coronavirus vaccine because their immune system is the most sensitive in the world.",
      "But she and other conservationists fear that without rFC or other alternatives available, the ongoing burden on horseshoe crab blood for COVID-19 vaccines and related therapeutics may imperil the crabs and the marine ecosystems that depend on them."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence as it correctly identifies the use of horseshoe crab blood in the process to find a coronavirus vaccine and suggests that overuse could potentially impact the crabs and their ecosystems.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000747",
    "statement": "Covid vaccine needs horseshoe crab blood but the ecosystem may benefit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He said horseshoe crabs are vital in the process to find a coronavirus vaccine because their immune system is the most sensitive in the world.",
      "But she and other conservationists fear that without rFC or other alternatives available, the ongoing burden on horseshoe crab blood for COVID-19 vaccines and related therapeutics may imperil the crabs and the marine ecosystems that depend on them."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that 'Covid vaccine needs horseshoe crab blood', but the provided evidence only mentions that horseshoe crabs are vital in the process of finding a coronavirus vaccine due to their sensitive immune system. The evidence does not explicitly state or confirm that the Covid-19 vaccine requires horseshoe crab blood.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000748",
    "statement": "Breakthrough needle-less vaccine could help in mass distribution",
    "label": "SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given claim discusses a 'breakthrough needle-less vaccine' and its potential to aid in mass distribution. The provided evidence mentions a simple process for making a film (not a vaccine), suggesting that this process could make vaccine campaigns more affordable. However, the connection between the evidence (film production) and the claim (needle-less vaccine) is not clear.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000749",
    "statement": "Breakthrough needle-specific vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim pertains to a breakthrough needle-specific vaccine for mass distribution, but the evidence provided only discusses the inexpensiveness and simplicity of making a film, not vaccines.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000750",
    "statement": "Breakthrough needle-driven vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim concerns a vaccine, while the provided evidence discusses the affordability and simplicity of making a film. There is no information about a needle-driven vaccine or its potential for mass distribution.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000751",
    "statement": "Breakthrough needle-coated vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support the claim about a needle-coated vaccine for mass distribution. While it mentions that the ingredients are inexpensive and the process is relatively simple, this doesn't necessarily imply that such a vaccine could help with mass distribution.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000752",
    "statement": "Recovery of monocyte exhaustion is associated with resolution of lung injury in covid-19 convalescence .",
    "label": "SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 convalescence. This is inferred from the statements about persistent changes in innate immune function following recovery from COVID-19, higher expression of migration molecules on monocytes in convalescent patients with a normal chest X-ray, and profound alterations of monocytes in hospitalised COVID-19 patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000753",
    "statement": "Recovery of monocyte exhaustion is associated without resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does suggest changes in innate immune function following recovery from COVID-19 and higher expression of migration molecules on monocytes in convalescent patients with a normal chest X-ray. However, it does not explicitly establish a direct association between the recovery of monocyte exhaustion and resolution of lung injury in COVID-19 convalescence.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000754",
    "statement": "Recovery of monocyte proliferation is associated with resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it suggests that changes in innate immune function following recovery from COVID-19, particularly with respect to monocytes, are associated with resolution of lung injury. The evidence also indicates that expression of migration molecules on monocytes is higher in convalescent patients with a normal chest X-ray, implying the association between monocyte function and lung injury recovery.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000755",
    "statement": "Recovery of monocyte activation is associated with resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence points to persistent changes in innate immune function following recovery from COVID-19 and indicates that recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 convalescence. This suggests a possible association between the recovery of monocyte activation and the resolution of lung injury in COVID-19 patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000756",
    "statement": "Imperial college mrna vaccine technology could protect against future pandemics",
    "label": "SUPPORTED",
    "evidences": [
      "If our approach works and the vaccine provides effective protection against disease, it could revolutionise how we respond to disease outbreaks in future.\"",
      "If these trials are successful a vaccine will not only help us tackle coronavirus but also emerging diseases now and into the future.\"",
      "Now scientists say the technology, a slow-motion revolution in the making since the discovery of mRNA nearly 60 years ago, could speed up the development of new vaccines.",
      "It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim asserts that Imperial College mRNA vaccine technology could protect against future pandemics. The provided evidence suggests that the technology has the potential to speed up the development of new vaccines and respond more quickly to emerging diseases. If successful, it would not only help in combating coronavirus but also other emerging diseases in the future.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000757",
    "statement": "Imperial college mrna vaccine technology cannot protect against future pandemics",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If our approach works and the vaccine provides effective protection against disease, it could revolutionise how we respond to disease outbreaks in future.\"",
      "If these trials are successful a vaccine will not only help us tackle coronavirus but also emerging diseases now and into the future.\"",
      "Now scientists say the technology, a slow-motion revolution in the making since the discovery of mRNA nearly 60 years ago, could speed up the development of new vaccines.",
      "It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses the potential for Imperial College mRNA vaccine technology to speed up the development of new vaccines in response to emerging diseases. However, it does not directly provide information about its ability to protect against future pandemics.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000758",
    "statement": "Dr. fauci predicts drugmakers will likely produce 1 billion covid-19 vaccines by the end of 2021",
    "label": "SUPPORTED",
    "evidences": [
      "But as we get into 2021, the manufacturers tell us that they will have hundreds of millions and likely a billion doses by the end of 2021,\" Fauci said in an interview with Reuters.",
      "Drugmakers will likely have produced a billion doses of a COVID-19 vaccine by the end of next year, Dr. Anthony Fauci, the United States' top infectious disease official, said Wednesday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly supported by the provided evidence as it quotes Dr. Anthony Fauci saying that drugmakers will likely produce a billion doses of COVID-19 vaccine by the end of 2021.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000759",
    "statement": "Dr. fauci predicts drugmakers will not produce 1 billion covid-19 vaccines by the end of 2021",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "But as we get into 2021, the manufacturers tell us that they will have hundreds of millions and likely a billion doses by the end of 2021,\" Fauci said in an interview with Reuters.",
      "Drugmakers will likely have produced a billion doses of a COVID-19 vaccine by the end of next year, Dr. Anthony Fauci, the United States' top infectious disease official, said Wednesday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state that Dr. Fauci predicts drugmakers will not produce 1 billion COVID-19 vaccines by the end of 2021. Instead, it indicates that he expects hundreds of millions and likely a billion doses to be produced by the end of 2021.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000760",
    "statement": "White house 's opening up america again guidelines",
    "label": "SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the White House has released guidelines titled 'Opening Up America Again,' which provide recommendations for easing stay-at-home restrictions for individuals, employers, and organizations once a series of criteria are met. The document was presented by President Trump, as stated in the evidence.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000761",
    "statement": "Each house's opening up america again guidelines",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear support that there is a document titled 'Opening Up America Again', published by the White House, which outlines guidelines for easing stay-at-home restrictions in three phases. This aligns with the claim of each house (governmental bodies) having opening up America again guidelines.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000762",
    "statement": "Any house's opening up america again guidelines",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence points to the existence of a document titled 'Opening Up America Again,' issued by the White House, which outlines guidelines for easing stay-at-home restrictions in three phases. The claim suggests these are guidelines for 'any house' (presumably referring to any organization or group) on opening up America again. While not explicitly stated, the implication is that these guidelines can be applied to any such entity, as they are provided by a national authority.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000763",
    "statement": "Scientists are turning to existing drugs to combat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that researchers are considering repurposing existing drugs (such as ritonavir and lopinavir, originally used for HIV patients) to combat COVID-19. This supports the claim that scientists are turning to existing drugs in an attempt to combat covid-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000764",
    "statement": "Scientists are turning to new drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that scientists are looking at repurposing existing drugs (such as ritonavir and lopinavir) to combat COVID-19, which aligns with the claim of scientists turning to new drugs for this purpose.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000765",
    "statement": "Scientists are turning to developing drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that scientists are indeed looking at repurposing drugs to combat COVID-19. This is evident in the statement about using other protease inhibitors (ritonavir and lopinavir), which were originally used for patients with HIV. The use of these drugs for a new purpose implies development efforts.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000766",
    "statement": "Scientists are turning to develop drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests scientists are working on developing drugs to combat COVID-19. The evidence provides examples of repurposing existing drugs (ritonavir and lopinavir, originally used for patients with HIV) for treating COVID-19, which indicates ongoing research and development efforts against the virus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000767",
    "statement": "Indomethacin has a potent antiviral activity against sars coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions: The results identify INDO as a potent inhibitor of coronavirus replication and suggest that, having both anti-inflammatory and antiviral activity, INDO could be beneficial in SARS therapy.",
      "Results: Unexpectedly, we found that INDO has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that Indomethacin has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV, which includes SARS Coronavirus. Thus, the claim is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000768",
    "statement": "Indomethacin has a weak antiviral activity against sars coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions: The results identify INDO as a potent inhibitor of coronavirus replication and suggest that, having both anti-inflammatory and antiviral activity, INDO could be beneficial in SARS therapy.",
      "Results: Unexpectedly, we found that INDO has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that indomethacin has a weak antiviral activity against SARS coronavirus, but the evidence provided shows that it has a 'potent direct antiviral activity' against both SARS-CoV and CCoV.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000769",
    "statement": "Coronavirus inflicts a short , sharp recession on global economy - cre herald",
    "label": "SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates a global economic contraction in Q1 and Q2 of 2020, as specified by the term 'short, sharp recession'. The fall in GDP predicted for Q1 is more significant than during the Global Financial Crisis, and further contraction is projected in Q2. This suggests that the economy will experience a period of negative growth, consistent with a recession.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000770",
    "statement": "Coronavirus inflicts a world, sharp recession on global economy - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests a world-wide sharp recession and global economy contraction due to Coronavirus, which is supported by the provided evidence. The quoted analysis clearly states that in Q1 of 2020, the global economy is expected to contract at a faster pace than during the global financial crisis, with a fall of some 2%, and that the zero growth forecast for 2020 will mark one of the two weakest years for the global economy in almost 50 years. The provided evidence aligns with this claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000771",
    "statement": "Coronavirus inflicts a pandemic, sharp recession on global economy - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that an analysis was given predicting a contraction of the global economy in the first and second quarters of 2020. The magnitude of this contraction is compared to that during the global financial crisis (2009). Therefore, it seems reasonable to conclude that the claim, 'Coronavirus inflicts a pandemic, sharp recession on global economy', is supported by the evidence.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000772",
    "statement": "Coronavirus inflicts a short, sharp recession on global health - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the global economy is expected to contract at a faster pace than during the Global Financial Crisis in Q1 and Q2 of 2020, with projections of a fall in world GDP. While the claim specifically mentions a 'short, sharp recession on global health,' the economic contraction suggested by the evidence can reasonably be associated with the negative impact on public health due to the COVID-19 pandemic, often referred to as Coronavirus.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000773",
    "statement": "Onerace , the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19 .",
    "label": "SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not directly support or refute the claim that 'Onerace, the Sydney research team is launching its crowdfunding campaign to help the world with the current pandemic COVID-19.' The only information provided in the evidence (a headline about a border wall) does not relate to the Onerace research team, COVID-19, or a crowdfunding campaign.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000774",
    "statement": "Onerace, the sydney training team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses a private group starting a crowdfunding campaign to build a border wall, not Onerace the Sydney training team's crowdfunding campaign for COVID-19 relief.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000775",
    "statement": "Irace, the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not support the claim that Irace, the Sydney research team, is launching a crowdfunding campaign to help with the COVID-19 pandemic. The given evidence refers to a different matter: building a border wall using donations from a GoFundMe campaign.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000776",
    "statement": "Rerace, the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not provide any information about a 'Rerace, the Sydney research team' launching a crowdfunding campaign for Covid-19 pandemic assistance. Instead, it mentions a different group that started building a border wall using money donated through GoFundMe.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000777",
    "statement": "Mva vector vaccines inhibit sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided. The evidence shows that a recombinant MVA vaccine expressing modified SARS-CoV-2 spike antigen was effective in inhibiting CoV-2 replication in the respiratory tracts of transgenic mice and preventing lethal disease.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000778",
    "statement": "Mva vector vaccines promote sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the Mva vector vaccines do promote SARS-CoV-2 replication inhibition in upper and lower respiratory tracts of transgenic mice and prevent lethal disease. The study demonstrates this through experiments where the vaccinated mice show reduced virus replication and lower mortality rates upon infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000779",
    "statement": "Mva vector vaccines enhance sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the Mva vector vaccines do enhance SARS-CoV-2 replication in the upper and lower respiratory tracts of transgenic mice and prevent lethal disease. The experiment demonstrates this by showing weight loss and lethality following intranasal infection are prevented with one or two immunizations of rMVAs, or by passive transfer of serum from vaccinated mice.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000780",
    "statement": "Mva vector vaccines induce sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the recombinant MVA (Modified Vaccinia Ankara) vaccines expressing modified forms of S induce replication inhibition in the upper and lower respiratory tracts of transgenic mice and prevent lethal disease following CoV-2 infection. The paper provides data on weight loss and lethality that supports this claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000781",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to block stat nuclear import and antagonize interferon signaling",
    "label": "SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that Sars-cov-2 Orf6 hijacks nup98 to block stat nuclear import and antagonize interferon signaling. The provided evidence shows the interaction between SARS-CoV-2 Orf6 and Nup98-Rae1 is critical in impairing docking of cargo-receptor complexes and disrupting nuclear import, which directly relates to blocking STAT nuclear translocation and IFN signaling.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000782",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to promote stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented in the study indicates that SARS-CoV-2 Orf6 interacts with Nup98-Rae1, which is critical to block STAT nuclear translocation and IFN signaling. The study also demonstrates that this interaction disrupts nuclear import, suggesting a mechanism for how SARS-CoV-2 antagonizes interferon signaling.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000783",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to facilitate stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented shows that the Orf6 protein of SARS-CoV-2 interacts with Nup98-Rae1 and localizes at the nuclear pore complex (NPC). Additionally, it has been demonstrated that this interaction impairs docking of cargo-receptor (karyopherin/importin) complex and disrupts nuclear import. Furthermore, the study shows that SARS-CoV-2 is able to block STAT1 and STAT2 nuclear translocation and impair transcriptional induction of IFN-stimulated genes (ISGs). These findings suggest that Orf6 hijacks Nup98 to facilitate stat nuclear import and antagonize interferon signaling.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000784",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to induce stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented in the text supports the claim that SARS-cov-2 orf6 hijacks nup98 to induce STAT nuclear import and antagonize interferon signaling. The evidence shows that Orf6 interacts with Nup98-Rae1 at the nuclear pore complex, which is critical for blocking STAT nuclear translocation and IFN signaling.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000785",
    "statement": "Patients are coming in too late for treatment .",
    "label": "SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes scenarios where late diagnosis can occur, but it does not provide any specific data or examples of patients coming in too late for treatment.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000786",
    "statement": "Patients are coming in too short for treatment.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses late diagnosis and misdiagnosis scenarios, but it does not indicate that patients are coming in too short for treatment. In fact, it points to instances where patients either delay seeking help or are initially given incorrect diagnoses, which can delay treatment. The claim is broader than the evidence presented.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000787",
    "statement": "Patients are coming in too time for treatment.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about the timing of patients coming in for treatment, while the evidence provided discusses potential causes for late diagnosis, not the timeliness of treatments.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000788",
    "statement": "Irish-developed kit that confirms covid-19 infection in 15 minutes could be released in seven days",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: PA Laura Lynott March 16 2020 02:30 AM Facebook Twitter Email An Irish company is preparing to release rapid Covid-19 testing kits, which can provide results in 15 minutes and potentially act as a \"clinical weapon\" against coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the claim states that an Irish company is preparing to release rapid Covid-19 testing kits in 7 days, it does not provide evidence of a concrete timeline for its release or the specific technology used by the kit that ensures a 15-minute confirmation of infection. More detailed information would be needed to evaluate this claim accurately.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000789",
    "statement": "Irish-developed kit that confirms covid-19 infection in 15 minutes could be released in seven hours",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: PA Laura Lynott March 16 2020 02:30 AM Facebook Twitter Email An Irish company is preparing to release rapid Covid-19 testing kits, which can provide results in 15 minutes and potentially act as a \"clinical weapon\" against coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that an Irish-developed Covid-19 testing kit could be released in seven hours, providing results in 15 minutes. The evidence shows that the company is preparing to release rapid testing kits but does not provide any information about the timeframe for their release or whether they can truly deliver results in 15 minutes.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000790",
    "statement": "Normally invisible saliva droplets can linger in the air , visualized by researchers using laser technology .",
    "label": "SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides results of a laser light-scattering experiment conducted by researchers to visualize and count droplets in the air produced during speaking. This technique is described as a common method for observing and counting airborne droplets. The experimental findings also report that these small droplets can dehydrate, linger in the air, and behave like an aerosol. These observations support the claim that normally invisible saliva droplets can linger in the air when visualized by laser technology.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000791",
    "statement": "Normally invisible saliva droplets can spread in the air, visualized by researchers using laser technology.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence from a study that used laser technology to visualize and measure speech-generated droplets and their trajectories. The study found that small droplets can dehydrate and linger as droplet nuclei in the air, which can expand the spatial extent of emitted infectious particles.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000792",
    "statement": "Normally invisible saliva droplets can increase in the air, visualized by researchers using laser technology.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that laser technology was used by researchers to visualize and study speech-generated droplets, implying that these normally invisible droplets do increase in the air as stated in the claim. Furthermore, the evidence indicates that these droplets can persist in the air for several minutes.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000793",
    "statement": "Sex differences in immune responses to sars-cov-2 that underlie disease outcomes",
    "label": "SUPPORTED",
    "evidences": [
      "In this study, we examined sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.",
      "Conversely, higher innate immune cytokines in female patients associated with worse disease progression, but not in male patients.",
      "In contrast, female patients mounted significantly more robust T cell activation than male patients during SARS-CoV-2 infection, which was sustained in old age."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence discusses a study on sex differences in immune responses to SARS-CoV-2, examining viral loads, antibody titers, cytokines, and blood cell phenotyping in COVID-19 patients. The study shows that female patients had higher innate immune cytokines associated with worse disease progression but sustained T cell activation during SARS-CoV-2 infection compared to male patients. This supports the claim of sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000794",
    "statement": "Sex differences in immune responses to sars-cov-2 that underlie protection outcomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this study, we examined sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.",
      "Conversely, higher innate immune cytokines in female patients associated with worse disease progression, but not in male patients.",
      "In contrast, female patients mounted significantly more robust T cell activation than male patients during SARS-CoV-2 infection, which was sustained in old age."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that this study examines sex differences in immune responses to SARS-CoV-2 in COVID-19 patients by analyzing viral loads, antibody titers, cytokine levels, and blood cell phenotyping. Additionally, the study suggests that higher innate immune cytokines in female patients are associated with worse disease progression, but not in male patients, and that female patients mount significantly more robust T cell activation during SARS-CoV-2 infection, which is sustained in old age. These findings support the claim that there may be sex differences in immune responses to SARS-CoV-2 underlying protection outcomes.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000795",
    "statement": "Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and th17 responses",
    "label": "SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal EαQ11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, γδ T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the intranasal administration of EαQ11 nanofibers without adjuvants can induce antigen-specific TH17 responses in the lung and lymph nodes. The evidence also suggests that during primary immune responses to Gram-negative bacteria, IL-17 is produced by cells such as NK cells, γδ T cells, and ILCs. Therefore, it is reasonable to conclude that the nanofiber vaccine induces in situ lung dendritic cell activation and TH17 responses.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000796",
    "statement": "Adjuvant-free nanofiber vaccine knocks in situ lung dendritic cell activation and th17 responses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal EαQ11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, γδ T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim concerns a specific scientific study about a vaccine. The evidence provided only discusses the observations of CD4+ T cells in the lung and TH17 responses elicited by the vaccine, but it does not directly prove that the vaccine 'knocks in situ lung dendritic cell activation and th17 responses'. Furthermore, the claim seems to be about a specific study or experiment, and more concrete evidence such as specific research findings, results, or data from that study would be required to verify the claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000797",
    "statement": "Adjuvant-free nanofiber vaccine induces in situ memory dendritic cell activation and th17 responses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal EαQ11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, γδ T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided. The evidence shows that intranasally administered nanofiber vaccines can induce robust antigen-specific TH17 responses without the need for exogenous adjuvants. This is demonstrated through the observations of CD4+ T cells accumulating in both the LN and lung. While the claim does not directly mention 'memory dendritic cell activation', it is implied by the description of the primary immune response elicited by pathogens, which involves TH17 responses at the mucosal surface produced by various cells including NK cells, γδ T cells, and ILCs. The evidence also suggests that these responses occur in situ.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000798",
    "statement": "The fda has canceled emergency use of hydroxychloroquine for covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the FDA has revoked the emergency use authorization for both chloroquine and hydroxychloroquine in treating COVID-19. This implies that the FDA has canceled the emergency use of these drugs specifically for this purpose.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000799",
    "statement": "The fda has increased emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that the FDA revoked the emergency use authorization for chloroquine and hydroxychloroquine, which suggests they were previously authorized for emergency use. However, it does not state that the FDA has increased their emergency use for COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000800",
    "statement": "The fda has potential emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not confirm or deny the potential emergency use of hydroxychloroquine for COVID-19. Instead, it suggests that the FDA no longer believes in the effectiveness of these drugs for treating COVID-19, but it does not mention their potential emergency use.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000801",
    "statement": "The fda has good emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the FDA has revoked the emergency use authorization for chloroquine and hydroxychloroquine in treating COVID-19, suggesting they are not effective. However, it does not necessarily mean they have 'no good emergency use' for COVID-19, as the claim suggests. More specific information about potential emergency uses, if any, would be needed to support or refute this claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000802",
    "statement": "Antibody testing will enhance the power and accuracy of covid-19-prevention trials",
    "label": "SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that serological testing can provide additional information on immunity status, even in asymptomatic individuals, which could be valuable in COVID-19 prevention trials. This is because it allows for the identification of individuals who have developed immunity despite not showing symptoms, which may be more indicative of the trial's efficacy.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000803",
    "statement": "Antibody testing will reduce the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that serological testing could potentially enhance the interpretation of covid-19 prevention trials by providing insights into immunity status, but it does not explicitly support the claim that antibody testing will reduce the power or accuracy of such trials. The claim seems to imply a negative impact on trial quality due to antibody testing, which is not substantiated in the provided evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000804",
    "statement": "Antibody testing will limit the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that serological testing of trial participants during COVID-19 prevention trials can provide valuable insights for the interpretation and understanding of these studies. However, the claim in question is not directly supported by this evidence, which focuses on the benefits of such testing rather than its impact on limiting the power or accuracy of trials.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000805",
    "statement": "Antibody testing will decrease the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that antibody testing will decrease the power and accuracy of COVID-19 prevention trials. However, the evidence provided discusses the value of serological testing for enhancing the interpretation of such studies by identifying individuals who have developed immunity during the trial. The relationship between serological testing and decreasing the power or accuracy is not directly supported in this evidence.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000806",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; majority of patients have demonstrated remarkable recoveries",
    "label": "SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to 'strong results' and 'remarkable recoveries' from eIND COVID-19 patients treated with leronlimab by Cytodyn. The provided evidence suggests that the results are impressive but does not provide concrete numerical data or specific details about patient recoveries, nor is it peer-reviewed or published in a reputable scientific journal. Thus, the claim cannot be definitively supported based on the given evidence.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000807",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; none of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specify that none of the COVID-19 patients treated with leronlimab demonstrated remarkable recoveries. It mentions that 'important powerful results' were demonstrated in almost all of the patients, but it doesn't directly claim or imply that no patient had a remarkable recovery.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000808",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; few of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is based on anecdotal evidence and statements by a CEO and advisor of another company (IncellDx), rather than objective, verifiable data from a controlled study. While the subjects reportedly showed 'remarkable recoveries' after treatment with leronlimab, this does not necessarily mean that the drug is effective against COVID-19 without further investigation.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000809",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; two of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that 'Cytodyn reports strong results from eind covid-19 patients treated with leronlimab; two of the patients have demonstrated remarkable recoveries'. However, the provided evidence only consists of statements made by Dr. Bruce Patterson and Nader Pourhassan expressing excitement about the drug's effects on COVID-19 patients, without providing concrete data or specific cases that demonstrate these 'remarkable recoveries'.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000810",
    "statement": "Sars-cov-2 infects brain choroid plexus and disrupts the blood-csf-barrier",
    "label": "SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides multiple lines of support for the claim that SARS-CoV-2 infects brain choroid plexus and disrupts the blood-CSF-barrier: (1) The choroid plexus is found to be an Apolipoprotein and ACE2 expressing subset of epithelial barrier cells, suggesting susceptibility to SARS-CoV-2 infection. (2) Both pseudovirus and live virus are demonstrated to infect choroid plexus epithelial cells but not stromal cells or neurons/glia. (3) Infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000811",
    "statement": "Sars-cov-2 infects intestinal choroid plexus and disrupts the blood-csf-barrier",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that infected cells of the choroid plexus express apolipoprotein and ACE2, which are receptors for SARS-CoV-2. The findings suggest these cells can be targeted by the virus. The study also demonstrates high viral tropism for choroid plexus epithelial cells but not stromal cells or neurons/glia, and infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus. These results indicate that Sars-cov-2 can infect the intestinal choroid plexus and potentially disrupt the blood-CSF-barrier.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000812",
    "statement": "Sars-cov-2 infects brain choroid plexus and backs the blood-csf-barrier",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides several indicators suggesting that Sars-Cov-2 infects brain choroid plexus: (1) It states infected cells of the choroid plexus express ACE2, a receptor through which SARS-CoV-2 enters host cells. (2) The study shows high viral tropism for choroid plexus epithelial cells but not stromal cells and little to no infection of neurons or glia. (3) Lastly, the evidence indicates that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000813",
    "statement": "Coronial autopsies identify the indirect effects of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not support a direct link between coronial autopsies identifying the indirect effects of COVID-19. While it mentions an increase in deaths from drug and alcohol misuse during the lockdown period, which could potentially be related to COVID-19 indirectly, there is no concrete proof in the given evidence that coronial autopsies specifically identified these indirect effects of COVID-19.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000814",
    "statement": "Coronial autopsies identify the therapeutic effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that coronial autopsies identify the therapeutic effects of covid-19. However, the provided evidence only discusses increases in deaths from drug and alcohol misuse during lockdown periods and an analysis of autopsy reports to determine the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths. It does not provide any information about how autopsies identify therapeutic effects of covid-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000815",
    "statement": "Coronial autopsies identify the biological effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that coronial autopsies identify the biological effects of Covid-19. However, the provided evidence discusses an increase in deaths due to drug and alcohol misuse during lockdowns but does not directly show whether individual cases were influenced by COVID-19 or its movement restrictions. Additionally, it mentions a review of autopsy reports, but there is no clear statement that these reports provide information about the biological effects of Covid-19.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000816",
    "statement": "Coronial autopsies identify the cytotoxic effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided in this case does not directly support the claim that coronial autopsies can identify the cytotoxic effects of COVID-19. Instead, it focuses on the indirect impact of lockdown measures on deaths due to drug and alcohol misuse, which is unrelated to the cytotoxic effects of COVID-19. The review of autopsy reports could potentially shed light on this issue, but it is not explicitly stated that they were used to identify cytotoxic effects specifically related to COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000817",
    "statement": "3blue1brown provided detailed simulations of an epidemic",
    "label": "SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly mentions a simulation of an epidemic that is inspired by the '3Blue1Brown's Simulating an Epidemic' video. Therefore, it is supported that 3blue1brown provided detailed simulations of an epidemic.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000818",
    "statement": "3blue1brown provided detailed simulations of an algorithm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides an interactive simulation based on a video titled 'Simulating an Epidemic' by 3blue1brown. This implies that the simulations provided in the video are detailed and accurate.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000819",
    "statement": "3blue1brown provided detailed simulations of an equation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a simulation inspired by the video 'Simulating an Epidemic' from the YouTube channel 3blue1brown. This strongly suggests that 3blue1brown provided detailed simulations of an equation.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000820",
    "statement": "3blue1brown provided detailed simulations of an alignment",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions an epidemic simulation that is inspired by a 3blue1brown video. However, the claim specifically states 'provided detailed simulations of an alignment.' While the source does reference a video about simulating an epidemic, there's no evidence to suggest that it includes 'alignment' simulations.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000821",
    "statement": "Delaware medical supplier says fema seized 400,000 n95 masks , now he 's out millions of dollars",
    "label": "SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Delaware medical supplier Indutex says FEMA seized 400,000 N95 masks and now he is out millions of dollars due to unpaid compensation. While the evidence shows that FEMA took possession of two shipments of masks intended for customers of Indutex USA, it does not provide information on the quantity or type of masks seized (whether 400,000 N95 masks as claimed) nor does it confirm whether there was an unpaid claim by the supplier. Further investigation would be necessary to verify this claim.",
    "confidence": 0.65
  },
  {
    "id": "covid_fact-000822",
    "statement": "Delaware medical supplier and fema seized 400,000 n95 masks, now he's out millions of dollars",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that FEMA seized two shipments of N95 masks from Indutex USA. However, it does not confirm that Delaware medical supplier Indutex is out millions of dollars due to the seizure. The claim requires evidence showing that these masks were intended for customers across the United States and that they were worth millions of dollars.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000823",
    "statement": "Delaware medical supplier with fema seized 400,000 n95 masks, now he's out millions of dollars",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that FEMA seized two shipments of N95 masks from Indutex USA, but it does not provide information about the current financial state or losses of the company. Therefore, the claim cannot be supported or refuted based on this evidence.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000824",
    "statement": "Fauci predicts us deaths from coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Dr. Anthony Fauci stated a projection that between 100,000 and 200,000 people may die from COVID-19 in the U.S., based on current modeling of the spread of the virus.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000825",
    "statement": "Fauci predicts us deaths globally coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states Dr. Anthony Fauci's prediction regarding the potential number of deaths globally from the coronavirus. The quoted statement indicates that between 100,000 and 200,000 people may die from COVID-19, which is a direct reference to the global impact of the virus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000826",
    "statement": "Fauci predicts us deaths worldwide coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim that Dr. Anthony Fauci predicts a range of 100,000 to 200,000 deaths worldwide due to COVID-19 based on the current pace of its spread.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000827",
    "statement": "Leronlimab used in seven patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu , removed from icu and extubated with reduced pulmonary inflammation",
    "label": "SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specify the number and condition of COVID-19 patients treated with leronlimab in NYC nor does it confirm any specific improvement like two intubated patients being removed from ICU or reduced pulmonary inflammation. While the evidence suggests that leronlimab may help improve immune response, reduce cytokine storms, and potentially prevent viral escape in HIV-infected patients, more specific data is needed to verify the claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000828",
    "statement": "Leronlimab used in two patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that leronlimab may help reduce pulmonary inflammation in patients with severe COVID-19 and could potentially prevent the need for ventilators. However, it does not explicitly state that two specific patients in NYC were removed from ICU and extubated after receiving leronlimab treatment. The evidence focuses more on the potential benefits of the drug rather than direct results from individual cases.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000829",
    "statement": "Leronlimab used in three patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that leronlimab demonstrated promise in three NYC patients with severe COVID-19, specifically mentioning two intubated patients who were removed from the ICU and extubated with reduced pulmonary inflammation. The evidence provided describes the positive effects of leronlimab on the immune profile and cytokine levels of patients with COVID-19 but does not provide specific details about individual cases or their treatment outcomes, such as whether they were intubated, removed from the ICU, or extubated.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000830",
    "statement": "Leronlimab used in four patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions that leronlimab treatment showed promise for COVID-19 patients with pulmonary inflammation and improved cytokine levels. However, it does not provide specific numbers or identities of the four patients in NYC who were treated nor does it offer detailed information about the outcome of those treatments, such as intubation and removal from ICU. Thus, it is not supported that two intubated patients were successfully removed from ICU due to leronlimab treatment.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000831",
    "statement": "Home testing for coronavirus to track levels of infection in the community",
    "label": "SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that home testing kits for coronavirus are possible since they mention the use of a laboratory PCR test, which is commonly used in medical diagnostics. Furthermore, there is an example given where such kits are already being used in healthcare, specifically for diabetes management and HIV diagnosis.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000832",
    "statement": "Laboratory testing for coronavirus to track levels of infection in the community",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that laboratory testing for coronavirus involves collecting samples by courier and using PCR tests to detect the presence of genetic material from the virus is supported by the evidence provided. The use of home testing kits in health care settings was also mentioned in the evidence as a comparison, further supporting the idea that laboratory testing can be done in this manner.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000833",
    "statement": "Studies testing for coronavirus to track levels of infection in the community",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that studies test for coronavirus to track levels of infection in the community, which is supported by the evidence provided that samples will be collected and tested using PCR tests, a method commonly used for detecting viral genetic material.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000834",
    "statement": "The sars-cov-2-like virus found in captive pangolins from guangdong should be better sequenced .",
    "label": "SUPPORTED",
    "evidences": [
      "bioRxiv - Bioinformatics Pub Date : 2020-05-07 , DOI: 10.1101/2020.05.07.077016 Alexandre Hassanin Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins ( Manis javanica ) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3.",
      "The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus.",
      "To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS- CoV-2-like viruses detected in five captive pangolins from Guangdong."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the SARS-CoV-2-like virus found in captive pangolins from Guangdong should be better sequenced. The provided evidence describes the sequencing of such viruses in pangolins seized between 2017 and 2019, suggesting that they were indeed sequenced, but the sequencing process could have room for improvement. Therefore, the claim is supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000835",
    "statement": "The sars-cov-2-like virus found in captive pangolins from guangdong cannot be better sequenced.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "bioRxiv - Bioinformatics Pub Date : 2020-05-07 , DOI: 10.1101/2020.05.07.077016 Alexandre Hassanin Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins ( Manis javanica ) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3.",
      "The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus.",
      "To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS- CoV-2-like viruses detected in five captive pangolins from Guangdong."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the SARS-CoV-2-like virus found in captive pangolins from Guangdong cannot be better sequenced. However, the provided evidence only indicates that the genomes of SARS-CoV-2-like viruses were assembled from Sequence Read Archive (SRA) data available for SARS-CoV-2-like viruses detected in five captive pangolins from Guangdong. The evidence does not provide information about whether this sequencing process can be considered the best method or if there are possibilities for improvement. Therefore, the claim cannot be definitively supported or refuted based on the given evidence.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000836",
    "statement": "High dose vitamin d improves total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only states that vitamin D has potential benefits on various bodily functions and its status in critically ill patients. It does not directly support or refute the claim that high dose vitamin D improves total serum antioxidant capacity and ICU outcome in critically ill patients.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000837",
    "statement": "High dose vitamin d reduces total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided claim states that 'High dose vitamin D reduces total serum antioxidant capacity and ICU outcome in critically ill patients.' The evidence provided is a reference to a study titled 'Efficacy of high-dose vitamin D supplementation in the critically ill patients,' which suggests vitamin D may have an impact on immune response, lung epithelial function, muscle function, metabolism and cardiac function. However, it does not directly provide evidence that high dose vitamin D reduces total serum antioxidant capacity or ICU outcome in critically ill patients.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000838",
    "statement": "High dose vitamin d decreased total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence points out that vitamin D has various effects on the immune response, lung epithelial function, muscle function and metabolism, and cardiac function. However, it does not directly support the claim that high dose vitamin D decreased total serum antioxidant capacity and ICU outcome in critically ill patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000839",
    "statement": "High dose vitamin d reduced total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly show a causal relationship between high dose vitamin D and reduced total serum antioxidant capacity or improved ICU outcomes in critically ill patients. The evidence suggests that vitamin D may have effects on the immune response, lung epithelial function, muscle function, and cardiac function; however, it does not establish a correlation between these effects and antioxidant capacity or ICU outcome.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000840",
    "statement": "Epidemiologic features and clinical course of 1st 18 patients infected with sars-cov-2 in singapore",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim requires evidence supporting specific epidemiologic features and the clinical course of each individual patient among the first 18 infected with SARS-CoV-2 in Singapore. The provided evidence only mentions that the patients frequently had a mild respiratory tract infection but does not provide detailed information on the demographics, symptoms, or treatment for each patient.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000841",
    "statement": "Epidemiologic features and clinical course of 10 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the data presented is about the 18 patients diagnosed with SARS-CoV-2 infection in Singapore and mentions their clinical presentation as frequently mild respiratory tract infection.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000842",
    "statement": "Epidemiologic features and clinical course of all 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only describes the clinical presentation of the first 18 patients diagnosed with SARS-CoV-2 in Singapore, but it does not provide detailed epidemiological features or a comprehensive account of their clinical course.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-000843",
    "statement": "Epidemiologic features and clinical course of over 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the clinical course and epidemiological features of 18 patients infected with SARS-CoV-2 in Singapore. It mentions that the clinical presentation was often a mild respiratory tract infection. Thus, the claim is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000844",
    "statement": "A bifidobacterial protein that can reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not support the claim that a specific bifidobacterial protein found by a rudn geneticist can reduce inflammation in COVID-19. The evidence only states that bifidobacterial surface proteins can recognize certain cytokines and a fragment of this protein can be used as an anti-inflammatory medication, but it does not specify the name of the protein, the researcher who discovered it, or its specific effectiveness in treating COVID-19.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000845",
    "statement": "A bifidobacterial protein that cannot reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that the bifidobacterial protein can recognize specific classes of cytokines and potentially be used as an anti-inflammatory medication for treating coronavirus and other diseases. However, it does not provide any evidence to support that this specific protein reduces inflammation in COVID-19 or was discovered by a researcher named Rudn.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000846",
    "statement": "A bifidobacterial virus that can reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly confirm that a bifidobacterial virus reducing inflammation in COVID-19 was found by a Rudn geneticist. While it shows that the bacterium's surface proteins can potentially regulate immune response and be used as an anti-inflammatory medication for coronavirus, it does not provide information on who discovered this property or its specific connection to a virus.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000847",
    "statement": "Swissmedic begins rolling review of moderna 's mrna vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that Swissmedic uses a rolling review process for clinical trial data, but this does not directly support the claim that they are currently reviewing Moderna's mRNA vaccine against COVID-19. To confirm the claim, it would be necessary to find evidence showing that Moderna has submitted their COVID-19 vaccine for rolling review by Swissmedic.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000848",
    "statement": "Swissmedic begins rolling production of moderna's mrna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that Swissmedic has a rolling review process for new data from ongoing clinical trials. However, this does not confirm that Swissmedic is beginning production of Moderna's mRNA vaccine against COVID-19.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000849",
    "statement": "Sars-cov-2 spike protein promotes hyper-inflammatory response that can be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro",
    "label": "SUPPORTED",
    "evidences": [
      "We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines.",
      "Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-κB activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided demonstrates that the S1-ACE2 interaction induces pro-inflammatory cytokines and NF-κB activations, which are markers of hyper-inflammatory response. The development of an antagonistic peptide that inhibits this interaction suggests a potential means to ameliorate the hyper-inflammatory response. Furthermore, the use of FDA-approved ER stress and MAP kinase inhibitors in vitro was shown to have an impact on this response, further supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000850",
    "statement": "Sars-cov-2 spike protein promotes hyper-inflammatory response that cannot be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines.",
      "Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-κB activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does demonstrate that the S1 subunit of SARS-CoV-2 spike protein induces high levels of NF-κB activation and pro-inflammatory cytokine production in human bronchial epithelial cells, as well as mild epithelial damage. However, it does not show that a spike-antagonistic peptide or FDA-approved ER stress and MAP kinase inhibitors cannot ameliorate this hyper-inflammatory response in vitro.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000851",
    "statement": "Finding suggests technology can be installed in air conditioning , vacuum , and water systems",
    "label": "SUPPORTED",
    "evidences": [
      "Eventually, as the science develops, the industry will be able to make the necessary adjustments and install the bulbs in robotic systems or air conditioning, vacuum, and water systems, and thereby be able to efficiently disinfect large surfaces and spaces.",
      "Disinfection systems based on LED bulbs, however, can be installed in the ventilation system and air conditioner, for example, and sterilize the air sucked in and then emitted into the room.",
      "In the future, the researchers will test their unique combination of integrated damage mechanisms and more ideas they recently developed on combined efficient direct and indirect damage to bacteria and viruses on different surfaces, air, and water."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that technology can be installed in air conditioning, vacuum, and water systems for disinfection purposes. The evidence provided supports this, as it states that the industry will make necessary adjustments to install bulbs (presumably with disinfectant properties) into robotic systems or air conditioning, vacuum, and water systems, enabling them to efficiently sterilize surfaces and spaces.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000852",
    "statement": "Finding suggests technology cannot be installed in air conditioning, vacuum, and water systems",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eventually, as the science develops, the industry will be able to make the necessary adjustments and install the bulbs in robotic systems or air conditioning, vacuum, and water systems, and thereby be able to efficiently disinfect large surfaces and spaces.",
      "Disinfection systems based on LED bulbs, however, can be installed in the ventilation system and air conditioner, for example, and sterilize the air sucked in and then emitted into the room.",
      "In the future, the researchers will test their unique combination of integrated damage mechanisms and more ideas they recently developed on combined efficient direct and indirect damage to bacteria and viruses on different surfaces, air, and water."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that LED disinfection systems can be installed in ventilation systems and air conditioners, but does not explicitly state or imply that technology cannot be installed in other systems like vacuums or water systems. The claim needs additional supporting evidence to confirm its validity.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000853",
    "statement": "Oxford university vaccine shows 70 % protection - bbc news",
    "label": "SUPPORTED",
    "evidences": [
      "The researchers said it worked out at 70% protection, which is better than the seasonal flu jab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that the Oxford University vaccine provides 70% protection, according to the researchers.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000854",
    "statement": "Oxford university vaccine shows 70 % protection -19 news",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The researchers said it worked out at 70% protection, which is better than the seasonal flu jab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the Oxford university vaccine shows 70% protection. The evidence provided confirms this, stating that the researchers found it to work out at 70% protection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000855",
    "statement": "Mast cells activated by sars-cov-2 release histamine which increases il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that mast cells activated by SARS-CoV-2 release histamine and cytokines (including IL-1) which contributes to an inflammatory response in COVID-19 patients. The second piece of evidence also connects IL-1 with the production of TxA2, a compound causing inflammation and micro-thrombi in COVID-19, further supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000856",
    "statement": "Mast cells activated by sars-cov-2 release histamine which reduces il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that mast cells activated by SARS-CoV-2 release histamine and other compounds involved in the inflammatory network (e.g., proteases, cytokines, chemokines, arachidonic acid compounds). Additionally, it is mentioned that IL-1 induces TxA2 which leads to inflammation and micro-thrombi in COVID-19. The claim seems to be supported by the evidence by implying a cause-effect relationship between mast cell activation, histamine release, reduced IL-1 levels, cytokine storm, and inflammatory reaction in COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000857",
    "statement": "Mast cells activated by sars-cov-2 release histamine which decreases il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim mentions Mast cells activated by SARS-CoV-2 releasing histamine and decreasing IL-1 levels, causing a cytokine storm and inflammatory reaction in COVID-19. The evidence provides information about the substances released by mast cells during activation (including histamine), and suggests that IL-1 induces TxA2 in COVID-19, which can cause inflammation and micro-thrombi. While the evidence does not explicitly state that decreased IL-1 levels cause a cytokine storm and inflammatory reaction, it is reasonable to infer this based on the information provided.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000858",
    "statement": "Mast cells activated by sars-cov-2 release histamine which inhibits il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that mast cells activated by SARS-CoV-2 release various compounds involved in the inflammatory network, including histamine and IL-1. However, it does not directly show a causal relationship between the release of histamine inhibiting IL-1 levels, causing cytokine storm and inflammatory reaction specifically in COVID-19. Further research or evidence is needed to confirm this specific chain of events.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000859",
    "statement": "The furin cleavage site of sars-cov-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells .",
    "label": "SUPPORTED",
    "evidences": [
      "Using lentiviral pseudotypes and a cell- culture adapted SARS-CoV-2 virus with a S1/S2 deletion, we show that the polybasic insertion is selected for in lung cells and primary human airway epithelial cultures but selected against in Vero E6, a cell line used for passaging SARS-CoV-2.",
      "The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission",
      "We find this selective advantage depends on expression of the cell surface protease, TMPRSS2, that allows virus entry independent of endosomes thus avoiding antiviral IFITM proteins.",
      "SARS-CoV-2 has a unique polybasic insertion at the S1/S2 CS, which we demonstrate can be cleaved by furin."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the polybasic insertion in the furin cleavage site of SARS-CoV-2 spike protein is selected for in lung cells and primary human airway epithelial cultures, but not in Vero E6 cells. This selective advantage depends on expression of the cell surface protease TMPRSS2 that allows virus entry independent of endosomes, thus avoiding antiviral IFITM proteins. The polybasic insertion can also be cleaved by furin. These findings collectively suggest that the furin cleavage site in SARS-CoV-2 spike protein plays a role in enhanced replication in airway cells and may contribute to its transmission.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000860",
    "statement": "The furin cleavage site of sars-cov-2 spike protein is a key determinant for transmission due to enhanced infection in airway cells.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using lentiviral pseudotypes and a cell- culture adapted SARS-CoV-2 virus with a S1/S2 deletion, we show that the polybasic insertion is selected for in lung cells and primary human airway epithelial cultures but selected against in Vero E6, a cell line used for passaging SARS-CoV-2.",
      "The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission",
      "We find this selective advantage depends on expression of the cell surface protease, TMPRSS2, that allows virus entry independent of endosomes thus avoiding antiviral IFITM proteins.",
      "SARS-CoV-2 has a unique polybasic insertion at the S1/S2 CS, which we demonstrate can be cleaved by furin."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided demonstrates that the furin cleavage site of SARS-CoV-2 spike protein is advantageous for virus transmission in lung cells and primary human airway epithelial cultures, as it allows for virus entry independent of endosomes and avoids antiviral IFITM proteins. Additionally, the study shows that this polybasic insertion can be cleaved by furin, which further supports its role as a key determinant in SARS-CoV-2 transmission.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000861",
    "statement": "Is there an airborne component to the transmission of covid-19 ?",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that SARS-CoV-2 virions are shed in high concentrations from the nasal cavity of COVID-19 patients and transmission may occur through respiratory aerosols, especially in enclosed spaces. Additionally, the computer modeling study simulates transmission in an office building, implying the potential for airborne spread.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000862",
    "statement": "Is there an airborne component to the entry of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented suggests that COVID-19 can be transmitted through respiratory aerosols in enclosed spaces. While it does not explicitly state that the virus is airborne, the fact that it poses a risk during prolonged exposure even with social distancing indicates possible airborne transmission.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000863",
    "statement": "Is there an airborne component to the development of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that COVID-19 can be transmitted through the airborne route in enclosed spaces when people share the same environment for extended periods. This supports the idea of an airborne component to the development of COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000864",
    "statement": "Is there an airborne component to the use of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that COVID-19 can be transmitted through respiratory aerosols in enclosed spaces, implying an airborne component to the virus's transmission. While the evidence does not explicitly state that the virus is itself 'airborne,' it does demonstrate that particles containing the virus can remain suspended in the air and potentially infect others when sharing enclosed spaces for extended periods.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000865",
    "statement": "Saliva-based antigen testing is better than the pcr swab",
    "label": "SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not directly supported by the provided evidence. While the evidence discusses advantages of saliva-based antigen testing (ease of use, cost-effectiveness, and speed), it does not specifically compare these tests to PCR swab tests or state that one is 'better' than the other.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000866",
    "statement": "Saliva-based antigen testing is lower than the pcr swab",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides several points supporting the claim that saliva-based antigen testing is lower than PCR swab tests in terms of requirements (no specific personnel or laboratory instrument), speed of results, cost, and convenience. The evidence also states that antigen-based testing is highly specific, which implies higher accuracy compared to its PCR counterpart.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000867",
    "statement": "Saliva-based antigen testing is less than the pcr swab",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that saliva-based antigen testing is less complex, faster, cheaper, and potentially more convenient than PCR swab testing for COVID-19 diagnostics. The fact that it doesn't require trained personnel, specific chemical supplies, or centralized laboratory instrumentation, nor is it vulnerable to supply chain bottlenecks, supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000868",
    "statement": "10 % of stockholmers infected",
    "label": "SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that 10 percent of Stockholmers had been infected with the coronavirus and developed antibodies according to sampling collected from 1,000 of the city's residents.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000869",
    "statement": "10 % of authorers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that by the first weeks of April, 10 percent of Stockholm's population had been infected with the coronavirus and developed antibodies.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000870",
    "statement": "10 % of readers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that '10% of readers infected' is supported by the evidence provided, as it states that 'By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies.' The article further specifies this information through sampling data from 1,000 residents of Stockholm.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000871",
    "statement": "10 % of allers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim '10 % of allers infected' is supported by the evidence provided. The evidence states that 'By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies.' This shows that 10% of the people in Stockholm were infected.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000872",
    "statement": "Sars-cov-2 d614g variant exhibits enhanced replication ex vivo and earlier transmission in vivo",
    "label": "SUPPORTED",
    "evidences": [
      "Our study demonstrated the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission.",
      "This article has been published \"SARS-CoV-2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo\" in Science."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission, as well as it being published in a peer-reviewed article titled 'SARS-CoV2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo' in the journal Science. This directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000873",
    "statement": "Sars-cov-2 d614g variant inhibited enhanced replication ex vivo and earlier transmission in vivo",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our study demonstrated the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission.",
      "This article has been published \"SARS-CoV-2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo\" in Science."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that the SARS-CoV2 D614G variant enhances infectivity, replication fitness, and early transmission. However, it does not explicitly demonstrate that this variant inhibits enhanced replication ex vivo or earlier transmission in vivo as claimed.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000874",
    "statement": "Orf8 and orf3b antibodies are accurate serological markers of early and late sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses.",
      "We have identified ORF8 antibodies as a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection because of its immunodominance and specificity, in addition to N protein."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that ORF8 and ORF3b are targets of the immune response to SARS-CoV-2 and that ORF8 antibodies are a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection. This suggests that ORF8 and ORF3b antibodies can be used as serological markers for early and late SARS-CoV-2 infections.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000875",
    "statement": "Orf8 and orf3b antibodies are accurate serological markers of early and acute sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses.",
      "We have identified ORF8 antibodies as a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection because of its immunodominance and specificity, in addition to N protein."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that ORF8 and ORF3b antibodies are identified as strong targets of the immune response to SARS-CoV-2 and shown to be major markers of acute, convalescent, and long-term antibody responses. The language used in the evidence suggests these antibodies are accurate serological markers of early and acute SARS-CoV-2 infection.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000876",
    "statement": "Plasma from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents a microsphere-based inhibition assay which shows that plasma from recovered COVID-19 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and this inhibition correlated with anti-trimer IgG levels. This suggests that the plasma from recovered COVID-19 patients contains antibodies that can inhibit the spike protein binding to ACE2.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000877",
    "statement": "Blood from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that plasma from recovered COVID-19 subjects inhibited ACE2-trimer binding to a greater degree than controls and this inhibition correlated with anti-trimer IgG levels. The assay used (microsphere-based Flow Cytometry) quantifies both anti-spike IgGs in plasma and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2), suggesting that the blood from recovered COVID-19 subjects contains inhibitors for the spike protein binding to ACE2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000878",
    "statement": "Rna from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that plasma from recovered COVID-19 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, which suggests that RNA from recovered COVID-19 subjects may indeed inhibit spike protein binding to ACE2 in a microsphere-based inhibition assay.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000879",
    "statement": "Cdna from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that plasma from subjects recovered from COVID-19 inhibits ACE2-trimer binding to a greater degree than controls, which suggests that CDNA from recovered COVID-19 subjects may indeed inhibit spike protein binding to ACE2 in a microsphere-based inhibition assay. The fact that the degree of inhibition correlated with anti-trimer IgG levels provides further support for this claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000880",
    "statement": "Dana-farber to test blood cancer drug in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that Dana-Farber will test a blood cancer drug in COVID-19 patients. However, the provided evidence only mentions collaboration for corollary studies to understand how BTK-inhibitors can affect immune over-activity in response to the virus and not necessarily testing the drug itself on patients.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000881",
    "statement": "Dana-farber to test breast cancer drug in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not explicitly state that Dana-Farber will test a breast cancer drug specifically in COVID-19 patients. Instead, it mentions collaboration on corollary studies to understand how BTK-inhibitors can stop immune over-activity in response to the virus.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000882",
    "statement": "Dana-farber to test human cancer drug in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions Dana-Farber collaborating on a study related to COVID-19 and BTK-inhibitors, but it does not explicitly state that they will be testing a human cancer drug in COVID-19 patients. To confirm this claim, additional information about the nature of the specific drug being tested, its intended purpose, and its status in clinical trials would be necessary.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000883",
    "statement": "Hydroxychloroquine improves airflow and lowers circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug and has proven efficacy in rheumatic diseases. It suggests potential utility in the treatment of asthma due to its known actions. However, it does not provide specific evidence that HCQ improves airflow or lowers circulating IgE levels in subjects with moderate symptomatic asthma.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000884",
    "statement": "Hydroxychloroquine improves airflow and increases circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that Hydroxychloroquine (HCQ) is a well-tolerated, safe drug with potential utility in the treatment of asthma due to its immunomodulating properties. However, it does not directly support the claim that HCQ improves airflow and increases circulating IgE levels specifically in subjects with moderate symptomatic asthma.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000885",
    "statement": "Hydroxychloroquine decreases airflow and lowers circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that hydroxychloroquine (HCQ) may have potential utility in the treatment of asthma due to its immunomodulating effects and safety profile. However, it does not directly show that HCQ decreases airflow or lowers circulating IgE levels in subjects with moderate symptomatic asthma.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000886",
    "statement": "Hydroxychloroquine improves airflow and increased circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that Hydroxychloroquine has been used to treat rheumatic diseases and may have potential utility in treating asthma due to its immunomodulating properties. However, the evidence does not directly support the claim that Hydroxychloroquine improves airflow and increases circulating IgE levels in subjects with moderate symptomatic asthma.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000887",
    "statement": "Moderna has completed case accrual for first planned interim analysis of its mrna vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that Moderna has produced an mRNA vaccine against COVID-19 (mRNA-1273) and it was shipped to the NIH on February 24, 2020. However, the claim asks whether they have completed case accrual for first planned interim analysis, which is not directly addressed in this evidence.",
    "confidence": 0.65
  },
  {
    "id": "covid_fact-000888",
    "statement": "Moderna has no case accrual for first planned interim analysis of its mrna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state whether Moderna has a case accrual for the first planned interim analysis of its mRNA vaccine against COVID-19. The information focuses on the development process and timeline but lacks details about the study design that could confirm or refute the claim.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000889",
    "statement": "Moderna has completed case accrual for first planned interim analysis of its dna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the completion of the first clinical batch and shipping to NIH on February 24, 2020, but it does not explicitly state that case accrual for the first planned interim analysis has been completed.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000890",
    "statement": "Amplicon contamination in labs masquerades as covid19 in surveillance tests",
    "label": "SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that amplicon contamination in labs masquerades as COVID-19 in surveillance tests. While it mentions the importance of minimizing amplicon contamination and handling suspected cases, there is no information indicating that this contamination results in false positives for COVID-19 specifically.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000891",
    "statement": "Amplicon contamination in human masquerades as covid19 in surveillance tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the importance of minimizing instances of amplicon contamination to avoid diverting resources from patients with COVID-19. However, it does not directly provide supporting evidence that such contamination has masqueraded as COVID-19 in surveillance tests.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000892",
    "statement": "Amplicon contamination in labs masquerades as covid19 in preparation tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the importance of minimizing instances of amplicon contamination in lab settings and developing protocols for handling suspected cases. It does not directly support the claim that amplicon contamination masquerades as COVID-19 in preparation tests.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000893",
    "statement": "Amplicon contamination in labs masquerades as covid19 in children tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence speaks about the importance of minimizing amplicon contamination in labs to avoid diverting resources from patients with COVID-19. However, it does not directly support or refute the claim that amplicon contamination masquerades as COVID-19 in children tests.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000894",
    "statement": "Male sex hormones appear to help the coronavirus infiltrate human cells",
    "label": "SUPPORTED",
    "evidences": [
      "Her studies at the UCSF stem cell laboratory found that androgens -- male hormones, including testosterone -- actually help SARS-CoV-2, the specific coronavirus that causes COVID-19, infiltrate human cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly supports the claim that male sex hormones appear to help the coronavirus (SARS-CoV-2) infiltrate human cells.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000895",
    "statement": "Male sex hormones fail to help the coronavirus infiltrate human cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Her studies at the UCSF stem cell laboratory found that androgens -- male hormones, including testosterone -- actually help SARS-CoV-2, the specific coronavirus that causes COVID-19, infiltrate human cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly supports the claim that male sex hormones (specifically androgens like testosterone) help SARS-CoV-2, the coronavirus that causes COVID-19, infiltrate human cells.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000896",
    "statement": "Il-6 : a novel signature associated with covid-19 disease progression and development of anti-sars-cov-2 antibodies",
    "label": "SUPPORTED",
    "evidences": [
      "Findings IL-6 and sMAdCAM expressed as a novel integrative marker (sMIL index) are associated both with disease-states (early infection and convalescence) as well as development of antiviral humoral responses.",
      "Share sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 Share This Article: Copy Citation Tools sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 "
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a study that suggests the sMAdCAM:IL-6 (sMIL index) is associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies. The claim is directly supported by this finding.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000897",
    "statement": "Il-6 : a common signature associated with covid-19 disease progression and development of anti-sars-cov-2 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Findings IL-6 and sMAdCAM expressed as a novel integrative marker (sMIL index) are associated both with disease-states (early infection and convalescence) as well as development of antiviral humoral responses.",
      "Share sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 Share This Article: Copy Citation Tools sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 "
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a study that found the sMAdCAM:IL-6 (sMIL Index) to be associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies. While it does not explicitly say 'Il-6' is a common signature, IL-6 is one component of the sMAdCAM:IL-6 (sMIL Index) signature mentioned in the evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000898",
    "statement": "Slovakia to test all adults for sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Slovakia to test all adults for sars-cov-2' is supported by the evidence that Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000899",
    "statement": "He to test all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Slovakia is conducting a mass operation to test its entire adult population for SARS-CoV-2. This implies that they are testing adults for the virus, which is what the claim states.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000900",
    "statement": "Slovakia to represent all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that Slovakia is testing its entire adult population for SARS-CoV-2, which suggests a national effort to combat the spread of COVID-19. However, this does not imply or support the claim that Slovakia represents all adults for SARS-CoV-2 in any broader context.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000901",
    "statement": "failed to test all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence states that Slovakia has begun a massive operation to test its adult population for SARS-CoV-2, it does not necessarily mean they have failed to do so in the past or completely at present. The claim requires evidence showing that testing was not done on all adults at any point in time.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000902",
    "statement": "Extra doses found in pfizer 's coronavirus vaccine.",
    "label": "SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that pharmacists have discovered extra doses in Pfizer's coronavirus vaccine vials, and the FDA has confirmed that these extra doses can be used. The article also references a Reuters report confirming this information.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000903",
    "statement": "No doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that extra doses can be extracted from the vials of Pfizer's coronavirus vaccine, not that there are no doses in the vials.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000904",
    "statement": "One doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that pharmacists have discovered extra doses in Pfizer's coronavirus vaccine vials. Additionally, the FDA has approved the use of these extra doses.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000905",
    "statement": "Low doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that extra doses are found in Pfizer's coronavirus vaccine vials. The evidence indicates that pharmacists have discovered extra doses in the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine and FDA allows these extra doses to be used.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000906",
    "statement": "Bradykinin initiates cytokine-mediated inflammatory hyperalgesia",
    "label": "SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that bradykinin can trigger the release of TNF-alpha, a cytokine, and this release plays a key role in the development of inflammatory hyperalgesia as demonstrated by the sensitivity to carrageenin and endotoxin. Therefore, the claim that bradykinin initiates cytokine-mediated inflammatory hyperalgesia is supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000907",
    "statement": "Bradykinin initiates cytokine-independent inflammatory hyperalgesia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that bradykinin initiates cytokine-independent inflammatory hyperalgesia, while the evidence suggests that bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia. Since cytokines are a type of protein released by cells in response to infection or injury, and the evidence mentions 'cytokine-independent', it implies that bradykinin can initiate this process without the need for cytokines.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000908",
    "statement": "Bradykinin cans cytokine-mediated inflammatory hyperalgesia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that bradykinin can trigger cytokine release which mediates hyperalgesic responses, specifically in the case of carrageenin and endotoxin at a concentration of 1 microgram. Additionally, it states that bradykinin release of TNF-alpha (a type of cytokine) plays a key role in the development of inflammatory hyperalgesia.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000909",
    "statement": "Potently neutralizing human antibodies that block sars-cov-2 receptor binding and protect animals",
    "label": "SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim discusses the identification of monoclonal antibodies (mAbs) with potent neutralizing activity against SARS-CoV-2. The evidence provided shows IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type SARS-CoV-2 neutralization tests, which are strong indicators of such potent neutralizing activity.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000910",
    "statement": "Potently neutralizing mouse antibodies that block sars-cov-2 receptor binding and protect animals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides direct support for the claim by demonstrating the identification of monoclonal antibodies that potently neutralize SARS-CoV-2 and have IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type (wt) SARS-CoV-2 neutralization tests.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000911",
    "statement": "Potently neutralizing human antibodies that block sars-cov-2 receptor binding and neutralization animals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows the identification of monoclonal antibodies (mAbs) that exhibit potent neutralizing activity against SARS-CoV-2. The IC50 values provided for these mAbs indicate their effectiveness in inhibiting the virus, as they have low IC50 values (e.g., 0.9 ng/mL). This supports the claim that the mAbs can potently neutralize human antibodies blocking SARS-CoV-2 receptor binding and neutralization.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000912",
    "statement": "Persistence of viral rna , pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence consists of two studies that examine the pathology of COVID-19 in patients who died from the disease (1) and the implications of thrombosis associated with COVID-19 (2). The first study confirms the presence of viral RNA, which is consistent with persistent viral presence. The second study highlights thrombosis as a significant complication in advanced COVID-19 cases, and pneumocyte syncytia, or the fusing of alveolar epithelial cells into multinucleated giant cells in the lung tissue, is often associated with pathological conditions like viral infection and inflammation. These findings support the claim that persistence of viral RNA, pneumocyte syncytia, and thrombosis are hallmarks of advanced COVID-19 pathology.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000913",
    "statement": "Persistence of viral dna, pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided from the two studies supports the claim that persistence of viral DNA, pneumocyte syncytia (a pathological change in the alveolar cells of the lung), and thrombosis are hallmarks of advanced COVID-19 pathology. The first study examines immunopathology in patients with lethal COVID-19, highlighting the presence of viral RNA and the role it plays in tissue damage. The second study discusses the link between COVID-19 and thrombotic or thromboembolic disease, providing evidence for the occurrence of blood clots as a part of advanced COVID-19 pathology.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000914",
    "statement": "Persistence of viral replication, pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that persistence of viral replication, pneumocyte syncytia (cell fusion), and thrombosis are hallmarks of advanced COVID-19 pathology. Both provided references support this claim. The first study discusses viral presence in autopsies of patients with lethal COVID-19, implying persistence of viral replication. The second reference focuses on the implications of thrombotic or thromboembolic disease in COVID-19, which includes the development of thrombosis. Additionally, pneumocyte syncytia are mentioned as a key feature in severe COVID-19 cases due to the cytopathic effects caused by SARS-CoV-2 infection.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000915",
    "statement": "The novel severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows that SARS-CoV-2 infection induces severe tissue damage in the spleen and lymph nodes, which includes depletion of lymph follicles, splenic nodule atrophy, histiocyte hyperplasia, and lymphocyte reductions. The word 'decimates' might be considered strong, but these observed effects can reasonably be understood as significant damage to these tissues, which aligns with the meaning of 'decimate'.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000916",
    "statement": "The primary severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the provided evidence which states that SARS-CoV-2 infection induces severe tissue damage in human spleens and lymph nodes.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000917",
    "statement": "The first severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that SARS-CoV-2 infection leads to severe tissue damage including depletion of lymph follicles (a part of lymph nodes) and atrophy (shrinking or wasting away) of splenic nodules (part of the spleen), which can be considered as decimation. The evidence also mentions histiocyte hyperplasia (an increase in cells called histiocytes, which are found in lymph nodes) and lymphocyte reductions (a reduction in white blood cells called lymphocytes that are key components of the immune system found in spleen), further supporting the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000918",
    "statement": "Researchers discover new variant of covid-19 virus in columbus , ohio.",
    "label": "SUPPORTED",
    "evidences": [
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- Cov-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus.",
      "Doctors at Ohio State talked about the COVID-19 vaccine and the new variant of the coronavirus in the briefing below.",
      "Scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.",
      "> OSU COVID variant > > Researchers at Ohio State discuss COVID-19 vaccinations and a new variant of > the virus discovered in Columbus.",
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- CoV-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions that scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19. Additionally, the context indicates this discovery took place in Columbus, Ohio.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000919",
    "statement": "Researchers no new variant of covid-19 virus in columbus, ohio.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- Cov-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus.",
      "Doctors at Ohio State talked about the COVID-19 vaccine and the new variant of the coronavirus in the briefing below.",
      "Scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.",
      "> OSU COVID variant > > Researchers at Ohio State discuss COVID-19 vaccinations and a new variant of > the virus discovered in Columbus.",
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- CoV-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that 'Researchers no new variant of covid-19 virus in Columbus, Ohio.' However, the evidence provided states that a new strain of COVID-19 was discovered at The Ohio State University Wexner Medical Center. This contradicts the claim as it indicates that there is indeed a new variant of the virus in Columbus.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000920",
    "statement": "Coronavirus vaccine shows promising early results in china",
    "label": "SUPPORTED",
    "evidences": [
      "Lab research at CanSino Biologics in Tianjin, China, in 2018.Credit...China Stringer Network/Reuters By Apoorva Mandavilli Published May 22, 2020Updated July 16, 2020 A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.",
      "A vaccine for the new coronavirus is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.",
      "That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided refers to a vaccine developed in China that has entered mid-stage human trials and appears safe. However, the claim specifically states 'early results in China', but the evidence does not provide such results or specify where they were obtained.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000921",
    "statement": "Coronavirus vaccine shows no early results in china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Lab research at CanSino Biologics in Tianjin, China, in 2018.Credit...China Stringer Network/Reuters By Apoorva Mandavilli Published May 22, 2020Updated July 16, 2020 A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.",
      "A vaccine for the new coronavirus is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.",
      "That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence mentions a vaccine developed in China is safe and may protect people from the coronavirus, and that it has entered mid-stage human trials. However, the claim is about early results of a vaccine in China, which cannot be confirmed based on this information as it does not provide details regarding the timeline or outcomes of these early trials.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000922",
    "statement": "Sars-cov-2 triggers inflammatory responses and cell death through caspase-8 activation",
    "label": "SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1β processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows consistent findings of SARS-CoV-2 infection activating caspase-8, which in turn triggers apoptosis and inflammatory cytokine processing. The multiple studies reporting these results support the claim that Sars-cov-2 triggers inflammatory responses and cell death through caspase-8 activation.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000923",
    "statement": "Sars-cov-2 suppress inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1β processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that SARS-CoV-2 infection activates caspase-8, which in turn triggers cell apoptosis (programmed cell death) and inflammatory cytokine processing. Multiple references to this effect have been cited.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000924",
    "statement": "Sars-cov-2 inhibits inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1β processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by multiple lines of evidence provided: SARS-CoV-2 infection triggers apoptosis through caspase-8 activation (first two pieces of evidence), induces caspase-8 activation to mediate pro-IL-1β processing (second and third pieces of evidence), and induces cell death through the activation of caspase-8 (fourth piece of evidence). Additionally, the final sentence directly states that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in lung epithelial cells, which reinforces the connection between SARS-CoV-2 infection, caspase-8 activation, and induction of apoptosis.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000925",
    "statement": "Sars-cov-2 inhibited inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1β processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that SARS-CoV-2 induces cell death through caspase-8 activation and triggers apoptosis, inflammatory cytokine processing in the lung epithelial cells. The provided evidence supports this claim by stating that SARS-CoV-2 infection activates caspase-8, which leads to cell death (apoptosis) and inflammatory cytokine processing.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000926",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks.",
    "label": "SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that a study was conducted on a cohort of 43,000 individuals who were positive for SARS-CoV-2 antibodies. The results indicate that after a median follow-up period of 16.3 weeks, 0.7% of these individuals had at least one PCR-positive swab 14 days after their first positive antibody test, which suggests possible reinfection or false negative initial tests.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000927",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 years.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that a study was conducted on a cohort of 43,000 individuals who tested positive for SARS-CoV-2 antibodies and were followed for up to 35 years. The results indicate that 0.7% (314 individuals) had at least one PCR positive swab 14 days after the first-positive antibody test, suggesting possible reinfections.",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000928",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 days.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides data about the rate of SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals who were followed for up to 35 days. Specifically, it states that 0.7% (314 individuals) had at least one PCR positive swab 14 days after the first-positive antibody test.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000929",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 hours.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that among a cohort of 43,044 individuals who tested positive for anti-SARS-CoV-2 antibodies and were followed for a median of 16.3 weeks, 314 (or 0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test. This indicates that reinfection within this timeframe is possible.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000930",
    "statement": "Anakinra to prevent respiratory failure in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that Anakinra can prevent respiratory failure in COVID-19. The evidence provided suggests an investigation into whether early treatment with suPAR-guided Anakinra could prevent COVID-19-associated SRF (severe respiratory failure). The findings show that Anakinra treatment was associated with a decrease in SOFA score and several inflammatory markers, which is indicative of the successful prevention or mitigation of severe respiratory complications.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000931",
    "statement": "Anakinra to prevent neurological failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses a study investigating if early treatment of anakinra could prevent secondary renal failure (SRF) in COVID-19 patients by modulating the inflammatory balance. It mentions that anakinra treatment decreased SOFA score, IL-6, sCD163 and sIL2-R levels and increased the serum IL-10/IL-6 ratio, all of which could suggest potential benefits for COVID-19 patients. However, there is no direct reference to neurological failure or any conclusion that anakinra can prevent it in COVID-19 cases.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000932",
    "statement": "Anakinra to cause respiratory failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly link Anakinra to causing respiratory failure in COVID-19 patients. Instead, it suggests that early treatment with Anakinra may be associated with a decrease in the risk for SRF (respiratory failure) and an improvement in the pro-/anti-inflammatory balance. However, the evidence does not establish causality or suggest that Anakinra itself causes respiratory failure.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000933",
    "statement": "Anakinra to causes respiratory failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses a study that investigates if early treatment of anakinra (a medication targeting interleukin-1) can prevent severe respiratory failure (SRF) in COVID-19 patients. However, it does not present any concrete evidence directly showing that anakinra causes SRF in COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000934",
    "statement": "Hadassah doctors crack the cause of fatal corona blood clots",
    "label": "SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that Hadassah doctors discovered the cause of fatal corona blood clots. The evidence provided indicates that researchers at Hadassah have found an increased level of alpha defensin protein in patients with these fatal clots, and that this protein speeds up blood clot formation, which can lead to pulmonary embolism, heart attacks, and stroke. This directly supports the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000935",
    "statement": "Hadassah virus crack the cause of fatal corona blood clots",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that increased levels of alpha defensin protein in the blood contribute to blood clot formation, which can lead to pulmonary embolism, heart attacks and stroke. However, it does not establish a direct link between this finding and the Hadassah virus, as the latter was not mentioned in the evidence.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000936",
    "statement": "Hadassah doctors remain the cause of fatal corona blood clots",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only shows a correlation between increased levels of alpha defensin protein in the blood and the formation of fatal clots. It does not establish causality or imply that Hadassah doctors are responsible for these conditions.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000937",
    "statement": "Virus can infect heart cells in lab dish",
    "label": "SUPPORTED",
    "evidences": [
      "The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular \"defense mechanisms\" in an effort to help clear out the virus.",
      "A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a study has shown SARS-CoV-2 can infect human stem cell-derived heart cells in a lab dish. This directly supports the claim that viruses can infect heart cells.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000938",
    "statement": "Virus cannot infect heart cells in lab dish",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular \"defense mechanisms\" in an effort to help clear out the virus.",
      "A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that SARS-CoV-2 can infect human stem cell-derived heart cells in a lab dish, thus contradicting the claim that virus cannot infect heart cells in lab dishes.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000939",
    "statement": "Alpha-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Our findings show that endogenous α1-AT restricts SARS-CoV-2 and repurposes α1-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified α1-antitrypsin (α1-AT) as specific inhibitor of SARS-CoV-2.",
      "α1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows that Alpha-1 antitrypsin (α1-AT) has been identified as a specific inhibitor of SARS-CoV-2. Additionally, it targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations. Thus, the claim that Alpha-1 antitrypsin inhibits SARS-CoV-2 infection is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000940",
    "statement": "Cox-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous α1-AT restricts SARS-CoV-2 and repurposes α1-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified α1-antitrypsin (α1-AT) as specific inhibitor of SARS-CoV-2.",
      "α1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides direct support for the claim that Cox-1 antitrypsin inhibits SARS-CoV-2 infection. The evidence states that α1-AT (antitrypsin) restricts SARS-CoV-2 and blocks its infection of human airway epithelium at physiological concentrations.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000941",
    "statement": "Mcp-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous α1-AT restricts SARS-CoV-2 and repurposes α1-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified α1-antitrypsin (α1-AT) as specific inhibitor of SARS-CoV-2.",
      "α1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows that α1-antitrypsin (α1-AT) inhibits SARS-CoV-2 infection by targeting the viral spike protein and blocking its infection of human airway epithelium at physiological concentrations. This suggests that Mcp-1 antitrypsin, which is another name for α1-antitrypsin, would have similar effects on SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000942",
    "statement": "Il-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous α1-AT restricts SARS-CoV-2 and repurposes α1-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified α1-antitrypsin (α1-AT) as specific inhibitor of SARS-CoV-2.",
      "α1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that α1-antitrypsin (α1-AT) inhibits SARS-CoV-2 infection by targeting the viral spike protein and blocking infection of human airway epithelium at physiological concentrations. The findings are based on a study where α1-AT was screened as a specific inhibitor of SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000943",
    "statement": "New study suggests children may carry covid-19 at high levels",
    "label": "SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'New study suggests children may carry covid-19 at high levels' is supported by the evidence provided which states 'Young children can potentially be important drivers of SARS-CoV-2 spread in the general population.' This implies that young children may indeed carry Covid-19, but further details are needed to determine if they do so at 'high levels.'",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000944",
    "statement": "New study suggests cats may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that cats may carry Covid-19 at high levels. Instead, it discusses the transmission potential of children in the context of SARS-CoV-2 spread, without making any mention of cats or their potential role in spreading the virus.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000945",
    "statement": "New study suggests bats may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that 'New study suggests bats may carry covid-19 at high levels.' However, the provided evidence does not support this claim directly. The evidence talks about how children can potentially spread SARS-CoV-2 to others and mentions a South Korean study on transmission rates among age groups, but it doesn't provide any information on bats carrying the virus.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000946",
    "statement": "New study suggests coronaviruses may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that coronaviruses may carry Covid-19 at high levels, but the evidence provided only indicates that children in specific age groups may transmit SARS-CoV-2 less or as well as adults do, not necessarily carrying high levels of the virus. More information regarding viral loads and their relationship to transmission would be required to support this claim.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000947",
    "statement": "In the coronavirus pandemic , we 're making decisions without reliable data",
    "label": "SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that decisions during the coronavirus pandemic are made without reliable data. However, the evidence provided does not offer any specific instances or examples to support this claim. The article simply states that we don't know whether the decisions were brilliant or catastrophic due to the absence of data on the real course of the epidemic.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000948",
    "statement": "In the coronavirus pandemic, we're making decisions with reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or refute the claim that 'we're making decisions with reliable data during the coronavirus pandemic'. The article states that there is a lack of data on the real course of the epidemic, which suggests unreliable data might be used in decision-making. However, it does not provide information about what specific decisions have been made and whether they were based on reliable or unreliable data.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000949",
    "statement": "In the coronavirus pandemic, we're making decisions and reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that during the coronavirus pandemic, decisions are being made with reliable data. However, the provided evidence points out a lack of data on the real course of the epidemic, which contradicts the claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000950",
    "statement": "In the coronavirus pandemic, we're making decisions in reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that during the coronavirus pandemic, decisions are being made based on reliable data. However, the evidence provided does not support this claim as it only discusses uncertainty in the absence of data and does not explicitly state that reliable data is driving decision-making.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000951",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly decreased mortality",
    "label": "SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma significantly reduces mortality. This conclusion is supported by the analysis of multiple sources, including the FDA's emergency use authorization for this therapy and an interim study showing a decrease in mortality.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000952",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increased mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IGG convalescent plasma increases mortality significantly. However, the provided evidence states the opposite, that it 'significantly reduces mortality.' This contradiction indicates that the claim is not supported by the available evidence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000953",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increase mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that transfusion of convalescent plasma containing high titer anti-spike protein RBD IgG significantly decreases mortality in COVID-19 patients. However, the claim is about a significant increase in mortality. The evidence does not support this opposite conclusion.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000954",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly higher mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that transfusion of convalescent plasma early in the treatment of COVID-19 patients may reduce mortality. However, it does not provide enough detail or contrasting evidence to confirm a signal of significantly higher mortality from early transfusion of high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000955",
    "statement": "Egyptian doctors are speaking out against health authorities over increasing coronavirus infections and deaths among medical staff across the country .",
    "label": "SUPPORTED",
    "evidences": [
      "Another Egyptian doctor told Amnesty International that doctors who speak out are subjected to threats, interrogations by the National Security Agency (NSA), administrative questioning, and penalties.",
      "A correspondent in Egypt Topics covered health care, medical supplies, covid-19, coronavirus, egyptian doctors, doctors Jun 8, 2020 Egyptian doctors have expressed anger in recent days, accusing the authorities of neglecting them and failing to protect and provide them with the protective equipment they need.",
      "Egypts arrests of medical professionals who criticized its Covid-19 policies warrant unambiguous opposition from the World Bank, in line with its commitment not to tolerate reprisals, said Amr Magdi, Middle East and North Africa researcher at Human Rights Watch."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that Egyptian doctors are speaking out against the authorities over increasing coronavirus infections and deaths among medical staff. The statements from an Amnesty International source, a correspondent reporting on health care, medical supplies, and Covid-19 policies in Egypt, as well as the comments from Amr Magdi of Human Rights Watch all support this claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000956",
    "statement": "Egyptian doctors are ruled out against health authorities over increasing coronavirus infections and deaths among medical staff across the country.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Another Egyptian doctor told Amnesty International that doctors who speak out are subjected to threats, interrogations by the National Security Agency (NSA), administrative questioning, and penalties.",
      "A correspondent in Egypt Topics covered health care, medical supplies, covid-19, coronavirus, egyptian doctors, doctors Jun 8, 2020 Egyptian doctors have expressed anger in recent days, accusing the authorities of neglecting them and failing to protect and provide them with the protective equipment they need.",
      "Egypts arrests of medical professionals who criticized its Covid-19 policies warrant unambiguous opposition from the World Bank, in line with its commitment not to tolerate reprisals, said Amr Magdi, Middle East and North Africa researcher at Human Rights Watch."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that Egyptian doctors have expressed anger over the authorities' handling of COVID-19, specifically their neglect and failure to protect medical staff. It also shows that those who speak out about the situation face threats, interrogations, and penalties. However, there is no direct or concrete evidence in this set of statements that supports the claim that Egyptian doctors are being ruled out against health authorities over increasing coronavirus infections and deaths.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000957",
    "statement": "High sars-cov-2 viral load is associated with a worse clinical outcome of covid-19 disease",
    "label": "SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a statistically significant correlation between high viral load and worse clinical prognosis of COVID-19 patients, independently of several previously identified risk factors. The data also highlights the importance of viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000958",
    "statement": "High sars-cov-2 viral load is associated with a greater clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a statistically significant correlation between high SARS-CoV-2 viral load and worse clinical prognosis of COVID-19 disease, independently of other factors such as age, sex, various diseases, and lung diseases. This suggests that high viral load is associated with a greater clinical outcome of COVID-19 disease.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000959",
    "statement": "High sars-cov-2 viral load is associated with a better clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that high SARS-CoV-2 viral load is associated with worse clinical prognosis in COVID-19 patients, contradicting the claim of a better clinical outcome. However, the evidence does not directly address the association between viral load and a better clinical outcome.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000960",
    "statement": "High sars-cov-2 viral load is associated with a higher clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a statistically significant correlation between high SARS-CoV-2 viral load and worse clinical prognosis of COVID-19 disease, independent of other risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease. This suggests that high viral load is associated with a higher clinical outcome of COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000961",
    "statement": "In silico mutagenesis of human ace2 with s protein and translational efficiency explain sars-cov-2 infectivity in different species",
    "label": "SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim connects SARS-CoV-2 infectivity in different species with in silico mutagenesis of human ACE2 with S protein and translational efficiency. The evidence provided discusses genomic variability across species affecting ACE2/SARS-CoV-2 recognition, cellular entry, and viral proteome translation efficiency, all factors that impact infection. It also mentions humans as the species in which SARS-CoV-2 is most efficiently translated and optimally interacts with ACE2, suggesting a possible correlation between these factors and infectivity.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000962",
    "statement": "In silico mutagenesis of bat ace2 with s protein and translational efficiency explain sars-cov-2 infectivity in different species",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim discusses the role of in silico mutagenesis of bat ACE2 with S protein, translational efficiency and its relation to SARS-CoV-2 infectivity across different species. The evidence provided explains that genomic variability leads to ACE2 variations affecting folding, recognition, or both; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2; two key factors for infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency; and it is observed that humans have both the most efficient translation of SARS-CoV-2 and optimal interaction with ACE2. All these details support the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000963",
    "statement": "In silico mutagenesis of human ace2 with s protein and translational efficiency inhibited sars-cov-2 infectivity in different species",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that in silico mutagenesis of human ACE2 with S protein and translational efficiency inhibited SARS-CoV-2 infectivity in different species. The evidence provided discusses genomic variability across species affecting ACE2/SARS-CoV-2 recognition, viral proteome translation efficiency, and SARS-CoV-2 cellular entry dependence on ACE2 and TMPRSS2. However, it does not provide direct evidence or information about the claim that in silico mutagenesis of human ACE2 with S protein and translational efficiency inhibited SARS-CoV-2 infectivity in different species.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000964",
    "statement": "Plasmin cascade mediates thrombolytic events in sars-cov-2 infection via complement and platelet-activating systems",
    "label": "SUPPORTED",
    "evidences": [
      "Our results indicate that plasmin is a crucial mediator which primes interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, with a potential for therapeutic intervention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that plasmin mediates interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection. This implies a role for the plasmin cascade in thrombolytic events related to SARS-CoV-2, as suggested in the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000965",
    "statement": "Plasmin cascade mediates thrombolytic events in sars-cov-2 production via complement and platelet-activating systems",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results indicate that plasmin is a crucial mediator which primes interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, with a potential for therapeutic intervention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the claim 'Plasmin cascade mediates thrombolytic events in SARS-CoV-2 production via complement and platelet-activating systems' is supported. The statement in the evidence indicates that plasmin plays a crucial role in interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, which aligns with the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000966",
    "statement": "Private firm running uk ppe stockpile was sold in middle of pandemic .",
    "label": "SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates a change in ownership of the management of the UK PPE stockpile from a German-owned multinational to an American one and a possible shift in distribution responsibilities to Movianto. However, it does not provide conclusive evidence that the sale occurred 'in the middle of the pandemic.' Additional information about the timing and circumstances of the sale would be needed to support or refute this claim.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000967",
    "statement": "Private firm running uk ppe stockpile was established in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not provide information about when the private firm running the UK PPE stockpile was established. It only mentions a change in management from a German-owned multinational to an American one and a possible change in distribution responsibility.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000968",
    "statement": "No firm running uk ppe stockpile was sold in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that 'No firm running UK PPE stockpile was sold in middle of pandemic.' However, the provided evidence only mentions a change in ownership from German to American and a shift in distribution responsibility, not a sale or exhaustion of the UK PPE stockpile. Further information about the status and use of the UK PPE stockpile during the pandemic is needed to validate this claim.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000969",
    "statement": "Private firm running uk ppe stockpile was developed in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions that a private firm running the UK PPE stockpile was developed in the middle of the pandemic. However, the provided evidence only discusses a change in management from a German-owned multinational to an American one, and a shift in distribution responsibility, but it does not provide information about when the firm was actually developed.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000970",
    "statement": "A systematic review uncovers a wide-gap between covid-19 in humans and animal models",
    "label": "SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'A systematic review uncovers a wide-gap between covid-19 in humans and animal models' is supported by the provided evidence. The evidence indicates that no severe illness or mortality was observed in animal models, which suggests a difference compared to COVID-19 in humans.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000971",
    "statement": "A systematic review focuseds a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that a systematic review found a wide gap between COVID-19 in humans and animal models. However, the evidence provided only states that no severe illness associated with mortality was observed in some animal models, suggesting a possible difference but does not necessarily mean there is a 'wide gap'. Furthermore, the evidence lacks specific information about the systematic review process or results, making it difficult to fully evaluate its claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000972",
    "statement": "A systematic review focusess a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes the observation of a wide gap between COVID-19 in humans and animal models based on the lack of severe illness associated with mortality. However, it does not explicitly state that this is part of a systematic review. A systematic review would involve a comprehensive and structured approach to identify, evaluate, and synthesize all relevant research studies addressing a specific research question.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000973",
    "statement": "A systematic review focuss a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that no severe illness associated with mortality was observed in animal models of COVID-19, suggesting a wide gap between the disease in humans and these specific animal models (hamsters, nonhuman primates, macaques, rodents, ferrets, rabbits, cats, dogs). However, to confirm if this is indeed a systematic trend across all animal models for COVID-19, a more comprehensive review of a larger set of animal models would be required.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-000974",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the heart.",
    "label": "SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that cardiac SARS-CoV-2 infection is associated with distinct transcriptomic changes within the heart. The evidence suggests that cardiac replication of SARS-CoV-2 leads to early death, and that there are several studies reporting a direct effect on heart function by coronaviruses similar to SARS-CoV-2. Furthermore, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in patients with compromised myocardial function. While this evidence does not directly prove distinct transcriptomic changes, it supports the idea that SARS-CoV-2 affects heart function, which implies some form of change at the transcriptional level.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000975",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lung.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that cardiac replication of SARS-CoV-2 is associated with early death and that there are several studies reporting a direct effect on heart function by coronaviruses similar to SARS-CoV-2. Furthermore, the evidence mentions that cardiac insufficiency is more likely to occur in patients where cardiac function is already compromised by myocardial ischemia, which suggests distinct transcriptomic changes within the lung due to SARS-CoV-2 infection as a response to damage caused to the heart. This supports the claim that Cardiac SARS-CoV-2 infection is associated with distinct transcriptomic changes within the lung.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000976",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lungs.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that cardiac replication of SARS-CoV-2 is associated with early death and direct effects on heart function. This suggests distinct transcriptomic changes within the lungs due to infection as a result of the body's response to the virus in the heart and vascular system. The evidence also indicates that compromised cardiac function increases the likelihood of cardiac insufficiency during SARS-CoV-2 infection.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000977",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the liver.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence points to the cardiac replication of SARS-CoV-2 being associated with early death and cardiac insufficiency in patients with compromised myocardial function. Although it does not directly mention transcriptomic changes within the liver, the association between cardiac infection and negative cardiac outcomes suggests potential systemic effects that may extend to other organs such as the liver.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000978",
    "statement": "'in a few weeks , we will have coronavirus vaccine '",
    "label": "SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the vaccine 'could' achieve safety approval in 90 days, indicating a possible timeline. However, it does not guarantee that the vaccine will be ready within a few weeks or that it has already been approved for use.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000979",
    "statement": "'in a few years, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that 'in a few years, we will have coronavirus vaccine'. The evidence provided suggests that a vaccine could potentially receive safety approval in 90 days and might be available within a few weeks if everything goes as planned. However, the timeframe of 'a few weeks' doesn't necessarily correspond to the typical development timeline for vaccines, which is usually measured in years rather than months.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000980",
    "statement": "'in a few hours, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that 'in a few hours, we will have coronavirus vaccine.' However, the evidence provided does not indicate that the vaccine would be ready in a matter of hours. The statement suggests it could achieve safety approval in 90 days and they are in the middle of the process. It's unclear if the final stages of development and manufacturing would take only a few hours.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000981",
    "statement": "'in a few decades, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that 'in a few decades', a coronavirus vaccine will be available. The evidence provided states that the vaccine could potentially achieve safety approval in 90 days and is currently being developed. However, this does not confirm or support the claim of 'in a few decades'.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000982",
    "statement": "Indiana bans all non-essential gatherings over 250 people",
    "label": "SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that Indiana bans all non-essential gatherings over 250 people is supported by the evidence provided, which states that Gov. Eric Holcomb has announced a ban on non-essential gatherings exceeding 250 people to reduce the spread of COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000983",
    "statement": "Indiana bans all non-essential gatherings over 15 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Indiana bans all non-essential gatherings over 15 people, but the evidence provided states the limit is 250 people. Therefore, the claim does not seem to be supported by the available evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000984",
    "statement": "Indiana bans all non-essential gatherings over 10 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Indiana bans all non-essential gatherings over 10 people. However, the provided evidence only specifies a limit of 250 people for non-essential gatherings, not a complete ban on gatherings over 10 people.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000985",
    "statement": "Indiana bans all non-essential gatherings over 20 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Indiana bans all non-essential gatherings over 20 people. However, the evidence states that the limit for non-essential gatherings is 250 people or fewer. The provided evidence does not explicitly confirm or deny a ban on gatherings of more than 20 people.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000986",
    "statement": "Evaluation of four commercial , fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents conclusions suggesting that the Siemens COV2G assay may have impaired sensitivity, and it recommends switching to the company's newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies. Additionally, it suggests a lowering of the cut-off index for the Siemens COV2G assay, which could imply a revision is needed.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000987",
    "statement": "Evaluation of two commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear conclusions that the Siemens COV2G assay may have impaired sensitivity and requires a switch to the new SARS-CoV-2 IgG assay (sCOVG) for follow-up studies. Additionally, it suggests lowering the cut-off index for the COV2G assay, which implies a revision of this specific assay.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000988",
    "statement": "Evaluation of each commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a revision of the Siemens SARS-CoV-2 IgG assay based on evaluations of commercially available serologic tests for detection of antibodies against SARS-CoV-2. The ROC curve analyses indicate a lowering of the cut-off index for the Siemens COV2G assay, and it is recommended to switch to the company's newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies. Moreover, the evidence recommends the combination of two anti-SARS-CoV-2 antibody assays when considering borderline reactive results.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000989",
    "statement": "Evaluation of both commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim that evaluation of commercially available SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000990",
    "statement": "Global covid-19 cases surpass 75 million.",
    "label": "SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that global Covid-19 cases have surpassed 75 million. The news source is reliable (YouTube) and the timestamp on the video suggests it was updated recently.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000991",
    "statement": "Global covid-19 cases surpass 75 days.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that as of the date provided (January 23, 2021), global Covid-19 cases have surpassed 75 million. Therefore, the claim is supported.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000992",
    "statement": "Global covid-19 cases surpass 75 persons.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that global Covid-19 cases have surpassed 75 million. This claim is thus supported by the presented evidence.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000993",
    "statement": "Global covid-19 cases surpass 75 deaths.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided in the form of a video title 'Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million'. The title explicitly states that the number of deaths has surpassed 1.7 million which is greater than 75.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000994",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in women.",
    "label": "SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly debunk or confirm the claim that COVID-19 vaccines cause infertility in women. The evidence only states that a specific argument suggesting such a correlation is incorrect due to shared amino acid sequences between the SARS-CoV-2 spike protein and a placental protein. However, this does not definitively prove that the vaccines do not affect fertility.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000995",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in dogs.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that COVID-19 vaccine causes infertility in dogs is not supported by the provided evidence. The evidence specifically discusses the effect of COVID-19 vaccines on humans and the shared amino acid sequence between SARS-CoV-2 spike protein and placental protein, not about dogs.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000996",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in children.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that COVID-19 vaccines cause infertility in children, but the provided evidence only clarifies that there is an incorrect suggestion (not supported by evidence) about a shared amino acid sequence between a placental protein and the spike protein of SARS-CoV-2 virus. However, no direct proof or debunking of the claim regarding the vaccines causing infertility is presented.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000997",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in adults.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that COVID-19 vaccines cause infertility in adults. The provided evidence states that the claim is 'Not True', but it does not directly disprove or confirm the safety of the vaccine for adult fertility. Instead, it points out an incorrect assumption about shared amino acid sequences between a protein in SARS-CoV-2 and a placental protein, which suggests that further research and evidence are needed to address the claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000998",
    "statement": "Expert reaction to people being re-tested positive for coronavirus after initial recovery",
    "label": "SUPPORTED",
    "evidences": [
      "Clearly we need more information about these patients, such as were there underlying medical conditions or a change in circumstances that might have allowed the virus to escape immune control?",
      "However, the report reinforces the fact that we have to investigate all such findings really thoroughly and report such information if we are to make the best decisions based on sound scientific evidence.",
      "She has a prolonged excretion of virus from her initial infection and tests were either not done or were not done sufficiently well or enough to confirm clearance.",
      "Although coronaviruses generally cause short- term self-limiting infections which are cleared, there is some evidence in the scientific literature for persistent infections of animal coronaviruses (mainly in bats).",
      "This highlights the need for more research into the biology of the new coronavirus, it is very much early days in our efforts to understand it. On case in Japan: Prof Paul Hunter, Professor in Medicine, University of East Anglia (UEA), said: Regarding this reported case: There is so much we do not know about this case to give a properly informed opinion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that the evidence supports the need for further investigation and research into the possibility of re-emergence or persistence of COVID-19 after initial recovery, which is supported by statements about investigating findings thoroughly, the prolonged excretion of virus, and the mention of persistent infections of animal coronaviruses (mainly in bats) found in scientific literature.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000999",
    "statement": "Expert reaction to people being re-tested positive for coronavirus before initial recovery",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Clearly we need more information about these patients, such as were there underlying medical conditions or a change in circumstances that might have allowed the virus to escape immune control?",
      "However, the report reinforces the fact that we have to investigate all such findings really thoroughly and report such information if we are to make the best decisions based on sound scientific evidence.",
      "She has a prolonged excretion of virus from her initial infection and tests were either not done or were not done sufficiently well or enough to confirm clearance.",
      "Although coronaviruses generally cause short- term self-limiting infections which are cleared, there is some evidence in the scientific literature for persistent infections of animal coronaviruses (mainly in bats).",
      "This highlights the need for more research into the biology of the new coronavirus, it is very much early days in our efforts to understand it. On case in Japan: Prof Paul Hunter, Professor in Medicine, University of East Anglia (UEA), said: Regarding this reported case: There is so much we do not know about this case to give a properly informed opinion."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim does not clearly state that the evidence is about people being re-tested positive for coronavirus before initial recovery. Instead, it discusses cases where patients had prolonged virus excretion or possible persistent infections. However, the evidence does suggest the need for further research to understand the biology of the new coronavirus.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-001000",
    "statement": "Il-6 inhibition could be key to covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.",
      "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that blocking IL-6 could be key to treating severe COVID-19 cases. The evidence provided indicates that Tocilizumab, an IL-6 receptor blocker, can effectively block the IL-6 signal transduction pathway and is likely to become an effective drug for patients with severe COVID-19. Since Tocilizumab works by blocking IL-6, the evidence supports the claim that inhibiting IL-6 could indeed be a potential method for treating severe COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001001",
    "statement": "Il-6 inhibition could be resistant to covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.",
      "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides information about a potential treatment (blocking the signal transduction pathway of IL-6) for severe COVID-19 and mentions Tocilizumab as a drug that can effectively block this pathway. By blocking the pathway, it is suggested that the disease's progression could be inhibited in severe COVID-19 patients.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001002",
    "statement": "Il-6 overexpression could be key to covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.",
      "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that Il-6 overexpression could be key to Covid-19 and the evidence supports this by suggesting a new method for treating severe COVID-19 patients involves blocking the signal transduction pathway of IL-6. Additionally, Tocilizumab, an IL-6 receptor blocker, is suggested as an effective drug for such treatment.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001003",
    "statement": "Il-6 expression could be key to covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.",
      "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that blocking the IL-6 signal transduction pathway could potentially be a new method for treating severe COVID-19 patients, and Tocilizumab, an IL-6 receptor blocker, is expected to be effective in doing so. While it doesn't directly prove that IL-6 expression is key to COVID-19, the implication from the evidence supports this claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001004",
    "statement": "Pompeo saying that chinese labs created covid-19 .",
    "label": "SUPPORTED",
    "evidences": [
      "ANDREW HARNIK/POOL/AFP via Getty Images Secretary of State Mike Pompeo on Sunday said there was \"enormous evidence\" that COVID-19 originated in a Chinese lab.",
      "Secretary of State Mike Pompeo on Sunday claimed there was \"enormous evidence\" that COVID-19, the disease caused by the novel coronavirus, originated in a laboratory in Wuhan, China, though there has been so far no public evidence to support such a theory."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only mentions that Secretary of State Mike Pompeo claimed there was 'enormous evidence' that COVID-19 originated in a Chinese lab, but it does not provide any direct or concrete evidence to support this claim.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-001005",
    "statement": "Pompeo saying that our labs created covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ANDREW HARNIK/POOL/AFP via Getty Images Secretary of State Mike Pompeo on Sunday said there was \"enormous evidence\" that COVID-19 originated in a Chinese lab.",
      "Secretary of State Mike Pompeo on Sunday claimed there was \"enormous evidence\" that COVID-19, the disease caused by the novel coronavirus, originated in a laboratory in Wuhan, China, though there has been so far no public evidence to support such a theory."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that Pompeo said our labs created COVID-19 is based on his statement about there being 'enormous evidence' that the virus originated in a Chinese lab. However, the evidence does not support the claim that our labs were involved in creating the virus. It only mentions that Pompeo believes the virus originated in a lab in Wuhan, China.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001006",
    "statement": "Interferons and viruses induce a novel truncated ace2 isoform and not the full-length sars-cov-2 receptor",
    "label": "SUPPORTED",
    "evidences": [
      "We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.",
      "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that dACE2, a truncated version of ACE2, is induced by IFNs (interferons) and viruses, including SARS-CoV-2. This directly contradicts the claim that the full-length SARS-CoV-2 receptor (ACE2) is induced by interferons and viruses. Thus, it supports the opposite of the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001007",
    "statement": "Interferons and viruses induce a novel truncated ace2 isoform and produce the full-length sars-cov-2 receptor",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.",
      "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that a truncated version of ACE2 (dACE2) is induced by interferons and viruses, including SARS-CoV-2. The full-length SARS-CoV-2 receptor required for virus entry into host cells is ACE2, but the evidence indicates that it's dACE2, not ACE2, that is produced in response to interferons and viruses.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001008",
    "statement": "Interferons and viruses induce a novel truncated ace2 isoform and induce the full-length sars-cov-2 receptor",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.",
      "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that dACE2 (a truncated form of ACE2) is induced in various human cell types by IFNs and viruses, including SARS-CoV-2. It also shows that this induction occurs rather than the full-length ACE2.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-001009",
    "statement": "Interferons and viruses induce a novel truncated ace2 isoform and form the full-length sars-cov-2 receptor",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.",
      "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that a truncated version of ACE2, called dACE2, is induced by IFNs and viruses, including SARS-CoV-2. This indicates that it is dACE2, not the full-length ACE2, which forms the receptor for SARS-CoV-2 when cells are exposed to interferons and viruses.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001010",
    "statement": "Neutralizing antibodies correlate with protection from sars-cov-2 in humans during a fishery vessel outbreak with high attack rate",
    "label": "SUPPORTED",
    "evidences": [
      "This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided since it matches exactly with the title of the published article.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001011",
    "statement": "Neutralizing antibodies correlate with protection from sars-cov-2 in pigs during a fishery vessel outbreak with high attack rate",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about pigs and SARS-CoV-2 infection, while the evidence provided is about humans in a fishery vessel outbreak. Although the title of the article suggests it involves SARS-CoV-2 in animals (pigs), it does not explicitly specify whether the findings can be directly extrapolated to pigs during an outbreak with high attack rate.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001012",
    "statement": "Neutralizing antibodies correlate with protection from sars-cov-2 in mice during a fishery vessel outbreak with high attack rate",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim and evidence are directly linked through the title of the article which confirms that neutralizing antibodies correlate with protection from SARS-CoV-2 in mice during a fishery vessel outbreak with high attack rate.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001013",
    "statement": "Neutralizing antibodies correlate with protection from sars-cov-2 in animals during a fishery vessel outbreak with high attack rate",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The title of the article directly states that neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. Since the study was performed on animals, we cannot confirm the exact correlation between the antibodies and protection for those specific animals in this situation. However, the title clearly indicates that similar findings were made in human studies, which supports the claim when considering its broader context.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001014",
    "statement": "Covid-19 infections leave an impact on the heart",
    "label": "SUPPORTED",
    "evidences": [
      "If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.",
      "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.",
      "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Covid-19 infections leave an impact on the heart' is supported by two studies that suggest a connection between Covid-19 and involvement of the heart. Additionally, a mention of the connection between Covid-19 and blood clots (pulmonary aneurysms, strokes, and heart attacks) further supports this claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001015",
    "statement": "Covid-19 infections leave an impact on the pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.",
      "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.",
      "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions that Covid-19 infections can have an impact on the cardiovascular system, causing complications such as heart failure and blood clots (pulmonary aneurysms, strokes, and heart attacks). The fact that studies suggest a high likelihood of these complications associated with Covid-19 infections implies that the pandemic will shift to new incidences of chronic cardiovascular complications.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001016",
    "statement": "Covid-19 infections leave an impact on the epidemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.",
      "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.",
      "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Covid-19 infections can have an impact on the cardiovascular system by increasing the likelihood of heart complications and blood clots. This supports the claim that Covid-19 infections leave an impact on the epidemic.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001017",
    "statement": "Covid-19 infections leave an impact on the future",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.",
      "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.",
      "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that Covid-19 infections can have an impact on the future health of individuals, specifically their hearts and cardiovascular systems. This is supported by two studies indicating a high likelihood of heart involvement upon infection and the connection between Covid-19 and blood clots leading to complications such as pulmonary aneurysms, strokes, and heart attacks.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001018",
    "statement": "Sars-cov1 frequent mask use in public venues , frequent hand washing , and disinfecting the living quarters were significant protective factors",
    "label": "SUPPORTED",
    "evidences": [
      "In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).",
      "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.",
      "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.",
      "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors against a specific event. The claim is supported by this statement.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-001019",
    "statement": "Sars-cov1 frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were not protective factors",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).",
      "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.",
      "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.",
      "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly indicates that frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors against SARS-CoV-1. The claim that these practices were not protective factors is contradicted by the findings presented in the evidence.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001020",
    "statement": "Sars-cov1 frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were no protective factors",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).",
      "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.",
      "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.",
      "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is in direct contradiction to the provided evidence. The evidence clearly states that frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors against SARS-CoV-1.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001021",
    "statement": "Sars-cov1 frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were less protective factors",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).",
      "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.",
      "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.",
      "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that frequent mask use in public venues, frequent hand washing, and disinfecting living quarters are significant protective factors against the spread of a disease. The claim incorrectly states that these factors are 'less protective,' which contradicts the presented data.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001022",
    "statement": "Major new lineages of sars-cov-2 emerge and spread in south africa during lockdown .",
    "label": "SUPPORTED",
    "evidences": [
      "We also show that three lineages spread widely in South Africa and contributed to ~42% of all of the infections in the country.",
      "C.1 was the most geographically widespread lineage in South Africa, causing infections in multiple provinces and in all of the eleven districts in KwaZulu-Natal (KZN), the most sampled province."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that new lineages of SARS-CoV-2 emerged and spread in South Africa during lockdown, and the evidence shows that three lineages (C.1) spread widely in South Africa causing ~42% of all infections in the country. The lineage was geographically widespread, causing infections in multiple provinces and all districts in KwaZulu-Natal, which is the most sampled province. This implies that new lineages did indeed emerge and spread during the lockdown.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001023",
    "statement": "Major new lineages of sars-cov-2 emerge and spread in south china during lockdown.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We also show that three lineages spread widely in South Africa and contributed to ~42% of all of the infections in the country.",
      "C.1 was the most geographically widespread lineage in South Africa, causing infections in multiple provinces and in all of the eleven districts in KwaZulu-Natal (KZN), the most sampled province."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided focuses on lineages of SARS-CoV-2 spreading in South Africa and does not provide information about any new lineages emerging and spreading in south China during lockdown.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-001024",
    "statement": "Major new lineages of sars-cov-2 emerge and spread in south asia during lockdown.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We also show that three lineages spread widely in South Africa and contributed to ~42% of all of the infections in the country.",
      "C.1 was the most geographically widespread lineage in South Africa, causing infections in multiple provinces and in all of the eleven districts in KwaZulu-Natal (KZN), the most sampled province."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that three lineages of SARS-CoV-2 spread widely in South Africa and contributed to about 42% of the total infections there. However, it does not specify whether these lineages are new or have emerged during a lockdown, nor does it directly state or imply that they have spread extensively in South Asia.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-001025",
    "statement": "Researchers race to develop in-home testing for covid-19 , a potential game changer",
    "label": "SUPPORTED",
    "evidences": [
      "The company has already developed a lab-based test thats handheld and gives results in 15 minutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that a lab-based test has been developed which is handheld and provides results in 15 minutes. However, this does not necessarily mean that the company is currently racing to develop an 'in-home' testing solution for COVID-19 or that such development would be a game changer. More evidence about the specific in-home test being developed, its status, and its potential impact on COVID-19 testing would be needed to support the claim.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-001026",
    "statement": "Researchers race to develop in-hospital testing for covid-19, a potential game changer",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The company has already developed a lab-based test thats handheld and gives results in 15 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a lab-based COVID-19 test has been developed which is portable and provides results within 15 minutes. While the claim mentions 'in-hospital' testing, this test can be used in a hospital setting due to its portability, making it a potential game changer.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001027",
    "statement": "Researchers race to develop in-line testing for covid-19, a potential game changer",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The company has already developed a lab-based test thats handheld and gives results in 15 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence demonstrates the existence of a rapid lab-based Covid-19 test that offers quick results. Although the claim mentions 'in-line' testing, which is not explicitly stated in the evidence, it can be reasonably inferred that developing an on-the-spot or portable version of such a test would indeed be a potential game changer for managing the spread of Covid-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001028",
    "statement": "Researchers race to develop in-site testing for covid-19, a potential game changer",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The company has already developed a lab-based test thats handheld and gives results in 15 minutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the evidence refers to in-site testing for COVID-19, which is a test that can be performed outside of a lab setting. However, the evidence only mentions a lab-based handheld test with results in 15 minutes. In order to support the claim, it would be necessary to have additional evidence showing that this test is indeed designed for on-site use.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001029",
    "statement": "Estimating the generation interval for covid-19 based on symptom onset data",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Estimating generation and serial interval distributions from outbreak data requires careful investigation of the underlying transmission network."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not provide sufficient information to calculate or estimate the generation interval for COVID-19 based on symptom onset data. To determine this value, one needs actual data about transmission events and their timing relative to symptom onset.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-001030",
    "statement": "Estimating the survival interval for covid-19 based on symptom onset data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Estimating generation and serial interval distributions from outbreak data requires careful investigation of the underlying transmission network."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses the methodology for estimating the survival interval (generation and serial interval distributions) of an infectious disease based on outbreak data, but it does not provide specific data about covid-19's symptom onset or survival interval. Without relevant symptom onset data, it is not possible to estimate the survival interval for covid-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001031",
    "statement": "Estimating the time interval for covid-19 based on symptom onset data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Estimating generation and serial interval distributions from outbreak data requires careful investigation of the underlying transmission network."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that we can estimate the time interval for COVID-19 based on symptom onset data. The evidence provided discusses how to estimate generation and serial interval distributions from outbreak data but does not directly support the estimation of time intervals based solely on symptom onset data.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-001032",
    "statement": "Inactivated rabies virus vectored sars-cov-2 vaccine prevents disease in a syrian hamster model .",
    "label": "SUPPORTED",
    "evidences": [
      "Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.",
      "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions an inactivated rabies vectored SARS-CoV-2 vaccine (CORAVAX) being evaluated in a Syrian hamster model, suggesting that the vaccine is tested on this animal model to determine if it prevents disease caused by SARS-CoV-2. The claim is therefore supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001033",
    "statement": "Inactivated rabies virus vectored sars-cov-2 vaccine causes disease in a syrian hamster model.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.",
      "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses a study evaluating the safety and immunogenicity of an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. However, it does not mention whether the vaccine causes disease or not.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001034",
    "statement": "Inactivated rabies virus vectored sars-cov-2 vaccine induces disease in a syrian hamster model.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.",
      "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the inactivated rabies virus vectored SARS-CoV-2 vaccine induces disease in a Syrian hamster model. However, the provided evidence does not directly address this specific point. Instead, it talks about interim analysis of two randomized clinical trials involving the safety and immunogenicity outcomes of the same vaccine in humans. No information is given about the vaccine causing disease in a Syrian hamster model.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001035",
    "statement": "Inactivated rabies virus vectored sars-cov-2 vaccine causing disease in a syrian hamster model.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.",
      "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the inactivated rabies virus vectored SARS-CoV-2 vaccine causes disease in a Syrian hamster model. The evidence provided does mention an evaluation of this specific vaccine (CORAVAX) in a Syrian hamster model, but it does not state or imply that the vaccine caused disease. The interpretation is not supported by the available data.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001036",
    "statement": "100 percent of regular icu beds in texas medical center occupied , but hospitals have space for surge",
    "label": "SUPPORTED",
    "evidences": [
      "Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.",
      "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that '100 percent of regular icu beds in Texas Medical Center occupied, but hospitals have space for surge.' The evidence provided states the average ICU occupancy rate is 70 to 80 percent, not 100 percent. Additionally, the statement about hospitals having space for a surge seems to be based on them moving some ICU patients to beds not normally used for critical care, but this doesn't necessarily mean there's ample capacity for all potential patients.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-001037",
    "statement": "Two percent of regular icu beds in texas medical center occupied, but hospitals have space for surge",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.",
      "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not directly state the current ICU bed occupation rate in Texas Medical Center or confirm if there is surge capacity available. The statement only mentions an average ICU occupancy rate of 70-80% at 'the world's largest medical center', without specifying where that medical center is located. Additionally, the evidence suggests that some ICU patients are being moved to beds not normally used for critical care, but this does not necessarily imply there is surge capacity available.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-001038",
    "statement": "One percent of regular icu beds in texas medical center occupied, but hospitals have space for surge",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.",
      "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states 'One percent of regular icu beds in Texas Medical Center occupied, but hospitals have space for surge'. However, the evidence provided only mentions that the average ICU occupancy rate at the world's largest medical center is 70 to 80 percent and that some ICU patients will be moved to beds not normally used for critical care. This evidence does not indicate that one percent of regular ICU beds are currently occupied, nor does it clearly show that hospitals have space for a surge in patients.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-001039",
    "statement": "Five percent of regular icu beds in texas medical center occupied, but hospitals have space for surge",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.",
      "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that 5% of regular ICU beds in Texas Medical Center are occupied but hospitals have space for a surge. However, the provided evidence only mentions that the average ICU occupancy rate is 70-80%, and some ICU patients will be moved to non-critical care beds during a surge. This does not provide concrete data about the current percentage of occupied ICU beds or whether there is actual spare capacity in case of a surge.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-001040",
    "statement": "U.s. to suspend visa services in virus-hit countries including japan",
    "label": "SUPPORTED",
    "evidences": [
      "(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.",
      "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.",
      "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.",
      "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue, as a response to worldwide challenges related to the outbreak of COVID-19. This implies that the U.S. is taking measures to suspend visa services, including in Japan, which aligns with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001041",
    "statement": "U.s. to provide visa services in virus-hit countries including japan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.",
      "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.",
      "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.",
      "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the US Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments. This implies that the US is providing visa services, albeit temporarily suspending them due to the COVID-19 pandemic. The countries mentioned, Japan and South Korea, are experiencing higher levels of travel advisories (Level 2 and Level 3 respectively), which necessitates increased caution or reconsideration of travel. This does not necessarily mean that visa services will be completely unavailable in those countries during the pandemic.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001042",
    "statement": "U.s. to include visa services in virus-hit countries including japan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.",
      "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.",
      "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.",
      "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly state or imply that the U.S. will include visa services in virus-hit countries including Japan. The text mentions the suspension of routine nonimmigrant visa appointments for the US Embassy in Tokyo and all consulates in Japan due to COVID-19, but it does not provide any information about expanding visa services to these or other countries.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-001043",
    "statement": "U.s. to create visa services in virus-hit countries including japan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.",
      "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.",
      "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.",
      "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates a suspension of routine nonimmigrant visa appointments and continued services for U.S. citizens at the U.S. Embassy in Tokyo, as well as suspensions in all consulates in Japan. However, it does not support the creation of new visa services in virus-hit countries like Japan.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-001044",
    "statement": "Chloroquine inhibits hmgb1 inflammatory signaling and protects mice from lethal sepsis",
    "label": "SUPPORTED",
    "evidences": [
      "Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal Figure 3.",
      "Here, we show that chloroquine, an anti-malarial drug, prevents lethality in mice with established endotoxemia or sepsis.",
      "The protective effects of chloroquine were mediated through inhibition of HMGB1 release in macrophages, monocytes, and endothelial cells, thereby preventing its cytokine-like activities.",
      "Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal ligation and puncture technique was used to induce intraabdominal sepsis in mice (n = 20 per group)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that chloroquine protects mice from lethal sepsis and inhibits HMGB1 release, as indicated by experiments using the cecal ligation and puncture technique. The paper also explains how this protection is mediated through inhibition of HMGB1 release in certain cell types.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001045",
    "statement": "Chloroquine inhibits hmgb1 inflammatory signaling and protects humans from lethal sepsis",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal Figure 3.",
      "Here, we show that chloroquine, an anti-malarial drug, prevents lethality in mice with established endotoxemia or sepsis.",
      "The protective effects of chloroquine were mediated through inhibition of HMGB1 release in macrophages, monocytes, and endothelial cells, thereby preventing its cytokine-like activities.",
      "Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal ligation and puncture technique was used to induce intraabdominal sepsis in mice (n = 20 per group)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that chloroquine protects mice against lethal sepsis and inhibits HMGB1 release in macrophages, monocytes, and endothelial cells. The experiment was conducted on mice (n=20 per group) using the cecal ligation and puncture technique to induce sepsis. Therefore, it supports the claim that chloroquine inhibits hmgb1 inflammatory signaling and protects humans from lethal sepsis.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001046",
    "statement": "Significant expression of furin and ace2 on oral epithelial cells may facilitate the efficiency of 2019-ncov entry",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.",
      "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.",
      "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.",
      "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the authors speculated on the possible routes for 2019-nCoV to invade oral mucosal cells, suggesting binding to ACE2 receptors and fusion with cell membranes activated by FURIN protease. Additionally, the results showed differential expression of both ACE2 and FURIN on oral epithelial cells. The S-glycoprotein, which is a key factor for 2019-nCoV entry into the cell, contains an ACE2 receptor binding domain and a domain necessary for fusion with the cell membrane.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001047",
    "statement": "Significant expression of furin and ace2 on oral epithelial cells may reduce the efficiency of 2019-ncov entry",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.",
      "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.",
      "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.",
      "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the S-glycoprotein of 2019-nCoV binds to the ACE2 receptor and requires fusion with cell membranes activated by FURIN protease for entry into cells. The bioinformatics results indicate differential expression of ACE2 and FURIN on oral epithelial cells, with a higher proportion of FURIN-positive cells. This implies that the presence of significant expression of furin and ace2 on oral epithelial cells may potentially reduce the efficiency of 2019-nCoV entry by providing more targets for viral binding and fusion.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-001048",
    "statement": "Significant expression of furin and ace2 on oral epithelial cells may decrease the efficiency of 2019-ncov entry",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.",
      "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.",
      "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.",
      "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that there is differential expression of ACE2 and FURIN on oral epithelial cells. Additionally, the S-glycoprotein of 2019-nCov, which is responsible for cell entry, contains a domain that binds to ACE2 receptors and another necessary for fusion with cell membranes activated by FURIN protease. These findings support the claim that significant expression of furin and ace2 on oral epithelial cells may decrease the efficiency of 2019-ncov entry.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001049",
    "statement": "Significant expression of furin and ace2 on oral epithelial cells may limit the efficiency of 2019-ncov entry",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.",
      "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.",
      "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.",
      "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that 2019-nCov can effectively invade oral mucosal cells through two routes: binding to the ACE2 receptor and fusion with cell membranes activated by FURIN protease. The results also showed differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues, with a higher proportion of FURIN-positive cells than ACE2-positive cells. Significant expression of both furin and ace2 on oral epithelial cells suggests that this may limit the efficiency of 2019-nCov entry.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-001050",
    "statement": "High expression of angiotensin-converting enzyme-2 on tissue macrophages that may be targeted by virus sars-cov-2 in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Consequently, this broad expression of ACE2 associated with TMPRSS2 and FURIN may explain the high pathogenic potential of SARS-CoV-2 described in some COVID-19 patients with severe multi-organ dysfunction.",
      "Share High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients Xiang Song, Wei Hu, Haibo Yu, Laura Zhao, Yeqian Zhao, Yong Zhao bioRxiv 2020.07.18.210120; doi: https://doi.org/10.1101/2020.07.18.210120 Share This Article: Copy Citation Tools High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients Xiang Song, Wei Hu, Haibo Yu, Laura Zhao, Yeqian Zhao, Yong Zhao bioRxiv 2020.07.18.210120; doi: https://doi.org/10.1101/2020.07.18.210120 ",
      "These data indicate that alveolar macrophages, as the frontline immune cells, may be directly targeted by the SARS-CoV-2 infection and therefore need to be considered for the prevention and treatment of COVID-19.",
      "To better understand the pathogenesis of COVID-19 and build up the host anti-viral immunity, we examined the levels of ACE2 expression on different types of immune cells including tissue macrophages.",
      "Wong, S. K., Li, W., Moore, M. J., Choe, H. & Farzan, M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin- converting enzyme 2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that there is a high expression of ACE2 on tissue macrophages which may be targeted by the SARS-CoV-2 virus in COVID-19 patients. The article 'High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients' presents data suggesting this, stating that alveolar macrophages, as the frontline immune cells, may be directly targeted by the SARS-CoV-2 infection. The article also mentions an earlier study ('193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin- converting enzyme 2') that supports this claim by showing that a fragment of the SARS-CoV-2 virus S protein efficiently binds ACE2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001051",
    "statement": "High expression of angiotensin-converting enzyme-2 on tissue macrophages that cannot be targeted by virus sars-cov-2 in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Consequently, this broad expression of ACE2 associated with TMPRSS2 and FURIN may explain the high pathogenic potential of SARS-CoV-2 described in some COVID-19 patients with severe multi-organ dysfunction.",
      "Share High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients Xiang Song, Wei Hu, Haibo Yu, Laura Zhao, Yeqian Zhao, Yong Zhao bioRxiv 2020.07.18.210120; doi: https://doi.org/10.1101/2020.07.18.210120 Share This Article: Copy Citation Tools High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients Xiang Song, Wei Hu, Haibo Yu, Laura Zhao, Yeqian Zhao, Yong Zhao bioRxiv 2020.07.18.210120; doi: https://doi.org/10.1101/2020.07.18.210120 ",
      "These data indicate that alveolar macrophages, as the frontline immune cells, may be directly targeted by the SARS-CoV-2 infection and therefore need to be considered for the prevention and treatment of COVID-19.",
      "To better understand the pathogenesis of COVID-19 and build up the host anti-viral immunity, we examined the levels of ACE2 expression on different types of immune cells including tissue macrophages.",
      "Wong, S. K., Li, W., Moore, M. J., Choe, H. & Farzan, M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin- converting enzyme 2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that high expression of ACE2 on tissue macrophages in COVID-19 patients may be targeted by virus SARS-CoV-2. The evidence provided indicates that the study (Xiang Song et al., 2020) examines the levels of ACE2 expression on different types of immune cells, including tissue macrophages, to understand the pathogenesis of COVID-19. Additionally, a separate source confirms that SARS coronavirus S protein binds to angiotensin-converting enzyme 2 (Wong et al., 2004), which is ACE2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001052",
    "statement": "Study adds to evidence that odor-sensing cells in the nose are the key entry point for sars cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "A study adds to evidence that it could be through odor-sensing cells in the nose.",
      "Because the cells lining the nose may prove to be a key entry point for SARS- CoV-2, Lane says there may be ways to target those particular cells with topical antiviral drugs or other therapies directly to that area."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions a study that adds to the hypothesis that odor-sensing cells in the nose could be a key entry point for SARS-CoV-2. The quote from Lane also supports this idea by suggesting possible ways to target those cells directly with antiviral drugs or therapies.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001053",
    "statement": "Study contrast to evidence that odor-sensing cells in the nose are the key entry point for sars cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A study adds to evidence that it could be through odor-sensing cells in the nose.",
      "Because the cells lining the nose may prove to be a key entry point for SARS- CoV-2, Lane says there may be ways to target those particular cells with topical antiviral drugs or other therapies directly to that area."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions a study that suggests odor-sensing cells in the nose could be a key entry point for SARS-CoV-2. The quote from the study directly supports this claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001054",
    "statement": "Mcconnell declares war on blue states , dismisses more covid-19 aid",
    "label": "SUPPORTED",
    "evidences": [
      "Rather than the big rescue fund for states and local governments that even Trump has acknowledged is necessary, McConnell says the states should just go bankrupt.",
      "Well, here's a hearty fuck you, McConnell, from all the blue states that have been paying Kentucky's goddamned bills."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests Mitch McConnell declared war on 'blue states' and dismissed more COVID-19 aid. The evidence provided shows that McConnell expressed a view that states should consider bankruptcy instead of receiving a big rescue fund, but it does not provide concrete evidence of him declaring war or explicitly dismissing COVID-19 aid.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001055",
    "statement": "Mcconnell declares war on blue states, enteres more covid-19 aid",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rather than the big rescue fund for states and local governments that even Trump has acknowledged is necessary, McConnell says the states should just go bankrupt.",
      "Well, here's a hearty fuck you, McConnell, from all the blue states that have been paying Kentucky's goddamned bills."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that McConnell declared war on blue states and entered more COVID-19 aid, but the provided evidence only discusses McConnell's stance on financial aid for states and local governments. No explicit declaration of war against blue states or any reference to COVID-19 aid is present in the given text.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-001056",
    "statement": "Mcconnell declares war on blue states, passes more covid-19 aid",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rather than the big rescue fund for states and local governments that even Trump has acknowledged is necessary, McConnell says the states should just go bankrupt.",
      "Well, here's a hearty fuck you, McConnell, from all the blue states that have been paying Kentucky's goddamned bills."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not support a claim that McConnell declared war on blue states or passed more COVID-19 aid. The evidence presents opinions and language that suggest frustration from an author over statements made by Mitch McConnell regarding state funding during the COVID-19 pandemic, but it does not provide any concrete actions or confirmations of such claims.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-001057",
    "statement": "Mcconnell declares war on blue states, mentes more covid-19 aid",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rather than the big rescue fund for states and local governments that even Trump has acknowledged is necessary, McConnell says the states should just go bankrupt.",
      "Well, here's a hearty fuck you, McConnell, from all the blue states that have been paying Kentucky's goddamned bills."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Senator Mitch McConnell declared war on 'blue states' and mentioned more COVID-19 aid. The provided evidence shows a statement by McConnell about providing funding to states and local governments but does not explicitly mention a declaration of war or further COVID-19 aid.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-001058",
    "statement": "A neutrophil activation signature predicts critical illness and mortality in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that a neutrophil activation signature present on the first day of hospitalization in patients with COVID-19 can predict critical illness and increased mortality as these patients later required transfer to intensive care units.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001059",
    "statement": "A neutrophil activation signature predicts mild illness and mortality in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the presence of neutrophil activation on the first day of hospitalization is associated with a higher likelihood of transfer to the intensive care unit and increased mortality in COVID-19 patients. This suggests that a neutrophil activation signature may serve as a predictor for mild illness progression to severe disease and mortality.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001060",
    "statement": "A neutrophil activation signature predicts respiratory illness and mortality in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that an increase in neutrophil activation on the first day of hospitalization for COVID-19 patients is associated with increased severity and mortality. While the evidence does not directly demonstrate causality, it indicates a significant correlation between the two.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001061",
    "statement": "A neutrophil activation signature immunes critical illness and mortality in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the presence of neutrophil activation on the first day of hospitalization is associated with a higher risk of requiring intensive care and increased mortality in COVID-19 patients. This could be interpreted as indicating that neutrophil activation may play a role in the immunopathology of critical illness and mortality in COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001062",
    "statement": "Candesartan could ameliorate the covid-19 cytokine storm",
    "label": "SUPPORTED",
    "evidences": [
      "Results: Hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were similarly upregulated by glutamate and normalized by Candesartan."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were normalized by Candesartan when affected by glutamate. This suggests a potential role for Candesartan in modulating the cytokine storm associated with COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001063",
    "statement": "Undesartan could ameliorate the covid-19 cytokine storm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results: Hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were similarly upregulated by glutamate and normalized by Candesartan."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were normalized by Candesartan, which is a drug known as Undesartan in some regions. Upregulation of genes can be indicative of an inflammatory response or 'cytokine storm', a key feature in severe COVID-19 cases. The normalization of these upregulated genes by Undesartan suggests that it could help ameliorate the cytokine storm associated with COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001064",
    "statement": "Exdesartan could ameliorate the covid-19 cytokine storm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results: Hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were similarly upregulated by glutamate and normalized by Candesartan."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were normalized by Candesartan (Exdesartan is a drug name commonly used for the angiotensin II receptor antagonist Candesartan). While this does not definitively prove that Exdesartan can ameliorate COVID-19 cytokine storm, it suggests that the drug may have an effect on gene expression patterns associated with COVID-19. Further studies would be needed to confirm its effectiveness in treating or preventing a cytokine storm specifically.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001065",
    "statement": "Redesartan could ameliorate the covid-19 cytokine storm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results: Hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were similarly upregulated by glutamate and normalized by Candesartan."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were normalized by Candesartan, a medication related to Redesartan. While the claim does not explicitly state that Redesartan can ameliorate the cytokine storm, the normalization of genes upregulated in COVID-19 transcriptomes is a potential mechanism for reducing the severity of the disease, including the cytokine storm.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001066",
    "statement": "Identifying silent covid-19 infections among children is critical for controlling the pandemic.",
    "label": "SUPPORTED",
    "evidences": [
      "Question What is the impact of a targeted strategy for identification of silent COVID-19 infections among children in the absence of their vaccination?",
      "The implications of silent transmission for the control of COVID-19 outbreaks.Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, Galvani AP.",
      "Conclusions and relevance: In the absence of vaccine availability for children, a targeted approach to rapid identification of silent COVID-19 infections in this age group can significantly mitigate disease burden.",
      "Key points: Question: What is the impact of a targeted strategy for identification of silent COVID-19 infections among children in the absence of their vaccination?",
      "Conclusions and Relevance In the absence of vaccine availability for children, a targeted approach to rapid identification of silent COVID-19 infections in this age group can significantly mitigate disease burden."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that identifying silent COVID-19 infections among children can help control the pandemic when they are not yet vaccinated, as a targeted approach can mitigate disease burden significantly.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001067",
    "statement": "Identifying silent covid-19 infections among adults is critical for controlling the pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Question What is the impact of a targeted strategy for identification of silent COVID-19 infections among children in the absence of their vaccination?",
      "The implications of silent transmission for the control of COVID-19 outbreaks.Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, Galvani AP.",
      "Conclusions and relevance: In the absence of vaccine availability for children, a targeted approach to rapid identification of silent COVID-19 infections in this age group can significantly mitigate disease burden.",
      "Key points: Question: What is the impact of a targeted strategy for identification of silent COVID-19 infections among children in the absence of their vaccination?",
      "Conclusions and Relevance In the absence of vaccine availability for children, a targeted approach to rapid identification of silent COVID-19 infections in this age group can significantly mitigate disease burden."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that identifying silent COVID-19 infections among children is crucial for controlling the pandemic, as it can mitigate disease burden in their absence of vaccination. The study also implies that a similar strategy could be critical for adults as well.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001068",
    "statement": "Politician raises alarm over trudeau govt 's plan to build covid quarantine/isolation camps",
    "label": "SUPPORTED",
    "evidences": [
      "Randy Hillier, Independent Ontario MPP for Lanark, Frontenac & Kingston, expressed concern over the \"Federal Quarantine/Isolation sites\" in the provincial question period late this week.",
      "\"The expansion of isolation/quarantine camps in Canada is something of concern and the Ontario government must know about it, so why won't they tell the people of Ontario?\"",
      "\"So your government must be in negotiations and aware of these plans to potentially detain and isolate citizens and residents of our country and our province, so speaker, to the Premier, where will these camps be built, how many people will be detained, and for what reason, for what reasons can people be kept in these isolation camps, and I'd like to have the Premier assure the people of Ontario,\" said Hillier, whose microphone was cut off before he could finish."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that a politician expressed concern over 'Federal Quarantine/Isolation sites', but it does not confirm the claim about the Trudeau government's plan to build COVID-19 quarantine/isolation camps. The evidence only indicates that there are concerns and questions raised, but it does not provide any substantiated information about a plan by the Trudeau government.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001069",
    "statement": "Politician raises support over trudeau govt's plan to build covid quarantine/isolation camps",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Randy Hillier, Independent Ontario MPP for Lanark, Frontenac & Kingston, expressed concern over the \"Federal Quarantine/Isolation sites\" in the provincial question period late this week.",
      "\"The expansion of isolation/quarantine camps in Canada is something of concern and the Ontario government must know about it, so why won't they tell the people of Ontario?\"",
      "\"So your government must be in negotiations and aware of these plans to potentially detain and isolate citizens and residents of our country and our province, so speaker, to the Premier, where will these camps be built, how many people will be detained, and for what reason, for what reasons can people be kept in these isolation camps, and I'd like to have the Premier assure the people of Ontario,\" said Hillier, whose microphone was cut off before he could finish."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a politician (Randy Hillier) has expressed concern over the 'Federal Quarantine/Isolation sites'. The context suggests that he is raising support against the Trudeau government's plan to build such camps for COVID-19 quarantine and isolation. Therefore, the claim is supported by the evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001070",
    "statement": "Cdc announces modifications and extension of no sail order for all cruise ships",
    "label": "SUPPORTED",
    "evidences": [
      "This order ceases operations of cruise ships in waters in which the United States may exert jurisdiction and requires that they develop a comprehensive, detailed operational plan approved by CDC and the USCG to address the COVID-19 pandemic through maritime focused solutions, including a fully implementable response plan with limited reliance on state, local, and federal government support.",
      "Cruise Lines International Association (CLIA) voluntarily suspended cruise ship operations in March in conjunction with the earlier No Sail Order issued March 14.",
      "The CDC, the U.S. Coast Guard, and the Department of Homeland Security have been working with the industry to determine the most appropriate public health strategy to limit the impact of COVID-19 at cruise ship ports of entry in the United States.",
      "The No Sail Order reinforces the strong action by President Donald J. Trump and the White House Coronavirus Task Force to combat the spread of COVID-19 in the United States."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the CDC has announced modifications and extension of a no sail order for all cruise ships operating in waters under US jurisdiction. The order requires the development of a comprehensive operational plan to address COVID-19, which suggests an ongoing or extended restriction on cruises. Furthermore, the CLIA's voluntary suspension of operations in March aligns with the initial no sail order issued by the CDC on March 14.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001071",
    "statement": "Cdc announces modifications and loss of no sail order for all cruise ships",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This order ceases operations of cruise ships in waters in which the United States may exert jurisdiction and requires that they develop a comprehensive, detailed operational plan approved by CDC and the USCG to address the COVID-19 pandemic through maritime focused solutions, including a fully implementable response plan with limited reliance on state, local, and federal government support.",
      "Cruise Lines International Association (CLIA) voluntarily suspended cruise ship operations in March in conjunction with the earlier No Sail Order issued March 14.",
      "The CDC, the U.S. Coast Guard, and the Department of Homeland Security have been working with the industry to determine the most appropriate public health strategy to limit the impact of COVID-19 at cruise ship ports of entry in the United States.",
      "The No Sail Order reinforces the strong action by President Donald J. Trump and the White House Coronavirus Task Force to combat the spread of COVID-19 in the United States."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence as it states that the CDC has announced modifications and loss of no sail order for all cruise ships. The evidence provides details about the operational plan required by CDC, the suspension of cruise ship operations by Cruise Lines International Association (CLIA), and mentions the work being done with the industry to determine an appropriate public health strategy. This clearly indicates that the no sail order is in place.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001072",
    "statement": "Cdc announces modifications and lack of no sail order for all cruise ships",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This order ceases operations of cruise ships in waters in which the United States may exert jurisdiction and requires that they develop a comprehensive, detailed operational plan approved by CDC and the USCG to address the COVID-19 pandemic through maritime focused solutions, including a fully implementable response plan with limited reliance on state, local, and federal government support.",
      "Cruise Lines International Association (CLIA) voluntarily suspended cruise ship operations in March in conjunction with the earlier No Sail Order issued March 14.",
      "The CDC, the U.S. Coast Guard, and the Department of Homeland Security have been working with the industry to determine the most appropriate public health strategy to limit the impact of COVID-19 at cruise ship ports of entry in the United States.",
      "The No Sail Order reinforces the strong action by President Donald J. Trump and the White House Coronavirus Task Force to combat the spread of COVID-19 in the United States."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the CDC has issued an order that ceases cruise ship operations within jurisdiction of the US and requires them to develop a comprehensive operational plan addressing COVID-19. Additionally, it is mentioned that the No Sail Order was voluntarily suspended by Cruise Lines International Association in March, indicating that there were no sail orders prior to this. Lastly, the evidence also mentions efforts between the CDC, US Coast Guard, and Department of Homeland Security to determine a public health strategy for cruise ships, which implies modifications in response to the pandemic.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001073",
    "statement": "Virological assessment of hospitalized patients with covid-2019",
    "label": "SUPPORTED",
    "evidences": [
      "For sputum samples, interpolation based on a probit model was done to obtain laboratory-based infectivity criteria for the discharge of patients (Fig.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that it is a 'virological assessment of hospitalized patients with covid-19.' The text mentions interpolation based on a probit model and laboratory-based infectivity criteria for patient discharge, but there is no information about the assessment of viruses or covid-19 specifically in hospitalized patients.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001074",
    "statement": "Virological assessment of hospitalized patients with covid-3",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For sputum samples, interpolation based on a probit model was done to obtain laboratory-based infectivity criteria for the discharge of patients (Fig.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim in question refers to the virological assessment of hospitalized patients with COVID-19. However, the provided evidence does not contain any explicit information regarding the assessment or test results of these patients. The given information mainly describes sources and definitions related to the coronavirus disease 2019 (COVID-19) and some entities such as MHRA, JCVI, PMC. Since no laboratory-based infectivity criteria for discharging COVID-19 patients are presented in this evidence, it is difficult to support or refute the claim.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001075",
    "statement": "Virological assessment of hospitalized patients with covid-1",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For sputum samples, interpolation based on a probit model was done to obtain laboratory-based infectivity criteria for the discharge of patients (Fig.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the use of probit models for interpolation in sputum samples to determine discharge criteria for hospitalized patients with COVID-19. However, it does not provide any information about the 'virological assessment' of these patients, which is the claim being evaluated.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001076",
    "statement": "Virological assessment of hospitalized patients with covid-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For sputum samples, interpolation based on a probit model was done to obtain laboratory-based infectivity criteria for the discharge of patients (Fig.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses the laboratory-based infectivity criteria for discharging patients with COVID-19 using sputum samples, but it does not contain any information about performing a virological assessment of hospitalized patients specifically with COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001077",
    "statement": "Afucosylated immunoglobulin g responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we report that afucosylated IgG which are of minor abundance in humans (6% of total IgG) are specifically formed against surface epitopes of enveloped viruses after natural infections or immunization with attenuated viruses, while protein subunit immunization does not elicit this low fucose response.",
      "In the case of COVID-19, the critically ill show aggravated afucosylated-IgG responses against the viral spike protein.",
      "Our findings indicate antibody glycosylation as a potential factor in inflammation and protection in enveloped virus infections including COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that afucosylated IgG responses are specifically formed against surface epitopes of enveloped viruses, including in the case of COVID-19. The critically ill patients show an aggravated response to these afucosylated-IgG against the viral spike protein of SARS-CoV-2. This supports the claim that afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001078",
    "statement": "Afucosylated immunoglobulin g responses are a hallmark of dengue virus infections and show an exacerbated phenotype in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report that afucosylated IgG which are of minor abundance in humans (6% of total IgG) are specifically formed against surface epitopes of enveloped viruses after natural infections or immunization with attenuated viruses, while protein subunit immunization does not elicit this low fucose response.",
      "In the case of COVID-19, the critically ill show aggravated afucosylated-IgG responses against the viral spike protein.",
      "Our findings indicate antibody glycosylation as a potential factor in inflammation and protection in enveloped virus infections including COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that afucosylated IgG responses are formed against surface epitopes of enveloped viruses during natural infections or immunization with attenuated viruses (according to the first sentence). Additionally, it is stated that critically ill COVID-19 patients show aggravated afucosylated-IgG responses against the viral spike protein (third paragraph). Therefore, the claim that afucosylated immunoglobulin g responses are a hallmark of dengue virus infections and show an exacerbated phenotype in covid-19 is supported by the provided evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001079",
    "statement": "Afucosylated immunoglobulin g responses are a hallmark of respiratory virus infections and show an exacerbated phenotype in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report that afucosylated IgG which are of minor abundance in humans (6% of total IgG) are specifically formed against surface epitopes of enveloped viruses after natural infections or immunization with attenuated viruses, while protein subunit immunization does not elicit this low fucose response.",
      "In the case of COVID-19, the critically ill show aggravated afucosylated-IgG responses against the viral spike protein.",
      "Our findings indicate antibody glycosylation as a potential factor in inflammation and protection in enveloped virus infections including COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that afucosylated IgG responses are specifically formed against surface epitopes of enveloped viruses after natural infections or immunization with attenuated viruses. The evidence also indicates that critically ill COVID-19 patients show aggravated afucosylated-IgG responses against the viral spike protein. Since SARS-CoV-2 is an enveloped virus, this supports the claim that afucosylated immunoglobulin g responses are a hallmark of respiratory virus infections and show an exacerbated phenotype in COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001080",
    "statement": "Covid-19 pandemic could end if 70 % of people wore masks consistently",
    "label": "SUPPORTED",
    "evidences": [
      "\"Even less efficient cloth masks could also slow the spread if worn consistently,\" Kumar added.",
      "The performance of face masks worn for many hours, such as by health care or other essential workers, impact how effective overall mask wearing can be, the researchers added.",
      "Singapore : The COVID-19 pandemic could end if at least 70% of the people wore face masks in public consistently, according to a review of studies which suggests that the type of material used and the duration of mask use play key roles in their effectiveness.",
      "According to the scientists, one key aspect of face mask function involves the size of fluid droplets expelled from the nose and mouth when a person talks, sings, sneezes, coughs, or even simply breathes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that Covid-19 pandemic could end if 70 % of people wore masks consistently. The evidence indicates that even less efficient cloth masks, when worn consistently, can slow the spread of the virus. Additionally, a study suggests that at least 70% of the people wearing masks in public could help control the pandemic. However, it's important to note that while mask-wearing is an effective measure for reducing transmission, ending the pandemic would also depend on other factors such as vaccination rates and adherence to social distancing guidelines.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001081",
    "statement": "Covid-19 pandemic could increase if 70 % of people wore masks consistently",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Even less efficient cloth masks could also slow the spread if worn consistently,\" Kumar added.",
      "The performance of face masks worn for many hours, such as by health care or other essential workers, impact how effective overall mask wearing can be, the researchers added.",
      "Singapore : The COVID-19 pandemic could end if at least 70% of the people wore face masks in public consistently, according to a review of studies which suggests that the type of material used and the duration of mask use play key roles in their effectiveness.",
      "According to the scientists, one key aspect of face mask function involves the size of fluid droplets expelled from the nose and mouth when a person talks, sings, sneezes, coughs, or even simply breathes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that wearing masks consistently can slow the spread of Covid-19 (as stated by Kumar). Moreover, another study indicates that at least 70% of people wearing masks in public could potentially end the pandemic (from Singapore findings). These pieces of evidence support the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001082",
    "statement": "Covid-19 pandemic could continue if 70 % of people wore masks consistently",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Even less efficient cloth masks could also slow the spread if worn consistently,\" Kumar added.",
      "The performance of face masks worn for many hours, such as by health care or other essential workers, impact how effective overall mask wearing can be, the researchers added.",
      "Singapore : The COVID-19 pandemic could end if at least 70% of the people wore face masks in public consistently, according to a review of studies which suggests that the type of material used and the duration of mask use play key roles in their effectiveness.",
      "According to the scientists, one key aspect of face mask function involves the size of fluid droplets expelled from the nose and mouth when a person talks, sings, sneezes, coughs, or even simply breathes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that Covid-19 pandemic could continue if 70 % of people wear masks consistently. The provided text states 'Singapore : The COVID-19 pandemic could end if at least 70% of the people wore face masks in public consistently' and also mentions studies suggesting that mask wearing plays a role in slowing the spread of Covid-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001083",
    "statement": "A front-runner vaccine shows promise in older people",
    "label": "SUPPORTED",
    "evidences": [
      "The robust antibody and T-cell responses seen in older people in our study are encouraging, said Maheshi Ramasamy, a consultant and co-lead investigator at the Oxford Vaccine Group."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a statement by Maheshi Ramasamy, a consultant and co-lead investigator at the Oxford Vaccine Group, indicating that robust antibody and T-cell responses are seen in older people for their study. This suggests that the vaccine being tested is showing promise when it comes to eliciting an immune response in this age group.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001084",
    "statement": "A front-runner vaccine shows promise in young people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The robust antibody and T-cell responses seen in older people in our study are encouraging, said Maheshi Ramasamy, a consultant and co-lead investigator at the Oxford Vaccine Group."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state that the vaccine shows promise in young people. Instead, it indicates encouraging responses in older people during a study. Without more information suggesting the same response in young people, we cannot confirm the claim.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001085",
    "statement": "Mexican doctor taken to icu after experiencing serious reaction to pfizer vaccine.",
    "label": "SUPPORTED",
    "evidences": [
      "A female doctor in Mexico was hospitalized after she received the Pfizer- BioNTech COVID-19 vaccine.",
      "REUTERS/Daniel Becerril MEXICO CITY (Reuters) - Mexican authorities said they are studying the case of a 32-year-old female doctor who was hospitalized after receiving the Pfizer- BioNTech COVID-19 vaccine.",
      "Mexican doctor hospitalized after receiving COVID-19 vaccine Wikimedia commons Acute Disseminated Encephalomyelitis ADEM is a rare kind of inflammation that affects the brain and the spinal cord.",
      "A 32-year-old female doctor in Mexico was hospitalized after receiving the Pfizer-BioNTech COVID-19 vaccine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a Mexican female doctor was hospitalized after receiving the Pfizer-BioNTech COVID-19 vaccine, but it does not specify whether her hospitalization was due to a serious reaction to the vaccine or other reasons. However, Acute Disseminated Encephalomyelitis (ADEM) is listed as an example of a rare kind of inflammation that affects the brain and spinal cord and can potentially occur after vaccination in some cases. Since we cannot confirm for certain that her hospitalization was due to a serious reaction to the Pfizer vaccine, the confidence level is reduced.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001086",
    "statement": "Mexican doctor taken to icu after no serious reaction to pfizer vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A female doctor in Mexico was hospitalized after she received the Pfizer- BioNTech COVID-19 vaccine.",
      "REUTERS/Daniel Becerril MEXICO CITY (Reuters) - Mexican authorities said they are studying the case of a 32-year-old female doctor who was hospitalized after receiving the Pfizer- BioNTech COVID-19 vaccine.",
      "Mexican doctor hospitalized after receiving COVID-19 vaccine Wikimedia commons Acute Disseminated Encephalomyelitis ADEM is a rare kind of inflammation that affects the brain and the spinal cord.",
      "A 32-year-old female doctor in Mexico was hospitalized after receiving the Pfizer-BioNTech COVID-19 vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that a 32-year-old female doctor in Mexico was hospitalized after receiving the Pfizer-BioNTech COVID-19 vaccine. However, it does not specify whether this reaction was 'no serious' or if there were any underlying medical conditions contributing to her hospitalization. Additionally, ADEM (Acute Disseminated Encephalomyelitis) is mentioned but there's no information about whether it was diagnosed in this case.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-001087",
    "statement": "The coronavirus is most deadly if you are older and male",
    "label": "SUPPORTED",
    "evidences": [
      "The results also revealed that men are more likely to die of the infection than are women  the gap increasing with age.",
      "Gender is also a strong risk factor, with men almost twice more likely to die from the coronavirus than women.",
      "2 The immune system might also explain the much higher risk of older people dying from the virus.",
      "Trends in coronavirus deaths by age have been clear since early in the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that men are more likely to die from COVID-19 than women and the risk increases with age. It also mentions that trends in coronavirus deaths by age have been clear since early in the pandemic.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001088",
    "statement": "The coronavirus is not deadly if you are older and male",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results also revealed that men are more likely to die of the infection than are women  the gap increasing with age.",
      "Gender is also a strong risk factor, with men almost twice more likely to die from the coronavirus than women.",
      "2 The immune system might also explain the much higher risk of older people dying from the virus.",
      "Trends in coronavirus deaths by age have been clear since early in the pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence shows that men are more likely to die from COVID-19 and the risk increases with age, it does not support the claim that the coronavirus is not deadly if you are older and male.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001089",
    "statement": "The coronavirus is less deadly if you are older and male",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results also revealed that men are more likely to die of the infection than are women  the gap increasing with age.",
      "Gender is also a strong risk factor, with men almost twice more likely to die from the coronavirus than women.",
      "2 The immune system might also explain the much higher risk of older people dying from the virus.",
      "Trends in coronavirus deaths by age have been clear since early in the pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that men are more likely to die from COVID-19 than women and that older people are at a higher risk. However, it does not explicitly state or imply that the coronavirus is less deadly if you are older and male.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-001090",
    "statement": "The coronavirus is most contagious if you are older and male",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results also revealed that men are more likely to die of the infection than are women  the gap increasing with age.",
      "Gender is also a strong risk factor, with men almost twice more likely to die from the coronavirus than women.",
      "2 The immune system might also explain the much higher risk of older people dying from the virus.",
      "Trends in coronavirus deaths by age have been clear since early in the pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that men are more likely to die from COVID-19 and older people are at higher risk of severe illness and death. However, it does not directly support the claim that the coronavirus is most contagious if you are older and male.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-001091",
    "statement": "Risk of covid-19 hospitalisation rises exponentially with age , inversely proportional to t-cell production",
    "label": "SUPPORTED",
    "evidences": [
      "This mirrors the well studied exponential decline of both thymus volume and T-cell production, which halve every 16 years.",
      "The strikingly simple inverse relationship between COVID-19 risk and thymic T-cell output reported here begs a mechanistic understanding and suggests that T-cell based therapies may be a promising target.",
      "In addition, incidence of severe disease and mortality due to COVID-19 are both higher in men, consistent with the degree to which thymic involution (and the decrease in T-cell production with age) is more severe in men compared to women."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that both COVID-19 risk and thymic T-cell output show an inverse relationship: the higher the age, the lower the T-cell production, which can lead to increased COVID-19 hospitalization risk. The evidence also suggests that this inverse relationship is more pronounced in men compared to women.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001092",
    "statement": "Risk of covid-19 hospitalisation decreased exponentially with age, inversely proportional to t-cell production",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This mirrors the well studied exponential decline of both thymus volume and T-cell production, which halve every 16 years.",
      "The strikingly simple inverse relationship between COVID-19 risk and thymic T-cell output reported here begs a mechanistic understanding and suggests that T-cell based therapies may be a promising target.",
      "In addition, incidence of severe disease and mortality due to COVID-19 are both higher in men, consistent with the degree to which thymic involution (and the decrease in T-cell production with age) is more severe in men compared to women."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the risk of COVID-19 hospitalization decreases exponentially with age and is inversely proportional to t-cell production. The provided evidence supports this by pointing out the exponential decline of both thymus volume and T-cell production over time, which halve every 16 years. Additionally, it mentions that severe disease and mortality due to COVID-19 are higher in men, consistent with the degree to which thymic involution (and the decrease in T-cell production with age) is more severe in men compared to women.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001093",
    "statement": "Risk of covid-19 hospitalisation decreases exponentially with age, inversely proportional to t-cell production",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This mirrors the well studied exponential decline of both thymus volume and T-cell production, which halve every 16 years.",
      "The strikingly simple inverse relationship between COVID-19 risk and thymic T-cell output reported here begs a mechanistic understanding and suggests that T-cell based therapies may be a promising target.",
      "In addition, incidence of severe disease and mortality due to COVID-19 are both higher in men, consistent with the degree to which thymic involution (and the decrease in T-cell production with age) is more severe in men compared to women."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that the risk of COVID-19 hospitalization decreases exponentially with age and is inversely proportional to t-cell production. The evidence supports this, as it mentions that both thymus volume and T-cell production halve every 16 years (a close approximation to exponential decrease) and also points out that the incidence of severe disease and mortality due to COVID-19 is higher in men, which aligns with a greater degree of thymic involution (and t-cell production decline) in males compared to females.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-001094",
    "statement": "Risk of covid-19 hospitalisation rises exponentially with death, inversely proportional to t-cell production",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This mirrors the well studied exponential decline of both thymus volume and T-cell production, which halve every 16 years.",
      "The strikingly simple inverse relationship between COVID-19 risk and thymic T-cell output reported here begs a mechanistic understanding and suggests that T-cell based therapies may be a promising target.",
      "In addition, incidence of severe disease and mortality due to COVID-19 are both higher in men, consistent with the degree to which thymic involution (and the decrease in T-cell production with age) is more severe in men compared to women."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a strong inverse relationship between the risk of COVID-19 hospitalization and T-cell production, as indicated by the exponential decline of both thymus volume and T-cell production over time. The evidence also points to men having a higher incidence of severe disease and mortality due to COVID-19, which aligns with the more severe thymic involution (and decrease in T-cell production with age) observed in men compared to women.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001095",
    "statement": "Experimental covid-19 vaccine protects upper and lower airways in nonhuman primates",
    "label": "SUPPORTED",
    "evidences": [
      "Moreover, none of the eight macaques vaccinated with 100 µg of mRNA-1273 had detectable virus in their noses two days after virus exposure.",
      "This is the first time an experimental COVID-19 vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that none of the eight macaques vaccinated with mRNA-1273 had detectable virus in their noses two days after virus exposure, indicating rapid viral control in the upper airway (nose). This suggests the experimental COVID-19 vaccine protects the upper airways in nonhuman primates.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001096",
    "statement": "Experimental covid-19 vaccine infects upper and lower airways in nonhuman primates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Moreover, none of the eight macaques vaccinated with 100 µg of mRNA-1273 had detectable virus in their noses two days after virus exposure.",
      "This is the first time an experimental COVID-19 vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that the experimental COVID-19 vaccine tested on nonhuman primates does not produce detectable virus in their noses two days after exposure. However, this information alone does not conclusively prove whether the vaccine infects upper and lower airways or not, as it only refers to the upper airway (nose). Additional evidence would be needed to confirm whether the vaccine affects the lower airways.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001097",
    "statement": "Covid-19 map was found to be malware",
    "label": "SUPPORTED",
    "evidences": [
      "Early COVID-19 related malicious email Now there are ongoing business email compromise (BEC) scams that use the disease as a hook.",
      "The emails had attachments that contain malware, which executes a PowerShell command that will download a file from a URL related to COVID-19.",
      "The URL is hxxps://recoverrryasitalycovid-19.xyz/over Upon further investigation, it was found that the malware used Evil Clippy, a tool for creating malicious MS Office Documents, to hide its macro.",
      "COVID-19 being used for extortion",
      "It contained recommendations on how to prevent infection and came with an attachment that supposedly contains the latest updates on COVID-19 but actually carried malware."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that emails related to COVID-19 have been used as a hook for business email compromise (BEC) scams which contain malware. The malicious file downloaded from the URL 'recoverrryasitalycovid-19.xyz/over' was found to use Evil Clippy, a tool for creating malicious MS Office Documents, to hide its macro. Therefore, it can be concluded that some COVID-19 related files or maps might have been malware.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001098",
    "statement": "Covid-19 map was found to be stableware",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Early COVID-19 related malicious email Now there are ongoing business email compromise (BEC) scams that use the disease as a hook.",
      "The emails had attachments that contain malware, which executes a PowerShell command that will download a file from a URL related to COVID-19.",
      "The URL is hxxps://recoverrryasitalycovid-19.xyz/over Upon further investigation, it was found that the malware used Evil Clippy, a tool for creating malicious MS Office Documents, to hide its macro.",
      "COVID-19 being used for extortion",
      "It contained recommendations on how to prevent infection and came with an attachment that supposedly contains the latest updates on COVID-19 but actually carried malware."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided in this case shows that there are malicious files and URLs related to COVID-19 being used for extortion, but it does not provide any indication that the COVID-19 map was found to be software called stableware.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001099",
    "statement": "Covid-19 map was found to be positiveware",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Early COVID-19 related malicious email Now there are ongoing business email compromise (BEC) scams that use the disease as a hook.",
      "The emails had attachments that contain malware, which executes a PowerShell command that will download a file from a URL related to COVID-19.",
      "The URL is hxxps://recoverrryasitalycovid-19.xyz/over Upon further investigation, it was found that the malware used Evil Clippy, a tool for creating malicious MS Office Documents, to hide its macro.",
      "COVID-19 being used for extortion",
      "It contained recommendations on how to prevent infection and came with an attachment that supposedly contains the latest updates on COVID-19 but actually carried malware."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that emails related to COVID-19 have been found containing malware and malicious links. While the claim does not explicitly mention 'Covid-19 map', it does reference URLs related to COVID-19 (hxxps://recoverrryasitalycovid-19.xyz/over), which could be interpreted as including maps of some sort, and the malicious content itself is disguised as containing updates on COVID-19. This supports the claim that a Covid-19 map was found to be positiveware.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001100",
    "statement": "Covid-19 map was found to be similarware",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Early COVID-19 related malicious email Now there are ongoing business email compromise (BEC) scams that use the disease as a hook.",
      "The emails had attachments that contain malware, which executes a PowerShell command that will download a file from a URL related to COVID-19.",
      "The URL is hxxps://recoverrryasitalycovid-19.xyz/over Upon further investigation, it was found that the malware used Evil Clippy, a tool for creating malicious MS Office Documents, to hide its macro.",
      "COVID-19 being used for extortion",
      "It contained recommendations on how to prevent infection and came with an attachment that supposedly contains the latest updates on COVID-19 but actually carried malware."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows the existence of a malicious email campaign using COVID-19 as a lure to deliver malware. However, it does not provide any information about a 'Covid-19 map' being similar or otherwise related.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001101",
    "statement": "Researchers identify multiple molecules that shut down sars-cov-2 polymerase reaction",
    "label": "SUPPORTED",
    "evidences": [
      "They then demonstrated that sofosbuvir and four other nucleotide analogues (the active triphosphate forms of the HIV inhibitors Alovudine, Zidovudine, Tenofovir alafenamide, and Emtricitabine) also inhibited the SARS-CoV-2 polymerase with different levels of efficiency.",
      "While all 11 molecules tested displayed incorporation, six exhibited immediate termination of the polymerase reaction, two showed delayed termination, and three did not terminate the polymerase reaction.",
      "In an earlier set of experiments testing the properties of the polymerase of the coronavirus that causes SARS, the researchers found that the triphosphate of sofosbuvir was able to terminate the virus polymerase reaction.",
      "Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction, a key step that establishes the potential of these molecules as lead compounds to be further modified for the development of COVID-19 therapeutics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that researchers have identified multiple molecules (including sofosbuvir) that inhibit the SARS-CoV-2 polymerase reaction, which is a key step in viral replication. The molecules are referred to as potential lead compounds for developing COVID-19 therapeutics.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001102",
    "statement": "Researchers identify multiple genes that shut down sars-cov-2 polymerase reaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "They then demonstrated that sofosbuvir and four other nucleotide analogues (the active triphosphate forms of the HIV inhibitors Alovudine, Zidovudine, Tenofovir alafenamide, and Emtricitabine) also inhibited the SARS-CoV-2 polymerase with different levels of efficiency.",
      "While all 11 molecules tested displayed incorporation, six exhibited immediate termination of the polymerase reaction, two showed delayed termination, and three did not terminate the polymerase reaction.",
      "In an earlier set of experiments testing the properties of the polymerase of the coronavirus that causes SARS, the researchers found that the triphosphate of sofosbuvir was able to terminate the virus polymerase reaction.",
      "Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction, a key step that establishes the potential of these molecules as lead compounds to be further modified for the development of COVID-19 therapeutics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that researchers have identified multiple genes that shut down sars-cov-2 polymerase reaction and have tested various molecules to evaluate their effectiveness in inhibiting the polymerase reaction. The fact that several molecules displayed immediate or delayed termination of the polymerase reaction supports the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-001103",
    "statement": "Researchers identify multiple sites that shut down sars-cov-2 polymerase reaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "They then demonstrated that sofosbuvir and four other nucleotide analogues (the active triphosphate forms of the HIV inhibitors Alovudine, Zidovudine, Tenofovir alafenamide, and Emtricitabine) also inhibited the SARS-CoV-2 polymerase with different levels of efficiency.",
      "While all 11 molecules tested displayed incorporation, six exhibited immediate termination of the polymerase reaction, two showed delayed termination, and three did not terminate the polymerase reaction.",
      "In an earlier set of experiments testing the properties of the polymerase of the coronavirus that causes SARS, the researchers found that the triphosphate of sofosbuvir was able to terminate the virus polymerase reaction.",
      "Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction, a key step that establishes the potential of these molecules as lead compounds to be further modified for the development of COVID-19 therapeutics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided demonstrates that a library of molecules was identified by researchers, which shut down the SARS-CoV-2 polymerase reaction. This is consistent with the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001104",
    "statement": "Remdesivir but not famotidine inhibits sars-cov-2 replication in human pluripotent stem cell-derived intestinal organoids",
    "label": "SUPPORTED",
    "evidences": [
      "Remdesivir, a promising drug to treat COVID-19, effectively suppressed SARS-CoV-2 infection of PSC-HIOs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the provided evidence. The evidence states that Remdesivir effectively suppresses SARS-CoV-2 infection in PSC-HIOs (human pluripotent stem cell-derived intestinal organoids), which suggests it inhibits sars-cov-2 replication in these organoids. Famotidine is not mentioned as having the same effect, indicating that it does not inhibit sars-cov-2 replication.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001105",
    "statement": "Remdesivir but also famotidine inhibits sars-cov-2 replication in human pluripotent stem cell-derived intestinal organoids",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir, a promising drug to treat COVID-19, effectively suppressed SARS-CoV-2 infection of PSC-HIOs."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only states that Remdesivir effectively suppressed SARS-CoV-2 infection in human pluripotent stem cell-derived intestinal organoids (PSC-HIOs). It does not mention famotidine and its effect on SARS-CoV-2 replication.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-001106",
    "statement": "Remdesivir but only famotidine inhibits sars-cov-2 replication in human pluripotent stem cell-derived intestinal organoids",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir, a promising drug to treat COVID-19, effectively suppressed SARS-CoV-2 infection of PSC-HIOs."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that Remdesivir effectively suppresses SARS-CoV-2 infection in human pluripotent stem cell-derived intestinal organoids (PSC-HIOs). However, it does not provide any information about the effect of Famotidine on SARS-CoV-2 replication in these organoids.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001107",
    "statement": "Remdesivir but its famotidine inhibits sars-cov-2 replication in human pluripotent stem cell-derived intestinal organoids",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir, a promising drug to treat COVID-19, effectively suppressed SARS-CoV-2 infection of PSC-HIOs."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that Remdesivir is effective in suppressing SARS-CoV-2 infection of PSC-HIOs (human pluripotent stem cell-derived intestinal organoids). However, it does not mention famotidine or provide any information about its ability to inhibit sars-cov-2 replication.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001108",
    "statement": "Two x-linked agammaglobulinemia patients develop pneumonia as covid-19 manifestation but recover",
    "label": "SUPPORTED",
    "evidences": [
      "Therefore, we evaluated the outcome of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI) such as X-linked agammaglobulinemia (XLA).",
      "Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection.",
      "Results: We describe two patients with X-linked agammaglobulinemia (XLA) aged 34 and 26 years with complete absence of B cells from peripheral blood who developed COVID-19, as diagnosed by SARS-CoV-2 detection by nasopharyngeal swab, while receiving immunoglobulin infusions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Two x-linked agammaglobulinemia patients develop pneumonia as covid-19 manifestation but recover' is supported by the evidence provided. The text states that two XLA patients developed COVID-19 (as diagnosed by SARS-CoV-2 detection) and recovered, though it does not explicitly mention pneumonia as a complication for both patients.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-001109",
    "statement": "5 x-linked agammaglobulinemia patients develop pneumonia as covid-19 manifestation but recover",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, we evaluated the outcome of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI) such as X-linked agammaglobulinemia (XLA).",
      "Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection.",
      "Results: We describe two patients with X-linked agammaglobulinemia (XLA) aged 34 and 26 years with complete absence of B cells from peripheral blood who developed COVID-19, as diagnosed by SARS-CoV-2 detection by nasopharyngeal swab, while receiving immunoglobulin infusions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides information about two patients with X-linked agammaglobulinemia (XLA) who developed COVID-19, as diagnosed by SARS-CoV-2 detection. The absence of B cells in their peripheral blood suggests that these patients are unable to produce antibodies effectively against the virus, which increases the risk of complications such as pneumonia. However, no recovery data was provided for all 5 XLA patients. Therefore, we can only confirm that at least two patients developed COVID-19 and experienced it as a manifestation.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001110",
    "statement": "4 x-linked agammaglobulinemia patients develop pneumonia as covid-19 manifestation but recover",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, we evaluated the outcome of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI) such as X-linked agammaglobulinemia (XLA).",
      "Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection.",
      "Results: We describe two patients with X-linked agammaglobulinemia (XLA) aged 34 and 26 years with complete absence of B cells from peripheral blood who developed COVID-19, as diagnosed by SARS-CoV-2 detection by nasopharyngeal swab, while receiving immunoglobulin infusions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that two patients with X-linked agammaglobulinemia (XLA) developed COVID-19 as a manifestation of SARS-CoV-2 infection. Therefore, it is supported that 4 x-linked agammaglobulinemia patients may develop pneumonia as a covid-19 manifestation, given the presence of two documented cases in this study.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001111",
    "statement": "1 x-linked agammaglobulinemia patients develop pneumonia as covid-19 manifestation but recover",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, we evaluated the outcome of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI) such as X-linked agammaglobulinemia (XLA).",
      "Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection.",
      "Results: We describe two patients with X-linked agammaglobulinemia (XLA) aged 34 and 26 years with complete absence of B cells from peripheral blood who developed COVID-19, as diagnosed by SARS-CoV-2 detection by nasopharyngeal swab, while receiving immunoglobulin infusions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence discusses two patients with X-linked agammaglobulinemia (XLA) who developed COVID-19 and were diagnosed by SARS-CoV-2 detection. Although the text does not explicitly state that these patients recovered from pneumonia as a manifestation of COVID-19, it implies they survived the infection, which is generally referred to as recovery.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001112",
    "statement": "Full-dose clot prophylaxis halted for severe covid-19 in nhlbi trial.",
    "label": "SUPPORTED",
    "evidences": [
      "Cite this: COVID-19 Anticoagulation Trials 'Paused' for Futility, Safety - Medscape - Dec 22, 2020.",
      "Therapeutic dosing was safe in this moderately ill COVID-19 population, unlike in the critically ill population for which the trials halted the full-dose strategy after seeing signals of harm.",
      "All three trials have paused enrollment of critically ill COVID-19 patients requiring intensive care unit support for whom therapeutic doses of anticoagulation drugs did not reduce the need for organ support, the NHLBI statement notes.",
      "Informed by the deliberations of the data safety monitoring boards of these trials, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that trials using full-dose anticoagulation strategies for critically ill COVID-19 patients requiring intensive care unit support were paused due to concerns about patient safety and potential lack of benefit. However, it does not clearly indicate whether the trials involving less severe COVID-19 patients, such as those receiving full-dose clot prophylaxis, have also been halted.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-001113",
    "statement": "Full-dose clot prophylaxis continued for severe covid-19 in nhlbi trial.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cite this: COVID-19 Anticoagulation Trials 'Paused' for Futility, Safety - Medscape - Dec 22, 2020.",
      "Therapeutic dosing was safe in this moderately ill COVID-19 population, unlike in the critically ill population for which the trials halted the full-dose strategy after seeing signals of harm.",
      "All three trials have paused enrollment of critically ill COVID-19 patients requiring intensive care unit support for whom therapeutic doses of anticoagulation drugs did not reduce the need for organ support, the NHLBI statement notes.",
      "Informed by the deliberations of the data safety monitoring boards of these trials, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about 'Full-dose clot prophylaxis continued for severe covid-19 in nhlbi trial'. The provided evidence does not directly support this claim as it discusses the pausing of enrollment for critically ill patients and therapeutic dosing, but it does not mention prophylactic dosing or severe COVID-19 patients.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-001114",
    "statement": "Full-dose clot prophylaxis allows for severe covid-19 in nhlbi trial.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cite this: COVID-19 Anticoagulation Trials 'Paused' for Futility, Safety - Medscape - Dec 22, 2020.",
      "Therapeutic dosing was safe in this moderately ill COVID-19 population, unlike in the critically ill population for which the trials halted the full-dose strategy after seeing signals of harm.",
      "All three trials have paused enrollment of critically ill COVID-19 patients requiring intensive care unit support for whom therapeutic doses of anticoagulation drugs did not reduce the need for organ support, the NHLBI statement notes.",
      "Informed by the deliberations of the data safety monitoring boards of these trials, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses three trials that were paused due to potential harm in the critically ill population receiving therapeutic doses of anticoagulation drugs for COVID-19. However, it does not explicitly state whether 'full-dose clot prophylaxis' (which may be a different dose or strategy) allows for severe COVID-19 cases within the NHLBI trial.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001115",
    "statement": "Full-dose clot prophylaxis allowed for severe covid-19 in nhlbi trial.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cite this: COVID-19 Anticoagulation Trials 'Paused' for Futility, Safety - Medscape - Dec 22, 2020.",
      "Therapeutic dosing was safe in this moderately ill COVID-19 population, unlike in the critically ill population for which the trials halted the full-dose strategy after seeing signals of harm.",
      "All three trials have paused enrollment of critically ill COVID-19 patients requiring intensive care unit support for whom therapeutic doses of anticoagulation drugs did not reduce the need for organ support, the NHLBI statement notes.",
      "Informed by the deliberations of the data safety monitoring boards of these trials, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly confirm or deny that full-dose clot prophylaxis was allowed for severe COVID-19 in the NHLBI trial. The article discusses the safety of therapeutic dosing in moderately ill COVID-19 patients, but it doesn't specify whether this dose is considered full-dose prophylaxis or not. It also mentions that enrollment of critically ill patients requiring intensive care unit support has been paused due to signals of harm from the therapeutic doses of anticoagulation drugs. However, it does not clarify if full-dose clot prophylaxis was allowed for severe COVID-19 patients who are not critically ill.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-001116",
    "statement": "Sars-cov-2 infects human neural progenitor cells and brain organoids",
    "label": "SUPPORTED",
    "evidences": [
      "h Representative images of SARS-CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and TUJ1.",
      "1: SARS-CoV-2 infects hNPCs, neurospheres and brain organoids.",
      "i Representative images of SARS- CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and NESTIN.",
      "f Representative images of SARS-CoV-2-infected brain organoids.",
      "1f), indicating that SARS-CoV-2 directly infected the brain organoids."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented shows representative images of SARS-CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and TUJ1 (neuronal marker), NESTIN (neural progenitor cell marker), and SARS-CoV-2-N alone. These images suggest that SARS-CoV-2 does infect human neural progenitor cells, brain organoids, and neurons, as claimed.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001117",
    "statement": "Sars-cov-2 infects human neural progenitor cells and lymphocytes organoids",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "h Representative images of SARS-CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and TUJ1.",
      "1: SARS-CoV-2 infects hNPCs, neurospheres and brain organoids.",
      "i Representative images of SARS- CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and NESTIN.",
      "f Representative images of SARS-CoV-2-infected brain organoids.",
      "1f), indicating that SARS-CoV-2 directly infected the brain organoids."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided consists of images showing SARS-CoV-2 infection in human neural progenitor cells (hNPCs) and brain organoids, as indicated by immunostaining for SARS-CoV-2-N protein and markers such as NESTIN. The presence of SARS-CoV-2 in brain organoids (1f) implies direct infection of these structures.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001118",
    "statement": "Sars-cov-2 infects human neural progenitor cells and fibroblasts organoids",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "h Representative images of SARS-CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and TUJ1.",
      "1: SARS-CoV-2 infects hNPCs, neurospheres and brain organoids.",
      "i Representative images of SARS- CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and NESTIN.",
      "f Representative images of SARS-CoV-2-infected brain organoids.",
      "1f), indicating that SARS-CoV-2 directly infected the brain organoids."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence presents representative images of SARS-CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and specific markers such as TUJ1, NESTIN. These images indicate that SARS-CoV-2 directly infected the brain organoids and thus support the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001119",
    "statement": "Serological responses to human virome define clinical outcomes of italian patients infected with sars-cov-2.",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes a study that analyzed antibody responses to a wide range of human viral peptides in 159 Italian COVID-19 patients with pneumonia. However, it does not directly establish a relationship between these serological responses and clinical outcomes specifically for SARS-CoV-2 infection.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001120",
    "statement": "Serological responses to bacterial virome define clinical outcomes of italian patients infected with sars-cov-2.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence studies antibody responses in Italian patients with pneumonia caused by SARS-CoV-2 using a phage-display method to characterize circulating antibodies binding to various viral peptides. However, the claim specifically states that serological responses to bacterial virome (bacteria) define clinical outcomes of Italian patients infected with SARS-CoV-2. The evidence does not support this claim as it focuses on viral peptides, not bacterial ones.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001121",
    "statement": "Coronavirus fatality rate estimated by imperial scientists",
    "label": "SUPPORTED",
    "evidences": [
      "According to the latest estimates from the team, from the MRC Centre for Global Infectious Disease Analysis at Imperial, one percent of people with the disease will die from their infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that according to estimates from the MRC Centre for Global Infectious Disease Analysis at Imperial, one percent of people with Coronavirus (Covid-19) will die from their infection. This suggests that this fatality rate is estimated by Imperial scientists.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001122",
    "statement": "Coronavirus fatality rate measured by imperial scientists",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the latest estimates from the team, from the MRC Centre for Global Infectious Disease Analysis at Imperial, one percent of people with the disease will die from their infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that the fatality rate of Coronavirus (COVID-19) according to the latest estimates from the MRC Centre for Global Infectious Disease Analysis at Imperial is 1%. This indicates that the claim is supported by the evidence.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-001123",
    "statement": "The human brain vasculature shows a distinct expression pattern of sars-cov-2 entry factors",
    "label": "SUPPORTED",
    "evidences": [
      "Our study serves as a publicly available single-cell atlas of SARS-CoV-2 related entry factors and interaction partners in human and mouse brain endothelial- and perivascular cells, which can be employed for future studies in clinical samples of COVID-19 patients.",
      "We observed a distinct expression pattern of the cathepsins B (CTSB) and -L (CTSL) - which are able to substitute for the ACE2 co-receptor TMPRSS2 - in the human vasculature with CTSB being mainly expressed in the brain vasculature and CTSL predominantly in the peripheral vasculature, and these observations were confirmed at the protein level in the Human Protein Atlas and using immunofluorescence stainings.",
      "This expression pattern of SARS-CoV-2 viral-entry associated proteases and SARS-CoV-2 interaction partners was also present in endothelial cells and microglia in the fetal brain, suggesting a developmentally established SARS-CoV-2 entry machinery in the human vasculature.",
      "At both the adult and fetal stages, we detected a distinct pattern of SARS-CoV-2 entry associated genes transcripts in brain vascular endothelial cells and microglia, providing a potential explanation for an inflammatory response in the brain endothelium upon SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents a study that examines the expression pattern of cathepsins B (CTSB) and -L (CTSL), which can function as SARS-CoV-2 entry factors in human brain vasculature. The expression pattern is supported at both the mRNA and protein levels, and the distinct expression in brain vasculature is also observed in fetal brain endothelial cells and microglia.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001124",
    "statement": "The rat brain vasculature shows a distinct expression pattern of sars-cov-2 entry factors",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our study serves as a publicly available single-cell atlas of SARS-CoV-2 related entry factors and interaction partners in human and mouse brain endothelial- and perivascular cells, which can be employed for future studies in clinical samples of COVID-19 patients.",
      "We observed a distinct expression pattern of the cathepsins B (CTSB) and -L (CTSL) - which are able to substitute for the ACE2 co-receptor TMPRSS2 - in the human vasculature with CTSB being mainly expressed in the brain vasculature and CTSL predominantly in the peripheral vasculature, and these observations were confirmed at the protein level in the Human Protein Atlas and using immunofluorescence stainings.",
      "This expression pattern of SARS-CoV-2 viral-entry associated proteases and SARS-CoV-2 interaction partners was also present in endothelial cells and microglia in the fetal brain, suggesting a developmentally established SARS-CoV-2 entry machinery in the human vasculature.",
      "At both the adult and fetal stages, we detected a distinct pattern of SARS-CoV-2 entry associated genes transcripts in brain vascular endothelial cells and microglia, providing a potential explanation for an inflammatory response in the brain endothelium upon SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided presents a study that creates a single-cell atlas of SARS-CoV-2 related entry factors and interaction partners in human and mouse brain endothelial- and perivascular cells. The study observed a distinct expression pattern of cathepsins B (CTSB) and -L (CTSL), which can substitute for the ACE2 co-receptor TMPRSS2, in the human vasculature with CTSB being mainly expressed in the brain vasculature. This suggests that there is indeed a distinct expression pattern of sars-cov-2 entry factors in the rat brain vasculature.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001125",
    "statement": "The mouse brain vasculature shows a distinct expression pattern of sars-cov-2 entry factors",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our study serves as a publicly available single-cell atlas of SARS-CoV-2 related entry factors and interaction partners in human and mouse brain endothelial- and perivascular cells, which can be employed for future studies in clinical samples of COVID-19 patients.",
      "We observed a distinct expression pattern of the cathepsins B (CTSB) and -L (CTSL) - which are able to substitute for the ACE2 co-receptor TMPRSS2 - in the human vasculature with CTSB being mainly expressed in the brain vasculature and CTSL predominantly in the peripheral vasculature, and these observations were confirmed at the protein level in the Human Protein Atlas and using immunofluorescence stainings.",
      "This expression pattern of SARS-CoV-2 viral-entry associated proteases and SARS-CoV-2 interaction partners was also present in endothelial cells and microglia in the fetal brain, suggesting a developmentally established SARS-CoV-2 entry machinery in the human vasculature.",
      "At both the adult and fetal stages, we detected a distinct pattern of SARS-CoV-2 entry associated genes transcripts in brain vascular endothelial cells and microglia, providing a potential explanation for an inflammatory response in the brain endothelium upon SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a study about SARS-CoV-2 related entry factors and interaction partners in human and mouse brain endothelial- and perivascular cells. The evidence shows the distinct expression pattern of sars-cov-2 entry factors, specifically cathepsins B (CTSB) and -L (CTSL), in the mouse brain vasculature. This expression pattern is observed at both the adult and fetal stages.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001126",
    "statement": "In the lab , st. jude researchers uncover origins of deadly inflammation caused by the novel coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Researchers further concluded that existing drugs, Remicade and Gamifant, which are used to treat such inflammatory diseases as Crohns disease and colitis prevented COVID-19 complications in laboratory models.",
      "A team led by Thirumala-Devi Kanneganti, PhD, vice chair of the St. Jude Department of Immunology, identified a previously unknown interaction between two messenger proteins that can unleash a cascade of inflammatory cell death, leading to tissue damage and multiple organ failure."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about discovering the origins of deadly inflammation caused by the novel coronavirus. The provided evidence talks about researchers identifying a previously unknown interaction between two messenger proteins that can lead to inflammatory cell death, but it does not discuss or link this discovery directly to the origins of the inflammation caused by the novel coronavirus.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-001127",
    "statement": "In the lab, st. chinese researchers uncover origins of deadly inflammation caused by the novel coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers further concluded that existing drugs, Remicade and Gamifant, which are used to treat such inflammatory diseases as Crohns disease and colitis prevented COVID-19 complications in laboratory models.",
      "A team led by Thirumala-Devi Kanneganti, PhD, vice chair of the St. Jude Department of Immunology, identified a previously unknown interaction between two messenger proteins that can unleash a cascade of inflammatory cell death, leading to tissue damage and multiple organ failure."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the researchers uncovered the origins of deadly inflammation caused by the novel coronavirus, but the evidence provided does not explicitly support this statement. Instead, it explains how a team of Chinese researchers identified an interaction between two messenger proteins and its potential consequences on tissue damage and multiple organ failure. However, it does not establish that these interactions are the origins of deadly inflammation caused by the novel coronavirus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001128",
    "statement": "In the lab, st.org researchers uncover origins of deadly inflammation caused by the novel coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers further concluded that existing drugs, Remicade and Gamifant, which are used to treat such inflammatory diseases as Crohns disease and colitis prevented COVID-19 complications in laboratory models.",
      "A team led by Thirumala-Devi Kanneganti, PhD, vice chair of the St. Jude Department of Immunology, identified a previously unknown interaction between two messenger proteins that can unleash a cascade of inflammatory cell death, leading to tissue damage and multiple organ failure."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that researchers from st.org uncovered the origins of deadly inflammation caused by the novel coronavirus. The evidence focuses on their discovery of an interaction between two messenger proteins and the treatment of COVID-19 complications with existing drugs in laboratory models. While these findings are significant in understanding COVID-19, they do not necessarily reveal the origin of the virus-induced inflammation.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001129",
    "statement": "In the lab, st.uk researchers uncover origins of deadly inflammation caused by the novel coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers further concluded that existing drugs, Remicade and Gamifant, which are used to treat such inflammatory diseases as Crohns disease and colitis prevented COVID-19 complications in laboratory models.",
      "A team led by Thirumala-Devi Kanneganti, PhD, vice chair of the St. Jude Department of Immunology, identified a previously unknown interaction between two messenger proteins that can unleash a cascade of inflammatory cell death, leading to tissue damage and multiple organ failure."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that researchers have identified an interaction between two messenger proteins and concluded that certain existing drugs prevent COVID-19 complications in laboratory models. However, the claim directly states the discovery of the origins of deadly inflammation caused by the novel coronavirus. While the evidence supports the conclusion about the drugs and inflammatory response, it does not provide direct evidence for the claim that they have uncovered the origins of deadly inflammation specifically due to the novel coronavirus.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001130",
    "statement": "Researchers set to begin clinical trials on coronavirus treatment",
    "label": "SUPPORTED",
    "evidences": [
      "Please note: Only people whove been diagnosed as COVID-19 positive and been admitted to a hospital where the clinical trial will take place can participate.",
      "University of Queensland Centre for Clinical Research Director and Consultant Infectious Diseases Physician at the Royal Brisbane and Womens Hospital (RBWH) Professor David Paterson said the drugs proved highly effective when first used against the virus in test tubes.",
      "Were now ready to begin patient trials with the drugs, one of which is an HIV medication and the other an anti-malaria drug, Professor Paterson said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that researchers are planning to begin clinical trials on coronavirus treatment using two drugs: an HIV medication and an anti-malaria drug. The claim is supported by the statement from University of Queensland Centre for Clinical Research Director Professor David Paterson that they are ready to begin patient trials with these drugs.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001131",
    "statement": "Participants set to begin clinical trials on coronavirus treatment",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Please note: Only people whove been diagnosed as COVID-19 positive and been admitted to a hospital where the clinical trial will take place can participate.",
      "University of Queensland Centre for Clinical Research Director and Consultant Infectious Diseases Physician at the Royal Brisbane and Womens Hospital (RBWH) Professor David Paterson said the drugs proved highly effective when first used against the virus in test tubes.",
      "Were now ready to begin patient trials with the drugs, one of which is an HIV medication and the other an anti-malaria drug, Professor Paterson said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions the plan to begin clinical trials with drugs for COVID-19 treatment on patients who have been admitted to a hospital. While it does not specify which stage of clinical trials this is (Phase I, II, III), and the focus is on hospitalized patients, the fact that they are ready to start human trials suggests that these drugs may be intended as potential treatments for COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001132",
    "statement": "Functional fear predicts public health compliance in the covid-19 pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "The effectiveness of moral messages on public health behavioral intentions during the COVID-19 pandemic.",
      "In the current context, this appears to be the case with negative emotions being protective (i.e., encouraging of public health-promoting behaviors) during the COVID-19 pandemic.",
      "Changes in risk perception and protective behavior during the first week of the COVID-19 pandemic in the United States.",
      "That is, for most individuals, the anxious responses being assessed by the FCV-19 may represent a normal and adaptive response to a real and present danger that one cannot fight or flee from, within the environment (i.e., the COVID-19 pandemic)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the effectiveness of moral messages and anxious responses in promoting public health behaviors during the COVID-19 pandemic, suggesting that functional fear predicts public health compliance. The first source states that negative emotions are protective during this pandemic, while the second source supports this by stating that for most individuals, anxious responses (fear) may represent a normal and adaptive response to the real and present danger of the COVID-19 pandemic.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001133",
    "statement": "Functional fear predicts public financial compliance in the covid-19 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The effectiveness of moral messages on public health behavioral intentions during the COVID-19 pandemic.",
      "In the current context, this appears to be the case with negative emotions being protective (i.e., encouraging of public health-promoting behaviors) during the COVID-19 pandemic.",
      "Changes in risk perception and protective behavior during the first week of the COVID-19 pandemic in the United States.",
      "That is, for most individuals, the anxious responses being assessed by the FCV-19 may represent a normal and adaptive response to a real and present danger that one cannot fight or flee from, within the environment (i.e., the COVID-19 pandemic)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a correlation between functional fear and public financial compliance during the COVID-19 pandemic. The first source discusses the effectiveness of moral messages on public health behavioral intentions, implying that negative emotions like functional fear might encourage such behaviors. The second source describes changes in risk perception and protective behavior during the initial phase of the pandemic, further indicating a potential link between fear and compliance.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001134",
    "statement": "Functional fear predicts public economic compliance in the covid-19 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The effectiveness of moral messages on public health behavioral intentions during the COVID-19 pandemic.",
      "In the current context, this appears to be the case with negative emotions being protective (i.e., encouraging of public health-promoting behaviors) during the COVID-19 pandemic.",
      "Changes in risk perception and protective behavior during the first week of the COVID-19 pandemic in the United States.",
      "That is, for most individuals, the anxious responses being assessed by the FCV-19 may represent a normal and adaptive response to a real and present danger that one cannot fight or flee from, within the environment (i.e., the COVID-19 pandemic)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a relationship between fear and compliance with public health measures during the COVID-19 pandemic. The first source mentions that negative emotions (fear) can encourage protective behaviors, which aligns with the claim. The second source also implies that fear responses to the pandemic are adaptive and may represent an appropriate response to a real danger.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001135",
    "statement": "Functional fear predicts public media compliance in the covid-19 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The effectiveness of moral messages on public health behavioral intentions during the COVID-19 pandemic.",
      "In the current context, this appears to be the case with negative emotions being protective (i.e., encouraging of public health-promoting behaviors) during the COVID-19 pandemic.",
      "Changes in risk perception and protective behavior during the first week of the COVID-19 pandemic in the United States.",
      "That is, for most individuals, the anxious responses being assessed by the FCV-19 may represent a normal and adaptive response to a real and present danger that one cannot fight or flee from, within the environment (i.e., the COVID-19 pandemic)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Functional fear predicts public media compliance in the covid-19 pandemic' is supported by the evidence provided. The evidence shows that negative emotions (fear) have been protective during the COVID-19 pandemic, encouraging public health-promoting behaviors, and changes in risk perception and protective behavior during the first week of the pandemic suggest that fear may represent a normal response to a real and present danger.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001136",
    "statement": "Modified vaccinia ankara based sars-cov-2 vaccine expressing full-length spike induces strong neutralizing antibody response",
    "label": "SUPPORTED",
    "evidences": [
      "Following immunizations with MVA/S or MVA/S1, both spike protein recombinants induced strong IgG antibodies to purified full-length SARS-CoV-2 spike protein.",
      "These results demonstrate MVA/S is a potential vaccine candidate against SARS-CoV-2 infection.",
      "The MVA/S induced a robust antibody response to purified RBD, S1 and S2 whereas MVA/S1 induced an antibody response to the S1 region outside of the RBD region."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that immunizations with MVA/S (Modified vaccinia ankara based sars-cov-2 vaccine expressing full-length spike) induce a strong IgG antibody response to purified full-length SARS-CoV-2 spike protein. This suggests the claim that Modified vaccinia ankara based sars-cov-2 vaccine expressing full-length spike induces strong neutralizing antibody response is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001137",
    "statement": "Modified vaccinia ankara based sars-cov-2 vaccine lacking full-length spike induces strong neutralizing antibody response",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following immunizations with MVA/S or MVA/S1, both spike protein recombinants induced strong IgG antibodies to purified full-length SARS-CoV-2 spike protein.",
      "These results demonstrate MVA/S is a potential vaccine candidate against SARS-CoV-2 infection.",
      "The MVA/S induced a robust antibody response to purified RBD, S1 and S2 whereas MVA/S1 induced an antibody response to the S1 region outside of the RBD region."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Modified vaccinia ankara based sars-cov-2 vaccine lacking full-length spike induces strong neutralizing antibody response' is supported by the provided evidence. The evidence shows that immunizations with MVA/S (modified vaccinia ankara based on SARS-CoV-2 spike protein) induced a strong IgG antibody response to the purified full-length SARS-CoV-2 spike protein, demonstrating its potential as a vaccine candidate against SARS-CoV-2 infection. The evidence also indicates that MVA/S induced a robust antibody response to purified RBD, S1 and S2 regions of the spike protein, while MVA/S1 only induced an antibody response to the S1 region outside of the RBD region.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001138",
    "statement": "Novel mutation identified in sars-cov-2 spike protein from sweden",
    "label": "SUPPORTED",
    "evidences": [
      "The mutation changes an arginine residue to a histidine residue at position 364 in the S1 subunit of the viral spike protein.",
      "The mutation is located at the surface of the S1 subunit of the SARS-CoV-2 spike protein, the main surface structure the virus uses to gain entry to host cells.",
      "SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein.",
      "Tatiany Soratto and colleagues from the Karolinska Institutet, Sweden, and the Federal University of Santa Catarina, in Brazil, say it is possible the unknown mutation could affect the ability of the virus to bind to host cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a novel mutation was identified in the spike protein of SARS-CoV-2 from Stockholm, Sweden. This mutation changes an arginine residue to a histidine residue at position 364 in the S1 subunit of the viral spike protein, which is located on the surface of the protein and crucial for cell entry. The authors also suggest that this mutation could affect the ability of the virus to bind to host cells.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001139",
    "statement": "No mutation identified in sars-cov-2 spike protein from sweden",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The mutation changes an arginine residue to a histidine residue at position 364 in the S1 subunit of the viral spike protein.",
      "The mutation is located at the surface of the S1 subunit of the SARS-CoV-2 spike protein, the main surface structure the virus uses to gain entry to host cells.",
      "SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein.",
      "Tatiany Soratto and colleagues from the Karolinska Institutet, Sweden, and the Federal University of Santa Catarina, in Brazil, say it is possible the unknown mutation could affect the ability of the virus to bind to host cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests the presence of a specific mutation in SARS-CoV-2 spike protein from Sweden, but it does not confirm that no other mutations have been identified. The claim should be evaluated based on comprehensive data regarding all potential mutations present within the spike protein across various samples from Sweden.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-001140",
    "statement": "One mutation identified in sars-cov-2 spike protein from sweden",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The mutation changes an arginine residue to a histidine residue at position 364 in the S1 subunit of the viral spike protein.",
      "The mutation is located at the surface of the S1 subunit of the SARS-CoV-2 spike protein, the main surface structure the virus uses to gain entry to host cells.",
      "SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein.",
      "Tatiany Soratto and colleagues from the Karolinska Institutet, Sweden, and the Federal University of Santa Catarina, in Brazil, say it is possible the unknown mutation could affect the ability of the virus to bind to host cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that a specific mutation (from arginine to histidine at position 364) has been identified in the S1 subunit of the SARS-CoV-2 spike protein from Sweden. The mutation is known to be located on the surface of the S1 subunit, which is involved in viral entry into host cells. While the evidence does not definitively prove that this mutation is unique or only found in Sweden, it suggests that such a mutation has been discovered in samples from Stockholm.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001141",
    "statement": "Our main findings are that cardiac involvement may occur with covid-19 even without respiratory tract signs and symptoms of infection .",
    "label": "SUPPORTED",
    "evidences": [
      "Heart palpitations have been reported to be the main presenting symptom of COVID-19 in patients without a fever or cough82.",
      "Patients with COVID-19 infection can present with symptoms mimicking CV events, including chest pain, dyspnoea, and shock, even in the absence of cardiac injury.",
      "An autopsy of a patient with COVID-19 and ARDS who died of a sudden cardiac arrest showed no evidence of myocardial structural involvement, suggesting that COVID-19 did not directly impair the heart57.",
      "These observations suggest that COVID-19 can cause ACS even in the absence of substantial systemic inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that heart palpitations and symptoms mimicking CV events (such as chest pain, dyspnea, and shock) have been reported in patients with COVID-19 who do not exhibit respiratory tract signs or symptoms of infection. Additionally, an autopsy of a patient with COVID-19 did not reveal evidence of myocardial structural involvement, suggesting that the heart was not directly impaired by the virus. These findings collectively support the claim that cardiac involvement may occur with COVID-19 even in the absence of respiratory tract signs and symptoms.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001142",
    "statement": "Our main findings are that cardiac involvement cannot occur with covid-19 even without respiratory tract signs and symptoms of infection.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Heart palpitations have been reported to be the main presenting symptom of COVID-19 in patients without a fever or cough82.",
      "Patients with COVID-19 infection can present with symptoms mimicking CV events, including chest pain, dyspnoea, and shock, even in the absence of cardiac injury.",
      "An autopsy of a patient with COVID-19 and ARDS who died of a sudden cardiac arrest showed no evidence of myocardial structural involvement, suggesting that COVID-19 did not directly impair the heart57.",
      "These observations suggest that COVID-19 can cause ACS even in the absence of substantial systemic inflammation."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that heart palpitations and other CV event-mimicking symptoms can occur in COVID-19 patients without respiratory signs, and cardiac arrest has been observed even with no myocardial structural involvement. However, the evidence does not establish that 'cardiac involvement cannot occur' with COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001143",
    "statement": "Sars-cov-2 viroporin triggers the nlrp3 inflammatory pathway",
    "label": "SUPPORTED",
    "evidences": [
      "We report that the SARS-CoV-2 viroporin encoded by ORF3a activates the NLRP3 inflammasome, the most promiscuous of known inflammasomes.",
      "In a pared-down system, we investigate the influence of ORF3a, an essential SARS-CoV-2 protein, on the inflammatory machinery and find that it activates NLRP3, the most prominent inflammasome by causing potassium loss across the cell membrane."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly stated and supported in the evidence: 'We report that the SARS-CoV-2 viroporin encoded by ORF3a activates the NLRP3 inflammasome.' Additionally, the evidence also provides a rationale for this activation (causing potassium loss across the cell membrane).",
    "confidence": 1
  },
  {
    "id": "covid_fact-001144",
    "statement": "Sars-cov-2 viroporin regulates the nlrp3 inflammatory pathway",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We report that the SARS-CoV-2 viroporin encoded by ORF3a activates the NLRP3 inflammasome, the most promiscuous of known inflammasomes.",
      "In a pared-down system, we investigate the influence of ORF3a, an essential SARS-CoV-2 protein, on the inflammatory machinery and find that it activates NLRP3, the most prominent inflammasome by causing potassium loss across the cell membrane."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that SARS-CoV-2 viroporin encoded by ORF3a activates the NLRP3 inflammasome, which is an essential component of the inflammatory pathway. This claim is fully supported by the provided evidence.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001145",
    "statement": "Gilead 's coronavirus wonder-drug remdesivir is masking a board contagion",
    "label": "SUPPORTED",
    "evidences": [
      "The report revealed that 36 of 53 patients hospitalized for severe COVID-19 who were treated with compassionate-use Remdesivir had clinical improvement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the clinical improvement of patients treated with remdesivir for severe COVID-19, but it does not suggest or imply a 'board contagion' or systemic issue within Gilead, the company that developed remdesivir. The claim goes beyond the scope of the given evidence.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-001146",
    "statement": "Inead's coronavirus wonder-drug remdesivir is masking a board contagion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The report revealed that 36 of 53 patients hospitalized for severe COVID-19 who were treated with compassionate-use Remdesivir had clinical improvement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that remdesivir, developed by Gilead Sciences under the brand name Veklury, has shown positive results in treating severe COVID-19 patients. However, this information does not suggest a 'board contagion' or any hidden issue with the drug.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-001147",
    "statement": "Anead's coronavirus wonder-drug remdesivir is masking a board contagion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The report revealed that 36 of 53 patients hospitalized for severe COVID-19 who were treated with compassionate-use Remdesivir had clinical improvement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that remdesivir led to clinical improvement in some patients with severe COVID-19. However, it does not suggest or indicate any kind of board contagion or masking thereof.",
    "confidence": 0.05
  },
  {
    "id": "covid_fact-001148",
    "statement": "Sead's coronavirus wonder-drug remdesivir is masking a board contagion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The report revealed that 36 of 53 patients hospitalized for severe COVID-19 who were treated with compassionate-use Remdesivir had clinical improvement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that remdesivir has a positive effect on some patients with severe COVID-19, but it does not support the claim that this drug is masking a broader contagion.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-001149",
    "statement": "The sars-cov-2 spike protein disrupts the cooperative function of human cardiac pericytes.",
    "label": "SUPPORTED",
    "evidences": [
      "To date, it is still not known if the S protein alone, without the other viral elements, is able to trigger vascular cell signalling and provoke cell dysfunction."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that SARS-CoV-2 spike protein disrupts the cooperative function of human cardiac pericytes. However, the evidence provided only states that it's not yet known if the S protein alone can trigger vascular cell signaling and provoke cell dysfunction, which doesn't necessarily mean it does or doesn't affect cardiac pericytes specifically.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001150",
    "statement": "The sars-cov-2 spike protein closelys the cooperative function of human cardiac pericytes.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To date, it is still not known if the S protein alone, without the other viral elements, is able to trigger vascular cell signalling and provoke cell dysfunction."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim concerns the interaction between SARS-CoV-2 spike protein and human cardiac pericytes. However, the provided evidence does not confirm nor deny this specific interaction. Instead, it discusses whether the S protein can trigger vascular cell signaling on its own. This is a different question that doesn't directly address the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-001151",
    "statement": "Cepi and sk bioscience extend collaboration to develop next generation covid-19 vaccine",
    "label": "SUPPORTED",
    "evidences": [
      "CEPI has also partnered with bioscience facilities SK bioscience and GC Pharma to reserve manufacturing capacities exclusively for one or more CEPI-funded COVID-19 vaccines.",
      "Im pleased to expand our partnership with SK bioscience to develop their vaccine candidate, GBP510, which marks CEPIs first investment in Wave 2 vaccines.",
      "For the COVID-19 vaccine response, SK bioscience is undergoing development for its vaccine candidate against SARS- CoV-2 with support from the Bill and Melinda Gates Foundation and CEPI, and using its established development and manufacturing capabilities, it has recently agreed to develop and manufacture AstraZenecas and Novavaxs COVID-19 vaccine candidates.",
      "SK bioscience and CEPI are committed to global equitable access of COVID-19 vaccines and have agreed that this vaccine candidate will be made available for procurement and allocation, if proven to be safe and effective, through the COVID-19 Vaccine Global Access (COVAX) Facility."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates a collaboration between Cepi and Sk bioscience to develop a next-generation Covid-19 vaccine. The text mentions that CEPI has partnered with SK bioscience for the development of their vaccine candidate GBP510, which is described as a Wave 2 vaccine in response to Covid-19. Additionally, it is stated that SK bioscience is undergoing development for its vaccine against SARS-CoV-2 with support from CEPI and the Bill and Melinda Gates Foundation, and that they have agreed to develop and manufacture AstraZeneca's and Novavax's Covid-19 vaccine candidates. Lastly, it is mentioned that this collaboration is committed to global equitable access of Covid-19 vaccines through the COVAX Facility.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001152",
    "statement": "Cepi and sk bioscience extend collaboration to develop first generation covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CEPI has also partnered with bioscience facilities SK bioscience and GC Pharma to reserve manufacturing capacities exclusively for one or more CEPI-funded COVID-19 vaccines.",
      "Im pleased to expand our partnership with SK bioscience to develop their vaccine candidate, GBP510, which marks CEPIs first investment in Wave 2 vaccines.",
      "For the COVID-19 vaccine response, SK bioscience is undergoing development for its vaccine candidate against SARS- CoV-2 with support from the Bill and Melinda Gates Foundation and CEPI, and using its established development and manufacturing capabilities, it has recently agreed to develop and manufacture AstraZenecas and Novavaxs COVID-19 vaccine candidates.",
      "SK bioscience and CEPI are committed to global equitable access of COVID-19 vaccines and have agreed that this vaccine candidate will be made available for procurement and allocation, if proven to be safe and effective, through the COVID-19 Vaccine Global Access (COVAX) Facility."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a partnership between CEPI and SK bioscience for the development of a COVID-19 vaccine. The passage mentions CEPI's investment in SK bioscience's GBP510 vaccine candidate, which is their first Wave 2 vaccine, and also states that SK bioscience is developing and manufacturing AstraZeneca's and Novavax's COVID-19 vaccine candidates with support from CEPI. Furthermore, the commitment to global equitable access of COVID-19 vaccines through the COVAX Facility also supports this claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001153",
    "statement": "Sars-cov-2 evolved into two major types",
    "label": "SUPPORTED",
    "evidences": [
      "term these two types L and S type: two major types (L and S types): the S type is ancestral, and the L type evolved from S type.",
      "We hypothesized that the two types of SARS-CoV-2 viruses might have experienced different selective pressures due to different epidemiological features."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only indicates the existence of two types (L and S) of SARS-CoV-2 viruses, with one being ancestral (the S type), and another evolving from it (the L type). However, the evidence does not provide any concrete support or detail on whether these two types can be categorized as 'major types.' Additional evidence such as genetic analysis, epidemiological data, or studies would be necessary to confirm that these two types are indeed 'major' types of SARS-CoV-2.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-001154",
    "statement": "Sars-cov-2 evolved into four major types",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "term these two types L and S type: two major types (L and S types): the S type is ancestral, and the L type evolved from S type.",
      "We hypothesized that the two types of SARS-CoV-2 viruses might have experienced different selective pressures due to different epidemiological features."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided identifies two types of SARS-CoV-2 viruses (L and S), but it does not show that these are the only major types or provide clear evidence for the existence of any other types. The statement about one type evolving from another is also not substantiated by the provided evidence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001155",
    "statement": "Sars-cov-2 evolved into five major types",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "term these two types L and S type: two major types (L and S types): the S type is ancestral, and the L type evolved from S type.",
      "We hypothesized that the two types of SARS-CoV-2 viruses might have experienced different selective pressures due to different epidemiological features."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only describes two types (L and S) of SARS-CoV-2, but it does not prove that these are the five major types as claimed.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-001156",
    "statement": "Sars-cov-2 evolved into six major types",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "term these two types L and S type: two major types (L and S types): the S type is ancestral, and the L type evolved from S type.",
      "We hypothesized that the two types of SARS-CoV-2 viruses might have experienced different selective pressures due to different epidemiological features."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only mentions two types (L and S) of SARS-CoV-2 viruses, without explicitly stating that there are six major types in total. Furthermore, the hypothesis about different selective pressures doesn't provide direct evidence for the existence of six major types.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-001157",
    "statement": "A bra manufacturer has begun making masks , instead of bras",
    "label": "SUPPORTED",
    "evidences": [
      "Share The worlds leading manufacturer of respirator masks may have originally intended them to be bras.",
      "The shift came when an employee realized that the bra materials were similar to ones used in masks.",
      "Companies create lacy masks out of BRAS after people started turning their old lingerie into makeshift PPE People have been making their own face masks out of bras Molded bra cups actually inspired the N95 mask, though these homemade versions offer considerably less protection A Japanese lingerie company is also selling masks made from their bra materials In the US, the $39.99 Emergency Bra 'can be transformed into two facemasks to reduce the inhalation of harmful chemical, biohazard and dust particulate' By Carly Stern For Dailymail.com Published: 16:45 EST, 29 April 2020 ",
      "Fast Company points out that it's actually not so surprising that masks are being made from bras  since bras inspired the N95 mask."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that a bra manufacturer has indeed begun making masks. The text mentions the shift from manufacturing bras to masks, and provides examples of companies creating lacy masks out of bras, selling masks made from bra materials, and even producing an emergency bra that can be transformed into two facemasks. Additionally, it is stated that bras inspired the N95 mask.",
    "confidence": 1
  },
  {
    "id": "covid_fact-001158",
    "statement": "A bra manufacturer has not making masks, instead of bras",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share The worlds leading manufacturer of respirator masks may have originally intended them to be bras.",
      "The shift came when an employee realized that the bra materials were similar to ones used in masks.",
      "Companies create lacy masks out of BRAS after people started turning their old lingerie into makeshift PPE People have been making their own face masks out of bras Molded bra cups actually inspired the N95 mask, though these homemade versions offer considerably less protection A Japanese lingerie company is also selling masks made from their bra materials In the US, the $39.99 Emergency Bra 'can be transformed into two facemasks to reduce the inhalation of harmful chemical, biohazard and dust particulate' By Carly Stern For Dailymail.com Published: 16:45 EST, 29 April 2020 ",
      "Fast Company points out that it's actually not so surprising that masks are being made from bras  since bras inspired the N95 mask."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests a shift in the manufacturing process by a bra manufacturer towards producing masks due to similarities between mask and bra materials. However, it does not definitively establish that the company has never made bras before or currently only produces masks. The claim requires direct evidence of the continuous non-production of bras.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-001159",
    "statement": "A bra manufacturer has no making masks, instead of bras",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share The worlds leading manufacturer of respirator masks may have originally intended them to be bras.",
      "The shift came when an employee realized that the bra materials were similar to ones used in masks.",
      "Companies create lacy masks out of BRAS after people started turning their old lingerie into makeshift PPE People have been making their own face masks out of bras Molded bra cups actually inspired the N95 mask, though these homemade versions offer considerably less protection A Japanese lingerie company is also selling masks made from their bra materials In the US, the $39.99 Emergency Bra 'can be transformed into two facemasks to reduce the inhalation of harmful chemical, biohazard and dust particulate' By Carly Stern For Dailymail.com Published: 16:45 EST, 29 April 2020 ",
      "Fast Company points out that it's actually not so surprising that masks are being made from bras  since bras inspired the N95 mask."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that companies have been creating lacy masks out of bra materials or using bra materials for homemade face masks due to the similarity in materials. However, this does not necessarily mean that a bra manufacturer specifically makes masks instead of bras. The claim requires evidence showing that the manufacturer in question has shifted their production towards mask manufacturing.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001160",
    "statement": "A bra manufacturer has begun making attention, instead of bras",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share The worlds leading manufacturer of respirator masks may have originally intended them to be bras.",
      "The shift came when an employee realized that the bra materials were similar to ones used in masks.",
      "Companies create lacy masks out of BRAS after people started turning their old lingerie into makeshift PPE People have been making their own face masks out of bras Molded bra cups actually inspired the N95 mask, though these homemade versions offer considerably less protection A Japanese lingerie company is also selling masks made from their bra materials In the US, the $39.99 Emergency Bra 'can be transformed into two facemasks to reduce the inhalation of harmful chemical, biohazard and dust particulate' By Carly Stern For Dailymail.com Published: 16:45 EST, 29 April 2020 ",
      "Fast Company points out that it's actually not so surprising that masks are being made from bras  since bras inspired the N95 mask."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests a bra manufacturer has begun making masks instead of bras. The evidence shows that companies are creating lacy masks out of bras and selling them as PPE, and the US Emergency Bra can be transformed into two facemasks. Additionally, the shift came when an employee realized the similarity between the materials used in masks and bras. Therefore, the claim is supported by the provided evidence.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-001161",
    "statement": "Higher ace2 expression found in fat and cancer cells",
    "label": "SUPPORTED",
    "evidences": [
      "ACE2 expression correlated with increased macrophage abundance in some tumors, while TMPRSS2 was strongly associated with epithelial cells.",
      "Results Matched normal tissues generally display higher ACE2 and TMPRSS2 expression compared with cancer, with normal and tumor from digestive organs expressing the highest levels.",
      "The expression of ACE2 and TMPRSS2 was significantly higher in normal tissues relative to tumors (figure 1C).",
      "By the search for network database and re-analysis of pubic data, we found the level of ACE2 expression in adipose tissue was higher than that in lung tissue, which indicated the adipose tissue might be vulnerable to SARS-CoV-2 as well; the levels of ACE2 expressed by adipocytes and adipose progenitor cells were similar between non-obese individuals and obese individuals, but obese individuals have more adiposes so as to increase the number of ACE2-expressing cells; the expression of ACE2 in tumor tissues posed by five different types of cancers increased significantly compared with that in adjacent tissues."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that ACE2 expression is found in higher levels in fat and cancer cells compared to normal tissues. This conclusion is based on the observations of increased ACE2 expression in adipose tissue compared to lung tissue, as well as the observation that obese individuals, who have more adipose tissue, have an increase in the number of ACE2-expressing cells. Additionally, the evidence shows that the expression of ACE2 in tumor tissues posed by five different types of cancers increased significantly compared with that in adjacent tissues.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-001162",
    "statement": "No ace2 expression found in fat and cancer cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ACE2 expression correlated with increased macrophage abundance in some tumors, while TMPRSS2 was strongly associated with epithelial cells.",
      "Results Matched normal tissues generally display higher ACE2 and TMPRSS2 expression compared with cancer, with normal and tumor from digestive organs expressing the highest levels.",
      "The expression of ACE2 and TMPRSS2 was significantly higher in normal tissues relative to tumors (figure 1C).",
      "By the search for network database and re-analysis of pubic data, we found the level of ACE2 expression in adipose tissue was higher than that in lung tissue, which indicated the adipose tissue might be vulnerable to SARS-CoV-2 as well; the levels of ACE2 expressed by adipocytes and adipose progenitor cells were similar between non-obese individuals and obese individuals, but obese individuals have more adiposes so as to increase the number of ACE2-expressing cells; the expression of ACE2 in tumor tissues posed by five different types of cancers increased significantly compared with that in adjacent tissues."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly address the claim about ACE2 expression specifically in fat and cancer cells. Instead, it discusses a correlation between ACE2 expression and macrophage abundance in some tumors, and higher levels of ACE2 expression in normal tissues compared to tumors. It also mentions that adipose tissue might be vulnerable to SARS-CoV-2 due to high ACE2 expression, but it does not specify whether this is found in fat cells or not.",
    "confidence": 0.9
  }
]